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Selectins are an extensively studied class of carbohydrate binding proteins. They mediate the 
first contact and rolling of leukocytes on endothelia cells, initiating leukocyte infiltration 
from blood circulation to the diseased or infected tissue. Many inflammatory diseases are 
associated with an excessive extravasation of leukocytes to the inflamed tissue, and several 
kinds of metastatic cancer adopt the selectin mediated pathways. Thus, blocking selectins 
with synthetic antagonists is a promising therapeutic approach. 
The common carbohydrate epitope present in all physiological selectin ligands is the 
tetrasaccharide sialyl Lewisx. To overcome the problem of structural complexity, nature 
rigidifies the 3 dimensional Lex core conformation by several stabilizing elements and thus, 
pre-organizes the pharmacophores in their bioactive conformation. For the development of 
potent sLex mimics it is crucial to understand the principles of stabilization and to adopt and 
optimize these structural motives.  
 
Schematically sLex can be divided into a rigid Lex trisaccharide core and a rather flexible 
neuraminic acid part. The first part of the thesis is focused on the core trisaccharide Lex, 
which bears five of six pharmacophores. Since there are contradictory reports about the 
conformation of Lewis antigens in solution, i.e. do they adopt a single conformation or are 
they flexible, the conformations of Lex and related oligosaccharides in solution were 
investigated. 
• An universal approach to analyze conformations of small molecules at room 
temperature in solution was developed. By converting the small Lex trisaccharide in a 
high-molecular-weight glycoconjugate the tumbling time was drastically increased, 
which is essential to obtain sufficient structural information by NMR spectroscopy. 
Thus, we achieved a well-defined solution conformation of Lex, which disclosed a 
nonconventional CH···O hydrogen bond as a major stabilizing element (Chapter 3.1.1 
/Publication).   
• It could be shown that nonconventional CH···O hydrogen bonds are a common 
structural element stabilizing the conformation of various branched oligosaccharides. 
A widespread database search revealed numerous fucosylated carbohydrate 
structures that fulfill the requirements of nonconventional CH···O hydrogen bonds. 
Furthermore, the structures of six representative fucosylated carbohydrates were 
elucidated in solution. All of them are stabilized by nonconventional CH···O 
hydrogen bonds (Chapter 3.1.2/Manuscript).   
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In the second part of this thesis, the effects of neuraminic acid replacements in sLex mimics 
on conformational flexibility were evaluated, and antagonists with an acid pharmacophore 
pre-organized in the bioactive conformation were synthesized. 
 • By solving the solution conformation of a potent selectin antagonist, it was shown 
that the acid pharmacophore is pre-organized prior to binding by intramolecular 
interactions of hydrophobic residues. This antagonist showed stronger binding 
affinities over mimics with a flexible acid moiety. Based on these results, a series of 
selectin antagonists was designed and synthesized, where the acid pharmacophore is 
incorporated in a ring system and therefore, locked in the bioactive conformation 
(Chapter 3.2.1/Manuscript).  
 The synthesis of two additional cyclic selectin antagonist series was not successful. 
Possible reasons are discussed in chapter 3.2.1.2. 
• In chapter 3.2.2, the potential for a bioisosteric replacement of the acid 
pharmacophore in cyclic selectin antagonists was evaluated by synthesis, biological 
assays and ab initio calculations (Manuscript). 
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2.1 Selectins 
Selectins are a family of Ca2+ dependent C-type transmembrane glycoproteins.1 They are the 
most intensively studied mammalian carbohydrate binding lectins,2 and can be divided in the 
three subclasses E-selectin (CD62E, ELAM-1, LECAM-2), P-selectin (CD62P, LECAM-3), 
and L-selectin (CD62L, LAM-1, LECAM-1).3 
 
2.1.1 Structure 
Selectins share a similar topology of a short cytoplasmatic tail, a transmembrane domain, 
several short consensus repeats (SCRs), an epidermal growth factor domain (EGF) and a N-
terminal carbohydrate recognition domain (CRD).4  
The N-terminal CRD is responsible for ligand binding and coordinates the Ca2+ ion.4 The 
function of the adjacent EGF domain is not solved completely, but the domain has an 
influence on ligand specifity and affinity.1 The SCRs extend the selectins beyond the 
glycocalix and differ in number and length between the three selectin subclasses and species. 
Humans P-selectin consists of 9, L-selectin of 2 and E-selectin of 6 SCR molecules.3 The 
transmembrane domain anchors the selectins in the membrane and the cytoplasmatic tail is 
involved in signaltransduction.5,6 
 
 
Figure 17. Schematic overview of the three selectin subclasses and binding partners.  
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The natural ligands of the three selectins are glycolipids and glycoproteins bearing the 
terminal tetrasaccharide epitops sialyl Lewisx (sLex) or sialyl Lewisa (sLea).8,9 They show 
relatively weak entropic driven binding and fast binding kinetics to their natural ligands. 
Ligands that bind L- and P-selectin, requires additional negatively charged groups like 
sulfates or carboxylates for tight binding. 
E-selectin is expressed on vascular endothelial cells after an inflammatory stimulus, and 
binds E-selectin ligand-1 (ESL-1), that is not recognized by P- and L-selectin.10-12 The 
dissociation constant for E-selectin ESL-1 binding is 62 µM, the dissociation rate constant 
koff is 4.6 s-1 and the association rate constant kon 7.4x104 M-1s-1.12 
P-selectin is expressed on platelets13 and on vascular endothelia cells,14 and binds the P-
selectin glycoprotein ligand 1 (PSGL-1) that is stored in Weible palade bodies in 
leukocytes.15 Three sulfated tyrosin groups ensure tight binding of PSGL-1.16 PSGL-1 is 
also recognized by E-selectin, but the binding is weaker, due to the lack of the secondary 
binding site for the sulfated tyrosine groups.26 The KD for P-selectin PSGL-1 binding is 0.3 
µM, the binding kinetic is faster than the E-selectin ESL-1 interaction, koff is 1.4 s-1 and the 
kon 4.4x106 M-1s-1.16 
L-selectin is expressed on monocytes, blood neutrophils, and on T- and B-cells17 and binds 
sulfated ligands, e.g. addressin (MAdCAM-1),18,19 CD34,20 endomucin,21 endoglycan22 and 
glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1).23  
 
2.1.2 Physiological and pathophysiological role 
Selectins are key players in the adaptive and innate immune response, more precisely in the 
first steps of the inflammation cascade (Figure 2).24 They mediate the initial contact and 
rolling of leucocytes on blood vessels, a crucial step for the infiltration into inflamed and 
infected tissue. After an inflammatory stimulus P- and E-selectin close to the side of lesion 
are displayed on endothelia cells in blood vessels and interact with selectin ligands located 
on leucocytes, leading to rolling along the endothelia vessels.25 Cytokine mediated 
activation of β2-integrins on the surface of the leucocytes and binding to ICAM-1 and 
VCAM-1 on the endothelial surface lead to firm adhesion and finally extravasation of 
leucocytes to the inflamed tissue.24,25   
Chapter 2. - Introduction 
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 Figure 2. Schematic overview of the inflammatory cascade.26 
 
All three selectins mediate the rolling of leucocytes,3 but they differ in spatially and 
temporally expression pattern.1 
P-selectins are pre-stored in Weibel palade bodies in the endothelia cells, are released within 
minutes after injury or inflammation and activate these cells to become adhesive for 
leucocytes.27 Furthermore, lipopolysaccharides (LPS), tumor necrosis factor-α (TNF-α) and 
various interleukins can induce de novo synthesis and expression on the endothelial surface 
after 2 - 4 hours.28,29  
E-selectin is expressed on endothelia cells 2 - 4 hours after stimulation with immunolatory 
modulators like TNF-α or interleukin-1, by de novo protein synthesis.30 While P-selectin 
mediates first contacts to the leucocytes and fast rolling, E-selectin allows slow rolling, 
which seems to be a prerequisite for firm adhensions.31 
L-selectin is constantly expressed on leucocytes and is involved in trafficking and homing 
between the lymphatic system and blood.1 Furthermore, free flowing leucocytes can interact 
with already adherent ones by L-selectin PSGL-1 interaction, and thus increase the number 
of adherent leucocytes by this secondary tethering.32  
An aberrant recruitment or hyperactive functioning of effector immune cells characterizes 
inflammation and causes destruction of healthy tissue.33 Inappropriate activity of selectins 
can be associated with a number of acute and chronic inflammatory disorders. Examples are 
rheumatoid arthritis,34 reperfusion injury,35-37 asthma,38 diabetes39 and atherosclerosis.40 
Furthermore, it was shown, that selectins mediate aggregation of erythrocytes and 
Chapter 2. - Introduction 
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leukocytes during vaso-occlusive crisis in a mouse model of sickle cell disease41 and that 
tumor cells exploit selectin pathways to extravasate out of the bloodstream.42,43 Thus, 
selectin inhibition can be considered as a promising approach to treat these diseases. 
 
2.1.3 Natural selectin binding epitop sialyl Lewisx 
The binding affinities of the sLex tetrasaccharide is low, with 0.3 to 1.1 mM for E-selectin, 
6.8 to 8.8 mM for P-selectin and 3.3 to 4.5 mM for L-selectin.44 Nature overcomes this 
problem of low affinity ligands by multivalency.45,46  
The binding mode of sLex to E-selectin was intensively studied by NMR spectroscopy47-49 
and confirmed by crystallography.50 The pharmacophores of sLex involved in binding were 
identified (Figure 3). The L-fucose moiety coordinates the Ca2+ ion with two hydroxy groups 
in 3- and 4-position and the 2-hydroxy group forms an additional hydrogen bond mediated 
by a water molecule. The 4- and 6-hydroxy groups of the D-galactose are involved in 
hydrogen bonding and the carboxylate of the neuraminic acid form a salt bridge to the 
protein. N-acetyl-glucosamine is not directly involved in binding and shows no interaction to 
the protein.  
 
   
Figure 3. Schematic representation of sLex in crystal with E-selectin (amino acids involved in binding are 
highlighted in red, pharmacophores in blue) and in solution. 
 
The sLex/selectin interactions take place under flow conditions, thus, the time to organize 
the pharmacophores in the bioactive conformation is limited. To overcome this problem, the 
tetrasaccharide sLex adopts a certain degree of pre-organization already in solution. Several 
NMR and MD studies explored the conformation of sLex in solution.44,48,51 The 
tetrasaccharide can be roughly divided in two parts, a rather flexible neuraminic acid 
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(Neu5NAc) and a relative rigid Lex (Galβ(1-4)[Fucα(1-3)]GlcNAc) trisaccharide core 
(Figure 3). 
It is hypothesized that the neuraminic acid residue adopts two main conformations in 
solution, whereof one is identical with the bioactive conformation.51 In contrast, the Lex 
conformation in solution is almost identical to the conformation observed in the complex 
with E-selectin, i.e. the 5 pharmacophoric groups of the L-fucose and D-galactose residue are 
pre-organized in the bioactive conformation. The Lex trisaccharide core is mainly stabilized 
by an exo-anomeric effect,52,53 hydrophobic interactions between the L-fucose and β-face of 
the D-galactose as well as the spatial proximity of the N-acetyl residue that restricts the 
movements of the L-fucose residue.54-56 The GlcNAc residue, which is not involved in 
protein binding, provides an ideal 3D scaffold for the L-fucose and D-galactose. However, it 
was discussed extensively in the past, if the previous reported stabilizing elements are 
sufficient for stabilizing the Lex trisaccharide in solution. The dihedral angles deviations of 
the glycosidic bonds between reported Lex conformations in solution cover a rather large 
range.54-58 But this could also be justified with drawbacks of NMR spectroscopy elucidating 
small to midsize molecules (chapter 2.4).  
 
2.2 Selectin antagonists  
 
 
Figure 4: Selected selectin antagonists in clinical trials. 
 
As a result of their high polarity, carbohydrates are unable to passively pass through the 
enterocyte layer in the small intestine, and if administered parenterally, they suffer from fast 
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renal excretion.2 When interactions with blood plasma components are possible, the plasma 
half-life required for a successful therapeutic application can be achieved.2  
Several synthetic selectin antagonists are currently in clinical evaluation, i.e. the pan-selectin 
antagonist Rivipansel (GMI-1070), which successfully finished clinical phase II to treat 
vaso-occlusive crisis in sickle cell disease,59,60 or the D-mannose based selectin antagonist 
TBC-1269.61 Furthermore, the non-carbohydrate antagonist PSI-697, which shows more 
drug like properties, was developed and is in clinical phases to treat atherothrombotic and 
venous thrombotic diseases.62,63 
As an alternative approach, biologicals (antibodies64,65, glycoproteins66) are currently 
explored for the treatment of selectin-mediated diseases. 
 
2.2.1 Evolution of sLex mimics  
The high polarity, complexity and low affinity of the lead structure are challenges for the 
development of sLex mimics. The goal is to mimic structural information of a functional 
carbohydrate on the one hand and to improve the physicochemical properties on the other 
hand.2 Starting from sLex, several compounds were synthesized to mimic the neuraminic 
acid moiety. (S)-cyclohexyl lactic acid turned out to be the most potent substitution 
(Scheme1; FB32926). The binding affinity could be increased by a factor of 3.5.  
The (1R, 2R)-cyclohexane diol mimic the GlcNAc chair conformation adjusting the L-
fucose and D-galactose moieties in a position similar as in sLex and lead to a 3.5 fold 
increase in affinity (FB329→CGP69669). An additional methyl group in 3-position of the 
(S)-cyclohexane residue gave a six-fold improvement (CGP69669→DS4115) of affinity by 
forcing the adjacent L-fucose moiety into the bioactive conformation.67 A benzoate 
substituent in 2’-position of the D-galactose, led to an improvement in binding affinity by a 
factor of 2.5 (DS4115→GMI-1077).67 Thoma et al. firstly described these positive effect of 
2’ benzoylation on binding affinity and explained it with a stabilizing effect on the Lex 
core.68 STD experiments indicated an interaction of the benzoate residue to the protein.69 
However, this observation could not be confirmed by a recently solved crystal structure.70        
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Scheme 1: Design of sLex antagonists. 
 
The benzoate in the 2’-position of the D-galactose moiety is pointing to solution and 
intramolecular σ-π stacking between the cyclohexane and the aromatic residue was 
observed.70 This benzoate-cyclohexane interaction could pre-organize the structure already 
before binding, and therefore lead to an entropic gain over flexible ligand DS4115.  
Recently, E-selectin antagonists with a affinity up to 0.03 µM could be developed by a 
fragment based drug discovery approach.71 
Although the affinity could be increased significantly and the high polarity could be 
decreased compared to lead structure sLex, druglikeness is still far from being reached. For 
the prediction of oral availability, several physicochemical rules and filters are available. 
The most common one is the Lipinski rule of 5 (RO5).72,73 Lipinski analyzed a dataset of 
orally available drugs and clinical candidates for their physicochemical properties, and 
defined cutoffs for 4 different parameters to be important for solubility and permeability. 
Oral available drugs that are actively transported were excluded in this study. The rule states 
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hydrogen bond donors, a molecular weight smaller than 500 and an octanol-water partition 
coefficient (logP) smaller than 5.73  
Another rule associated oral availability of drugs with less than 10 rotatable bonds (NRB) 
and a polar surface area (PSA) smaller than 140 Å2.74 However, subsequent studies showed, 
that this limit of 10 rotatable bonds is less stringent in several therapheutic areas,75 and that 
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the upper limits of free rotatable bonds in drugs in humans is 13.76  In summary, these rules 
are just indicators and exceptions will always exist. The estimated success of such 
predictivity tools is approximately 65 %.77  
An overview of the RO5, PSA and NRB values of the selectin antagonists GMI-1070, sLex, 
GMI-1077, FB329 and DS4115 reveal several violations of the rules mentioned above 
(Table 1). Strategies to improve the bioavailability are obviously directed towards 
replacement of the pharmacophores by bioisosteres,78 or the reduction of free rotatable 
bonds by intramolecular cyclisations. 
 
Table 1. Pharmacokinetic and structural parameters for selectin antagonists. 
 
 
2.3 Macrocycles in drug design 
The introduction of cyclic scaffolds can improve biological and physicochemical properties 
of drug candidates.79 Ring structures can be divided into macrocyclic (≥12 atoms), medium 
(8-11 atoms) and small rings (<8 atoms), which display qualitative differences in behavior.80 
The medium rings are rather dominated by transannular interactions and conformational 
strains that are not present in macrocycles. However, macrocycles contribute a particular 
degree of pre-organization due to restricted rotations.80,81  
A conformational pre-organization can result in improved affinity and selectivity for protein 
targets, while preserving sufficient bioavailability to reach intracellular targets. However, 
despite the proven success of more than 100 marketed drugs, this class has been poorly 
explored within drug discovery.82 The marketed drugs mainly derive from natural products 
or derivatives closely related to naturally occurring macrocycles.82 Examples are the 
macrolide antibiotic erythromycin, antituberculosis compound rifampicin and the 
immunosuppressant cyclosporine A.82 Reasons that macrocycles are under-explored and 
Compound sLex GMI-1070 FB329 CGP69669 DS4115 GMI-1077 
R 
O 
5 
MW 793.7 1447.4 697.7 578.7 592.7 696.8 
HD 24 13 9 6 6 5 
HA 25 37 18 13 13 14 
logP -6.7* -5.6* -3.1* -0.2* -0.1* 2.6 
free rot. bond 25 36 20 16 15 17 
PSA 330* 627* 255* 194* 189* 207* 
Affinity (IC50) 1 0.0043 0.28 0.08 0.019 0.006 
Color code 
Out of range (Deviation) In range 
> 100% 100% - 20% < 20% 
*calculated (Schrödinger) 
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poorly exploited for development of novel drug molecules are their structural complexity 
and accompanied difficulties in the synthesis of analogues and that the preferential adoption 
of rule of 5-compliant compounds for screening has become widespread. 73,82 
However, rigidified ligands would have an advantageous association rate of binding (kon), 
since they do not have to reorganize to adopt the bioactive conformation before binding. 
Furthermore, cyclisation will minimize the unfavorable loss of internal degrees of freedom, 
and therefore have an entropic gain upon binding. But the enthalpic contribution to the 
binding event may compensate the entropic term,83 and the assignment and predictions of 
the energetics are often complex.80,84 Several factors like water displacement upon binding 
and a change of the overall motion of the protein-ligand complex are influencing the 
thermodynamic fingerprint.85 
There are several synthetic strategies to insert cyclic scaffolds into drug molecules. The most 
common is to bridge functionalized termini of linear drug molecules by simple linkers. 
Examples for common synthetic methods for ring closure are lactonization by Yamaguchi, 
Mukaiyama and Mitsunobu conditions,86 Heck coupling,87 copper catalyzed azide-alkyne 
cycloaddition,88,89 and ring closing metathesis (RCM).90 
 
2.3.1 Olefin metathesis 
The olefin metathesis represents a powerful tool for C-C bond formation and is attracting a 
vast amount of interest in academia and industry.91-95 The mechanism for olefin metathesis 
was originally proposed by Hérisson and Chauvin and is generally accepted.96 According to 
this mechanism, olefin metathesis proceeds through metallobutane intermediates, generated 
by the coordination of an olefin to a molypdenum97 or ruthenium98-100 based alkylidene 
catalyst, via a series of alternating [2+2]-cycloadditions and cycloreversions (Scheme 
2a).95,101-103 As all steps in this catalytic cycle are reversible, the main goal is to shift the 
equilibrium to the desired products. This equilibrium can be influenced by varying the 
reaction conditions, e.g. by choice of catalyst, solvent, temperature or dilution. However, 
many details of the oflefin metathesis reaction still remain unclear.95 
The most common subtypes of olefin metathesis are illustrated in scheme 2b. The ring-
opening metathesis polymerization (ROMP) is the polymerization of monomers with 
unsaturated strained rings and is driven by ring-strain release.94,104  
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Scheme 2. Proposed mechanism of the catalytic cycle of olefin metathesis (a), and most common types of 
olefin metathesis (b).91,95 
 
Olefin cross metathesis (CM) has no enthalpic driving force (like ring strain release) and 
also no strong entropic benefit. By varying the types of catalysts and the properties of the 
olefins (steric, electronic) it is possible to reach good product selectivity and 
stereoselectivity.105 Chatterjee et al. developed a classification system of olefins, in which 
the olefins can be categorized by their relative abilities to undergo homodimerization via 
cross metathesis and the susceptibility of their homodimers toward secondary metathesis 
reactions (Figure 5).105 Terminal alkenes for example are type I olefins, while acrylates and 
acrylamides are type II olefins, due to the electron withdrawing groups in proximity to the 
olefins. The classification differs slightly for different catalysts.105 
 
 
Figure 5. Olefin categorization (a) and rules for selectivity (b). Primary metathesis reactions of Type I (R1) and 
Type II (R2) olefins (c).
105 
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The ring closing metathesis (RCM) is widely used in organic chemistry106,107 and the driving 
force is predominantly entropic, since one substrate molecule reacts to two product 
molecules, whereof one is volatile and can leave the equilibrium and thus, the reaction is 
irreversible and can proceed to completion. The efficiency of the metathesis reaction is 
influenced by several factors like type of catalyst, concentration, steric congestion near the 
double bond, presentation of functional groups which serves as a relay entity that assembles 
the reacting side, and the distance between this polar group and the alkenes to be 
metathesized.107   
RCM is a common method to introduce a medium- or macrocyclic scaffold in medicinal 
chemistry. The resulting alkene is in shorter olefin chain almost exclusive the cis isomer. 
With increasing chain length the ratio in favor of trans isomer is increasing. The olefin can 
be further modified,108,109 or reduced to the unmodified alkyl chain. By altering the length of 
the olefin metathesis substrate the size and conformation of the cycle can be easily 
modified.110,111 
 
2.4 Structure determination of carbohydrates by NMR spectroscopy 
The characterization of the conformational properties of carbohydrates is a significant 
challenge, as they are flexible, and populate multiple (defined) states under physiological 
conditions.112 For flexible molecules, NMR measurements reflect an average contribution of 
all conformations. The individual conformations can be discussed by MD simulations.112 
However, for selected oligosaccharides, structures were reported, which have a defined 
conformation in solution. 54-58,113 
But even for the probably most extensively studied oligosaccharide, the Lex trisaccharide 
epitope, which is assumed to exhibit a rigid conformation in solution (stabilized by different 
factors like the exo-anomeric effect,52,53 hydrophobic interactions of the L-fucose to the β-
face of the D-galactose moiety,114 and steric compression of the N-acetyl group of the D-
GlcNAc residue115) a significant variation in glycosidic torsion angles is reported.54-58 
The elucidation of carbohydrate conformations in solution by NMR spectroscopy is 
challenging due to the tight range of proton resonances between 3 and 4 ppm, which causes 
several overlaps for oligosaccharides. Furthermore, small oligosaccharides show an 
unfavorable tumbling time under physiological conditions, which leads to a NOE 
enhancement factor which is close to zero in nuclear Overhauser effect correlation 
spectroscopy (NOESY) experiments (Figure 6).117 To overcome the problem of signal 
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overlay the use of ultra high field spectrometers with their high resolution are useful.118 The 
unfavorable tumbling time and the resulting poor NOE enhancement factor (Figure 6; Me 
Lex trisaccharide (544 Da) is illustrated as a brown line) can be solved by using rotating 
frame nuclear Overhauser effect correlation spectroscopy (ROESY) experiments, but it has 
the drawback of smaller theoretical ROEs,119 difficulties in qualifying ROESY cross 
peaks117 and chemical shift degeneracy.  
 
 
Figure 6116. Maximal NOE and ROE enhancements calculated for a transient NOE experiment at two different 
field strenghts in D2O.117 The correlations for a NOESY experiment are essentially identical.  
 
When carbohydrates are attached to proteins, an increased NOE transfer is observed, leading 
to improved NOE cross peaks (Figure 6; Lex glycan is illustrated by a red line). Slynko et al. 
could elucidate a well-defined structure of a N-linked heptasaccharide glycan from a 
Camphylobacter jejuni glycoprotein by attaching an unlabeled heptasacccharide to a 13C,15N 
labeled protein using a in vitro glycosylation methods.113 With editing and filtering 
techniques120 they were able to suppress the protein signals and extract numerous NOEs. 
Using these experimental NOEs, they were able to calculate a well-defined conformation of 
the oligosaccharide. The drawback of this method is the limitation for substrates, which are 
accepted by the particular glycosidase. Other carbohydrates and mimics would not be 
recognized by glycosidases. 
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The distance restraints that are used for the structural calculations can be translated from the 
NOE cross peaks assuming a 1/r6 dependence of the peak volume (or in practice the peak 
intensities based on the signal to noise ratios). The distance can be calculated using the 
equation: rref / rx = ( Ix / Iref )-6. rref is the distance of a defined reference signal (for example 
the distance between the H61 and H62 protons in GlcNAc which is 1.77 Å)121 and Iref the 
corresponding signal intensity. rx is the unknown distance and Ix the measured cross peak 
intensity.   
Altogether, NMR spectroscopy can be a useful tool to analyze the solution conformation of 
oligosaccharides, which display a defined structure and also support the development of 
carbohydrate-based mimetics.  
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3.1.  Evaluating the solution conformation of Lewisx, core of lead 
structure sialyl Lewisx 
 
3.1.1 Stabilization of branched oligosaccharides: Lewisx benefits from a 
nonconventional C-H⋅ ⋅ ⋅hydrogen bond 
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Stabilization of Branched Oligosaccharides: Lewisx Beneﬁts from a
Nonconventional C−H···O Hydrogen Bond
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ABSTRACT: Although animal lectins usually show a high degree of speciﬁcity for
glycan structures, their single-site binding aﬃnities are typically weak, a drawback
which is often compensated in biological systems by an oligovalent presentation of
carbohydrate epitopes. For the design of monovalent glycomimetics, structural
information regarding solution and bound conformation of the carbohydrate lead
represents a valuable starting point. In this paper, we focus on the conformation of
the trisaccharide Lex (Gal[Fucα(1−3)]β(1−4)GlcNAc). Mainly because of the
unfavorable tumbling regime, the elucidation of the solution conformation of Lex by
NMR has only been partially successful so far. Lex was therefore attached to a
13C,15N-labeled protein. 13C,15N-ﬁltered NOESY NMR techniques at ultrahigh ﬁeld
allowed increasing the maximal NOE enhancement, resulting in a high number of distance restraints per glycosidic bond and,
consequently, a well-deﬁned structure. In addition to the known contributors to the conformational restriction of the Lex
structure (exoanomeric eﬀect, steric compression induced by the NHAc group adjacent to the linking position of L-fucose, and
the hydrophobic interaction of L-fucose with the β-face of D-galactose), a nonconventional C−H···O hydrogen bond between
H−C(5) of L-fucose and O(5) of D-galactose was identiﬁed. According to quantum mechanical calculations, this C−H···O
hydrogen bond is the most prominent factor in stabilization, contributing 40% of the total stabilization energy. We therefore
propose that the nonconventional hydrogen bond contributing to a reduction of the conformational ﬂexibility of the Lex core
represents a novel element of the glycocode. Its relevance to the stabilization of related branched oligosaccharides is currently
being studied.
■ INTRODUCTION
Selectins are probably the most intensely studied mammalian
carbohydrate binding proteins. First discovered in 1989,1 their
functions as adhesion molecules in the early stages of
inﬂammation are well understood.2 For diseases in which cell
adhesion, extravasation of leukocytes from the bloodstream, or
migration of speciﬁc lymphocytes has been implicated in the
pathology, selectins present an attractive therapeutic target.3
The family of selectins consisting of E-, P-, and L-selectin
recognizes the common carbohydrate epitope sialyl Lewisx
(Neu5Acα(2−3)Galβ(1−4)[Fucα(1−3)]GlcNAc, sLex (1);
Figure 1), which is present in all physiological selectin ligands
identiﬁed so far.4 SLex (1) was therefore regarded as lead
structure for almost 20 years. Countless studies aiming at its
optimization into a druglike mimetic have been reported.5
Although animal lectins usually display a high degree of
speciﬁcity for glycan structures, their single-site binding
aﬃnities are typically weak. This drawback is often
compensated in biological systems by an oligovalent
presentation of the carbohydrate epitopes or the carbohydrate
recognition domains (CRD) of the lectins.6 In addition, the
pharmacokinetic properties of carbohydrates such as bioavail-
ability and plasma half-life are typically insuﬃcient for
therapeutic applications.3 For the design of druglike mimetics
structural information regarding the solution and bound
conformation of the carbohydrate lead represent a valuable
starting point.
The conformation of sLex (1) bound to E- and P-selectin was
ﬁrst elucidated by NMR7 and later conﬁrmed by X-ray
crystallography.8 The analysis of the solution conformation of
Received: May 31, 2013
Published: August 12, 2013
Figure 1. Methyl sialyl Lewisx (sLex, 1) and methyl Lewisx (Lex, 2).
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sLex (1) can be divided into two parts: (i) the conformation of
the Lex core Galβ(1−4)[Fucβ(1−3)]GlcNAc (2) and (ii) the
conformation of the glycosidic bond in Neu5Acα(2−3)Gal
(Figure 1).
In this paper, we focus on the core conformation of Lex (2)
in solution that is stabilized by two distinct factors. First, the
acetyl group of the GlcNAc moiety or equatorial alkyl groups in
the 2-position of carbocyclic GlcNAc mimetics restrict the
conformational ﬂexibility of the core and therefore entropically
improve binding aﬃnities.5,9 Second, the methyl group of L-
fucose is optimally suited to stabilize the Lex core through a
hydrophobic interaction with the β-face of D-galactose.10 This
structural insight into the solution conformation of Lex was
obtained by molecular dynamics simulation (MD) and NMR
spectroscopy,11 as well as X-ray crystallography12 (Figure 2).
While individual MD11a−g and residual dipolar coupling
(RDC)11h,i studies yielded well-deﬁned values for the ϕ/ψ
torsion angles of the two glycosidic bonds of Lex, the total set of
ϕ/ψ values ranges e.g. from −55/120°11h to −93/153°11g for
the glycosidic bond Galβ(1−4)GlcNAc. Therefore, a single
deﬁned solution conformation of Lex (2) could not be obtained
so far. In particular, elucidating the solution conformation of
Lex by NMR was severely hampered by the unfavorable
tumbling regime, the small NOEs of usually performed ROESY
experiments,13 diﬃculties in quantifying ROESY cross-peaks,14
and chemical shift degeneracy. In the case of methyl Lex (2)
(MW 544 Da), the rotational correlation time τc at 293 K is
only 0.41 ns, resulting in a maximal NOE enhancement
between 0.0 and −0.4 for a NOESY experiment (Figure S1,
Supporting Information).14 Therefore, only a small number of
inter-residual distance restraints are observed that are not
suﬃcient to deduce a well-deﬁned structure.14 Finally, for the
two X-ray structures of Lex (2)12 ϕ/ψ torsion angles with
diﬀering values were reported: e.g. −71 and −80° for the ϕ
values of Galβ(1−4)GlcNAc. Diﬀerences in the crystal packing
may explain these deviations.
Slynko et al.15 demonstrated that the covalent attachment of
an oligosaccharide to a protein has the advantage that the NOE
transfer within the carbohydrate is largely enhanced because of
the increase of the overall rotational correlation time. By
attaching an unlabeled oligosaccharide to a 13C,15N-labeled
recombinantly expressed protein, 13C,15N-ﬁltered NOESY
NMR techniques at ultrahigh ﬁeld allowed increasing the
maximal NOE enhancement close to −1 (Figure S1,
Supporting Information), resulting in a high number of
distance restraints per glycosidic bond and consequently a
well-deﬁned structure with a single favored conformation.15
In this paper, we applied this approach to the structural
analysis of Lex chemically linked to a 13C,15N-labeled bacterial
lectin (MW of ∼20 kD). The resulting increase of the
correlation time τc together with the high resolution obtained at
900 MHz enabled the observation of numerous inter-residual
NOEs that could be readily quantiﬁed and converted into
distance restraints. On the basis of the hereby obtained well-
deﬁned solution structure, the stereoelectronic eﬀects respon-
sible for the stabilization of the Lex core structure were analyzed
and are presented within this work.
■ RESULTS
When Lewisx is covalently linked to a protein, the low-
molecular-weight carbohydrate is converted into a large
glycoconjugate with a drastically increased tumbling time and
consequently a more favorable range for the detection of
NOEs. For this purpose, we developed a generally applicable
approach featuring the carbohydrate or a mimic thereof with a
linker that can be chemically coupled to a cysteine of a 13C,15N-
labeled protein (Scheme 1).
For this work, Lex was equipped with a 3-propanolamine
aglycone (→3) and coupled to the carrier protein via a 3-
maleimidobenzoic acid linker (→4). For the protein
component we selected the 13C,15N-labeled bacterial protein
FimH with a Ser78Cys mutation.16
Figure 2. Previously reported Lex structures/substructures: ϕ/ψ angles
of the Fucα(1,3)GlcNAc linkage (a) and the Galβ(1,4)GlcNAc linkage
(b). Torsion angles based on NMR data and MD simulations are
shown in red,11a,e,g−j those of structures based on residual dipolar
coupling (RDC) data in green,11i and those from the crystal structure
of Lex in blue.12 The torsion angles are deﬁned as follows: ϕ, O5−C1−
O1−C′x, ψ, C1−O1−C′x−C′x−1. A detailed list containing angles and
references of all the displayed structures is given in the Supporting
Information (Table S1).
Scheme 1. a
aFor the improvement of the tumbling properties and consequently
the extractable NMR spectroscopic information, low-molecular-weight
Lex (3) was linked to the bacterial protein FimH (→4).
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Ligand Synthesis and Chemical Glycosylation of
Carrier Protein. To link oligosaccharides to carriers, 3-
propanolamine is typically used.17 3-Aminopropanyl Lex (3)
was obtained by glycosylating the GlcNAc derivative 518 ﬁrst
with the L-fucose building block 619 and then, after
deprotection of the 4-position, with the thiogalactoside 920
(Scheme 2). The ﬁrst glycosylation step was promoted by
tetrabutylammonium bromide and copper(II) bromide, yield-
ing the α-fucoside 7 in 77% yield. After the regioselective
cleavage of the benzylidene acetal in 7 using sodium
cyanoborohydride and hydrogen chloride in ether (→8), the
4-hydroxy group of the GlcNAc residue was galactosylated,
giving the protected trisaccharide 10 in 60% yield.
The acetyl groups and the carbobenzoxy protection were
removed by hydrolysis under Zempleń conditions and by
catalytic hydrogenolysis, respectively, giving 3-aminopropyl Lex
(3) in 77% yield.
As linker, we chose 3-maleimidobenzoic acid, because its
rigidity guarantees favorable tumbling properties and its 1H
NMR resonances are located outside the characteristic
carbohydrate ranges. With the bifunctional 3-maleimidobenzoic
acid N-hydroxysuccinimide ester (MBS), coupling with 3-
aminopropyl Lex (3) was performed in DMSO/water to give
maleimide 12 in 62% yield. The ﬁnal step was the coupling to
the S78C mutant of the 13C,15N-labeled bacterial FimH protein
(MW 19.714 kDa). Ser78 was selected for mutation to Cys,
because it is positioned in a solvent-exposed loop connecting
strands D1 and D′ (PDB entry 1TR7).21 The S78C mutant was
expressed as 13C,15N-labeled protein in E. coli BL21(DE3)
strain. Under physiological conditions, the nucleophilic thiol
group of the cysteine residue was conjugated selectively to the
maleimido group of the Lex derivative 12 (Scheme 2; for a
nonreducing SDS-PAGE, MALDI-TOF-MS data and a 1H,15N-
HSQC spectrum of the glycoconjugate see Figures S2 and S3 in
the Supporting Information). Although the Michael addition
proceeded only to approximately 50%, separation of the
glycoconjugate 4 from the unreacted FimH protein was not
necessary, because unreacted protein did not disturb the NMR
measurements of the carbohydrate.
Extracting Carbohydrate Distance Restraints by NMR
Spectroscopy. Similar to our study with the bacterial
glycoprotein AcrA,15 we used the 13C,15N-labeled glycoprotein
(see above) linked to unlabeled carbohydrate to detect
distance-related NOE cross-peaks within the carbohydrate by
recording 2D 13C F1-ﬁltered F2-ﬁltered NOESY22 (in D2O)
and 2D 15N F1-ﬁltered F2-ﬁltered NOESY15 spectra (in H2O)
(Figure 3a,b). In these types of NOESY experiments, the
signals of the 13C,15N-labeled protein are suppressed, resulting
in spectra containing only resonances of the unlabeled
carbohydrate and the linker. To obtain maximal resolution,
spectra were recorded at 900 MHz. The assignment of Lex
resonances was basically identical with that of free Lex (3),
which was conﬁrmed by 2D 13C F1-ﬁltered TOCSY and
1H,13C-HSQC spectra (Figure S4, Supporting Information).
Since no carbohydrate−protein NOE cross-peaks were present
Scheme 2. Synthesis of Lex Equipped with a Linker and Its
Coupling to the Carrier Protein, the FimH S78C Mutanta
a:Legend: (a) TBAB, CuBr2, 4 Å molecular sieves, DCM/DMF, 77%;
(b) NaBH3(CN), HCl, THF, 85%; (c) DMTST, 4 Å molecular sieves,
DCM, 60%; (d) NaOMe, MeOH; (e) Pd(OH)2, H2, DCM/MeOH/
H2O/AcOH, 77% over two steps; (f) 3-maleimidobenzoic acid N-
hydroxy-succinimide ester (MBS), DMSO, H2O, 62%; (g)
13C,15N-
labeled S78C FimH mutant protein, 37 °C, 15 h, sodium phosphate
buﬀer.
Figure 3. NOE cross-peaks between protons of the Lex trisaccharide:
(a) 15N ﬁltered-ﬁltered 2D NOESY recorded with 96 scans in 16 h;
(b) 13C ﬁltered-ﬁltered 2D NOESY recorded with 96 scans in 16 h for
Lex-FimH (4); (c) schematic overview of interresidual NOEs of Lex-
FimH (4) (red arrows) and the free Me Lex (2) (blue arrows).
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in the 2D 13C F2-ﬁltered NOESY experiment, the carbohydrate
moiety was assumed not to interact with the protein surface. As
a result, we could extract 24 unambiguous NOE cross-peaks
between various nonexchangeable protons (CHx) from a 2D
13C F1-ﬁltered F2-ﬁltered NOESY and 4 unambiguous NOE
cross-peaks between the exchangeable HN amide of the
acetamido group and proximal nonexchangeable protons from
a 2D 15N F1-ﬁltered F2-ﬁltered NOESY (Table S2, Supporting
Information).
To evaluate the improvement resulting from the increased
tumbling time, we compared 2D ﬁltered-ﬁltered NOESY
spectra of Lex attached to FimH (Lex-FimH (4)) with 2D
NOESY spectra of free methyl Lex (2) measured at 293 K. Due
to the unfavorable tumbling time of free Lex (2) most NOE
cross-peaks are either absent or very weak, even though the 2D
NOESY pulse sequence lacks the ﬁlter elements and hence is
more sensitive. Whereas 28 NOEs were observed for Lex-FimH
(4), only 9 NOEs were detected for the free Lex (2) (Table S2,
Supporting Information). The inter-residual NOE restraints
that are of particular importance for conformational studies are
shown schematically in Figure 3c and are summarized in Table
1. For Lex-FimH (4), 9 inter-residual restraints could be
detected, in contrast to 3 for the free Lex (2).
Solution Conformations of 2 and 4. With the help of
NOE distance restraints, the structural ensembles of Lex were
calculated using Cyana23 with subsequent reﬁnement by
Amber24a applying the GLYCAM06 force ﬁeld24b (Figure 4;
see Table S3 in the Supporting Information for NMR structure
determination statistics). From the 28 NOE restraints for Lex-
FimH (4) a well-deﬁned structural ensemble with narrow
distributions of the glycosidic torsion angles was obtained
(Figure 4a and Figure S5 (Supporting Information)). Figure 4b
shows a representative structure of this ensemble and Table S4
(Supporting Information) the corresponding 1H−1H distances.
In contrast, the structural ensemble of methyl Lex (2)
calculated from only 9 restraints displayed a considerable
scattering of torsion angles (Figure S6 in the Supporting
Information). Obviously, the obtained NOE restraints were not
suﬃcient to calculate an ensemble structure with high precision
(Figure 4c).
We then compared our structure model of Lex with those
reported from previous studies (Figure S7 in the Supporting
Information), namely the crystal structure of methyl Lex (2),12
protein structures containing Lex as ligand or as part of their
glycosylation,25 earlier solution structures obtained by residual
dipolar couplings, limited NOEs, and molecular modeling
(MD).11a,e,g−j We observed a high agreement of the glycosidic
torsion angles from our solution structure with those of the
crystal structure of methyl Lex (2)12 and some Lex structures
determined by NMR spectroscopy in combination with
MD,11a,h conﬁrming that the structures are identical and
accurate. Deviation among these conﬁrmations are of the same
order as that between the two Lex molecules in the asymmetric
unit cell of the methyl Lex (2) crystal structure.12
What Stabilizes the Lex Structure? We hypothesized that
the stabilization of the Lex conformation originates from the
interface between the stacked fucose and galactose moieties.
Previously, it was suggested that hydrophobic interactions
between the two moieties as well as steric eﬀects of the
acetamido group of GlcNAc both contributed to the increased
stability of the conformation.26,27 Since such interactions
should lead to changes of the chemical shifts in comparison
to the corresponding, unstacked disaccharides, we measured the
chemical shifts of Fucα(1−3)GlcNAcβ-OMe and Galβ(1−
4)GlcNAcβ-O-(CH2)3NH2
28 and compared them to those of
methyl Lex (2) (see Table 2 and Table S5 (Supporting
Information)). The expected hydrophobic interactions between
H6 of L-Fuc and H2 of D-Gal are not reﬂected in the shifts with
deviations of only 0.01 and 0.05 ppm, respectively. However,
another proton at the stacking interface exhibits a dramatic
chemical shift change: H5 of L-Fuc resonates at 4.33 ppm in
Fucα(1−3)GlcNAcβ-OMe and at 4.83 ppm in methyl Lex (2),
resulting in a diﬀerence in the chemical shift of 0.50 ppm (at
293 K). Furthermore, the NMR shifts calculated for the
optimized stacked geometry (Table 2; Table S5 (Supporting
Information)) are in excellent agreement with the experimental
data, thus supporting the experimental NMR conformation.
A close inspection of the structure ensemble of Lex-FimH (4)
reveals that the C5−H5 bond of L-Fuc points toward O5 of D-
Gal. The H5−O5 distance in the ensemble is 2.50 ± 0.01 Å.
The sum of the corresponding van der Waals radii is 2.61 Å,32
indicating the presence of a C−H···O hydrogen bond. C5−O5
distances of 3.55−3.58 Å in the ensemble are also slightly
shorter than the distance expected for the corresponding van
der Waals separation (3.71 Å). The large H5 chemical shift
deviation is a strong indication for such a nonconventional
Table 1. Inter-Residual NOEs of Lex-FimH (4) and Me Lex
(2) at 293 K and Their Corresponding Distances
Lex-FimH (4) methyl Lex (2)
proton pair
S/N of NOE
cross-peaks
1H−1H
distance
(Å)
S/N of NOE
cross-peaks
1H−1H
distance
(Å)
Inter-Residual NOEs
Gal H1-
GlcNAc H4
910 2.3a 206 2.6a
Gal H1-
GlcNAc
H62
438 2.6a 206c 2.6a
Gal H1-
GlcNAc
H61
795 2.4a 226 2.5a
Gal H2-Fuc
H5
209c 3.0a
Gal H2-Fuc
Q6
939c 2.8a,b
Gal H6-Fuc
H3
718c 2.7a,b
GlcNAc H3-
Fuc H1
286c 2.8a
GlcNAc Q8-
Fuc H1
142 3.8a,b
GlcNAc
HN2-Fuc
H1
129 3.2a
Intra-residual NOEs for Calibration
GlcNAc
H61−H62
1004c 1.77d 3209c 1.77d
GlcNAc
H61−H62
4577 1.77e 1837c 1.77d
aThe 1H−1H distances were calculated from experimentally obtained
NOE intensities. The H61−H62 cross-peak of GlcNAc was used as a
reference with a distance of 1.77 Å and assuming a r−6 dependence of
the NOE intensities. For the structure calculations the distances
reported in this table were increased by a 0.5 Å tolerance and used as
upper limit distance restraints. bSignal to noise ratios (S/N) from
cross-peaks involving methyl or methylene protons were divided by 3
or 2, respectively. cOnly one cross-peak was used because of artifacts
or overlap. dReference restraint for the 15N-ﬁltered-ﬁltered 2D
NOESY. eReference restraint for the 13C-ﬁltered-ﬁltered 2D NOESY.
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hydrogen bond.33 The C−H···O hydrogen bond locks the Lex
conformation, resulting in a narrow cluster of ϕ/ψ torsion
angles. Although C−H···O hydrogen bonds are only about half
as strong as “classical” O−H···O hydrogen bonds, they are
widespread and presumably represent 20−25% of the total
number of hydrogen bonds in protein structures.34 To our
knowledge, intramolecular C−H···O hydrogen bonds have not
been explicitly reported in carbohydrate solution structures so
far, in particular not in the context of stabilizing a certain
conformation. However, during his studies of the solution
conformation of Leb in 1989, Lemieux proposed that hydrogen
atoms in van der Waals contact with oxygen atoms of diﬀerent
sugar units are the reason for the conformational preferences.35
In the crystal structures of methyl Lex (2)12 and most of the
glycoproteins containing Lex as part of their glycosylation or as
ligand, a nonconventional C−H···O hydrogen bond can be
identiﬁed (Table 3) but have remained unnoticed so far. The
distance between C5 of L-Fuc and O5 of D-Gal varies between
3.21 and 3.78 Å in crystal structures in comparison to 3.56 ±
0.01 Å in our solution structure. We assume that the observed
deviations result from using diﬀerent force ﬁelds for structure
reﬁnement that prevent too close contacts by applying a van
der Waals repulsion term. It is therefore not surprising that the
smallest distances between C5 of L-Fuc and O5 of D-Gal,
namely 3.269 and 3.304 Å, were obtained from the crystal
structure of methyl Lex (2), where direct assignment methods
instead of force ﬁeld calculations were applied.12 We therefore
consider this structure as the most reliable with regard to the
C−H···O hydrogen bond stabilizing Lex. Other structures
reported so far were determined by MD and NMR methods,
and thus their ϕ/ψ glycosidic torsion angles are biased by the
van der Waals repulsion terms in the applied force ﬁelds.
Computational Analysis. The structure based on distance
restraints determined by NMR relied on the force ﬁeld
GLYCAM, which does not include any specialized terms for
C−H···O hydrogen bonding interactions but instead uses the
Lennard−Jones potential function to keep atoms at ideal
distances given by the sum of their van der Waals radii.
Therefore, geometry optimization in the solvent phase using
the density functional theory (DFT)36 and ONIOM-
(MP2:HF)37 quantum chemical methods was used to reﬁne
the geometry. The ab initio optimization led to a shortening of
the distance between H5 of L-Fuc and O5 of D-Gal typical for a
C−H···O hydrogen bond (Table S6, Supporting Information).
The resulting interatomic distances were in good agreement
with structural parameters observed in the crystal structure of
Lex.12
The DFT36 optimized conformation served as starting point
for a series of single point quantum mechanical calculations
aimed at the quantiﬁcation of the stacking interaction (Figure
Figure 4. Calculated and reﬁned structural ensembles of Lex at 293 K
using NOE restraints: (a) Lex-FimH (4); (b) a representative structure
thereof; (c) methyl Lex (2).
Table 2. Experimental and Calculateda Chemical Shifts
(ppm) of Selected Lex Protons at the Interface between
Fucose and Galactose and Deviation from the Shifts of
Fucα(1-3)GlcNAc and Galβ(1-4)GlcNAc
exptl calcd
proton Lex
Δδ(Lex-
Fucα(1−
3)
GlcNAc)
Δδ(Lex-
Galβ(1−
4)
GlcNAc) Lex
Δδ(Lex-
Fucα(1−
3)
GlcNAc)
Δδ(Lex-
Galβ(1−
4)
GlcNAc)
H3 of
L-Fuc
3.90 0.08 3.90 −0.02
H4 of
L-Fuc
3.79 −0.01 3.66 0.05
H5 of
L-Fuc
4.84 0.51 4.90 0.83
CH3 of
L-Fuc
1.18 0.01 1.13 −0.05
H2 of
D-Gal
3.50 0.04 3.64 0.04
aCalculated using B3LYP/6-31G(d,p) in water with the polarizable
conductor calculation model (CPCM).29
Table 3. Distance between C5 of L-Fuc and O5 of D-Gal in
Lex Crystal Structures with a Resolution <3.0 Å
glycan
PDBa or
CSDb code
resolution
(Å)
reﬁnement
method
Fuc C5−
Gal O5
distance
(Å) ref
Me Lex (2) ABUCEFb direct 3.269 12
3.304
Me Lex (2) 1UZ8a 1.8 Refmac 5.2 3.465 25a
3.312
Lex-β(1−3)
Gal
1SL5a 1.7 CNS 1.1 3.741 25b
Lex-β(1−3)
Galβ(1−4)
Glc
3AP9a 1.33 Refmac 5.5 3.778 25d
2OX9a 1.95 CNS 1.1 3.210 25c
3.329
3.289
3.352
Siaα(2−3)Lex-
OMe
1G1Ta 1.5 CNS 3.434 30
Siaα(2−3)Lex-
OMe
2KMBa 2.0 X-PLOR
3.54
3.350 31
3.256
3.343
Siaα(2−3)Lex-
β(1−3Gal)-
β(1−4)
GalNAc-Thr
1G1Sa 1.9 CNS 3.380 30
3.374
aPDB (Protein Data Bank). bCSD (Cambridge Structural Database).
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5). The C−H···O hydrogen bond between C5−H5 of L-Fuc
and O5 of D-Gal seems to be the most prominent factor in
stabilization, corresponding to almost 40% of the total
stabilization energy as calculated at the MP2/aug-cc-pVQZ
level including counterpoise correction (1.76 out of 4.52 kcal/
mol, Table S7, Supporting Information). For comparison, the
contribution of the C6 methyl group of L-Fuc toward
stabilization is only 0.5 kcal/mol (compare model systems A
and B, Figure 5). The calculated energy proﬁle for a typical C−
H···O hydrogen bonding interaction in carbohydrates (Figure
S8, Supporting Information) indicates an optimal H···O
distance between 2.35 and 2.45 Å, which is in excellent
agreement with the distance observed in the Lex crystal
structure,12 with the DFT optimized conformation (2.33 Å),
and also with statistical averages derived from neutron
diﬀraction crystal structures.38 On the basis of calculations at
the highest level (MP2/aug-cc-pVQZ), the C−H···O hydrogen
bond interaction energy at an optimal distance (2.4 Å) results
in a value between 1.72 (value corrected for BSEE) and 1.98
kcal/mol (value without correction). The presence of the
intramolecular C−H···O hydrogen bond was conﬁrmed also by
localizing the bond critical point (Figure S9, Supporting
Information) on the basis of the quantum theory of atoms in
molecules.39,40
■ DISCUSSION
In general, it is assumed that oligosaccharides are highly ﬂexible
and conformational restriction results predominantly from the
exoanomeric eﬀect41 and in special cases from steric eﬀects and
hydrophobic contacts.26,42 For the trisaccharide Lex, for
example, it could be demonstrated that two factors, the steric
eﬀect induced by the NHAc group adjacent to the linking
position of L-fucose and the hydrophobic interaction of L-fucose
with the β-face of D-galactose, are responsible for its low
conformational ﬂexibility.11,12 In the present communication, a
nonconventional C−H···O hydrogen bond33 between H−C(5)
of L-fucose and O(5) of D-galactose was identiﬁed as an
additional factor. This nonconventional C−H···O hydrogen
bond contributes to a reduction of the conformational ﬂexibility
and exhibits a novel dimension of the glycocode.43 We
speculate that such interactions are widespread among
glycoepitopes in mammalians. A corresponding inspection of
structures from the PDB is currently being performed.
Finally, the presented results uncovered a weakness of
approaches based on molecular mechanics in being unable to
produce an accurate geometry of C−H···O hydrogen bonds
due to van der Waals repulsion terms and to correctly evaluate
its energetic contribution. In our model glycan Lex such a bond
contributes 40% to the stabilization of the 3D structure: i.e., a
major contribution that should not be neglected. These results
therefore potentially challenge the results of molecular
modeling studies of carbohydrates. Our quantum mechanical
calculations, the X-ray crystal structure of Lex, and a statistical
analysis of neutron diﬀraction studies of carbohydrates revealed
the geometry of a typical C−H···O hydrogen bond in
carbohydrates.38 This information will help to develop more
accurate force ﬁelds for carbohydrates in the future.
■ EXPERIMENTAL METHODS
Commercially Available Carbohydrates. Methyl Lex (Galβ1,4-
[Fucβ1,3]GlcNAcβOMe) and the disaccaride Fucα1,3GlcNAcβOMe
were purchased from Carbosynth/UK.
Protein Expression and Puriﬁcation. All plasmids, bacterial
strains, and DNA primers are given in Table S8 (Supporting
Information). The plasmid pDsbA3 containing the carbohydrate
recognition domain of the bacterial adhesin FimH linked to a 6His
Tag (FimH-CRD-6His)44 was used to generate the FimH-CRD-6His
S78C mutant by site-directed mutagenesis.45 The mutation was
conﬁrmed by double-strand DNA sequencing (Microsynth, Galbach,
Switzerland). For uniform 13C/15N- labeling E. coli BL21(DE3) cells
harboring the FimH-CRD-6His (S78C) encoding plasmid were
cultivated in M9 minimal medium46 supplemented with 1% (v/v) of
Basal Medium Eagle vitamin mix solution (Sigma, Buchs, Switzerland)
and 100 μg/mL of ampicillin (Applichem, Baden-Daẗtwil, Switzerland)
overnight at 37 °C and 300 rpm. Cells were centrifuged, washed with
fresh M9 minimal medium, and further cultivated in M9 minimal
medium without glucose and ammonium chloride for 2 h. The cells
were centrifuged for 5 min at 5000 rpm, and the pellet was
resuspended in 1 L M9 minimal medium containing 13C6-glucose (2
g/L), 15N-ammonium chloride (1 g/L) and 1% (v/v) Basal Medium
Eagle (BME) vitamin mix solution. The cells were allowed to grow to
an OD600 of 0.8 followed by the addition of IPTG at a ﬁnal
concentration of 1 mM and further cultivated at 30 °C and 160 rpm
for 14 h. FimH-CRD-6His (S78C) was then extracted from the
periplasmic space and puriﬁed on a Ni-NTA column as described
previously.44 The purity of the protein was veriﬁed by SDS-PAGE
analysis, and the quantity (6.7 mg) was determined by HPLC47 using
BSA as standard.
FimH-Lex Glycoprotein (4). A mixture of the 13C,15N-labeled
FimH mutant (5.7 mg, 0.29 nmol) and maleimide 12 (13.4 mg, 17.1
μmol) was dissolved in 2 mL of phosphate buﬀer (pH 7, 50 mM) and
shaken (650 rpm) at 37 °C for 16 h. The mixture was lyophilized and
puriﬁed by dialysis and ultraﬁltation. The resulting mixture of protein
and glycoprotein 4 was analyzed by SDS-PAGE and MALDI-TOF MS
(Figure S2, Supporting Information).
NMR Spectroscopy of Carbohydrates, Proteins, and Glyco-
proteins. All NMR spectra were aquired on Bruker Avance or Avance
III spectometers equipped with triple-resonance cryogenic probes at a
ﬁeld strength of 500 or 900 MHz and a temperature of 293 K. The
glycoprotein sample was dialyzed against water and enriched to a
concentration of 0.5 mM using a centricon ﬁler unit (Vivaspin,
Sartorius stedim, Goettingen, Germany, 10 kDa cutoﬀ). Samples were
prepared in either 93% H2O/7% D2O or 100% D2O using
lyophilization for the preparation of the latter. 2D 13C F1-ﬁltered
F2-ﬁltered NOESY22 and 2D 15N F1-ﬁltered F2-ﬁltered NOESY
Figure 5. Model systems (A) 1-deoxy-galactose/1-deoxy-fucose, (B)
1-deoxy-galactose/1-deoxy-arabinose, (C) Me-OMe/Me-O-iPr, and
(D) Me-OMe/Me-O-Et and the corresponding stabilization energies
(Es in kcal/mol).
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spectra15 were recorded with a mixing time of 150 ms in D2O and
H2O/D2O, respectively, to obtain NOEs of the unlabeled glycan. At
this mixing time the NOE build-up curves are assumed to be in the
linear slope regions, where contributions from spin diﬀusion can be
neglected.15 For the assignment of the free sugars, 1H−13C HSQC,
long-range 1H−13C HSQC, 1H−13C HMQC−COSY, and 2D TOCSY
spectra were recorded.
Spectra were acquired and processed using Topspin 2.1 (Bruker)
and analyzed with the software Sparky (T. D. Goddard and D. G.
Kneller, SPARKY 3, University of California, San Francisco). Spectra
were referenced to DSS by an external sample of 2 mM sucrose/0.5
mM DSS (Bruker standard).
Structure Calculation and Reﬁnement. The structural template
of methyl Lex was generated using the Biomolecular Builder on the
GLYCAM Web site (Woods Group. (2005−2012) GLYCAM Web.
Complex Carbohydrate Research Center, University of Georgia,
Athens, GA; http://www.glycam.com). Initial structures were
calculated using CYANA 3.0.23 Signal to noise (S/N) ratios of all
NOE signals were extracted using the program Sparky (T. D. Goddard
and D. G. Kneller, SPARKY 3, University of California, San Francisco)
and converted to distances using the r−6 dependence and the GlcNAc
H61−H62 cross-peaks (1.77 Å) as reference. S/N ratios of signals
involving CH2 and CH3 groups were divided by a factor of 2 or 3,
respectively. Upper limit restraints with an additional tolerance of 0.5
Å were applied. Out of 200 structures, the 30 structures with the
lowest target function were further reﬁned in AMBER 924a applying
the Glycam06 force ﬁeld.24b A generalized Born model48 was used to
mimic solvent.
Calculation of 1H Chemical Shifts. The geometry of the NMR-
derived stacked conformation of Lex was optimized using the density
functional theory (DFT)36 method at the B3LYP/6-31G(d,p) level of
theory.49 Solvent eﬀects were accounted for using the CPCM model
(implicit solvation model).29 The NMR shielding tensors were
calculated using the gauge-independent atomic orbital (GIAO)50
method. Absolute values of shifts were adjusted relative to
tetramethylsilane (its structure was fully optimized in solvent and an
NMR spectrum was calculated using the same level of theory). The
same settings were used for calculating shifts of the disaccharides. At
the optimized geometry vibrational mode analysis was performed to
conﬁrm the stability of the obtained minimum. No imaginary
frequencies were found. All ab initio geometry optimizations and
spectral calculations were performed using Gaussian 09.51
Detailed Computational Analysis. As the DFT36 methods are
known to underestimate the ﬁne dispersion interaction that might play
an important role in stacking interaction of the two sugar units, a
calculation including electron correlation (second-order Møller−
Plesset perturbation theory, MP2)52 was performed for comparison.
Methyl Lex (2; C21H37NO15) consists of 37 heavy atoms. Due to
computational costs this hampers the use of large basis set and
electron correlation for all atoms. Therefore, a geometry optimization
run was set up for a two-layer ONIOM method. Parts of the Lex
molecule with the greatest impact on the stacking interaction (i.e., L-
Fuc and D-Gal) were treated at the MP2/6-31G(d,p) level, while a
smaller basis set along with a substantially less demanding level of
theoryHF/6-31G(d)was applied to the remaining part that has a
small impact on the stacking interaction. For more details on the
assignment of atoms to layers, see Figure S10 (Supporting
Information).
Accurate Evaluation of Stacking Interaction. In order to better
understand the nature and extent of stabilization between fucose and
galactose in the stacked conformation, several high-level calculations
were performed on simpliﬁed model systems. From the fully
minimized structure obtained at the B3LYP/6-31G(d,p) CPCM29
level, coordinates of fucose and galactose units were extracted and the
OH groups at C1 of both units were replaced by hydrogen atoms. The
interaction energy was then calculated as a diﬀerence of three single-
point calculations (1-deoxyfucose, 1-deoxygalactose, and their stacked
“complex”) in the gas phase at the MP2 level with 6-311++G(d,p),
aug-cc-pVTZ, and aug-cc-pVQZ basis sets with counterpoise
correction (CP)53 in order to remove the error caused by the basis
set superposition (BSSE). For comparison a calculation using the
OPLS-2005 force ﬁeld was performed using the very same model
system.
Accurate Evaluation of the C−H···O Hydrogen Bond. The
model system for studying the C−H···O hydrogen bond between the
two sugar units was constructed by extracting coordinates of C1, O5,
C4, C5, C6 and attached hydrogen atoms of the fucose (isopropyl
methyl ether) and C1, O5, C5 and attached hydrogen atoms of the
galactose (dimethyl ether). The same methodology as that used for the
evaluation of the stacking interaction was employed (Table S7,
Supporting Information).
Energy Proﬁle of the C−H···O Hydrogen Bond. The model
system for the C−H···O hydrogen bond was used to obtain the energy
proﬁle of the C−H···O hydrogen bond as a function of the H···O
distance. The interacting partners (iPro-O-Me and Me-O-Me) were
aligned to an assumed ideal geometry (angle C−H···O set to full linear
at 180°, H→O vector set at Me-O-Me angle axis with 35° deviation
from the plane; see Figure S8 (Supporting Information)). The energy
proﬁle was obtained from a series of single-point calculations at the
MP2 level with diﬀerent correlation consistent basis sets and CP
correction. The less computationally demanding level MP2/aug-cc-
pVTZ was used to obtain a proﬁle over a larger range of distances,
while the best applicable level MP2/aug-cc-pVQZ was used to
precisely localize the potential minimum in terms of preferred
interatomic distance and interaction energy.
C−H···O Bond Critical Point. The molecular wave function of Lex
obtained at the B3LYP/6-31G(d,p) level was exported to the program
AIMAll,54 which was used to localize the bond critical points on the
basis of the quantum theory of atoms in molecules.39,40
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Supplementary Figures 
 
 
 
Figure S1. Maximal NOE and ROE enhancements calculated for a transient NOE experiment at two different field 
strengths in D2O.[S1] !
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 S3 
 
 
Figure S2. a.) SDS-PAGE analysis of unmodified and glycosylated uniformly 13C,15N-labeled S78C-FimH. The 
glycosylated samples contained also unmodified protein, however this does not effect the measurements as the 
protein signals are suppressed in the NMR experiments. b.) MALDI-TOF MS analysis of the glycosylated uniformly 
13C,15N-labeled S78C-FimH.!
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 S4 
 
 
Figure S3. 1H15N-HSQC spectrum of the glycosylated 13C,15N-labeled S78C-FimH (0.7 mM in 93% H2O/7% D2O) 
recorded at 900 MHz and 293K with 2 scans and 256 increments.!
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Figure S4. 1H13C-HSQC spectra of the glycosylated 13C,15N-labeled S78C-FimH (red) and the free Lex trisaccharide 
(blue). Spectra were recorded at 500 MHz and 293 K with 8 scans and 512 increments or 4 scans and 400 
increments, respectively. The concentrations of the glycosylated protein and the trisaccharide were 0.7 mM and 12 
mM, respectively (both in D2O). 
!
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 S6 
 
Figure S5. Phi-psi plots of the solution structure of Lex (attached to FimH) superimposed with all entries in the PDB 
database containing the corresponding saccharide linkages are displayed in the upper panel whereas the bottom 
panel shows superimpositions on energy landscapes. Plots were generated with the software CARP.[S2] Angles of the 
presented structural ensemble of Lex consisting of 20 structures are designated by red crosses. The angles phi and psi 
are defined as H1-C1-O1-C'x and C1-O1-C'x-H'x, respectively. 
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Figure S6. phi-psi plots of the solution structure of methyl Lex (2) based on a 2D NOESY experiment. Note that 
these data were insufficient to derive a well-defined structure due to the unfavorable tumbling time. 
Superimpositions of phi-psi angles of all entries in the PDB database for a given linkage are shown in the upper 
panel whereas the bottom panel shows overlays on energy landscapes. Plots were generated with the software 
CARP.[S2] Angles of 20 structures are shown by red crosses. The angles phi and psi are defined as H1-C1-O1-C'x 
and C1-O1-C'x-H'x, respectively. 
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Figure S7. Comparison of glycosidic angles of the obtained NMR ensemble with previously reported Lex 
structures/substructures. φ/ψ-angles of the Fucα(1,3)GlcNAc linkage (a) and Galβ(1,4)GlcNAc linkage (b). Torsion 
angles of the here presented NMR ensemble are shown in black, angles of structures based on other NMR data and 
MD simulations are shown in red, of structures based on RDC data in green, and from the crystal structure of Lex in 
blue (see Table S1). The torsion angles are defined as follows: φ O5–C1–O1–C'x, ψ C1–O1–C'x–C'x-1. 
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Figure S8. Schematic representation of the model system for quantification of the non-conventional C-H⋅⋅⋅O 
hydrogen bond between H5 of L-fucose (resembling an isopropyl methyl ether) and O5 of D-galactose (resembling 
a dimethyl ether) of Lex and corresponding energy potential curves as a function of the interatomic distance dH⋅⋅⋅O 
(α = 35°). 
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Figure S9. Stereo view of the bond critical point (signature: 3,-1; density ρb = 0.01327 au; displayed as a blue 
sphere) identified for the C-H⋅⋅⋅O hydrogen bond between C5-H5 of L-Fuc and O5 of D-Gal of Me Lex (2) based on 
the B3LYP/6-31G(d,p) wavefunction. 
 
 
 
Figure S10. Stereo view of methyl Lex (2) optimized using the ONIOM method.[S3] Atoms displayed as balls and 
sticks were assigned to the high layer and atoms displayed as thin sticks were assigned in the low layer. 
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Supplementary Tables 
Table S1. Glycosidic torsion angles of Lex structures obtained by X-ray crystallography, NMR spectroscopy (NOE, 
ROE or RDC) and molecular modeling (MD). 
 
Method Fucα1,3GlcNAc torsion angles a,b Galβ1,4GlcNAc torsion angles a,b Reference 
 phi IUPAC 
[°] 
psi IUPAC 
[°] 
phi NMR 
[°] 
psi NMR 
[°] 
phi IUPAC 
[°] 
psi IUPAC 
[°] 
phi NMR 
[°] 
psi NMR 
[°] 
 
X-ray 
(ABUCEF) 
-72.4 -102.8 40.4 20.9 -80.1 136.7 36.3 14.8 [S4] 
 -76.7 -101.7 35.4 20.8 -70.5 134.0 44.3 15.5 [S4] 
RDC (Lex) -73.1 -90.5 (46.9) (29.5) -66.3 135.0 (53.7) (15.0) [S5] 
RDC (LNF-3) -67.6 -87.4 (52.4) (32.6) -70.8 134.6 (49.2) (14.6) [S5] 
RDC+NOE 
(LNF-3) 
-40.0 -90.0 (80.0) (30.0) -65.0 114.0 (55.0) (-6.0) [S5] 
MD -81.0 -89.0 (39.0) (31.0) -75.0 136.0 (45.0) (16.0) [S5] 
SIMNOE -45.0 -95.0 (75.0) (25.0) -55.0 120.0 (65.0) (0.0) [S6] 
MD -59.0 -88.0 (61.0) (32.0) -61.0 128.0 (59.0) (8.0) [S6] 
MD -64.0 -88.0 (56.0) (32.0) -64.0 128.0 (56.0) (8.0) [S6] 
MD+NOE -45.0 -96.0 (75.0) (24.0) -57.0 122.0 (63.0) (2.0) [S6] 
MD+NOE -83.0 -97.0 (37.0) (23.0) -65.0 132.0 (55.0) (12.00 [S6] 
MD+ROE -57.8 -84.0 (62.2) (36.0) -66.2 120.2 (53.8) (0.2) [S7] 
MD+ROE (-86.8) (-98.1) 33.20 21.90 (-92.9) (153.4) 27.10 33.40 [S8] 
MD+ROE (-72.0) (-96.0) 48.00 24.00 (-66.0) (129.0) 54.00 9.00 [S9] 
MD -81.3 (-89.3) (38.7) (30.7) -74.9 (136.4) (45.1) (16.4) [S10] 
          
NOE (present 
work) 
-71.1 ±0.9 -98.4 ±0.5 47.7±1.0 22.0±0.6 -67.0±1.1 127.6±0.8 52.5±1.3 8.1±0.8  
 
a) The glycosidic torsion angles phi and psi (IUPAC) are defined as O5-C1-O1-C'x and C1-O1-C'x-C'x-1, 
respectively. The NMR definition for the glycosidic torsion angles phi and psi is H1-C1-O1-C'x and C1-O1-C'x-
H'x, respectively. 
b) Values in brackets were interconverted between IUPAC nomenclature and NMR nomenclature by 
adding/subtracting 120°.  
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Table S2. Intra- and inter-residual NOEs of Lex attached to FimH (4) and Lex O-methylglycoside (2) at 293 K and 
900 MHz and the corresponding distances. 
 Lex attached to FimH (4)  Me Lex (2) (free) 
proton pair average S/N of NOEs cross peaks 
Corresponding 
1H-1H distanceb 
[Å] 
 average S/N of NOEs cross peaks 
Corresponding 
1H-1H distanceb 
[Å] 
intra      
Gal H1-H2 903 2.3f    
Gal H1-H3 710 2.4  146 1.7 
Gal H1-H5 1142 2.2  290a 2.4 
Gal H2-H3 2448a 2.0f    
Gal H3-H4 1581a 2.1    
Gal H4-H5 1577a 2.1    
GlcNAc H1-H3 207 3.0f    
GlcNAc H1-H5 474 2.6  290a 2.4 
GlcNAc H2-Q8 75a 4.2e    
GlcNAc H5-H62 435 2.6  192a 2.6 
GlcNAc H61-H62c 1004a 1.77  3209a 1.77!
GlcNAc H61-H62d 4577 1.77  1837a 1.77 
Fuc H1-H2 800 2.4  186 2.6 
Fuc H1-Q6 106a 4.0e    
Fuc H3-H5 253a 2.9    
Fuc H4-H5 590a 2.5  178 2.6 
Fuc H4-Q6 1357a 2.6e    
Fuc H5-Q6 844a 2.8e    
GlcNAc H1-HN2 60a 3.6    
GlcNAc H3-HN2 72a 3.5    
GlcNAc Q8-HN2 115a 3.9e    
inter      
Gal H1 - GlcNAc H4 910 2.3  206 2.6 
Gal H1 - GlcNAc H62 438 2.6  206a 2.6 
Gal H1 - GlcNAc H61 795 2.4  226 2.5 
Gal H2 - Fuc H5 209a 3.0    
Gal H2 - Fuc Q6 939a 2.8e    
Gal Q6 - Fuc H3 718a 2.7e    
GlcNAc H3 - Fuc H1 286a 2.8    
GlcNAc Q8 - Fuc H1 142 3.8e    
GlcNAc HN2 - Fuc H1 129 3.2    
a) Only one cross-peak was used because of artifacts or sever spectral overlap.  
b) The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H61-H62 cross-
peak of GlcNAc as a reference with a distance of 1.77 Å assuming a 1/r6 dependence of the NOE intensities. For 
the structure calculations the herein reported distances were increased by 0.5 Å tolerance and used as upper limit 
restraints. 
c) Reference restraints for the 15N-filtered-filtered NOESY.  
d) Reference restraints for the 13C-filtered-filtered NOESY.  
e) Based on signal to noise ratios from cross-peaks involving methyl or methylene protons that were divided by 3 
and 2, respectively, due to their number of protons.  
f) The tolerance of these distances was increased by 1 Å.!
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Table S3. NMR structure determination statistics of Lex attached to FimH (4), modeled as Lex O-methylglycoside 
(2)  
 Lex attached to FimH (4) Me Lex (2), free (insufficient 
restraints) 
NMR distance and dihedral restraints   
Total NOE restraints 28 9 
   Intra-residue 19 6 
   Inter-residue 9 3 
   Sequential (|i – j| = 1) 6 3 
   Nonsequential (|i – j| > 1 ) 3 0 
   Hydrogen bonds 0 0 
Total dihedral angle restraints 0 0 
   HN-CO peptide bonds of acetamido 0 0 
   Sugar pucker 0 0 
   
Structure statistics *   
Violations (mean and s.d.)   
   Number of distance constraint violations > 0.1 Å 0±0 0.31±0.31 
   Max. distance constraint violation (Å) 0.04±0.00 0.08±0.08 
Deviations from idealized geometry   
   Bond lengths (Å) 0.0154±0.0001 0.0158±0.0004 
   Bond angles (º) 1.88±0.05 2.02±0.15 
Heavy atom RMSD to mean (Å) 0.10±0.09 1.17±0.55 
   
Glycosidic linkage phi / psi angles **   
Fucα(1,3)GlcNAc –71.1±0.9/–98.4±0.5† 
(47.7±1.0 / 22.0±0.6)¶ 
–75.1±41.9/–103.9±20.7† 
(43.6±41.8 / 15.7±21.3) ¶ 
Galβ(1,4)GlcNAc –67.0±1.1/127.6±0.8† 
(52.5±1.3 / 8.1±0.8) ¶ 
–68.3±3.5/ 132.5±11.1† 
(51.1±3.8 / 13.6±12.1) ¶ 
* for an ensemble of 20 refined structures 
** phi is defined as O5-C1-Ox-C'x and psi as C1-Ox-C'x-C'x-1 
† extracted by XtalView [S11] 
¶ NMR dihedral angles extracted automatically by CARP [S2], phi is defined as H1-C1-O1-C'X and psi as C1-O1- 
C'X-H'X !
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Table S4. 1H-1H distances of Lex attached to FimH (4) used for the structure calculation and measured in a 
representative structure of the obtained ensemble. 
 
proton pair Calculated 
1H-1H 
distancesa [Å] 
Applied upper 
distances restraintb 
[Å] 
1H-1H distances in representative 
model of the final ensemble [Å] 
intra    
Gal H1-H2 2.3 3.3e 3.06 
Gal H1-H3 2.4 2.9 2.69 
Gal H1-H5 2.2 2.7 2.56 
Gal H2-H3 2.0 3.0e 3.04 
Gal H3-H4 2.1 2.6 2.46 
Gal H4-H5 2.1 2.6 2.47 
GlcNAc H1-H3 3.0 4.0e 2.60 
GlcNAc H1-H5 2.6 3.1 2.52 
GlcNAc H2-Q8 4.2 4.7 3.80f 
GlcNAc H5-H62 2.6 3.1 3.06 
GlcNAc H61-H62c 1.77 – 1.77 
GlcNAc!H61)H62d! 1.77 – 1.77!
Fuc H1-H2 2.4 2.9 2.40 
Fuc H1-Q6 4.0 4.5 4.20f 
Fuc H3-H5 2.9 3.4 2.53 
Fuc H4-H5 2.5 3.0 2.45 
Fuc H4-Q6 2.6 3.1 2.46f 
Fuc H5-Q6 2.8 3.3 1.81f 
GlcNAc H1-HN2 3.6 4.1 2.64 
GlcNAc H3-HN2 3.5 4.0 2.59 
GlcNAc Q8-HN2 3.9 4.4 2.12f 
inter    
Gal H1 - GlcNAc H4 2.3 2.8 2.45 
Gal H1 - GlcNAc H62 2.6 3.1 2.74 
Gal H1 - GlcNAc H61 2.4 2.9 2.34 
Gal H2 - Fuc H5 3.0 3.5 2.41 
Gal H2 - Fuc Q6 2.8 3.3 2.36f 
Gal Q6 - Fuc H3 2.7 3.2 2.50f 
GlcNAc H3 - Fuc H1 2.8 3.3 2.52 
GlcNAc Q8 - Fuc H1 3.8 4.3 3.01f 
GlcNAc HN2 - Fuc H1 3.2 3.7 2.38 
a) See Table S2.  
b) For the structure calculations upper limit restraints were generated from the calculated 1H-1H distances by adding 
a 0.5 Å tolerance. 
c) Reference restraints for the 15N-filtered-filtered NOESY.  
d) Reference restraints for the 13C-filtered-filtered NOESY.  
e) The tolerance of these distances was increased by 1 Å instead of a 0.5 Å tolerance.!
f) For methyl groups the distance to the average position the three protons (pseudoatom) was extracted and 0.66 Å 
subtracted. This corresponds to the treatment of upper distance restraints to methyl groups in Amber calculations.
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Table S5. Experimental and calculated chemical shifts of the Lex trisaccharide (3), the Fucα(1-3)GlcNAcβ 
methyl glycoside and Galβ(1-4)GlcNAcβ methyl glycoside. All chemical shifts are given in ppm. 
 
Lex 
expa 
Lex 
theob 
Lex 
cryst1c 
Lex 
cryst2c 
Fucα(1-3) 
GlcNAc 
(exp)d 
Galβ(1-4) 
GlcNAc 
(exp)d 
Fucα(1-3) 
GlcNAc 
(theo) 
Galβ(1-4) 
GlcNAc 
(theo) 
GlcNAc H1 4.52 4.18 4.31 4.31 4.47 4.51 4.24 4.24 
GlcNAc H2 3.94 3.92 3.98 3.99 3.82 3.76 3.94 3.83 
GlcNAc H3 3.86 3.67 3.55 3.55 3.66 3.72 3.82 3.58 
GlcNAc H4 3.94 3.36 3.42 3.43 3.51 3.72 3.33 3.10 
GlcNAc H5 3.60 3.53 3.39 3.38 3.50 3.60 3.59 3.54 
GlcNAc H61 3.87 3.80 3.69 3.69 3.77 3.84 3.80 3.80 
GlcNAc H62 4.01 4.29 4.10 4.09 3.95 4.00 4.28 4.10 
GlcNAc Q8 2.04 1.79 1.83 1.83 2.03 2.05 1.78 1.76 
Fuc H1 5.12 5.29 5.01 5.00 4.99  5.70  
Fuc H2 3.69 3.88 3.55 3.55 3.71  3.88  
Fuc H3 3.90 3.90 3.69 3.68 3.82  3.92  
Fuc H4 3.79 3.66 3.55 3.54 3.80  3.61  
Fuc H5 4.84 4.90 4.73 4.78 4.32  4.06  
Fuc Q6 1.18 1.13 1.13 1.11 1.17  1.18  
Gal H1 4.45 4.18 4.06 4.18  4.47  4.16 
Gal H2 3.50 3.64 3.49 3.66  3.54  3.60 
Gal H3 3.65 3.59 3.46 3.59  3.67  3.58 
Gal H4 3.90 3.80 4.12 4.11  3.93  3.84 
Gal H5 3.59 3.58 3.39 3.34  3.73  3.58 
Gal H61 3.73 3.57 3.59 3.71  3.76  3.58 
a) measured at 293 K of Lex propanolamine aglycone (3) in D2O.  
b) calculation based as presented in this paper.  
c) calculation based on the coordinates of the two models in the Lex crystal structure ABUCEF[S4]  
d) determined with Fucα1,3GlcNAcβ methyl glycoside and Galβ(1-4)GlcNAcβ propanolamine aglycone in D2O at 
293 K.  
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Table S6. Structural parameters of the C-H⋅⋅⋅O bond in the stacked conformation of Me Lex (2) as determined by 
experiment and calculated at different levels of theory.!
Structural 
parameter 
NMR 
 
OPLS 
2005 
B3LYP/ 
6-31G(d,p) 
ONIOM(MP2/6-31G(d,p): 
HF/6-31G(d)) 
CSD 
r(H⋅⋅⋅O) [Å] 2.50 ± 0.01 2.464 2.333 2.220 2.290, 2.311 
r(C⋅⋅⋅O) [Å] 3.56 ± 0.01 3.483 3.424 3.277 3.269, 3.304 
a(C-H⋅⋅⋅O) [°] 165.0 ± 0.9 156.0 175.2 163.7 163.1, 176.4 
 
 
Table S7. Stacking and C-H⋅⋅⋅O hydrogen bonding energy calculated at different levels of theory in kcal/mol. 
Model system 
OPLS 
2005 
B3LYP/ 
6-31G(d,p) 
MP2/ 
6-311++G(d,p) 
(CP*) 
MP2/ 
aug-cc-pVTZ 
(CP*) 
MP2/ 
aug-cc-pVQZ 
(CP*) 
1-deoxy-Fuc ⋅⋅⋅ 
    1-deoxy-Gal 
-4.83 -2.62 -7.81 (-3.49) -6.58 (-4.52) n/a 
Me-O-iPro ⋅⋅⋅ 
    Me-O-Me 
-1.23 -1.34 -2.86 (-1.23) -2.52 (-1.76) -2.14 (-1.84) 
1-deoxy-Ara ⋅⋅⋅ 
    1-deoxy-Gal 
-4.48 -2.75 -6.76 (-3.16) -5.83 (-4.03) n/a 
Me-O-Et ⋅⋅⋅ 
    Me-O-Me 
-1.32 -1.58 -2.51 (-1.30) -2.34 (-1.73) -2.05 (-1.80) 
* Values in brackets denote interaction energies corrected for the BSSE error by the counterpoise correction.!
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Table S8. Bacterial strains, plasmids and oligonucleotides used in this study. 
Strain, plasmid, or oligonucleotide Relevant characteristics or sequence Source or reference 
   
E.coli   
BL21(DE3) F- ompT hsdSB(rB- mB-) gal dcm (λDE3) Novagen 
   
pDsbA3 Cloning vector, Ptrc, ampr [S12] 
pFimH1 FimH expression vector based on pDsbA3 [S13] 
pFimH2 FimH-S78C expression vector based on pFimH1 This study 
   
Oligonucleotide Primers (5’→3’)a   
   
FimH-Extern Forward CC TCT AGA ATG ATT GTA ATG AAA CGA GTT ATT ACC CTG This study 
FimH-Extern Revers CC AAG CTT TCG GGC TTT GTT AGC AGC CGG ATC TCA GTG This study 
FimH-S78C Forward ACC GTA AAA TAT TGT GGC AGT AGC TAT This study 
FimH-S78C Revers ATA GCT ACT GCC ACA ATA TTT TAC GGT This study 
a) Bold and underlined: cleavage sites for restriction enzymes XbaI and HindIII in forward and reverse primers, 
respectively. Bold and italic: codon of the mutated amino acid. 
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Supplementary Methods 
 
General methods. Commercial materials (Sigma-Aldrich) were used without further 
purification, solvents were reagent grade (Acros). CH2Cl2 and MeOH were dried by passing 
through an Al2O3 (Fluka, type 5016 A basic) column. DMF extra dry (Acros) was used as is. All 
reactions were performed in oven dried glassware under an atmosphere of argon.  
1H and 13C NMR spectra were recorded on a Bruker Avance DMX-500 at room temperature. 
Chemical shifts are reported in ppm and referenced to TMS using residual solvent peaks.[S14] For 
complex molecules the following prefixes were used: Fuc (fucose), Gal (galactose) and GlcNAc 
(N-acetyl glucosamine). The coupling constants (J) are reported in Hertz (Hz). Analytical TLC 
was performed on Merck silica gel 60 F254 glass plates and visualized by UV light and charring 
with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and 
ammonium molybdate tetrahydrate in aq. 10% H2SO4) by heating for 5 min at 140°C. Column 
chromatography was performed on a CombiFlash Companion (Teledyne-ISCO, Inc.) using 
RediSep® normal phase disposable flash columns (silica gel). Reversed phase chromatography 
was carried out with LiChroprepRP-18 (Merck, 40-63 µm). Optical rotations were determined 
on a Perkin-Elmer Polarimeter 341. Low resolution mass spectra were measured on a Waters 
micromass ZQ. High resolution mass spectra (HRMS) were obtained on a micrOTOF 
spectrometer (Bruker Daltonics, Germany) equipped with a TOF hexapole detector. Purity of 
final compound was determined on an Agilent 1100 HPLC; detector: ELS, Waters 2420; 
column: Waters Atlantis dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 90% 
acetonitrile + 10% water + 0.1% TFA; linear gradient: 0 - 1 min 5% B; 1 - 16 min 5 to 70% B; 
flow: 0.5 mL/min 
MALDI-TOF and ESI-MS glycoprotein analyses were recorded by the Functional Genomic 
Center Zurich (FGCZ). VIVASPIN® 500 ultrafiltration tubes with 10000 MWCO PES 
membrane, and ZelluTrans/Roth dialysis membranes MWCO 8000-10000 were used for 
glycoprotein concentration and dialysis. 
 
(3-N-Benzyloxycarbonylamino)propyl (2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)-
(1-3)-2-acetamido-4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside (7) 
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Compound 5 (250 mg, 486 µmol), glycosyl donor 6 (465 mg, 972 µmol) and Bu4NBr (392 mg, 
1.22 mmol) were dried for 16 h at high vacuum. Powdered 4Å molecular sieves (600 mg) in 
DCM/DMF (5 ml, 4:1) was added and the suspension stirred for 4 h at r.t.. CuBr2 (272 mg, 1.22 
mmol) was dried for 20 h at 70°C and added to the suspension and the resulting mixture was 
stirred for 20 h at r.t.. The mixture was filtered over a short pad of celite and the filtrate was 
extracted (3x 20 ml) with NH3(25%)/ saturated NH4Cl (1:9) and brine (20 ml). The aqueous 
layers were washed with dichloromethane (DCM, 3× 20 ml). The combined organic layers were 
dried (Na2SO4) and the solvent was removed in vacuo. The crude product was purified by flash 
chromatography (EE/toluene 30 – 60%) to give pure 7 (351 mg, 374 µmol, 77%).   
Rf (PE/EE 2:3) 0.24; [α]D22 - 68.4 (c 1.56, CHCl3); 1H NMR (500.1 MHz, CDCl3) δ 7.50 – 7.23 
(m, 25H, Ar-H), 5.96 (d, J = 6.8 Hz, 1H, NHAc), 5.49 (s, 1H, benzylidene CH), 5.15 – 5.03 (m, 
3H, Fuc-H1, 2xCH2-Ph), 4.91 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.86 (d, J = 11.3 Hz, 1H, CH2-Ph), 
4.77 – 4.65 (m, 4H, GlcNAc-H1, 3× CH2-Ph), 4.58 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.31 (dd, J = 
10.4, 4.9 Hz, 1H, GlcNAc-H6), 4.17 – 4.03 (m, 3H, GlcNAc-H3, Fuc-H2, Fuc-H5), 3.93 (dd, J = 
10.2, 2.7 Hz, 1H, Fuc-H3), 3.91 – 3.86 (m, 1H, O-CH2), 3.74 (t, J = 10.3 Hz, 1H, GlcNAc-H6'), 
3.64 – 3.54 (m, 3H, Fuc-H4, GlcNAc-H2, -H4), 3.52 – 3.39 (m, 2H, O-CH2, GlcNAc-H5), 3.39 – 
3.25 (m, 1H, CH2-NH), 3.23 – 3.12 (m, 1H, CH2NH), 1.81 – 1.64 (m, 5H, 2xCH2-CH2-CH2, CO-
CH3), 0.86 (d, J = 6.4 Hz, 3H, Fuc-H6) ppm. 13C NMR (125.8 MHz, CDCl3) δ 171.2 (CO-CH3), 
156.7 (OCO-NH), 138.8 – 126.3 (25C, Ar-C), 101.6 (benzylidene CH), 101.58 (GlcNAc-C1), 
98.51 (Fuc-C1), 80.9 (Fuc-C4), 79.9 (Fuc-C3), 77.7 (GlcNAc-C4), 77.1 (Fuc-C2), 75.7 
(GlcNAc-C3), 75.1 (CH2-Ph), 74.2 (CH2-Ph), 72.8 (CH2-Ph), 68.9 (GlcNAc-C6), 67.5 (Fuc-C5), 
67.1 (O-CH2), 66.7 (GlcNAc-C5), 66.5 (CH2-Ph), 57.6 (GlcNAc-C2), 38.0 (CH2-NH), 29.6 
(CH2-CH2-CH2), 23.2 (CO-CH3), 16.5 (Fuc-C6) ppm. ESI-MS Calcd for C53H60N2O12 [M+Na]+: 
939.40; Found: 939.40. 
 
(3-N-Benzyloxycarbonylamino)propyl (2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)-
(1-3)-2-acetamido-6-O-benzyl-2-deoxy-β-D-glucopyranoside (8) 
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Compound 7 (166 mg, 181 µmol) and sodium cyanoborohydride (56.8 mg, 905 µmol) were 
suspended in THF (5ml) and treated with HCl in ether (1M). The completion of the reaction was 
monitored by TLC. The mixture was neutralized with sodium hydrogencarbonate and diluted 
with ethyl acetate (20ml). The mixture was washed with saturated aqueous NaHCO3 (15 ml) and 
brine (15 ml). The organic layer was dried (Na2SO4) and concentrated. The crude product was 
purified by flash chromatography to yield 8 as a white solid (141 mg, 154 µmol, 85%).  
Rf (PE/EE 2:3) 0.20; [α]D22 -37.2 (c 1.84, CHCl3); 1H NMR (500.1 MHz, CDCl3) δ 7.42 – 7.26 
(m, 25H, Ar-H), 5.08 (s, 2H, 2x CH2-Ph), 4.96 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.93 (d, J = 2.5 Hz, 
1H, Fuc-H1), 4.84 – 4.78 (m, 2H, CH2-Ph), 4.75 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.69 – 4.60 (m, 
3H, GlcNAc-H1, 2x CH2-Ph), 4.60 – 4.52 (m, 2H, 2x CH2-Ph), 4.13 – 4.04 (m, 2H, Fuc-H5, Fuc-
H2), 3.97 – 3.88 (m, 2H, Fuc-H3, O-CH2), 3.83 – 3.76 (m, 1H, GlcNAc-H6), 3.70 – 3.53 (m, 4H, 
Fuc-H4, GlcNAc-H6', GlcNAc-H2, O-CH2), 3.53 – 3.43 (m, 2H, GlcNAc-H3, GlcNAc-H5), 3.43 
– 3.34 (m, 2H, GlcNAc-H4, CH2-NH), 3.24 – 3.15 (m, 1H, CH2-NH), 1.82 – 1.74 (m, 1H, CH2-
CH2-CH2), 1.73 – 1.67 (m, 1H, CH2-CH2-CH2), 1.61 (s, 3H, CO-CH3), 1.14 (d, J = 6.4 Hz, 3H, 
Fuc-H6). 13C NMR (125.8 MHz, CDCl3) δ 156.9 (OCO-NH2), 138.7 – 127.7 (25C, Ar-C), 100.8 
(GlcNAc-C1), 99.7 (Fuc-C1), 85.1 (GlcNAc-C3), 79.2 (Fuc-C3), 77.4 (Fuc-C4), 76.3 (Fuc-C2), 
75.2 (CH2-Ph), 75.1 (GlcNAc-C5), 74.3 (CH2-Ph), 73.5 (CH2-Ph), 73.2 (CH2-Ph), 70.71 
(GlcNAc-C4), 69.7 (GlcNAc-C6), 68.3 (Fuc-C5), 67.0 (O-CH2), 66.7 (CH2-Ph), 55.7 (GlcNAc-
C2), 37.8 (CH2-NH), 29.6 (CH2-CH2-CH2), 23.0 (CO-CH3), 16.8 (Fuc-C6) ppm. ESI-MS Calcd 
for C53H62NaN2O12 [M+Na]+: 941.42; Found: 941.47. 
 
(3-N-Benzyloxycarbonylamino)propyl (2,3-di-O-acetyl-4,6-O-benzylidene-β-D-
galactopyranosyl)-(1-4)-[(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)-(1-3)]-2-
acetamido-6-O-benzyl-2-deoxy-β-D-glucopyranoside (10) 
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Compound 8 (781 mg, 0.850 mmol) and thioglycoside 9  (607 mg, 1.53 mmol) were dissolved in 
dry DCM (35 ml) and stirred together with powdered 4Å activated molecular sieves (10 g) for 4 
h at r.t. DMTST (658 mg, 2.55 mmol) was dissolved in DCM (15 ml) and stirred together with 
powdered 4 Å activated molecular sieves (5g) for 4 h at r.t. as well. Both suspensions were 
combined and stirred for 16 h at r.t.. The mixture was filtered over a short pad of celite, diluted 
with DCM (100 ml), and washed with a saturated solution of NaHCO3 (50 ml) and water (50 
ml). The aqueous phases were extracted with DCM (3× 30 ml). The combined organic layers 
were dried (Na2SO4) and the solvent was removed in vacuo. The crude product was purified by 
flash chromatography (PE/EE 1:1) to yield 10 as a colorless oil (640 mg, 0.51 mmol, 60 %). 
Rf (PE/EE 2:3) 0.25; [α]D22 -24.6 (c 0.82, CHCl3); [α]D22 -24.6 (c 0.82, CHCl3); 1H NMR (500.1 
MHz, CDCl3) δ 7.58 – 7.13 (m, 30H, Ar-H), 5.74 (d, J = 6.4 Hz, 1H, NHAc), 5.54 (s, 1H, CH 
benzylidene), 5.29 (dd, J = 10.2, 8.3 Hz, 2H, Gal-H2), 5.11 – 5.00 (m, 3H, 2x Ph-CH2, GlcNAc-
H1), 4.94 (d, J = 2.7 Hz, 1H, Fuc-H1), 4.84 (d, J = 11.8 Hz, 1H, Ph-CH2), 4.76 – 4.67 (m, 3H, 
Ph-CH2, Gal-H3, Fuc-H5), 4.67 – 4.59 (m, 3H, Ph-CH2, Gal-H6), 4.56 (d, J = 8.2 Hz, 1H, Gal-
H1), 4.38 (d, J = 12.1 Hz, 1H, Ph-CH2), 4.33 – 4.17 (m, 3H, 2x Ph-CH2, Gal-H4), 4.12 (t, J = 9.4 
Hz, 1H, GlcNAc-H3), 4.03 – 3.93 (m, 3H, Ph-CH2, GlcNAc-H4, Fuc-H2), 3.92 – 3.80 (m, 3H, 
Fuc-H3, O-CH2, GlcNAc-H6), 3.79 – 3.71 (m, 1H, GlcNAc-H6'), 3.56 (d, J = 11.2 Hz, 1H, Ph-
CH2), 3.53 – 3.47 (m, 1H, O-CH2), 3.43 – 3.36 (m, 1H, GlcNAc-H5), 3.29 – 3.17 (m, 4H, 2x 
CH2-NH2, GlcNAc-H2, Fuc-H4), 3.04 – 2.99 (m, 1H, Gal-H5), 2.12 (s, 3H, CO-CH3), 2.02 (s, 
3H, CO-CH3), 1.76 – 1.67 (m, 2H, CH2-CH2-CH2), 1.59 (s, 3H, CO-CH3), 1.12 (d, J = 6.5 Hz, 
3H, Fuc-H6). 13C NMR (125.8 MHz, CDCl3) δ 170.8 (CO-CH3), 169.9 (CO-CH3), 168.9 (CO-
CH3), 156.7 (OCO-NH), 139.6-125.9 (36C, Ar-C), 99.9 (benzylidene-CH), 99.8 (Gal-C1), 99.6 
(GlcNAc-C1), 98.2 (Fuc-C1), 79.6 (Fuc-C3), 78.9 (Fuc-C4), 76.0 (Fuc-C2), 75.1 (Ph-CH2), 75.0 
(GlcNAc-C5), 74.4 (GlcNAc-C4), 74.3 (Ph-CH2), 73.8 (GlcNAc-C3), 73.5 (Ph-CH2), 73.4 (Gal-
C4), 72.2 (Gal-C3), 71.5 (Gal-C6), 69.2 (Ph-CH2), 68.8 (Gal-C2), 68.0 (GlcNAc-C6), 67.0 (O-
CH2), 66.6 (Ph-CH2), 66.5 (Fuc-C5), 66.4 (Gal-C5), 59.4 (GlcNAc-C2), 37.9 (CH2-NH2), 29.4 
(CH2-CH2-CH2), 23.3 (NH-CO-CH3), 21.0 (CO-CH3), 20.9 (CO-CH3), 16.2 (Fuc-C6) ppm. ESI-
MS Calcd for C70H80N2NaO19 [M+Na]+: 1275.53; Found: 1275.74. 
 
3-Aminopropyl  (β-D-galactopyranosyl)-(1-4)-[(6-deoxy-α-L-galactopyranosyl)-(1-3)]-
2-acetamido-2-deoxy-β-D-glucopyranoside (3) 
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Compound 10 (24.8 mg; 19.8 µmol) was dissolved in MeOH (1 ml), treated with NaOMe/MeOH 
(200 µl, 0.02 M) and stirred for 16 h at r.t.. The reaction was quenched with two drops of glacial 
acetic acid and concentrated in vacuo. The resulting alcohol 11 was dissolved in 
DCM/MeOH/AcOH/H2O (1:1:2:2, 3 ml) and Pd(OH)2/C (5 mg) as added. The suspension was 
stirred under an atmosphere of hydrogen for 18 h. The reaction mixture was filtered and purified 
by reversed phase flash chromatography and size exclusion chromatography to yield 3 as a white 
foam (8.9 mg, 15.2 µmol, 77% over 2 steps). 
[α]D22 -68.6 (c 0.96, D2O); 1H NMR (500.1 MHz, D2O) δ 5.11 (d, J = 3.9 Hz, 1H, Fuc-H1), 4.85 
– 4.79 (m, 2H, Fuc-H5), 4.51 (d, J = 8.3 Hz, 1H, GlcNAc-H1), 4.44 (d, J = 7.8 Hz, 1H, Gal-H1), 
4.05 – 3.97 (m, 2H, O-CH2, GlcNAc-H6), 3.96 – 3.81 (m, 7H, GlcNAc-H2, -H4, Fuc-H3, Gal-
H4, GlcNAc-H3, -H6'), 3.80 – 3.77 (m, 1H, Fuc-H4), 3.76 – 3.66 (m, 4H, Gal-H6, -H6', O-CH2, 
Fuc-H2), 3.64 (dd, J = 9.8, 3.2 Hz, 1H, Gal-H3), 3.62 – 3.56 (m, 2H, GlcNAc-H5, Gal-H5), 3.51 
– 3.46 (m, 1H, Gal-H2), 3.10 – 3.04 (m, 2H, CH2-NH2), 2.03 (s, 3H, CO-CH3), 1.98 – 1.90 (m, 
2H, CH2-CH2-CH2), 1.17 (d, J = 6.6 Hz, 3H, Fuc-H6) ppm; 13C NMR (125.8 MHz, CDCl3) δ 
177.1 (CO-Ac), 104.5 (Gal-C1), 103.7 (GlcNAc-C1), 101.3 (Fuc-C1), 78.0 (GlcNAc-C5), 77.6 
(GlcNAc-C3), 77.5 (Gal-C5), 76.0 (GlcNAc-C4), 75.2 (Gal-C3), 74.6 (Fuc-C4), 73.7 (Gal-C2), 
71.9 (Fuc-C3), 71.0 (Gal-C4), 70.7 (O-CH2), 70.4 (Fuc-C2), 69.4 (Fuc-C5), 64.2 (Gal-C6), 62.4 
(GlcNAc-C6), 58.5 (GlcNAc-C2), 40.3 (CH2-NH2), 29.4 (CH2-CH2-CH2), 24.9 (CO-
CH3/Acetate), 18.0 (CO-CH3), 18.0 (Fuc-C6) ppm; HR-MS (ESI) Calcd for C23H42N2NaO15 
[M+Na]+: 609.2483; Found: 609.2484. 
 
3-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzamido)propyl (β-D-galactopyranosyl)-(1-
4)-[6-deoxy-α-L-galactopyranosyl]-2-acetamido-2-deoxy-β-D-glucopyranoside (12) 
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Compound 3 (11.0 mg, 18.8 µmol) was dissolved in H2O (400 µl) and a solution of 
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3-maleimidobenzoic acid N-hydroxysuccinimide ester (11.8 mg, 37.5 µmol) in DMSO (1 ml) 
was added. The solution was stirred for 1.5 h at r.t. The water was removed in vacuo and the 
crude product purified by flash chromatography (MeCN/MeOH + 0.01% TFA, 1 to 3/4) and 
lyophilized to give 12 as a white foam (9.1 mg, 11.6 µmol, 62%). 
Rf (DCM/MeOH 1.25:1) 0.20; [α]D22 -53.7 (c 0.54, H2O); 1H NMR (500.1 MHz, D2O) δ 7.87 – 
7.82 (m, 1H, Ar-H), 7.73 – 7.67 (m, 2H, Ar-H), 7.60 – 7.56 (m, 1H, Ar-H), 7.06 (s, 2H, -
CH=CH-), 5.12 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.85 (q, J = 6.8 Hz, 1H, Fuc-H5), 4.56 (d, J = 8.0 
Hz, 1H, GlcNAc-H1), 4.45 (d, J = 7.8 Hz, 1H, Gal-H1), 4.03 – 3.96 (m, 2H, O-CH2, GlcNAc-
H6), 3.96 – 3.64 (m, 14H, GlcNAc-H2, Gal-H4, Fuc-H3, GlcNAc-H4, -H3, -H6', Fuc-H4, Gal-
H6, -H6', O-CH2, Fuc-H2, Gal-H3), 3.64 – 3.55 (m, 2H, GlcNAc-H5, Gal-H5), 3.55 – 3.47 (m, 
2H, Gal-H2, CH2-NH), 3.45 – 3.37 (m, 1H, CH2-NH), 2.04 (s, 3H, CO-CH3), 1.95 – 1.88 (m, 2H, 
CH2-CH2-CH2), 1.19 (d, J = 6.6 Hz, 3H, Fuc-H6) ppm; 13C NMR (126 MHz, D2O) δ 174.3, 
171.8, 169.7 (3C, CO), 134.7 (2C, CO-CH), 135.3, 131.0, 130.2, 130.0, 127.3, 125.5 (6C, Ar-C), 
101.9 (Gal-C1), 101.0 (GlcNAc-C1), 98.6 (Fuc-C1), 75.4 (GlcNAc-C5), 75.0 (Gal-C5), 74.9 
(GlcNAc-C3), 73.5 (GlcNAc-C4), 72.5 (Fuc-C2), 71.9 (Fuc-C4), 71.0 (Gal-C2), 69.2 (Fuc-C3), 
68.3 (Gal-C4), 68.1 (O-CH2), 67.7 (Fuc-C2), 66.7 (Fuc-C5), 61.5 (Gal-H6), 59.8 (GlcNAc-C6), 
55.8 (GlcNAc-C2), 37.1 (CH2-NH), 28.3 (CH2-CH2-CH2), 22.2 (CO-CH3), 15.30(Fuc-C6) ppm; 
HR-MS (ESI) Calcd for C34H47N3NaO18 [M+Na]+: 808.2752; Found: 808.2752. 
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UP SFBDI B TUBCJMJ[FE DPOGPSNBUJPO BOE UIVT B EFGJOFE UISFF
EJNFOTJPOBM TUSVDUVSF JO TPMVUJPO 8F IBWF JEFOUJGJFE B DPOTFSWFE
USJTBDDIBSJEF BSDIJUFDUVSF UIBU JT DPNNPO UP NBOZ HMZDPFQJUPQFT
BOE DBO CF DPNQBSFE UP TFDPOEBSZ TUSVDUVSBM FMFNFOUT JO QSP
UFJOT TFSWJOH BT BO VOEFSMZJOH TDBGGPME GPS UIF QSFTFOUBUJPO PG
WBSJPVT TVCTUJUVUJPOT GPS EJGGFSFOU GVODUJPOT 0VS GJOEJOHT BSF
CBTFE PO TUSVDUVSBM EBUB PCUBJOFE XJUI BO FYQFSJNFOUBMMZ TJNQMF
BOE SPCVTU BQQSPBDI GPS EFUFSNJOJOH UIF % TPMVUJPO TUSVDUVSF
PG TNBMM PMJHPTBDDIBSJEFT BOE PO FYUFOTJWF TFBSDIFT UISPVHI B
DBSCPIZESBUF EBUBCBTF BOE UISPVHI SFQPSUFE DSZTUBM TUSVDUVSFT UP
EFSJWF UIF NJOJNBM SFRVJSFNFOUT GPS TVDI B TUBCJMJ[BUJPO
3IGNIlCANCE
4HIS STUDYWILL CHANGE OUR UNDERSTANDING OF FUNCTIONAL ENTITIES
IN CARBOHYDRATES  THE GLYCOCODE 7HEREAS SEVERAL THOUSAND
FUNCTIONAL GLYCOEPITOPES ARE ESTIMATED IN NATURE KNOWLEDGE
OF THEIR FUNCTIONS IS VERY LIMITED 5NDERSTANDING THE SPECIlC
RECOGNITION OF THOSE GLYCOEPITOPES ON A MOLECULAR LEVEL IS
KEY TO UNDERSTAND THEIR FUNCTION AND IN THAT CONTEXT THE
GLYCOEPITOPE CONFORMATION IS CENTRAL 7E FOUND WITH .-2
SPECTROSCOPY DENSITY FUNCTIONAL THEORY CALCULATIONS AND CRYS
TAL STRUCTURE DATABASE ANALYSIS A COMMON SECONDARY STRUCTURE
ELEMENT SHARED BY MANY GLYCOEPITOPES THAT PROVIDES A SCAF
FOLD FOR GENERATING FUNCTIONALLY DIFFERENT EPITOPES /UR RESULTS
NOT ONLY EXPLAIN HOW NATURAL CARBOHYDRATE LIGANDS STABILIZE
THEIR BIOACTIVE CONFORMATION BUT WILL BE VERY BENElCIAL FOR
DESIGNING POTENT MIMETICS FOR THERAPEUTIC APPLICATIONS
2ESERVED FOR 0UBLICATION &OOTNOTES




































































WWWPNASORG   0.!3 )SSUE $ATE 6OLUME )SSUE .UMBER 




































































Chapter 3.1.2 - Manuscript 1 
 68 
Submission PDF
&IG  3TRUCTURE DETERMINATION OF ˞FUCOSYLATED CHITOBIOSE &#H"	 IN SOLUTION !	 ./% ENHANCEMENT FACTORS OF A TRANSIENT ./% EXPERIMENT AS A FUNCTION
OF THE CORRELATION TIME ˱# INDICATED FOR TWO MAGNETIC lELDS CORRESPONDING TO  AND  -(Z %STIMATED CORRELATION TIMES OF &#H" -7  GMOL	 IN
$/ ARE INDICATED BY VERTICAL LINES "	 $ ./%39 SPECTRA OF &#H" 'LC.!C˟;&UC˞='LC.!C/#(	#//(  M-	 IN EITHER (/ RED LEFT	 OR IN $/
BLUE RIGHT	 RECORDED AT  -(Z AND  + #HEMICAL SHIFT ASSIGNMENTS ARE INDICATED ON THE TOP FOR ISOLATED RESONANCES #	 3CHEMATIC PRESENTATION OF
&#H" SHOWING THE OBTAINED INTERRESIDUE ./%S BY RED ARROWS $	 %NSEMBLE OF THE  BEST STRUCTURES OF &#H" BASED ON ./%39 DATA RECORDED AT  + %	
2EPRESENTATIVE .-2 STRUCTURE OF &#H" &	 3TRUCTURE OF &#H" IN COMPLEX WITH THE LECTIN ##, 	
2ESULTS
" HFOFSBM BQQSPBDI UP UIF %TUSVDUVSF EFUFSNJOBUJPO PG DBSCP
IZESBUFT CZ /.3 TQFDUSPTDPQZ
5IF NPTU SFMJBCMF BQQSPBDI UP UISFFEJNFOTJPOBM TUSVDUVSF
EFUFSNJOBUJPO JO TPMVUJPO JT CBTFE PO UIF OVDMFBS 0WFSIBVTFS
FGGFDU 	/0&
8IFSFBT OVDMFBS 0WFSIBVTFS FOIBODFNFOU GBDUPST
PG BO PQUJNBM WBMVF PG ದ BSF PCTFSWFE GPS CJPQPMZNFST GPS TNBMM
NPMFDVMFT XJUI NBTTFT BSPVOE  %B UIFTF GBDUPST BSF DMPTF
UP [FSP 	'JH "
 " NPSF GBWPSBCMF /0& FOIBODFNFOU GBDUPS
DBO CF BDIJFWFE CZ NFBTVSJOH BU MPX UFNQFSBUVSFT SFTVMUJOH JO
B MBSHFS WJTDPTJUZ BOE TMPXFS UVNCMJOH UJNF 5IVT B EFDSFBTF JO
UFNQFSBUVSF GSPN  |$ UP  |$ JODSFBTFT UIF FTUJNBUFE UVNCMJOH
UJNF BQQSPYJNBUFMZ CZ B GBDUPS PG  *O BEEJUJPO UIF VTF PG VMUSB
IJHI NBHOFUJD GJFMET GVSUIFS JODSFBTFT UIF BCTPMVUF WBMVF PG UIF
/0& FOIBODFNFOU GBDUPS GPS TNBMM NPMFDVMFT 	'JH "
 8IFO
BQQMJFE UP UIF GSFF USJTBDDIBSJEF (MD/"D˟<'VD˞>(MD/"D
	˞GVDPTZMBUFE DIJUPCJPTF '$I#
 XIJDI JT UIF UBSHFU PG UIF
SFDFOUMZ EJTDPWFSFE $PQSJOPQTJT DJOFSFB MFDUJO  	$$-
 	

FYDFMMFOU /0& DSPTTQFBLT JO % /0&4: TQFDUSB XFSF PCUBJOFE
	'JH # BOE $
 5P PCUBJO QVSF BCTPSQUJWF /0& DSPTTQFBLT
B NBHOFUJD GJFME PG  .)[ UPHFUIFS XJUI B UFNQFSBUVSF KVTU
BCPWF UIF GSFF[JOH QPJOU XFSF SFRVJSFE 5IF FYDFQUJPOBMMZ IJHI
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4ABLE  $ISTANCES BETWEEN ( OF &UC AND / OF 'AL'LC.!C IN THE .-2 STRUCTURES ONE #AMBRIDGE 3TRUCTURAL $ATABASE #3$	 STRUCTURE
AND 0ROTEIN $ATABANK 0$"	 STRUCTURES AS EVIDENCE FOR #ದ(ຘຘຘ/ HYDROGEN BOND &OR MORE DETAILS SEE 4ABLE 3
-ETHOD
'LYCOMOTIF 4YPE OF STRUCTURE OR 0$"#3$ ENTRY IDENTIFYER .UMBER OF
MOTIFS
$ISTANCE
(&UC	
/'AL'LC.!C	
.-2 &#H" ENSEMBLE   s   A
$&4 MINIMIZED   
,EX ENSEMBLE   s   A
$&4 MINIMIZED   
,EA ENSEMBLE   s   A
$&4 MINIMIZED   
,$.& ENSEMBLE   s   A
$&4 MINIMIZED   
"V ENSEMBLE   s   A
$&4 MINIMIZED   
,$&4 ENSEMBLE   s   A
$&4 MINIMIZED   
8RAY
#3$	
,EX !"5#%&   AND  
8RAY
0$"	
,EX '2 '3 '4 +-" 3, 3, 5: +-" /8 2 2$' :, !0
+-" 06$ $8' +-" B
  s   C
,EY #,9 #,: '3, 3+ *4 %96 ,%' 0! 05. !( '7 D   s   C
,EA &76 7( !32 E   s   C
,EB ,%$ !33 !34 ,%+ 3%* '7*   s   C
&#H" .GLYCAN
CORES	
,+ *5 %- %1%3ಹ  ONLY
SELECTION	
 s   C
DIFUCOSYLATED
.GLYCAN CORES
9- ", &. 11- ,2 17 !2. '7- '7. ':4 F   s   C
,EXLIKE 7&   s   C
,EYLIKE /, %&8 G   s   C
A AVERAGE DISTANCES AND STANDARD DEVIATION OF THE ENSEMBLE CONSISTING OF  STRUCTURES
B EXCLUDED :7 THAT DISPLAYED AN ELONGATED ,EX CONFORMATION
C AVERAGE DISTANCES AND STANDARD DEVIATIONS OF ALL MOTIFS WITHIN ONE CATEGORY PROTONS WERE ADDED TO THE STRUCTURES BY -AESTRO 3CHR¸DINGER	 BECAUSE THE
CRYSTAL STRUCTURES LACKED PROTONS DETAILS IN 4ABLE 3	
D EXCLUDED 7-' 7-+  STRUCTURES OF !( THAT DISPLAYED AN ELONGATED ,EY CONFORMATION
E EXCLUDED 5%4 THAT DISPLAYED AN ELONGATED ,EA CONFORMATION
F EXCLUDED 50 THAT DISPLAYED AN ELONGATED DIFUCOSYLATED .GLYCAN CORE CONFORMATION
G EXCLUDED CHAIN 3 OF /, THAT DISPLAYED AN ELONGATED ,EYLIKE CONFORMATION
OVNCFS PG  JOUFSSFTJEVBM /0&T 	'JH $
 DPSSFTQPOEJOH UP 
/0& EJTUBODF SFTUSBJOUT QFS HMZDPTJEJD MJOLBHF XBT VTFE GPS /.3
TUSVDUVSF EFUFSNJOBUJPO BOE SFTVMUFE JO B XFMMEFGJOFE FOTFNCMF
	'JH % TUBUJTUJDT JO 5BCMF 4
 UIBU JT WJSUVBMMZ JEFOUJDBM UP UIF
TUSVDUVSF PG UIF USJTBDDIBSJEF XIFO CPVOE UP $$- 	
 	'JH
'
 5IF EJTUBM (MD/"D NPJFUZ TUBDLT BHBJOTU 'VD 	'JH % BOE
&
 5P PVS TVSQSJTF UIF TUSVDUVSF SFWFBMFE UIF QSFTFODF PG B $
)ຘຘຘ0 IZESPHFO CPOE CFUXFFO ) PG 'VD BOE UIF SJOH PYZHFO 0
PG (MD/"D 	'JH &
 JOEJDBUFE CZ B $) CPOE WFDUPS EJSFDUMZ
PSJFOUFE UPXBSET UIF PYZHFO BOE B)ຘຘຘ0EJTUBODF PG  TMJHIUMZ
TIPSUFS UIBO FYQFDUFE GSPN UIF TVN PG UIF WBOEFS8BBMT SBEJJ PG
  	
 	5BCMF 
 )PXFWFS UIF (-:$". GPSDF GJFME 	
 VTFE
GPS UIF/.3TUSVDUVSF EFUFSNJOBUJPO EPFT OPU BMMPX DMPTF DPOUBDU
CFUXFFO OPOCPOEFE BUPNT JNQMZJOH UIBU UIF )ຘຘຘ0 EJTUBODF
NJHIU CF FWFO TIPSUFS 5IF $)ຘຘຘ0 IZESPHFO CPOE JO '$I#
SFTVMUT JO B DIBSBDUFSJTUJD DIFNJDBM TIJGU PG ) PG 'VD BSPVOE 
QQN BT JMMVTUSBUFE JO B $ )42$ 	'JH "
 8IFO UIF DIFNJDBM
TIJGUT BSF DPNQBSFE UP 'VD˞(MD/"D˟0.F UIBU MBDLT UIF TUBDL
JOH (MD/"D B MBSHF ) DIFNJDBM TIJGU EJGGFSFODF JT PCTFSWFE
GPS UIF ) PG 'VD XJUI Ⴄˡ   QQN XIFSFBT UIF PUIFS 'VD
DIFNJDBM TIJGUT IBSEMZ DIBOHF 	'JH " 5BCMF 4
 4VDI B EPXO
GJFME TIJGU JT POF PG UIF DIBSBDUFSJTUJDT PG B IZESPHFO CPOE 	

5IF (MD/"D TJHOBMT EJGGFS POMZ TMJHIUMZ FYDFQU GPS ) BOE $ UP
XIJDI UIF TUBDLJOH (MD/"D JT BUUBDIFE JO '$I# " TJNJMBS )
'VD DIFNJDBM TIJGU XBT PCTFSWFE QSFWJPVTMZ GPS UIF USJTBDDIBSJEF
(BM˟<'VD˞>(MD/"D UIF -FY CMPPE HSPVQ FQJUPQF MFBEJOH
UP UIF JOJUJBM JEFOUJGJDBUJPO PG B OPODPOWFOUJPOBM $)ຘຘຘ0IZESPHFO
CPOE BT TUBCJMJ[JOH FMFNFOU 	
 5P DSPTTWBMJEBUF UIF QSFTFOUFE
MPX UFNQFSBUVSF BQQSPBDI UP /.3 TUSVDUVSF EFUFSNJOBUJPO PG
TNBMM NPMFDVMFT JO TPMVUJPO XF BMTP BQQMJFE JU UP -FY NFUIZM
HMZDPTJEF 	5BCMF 4
 " WJSUVBMMZ JEFOUJDBM TUSVDUVSF BT SFQPSUFE CZ
;JFSLF FU BM 	
 XBT PCUBJOFE 	'JH 4
 CVU XJUIPVU UIF OFFE GPS
UIF DIFNJDBM BUUBDINFOU UP BO JTPUPQJDBMMZ MBCFMFE DBSSJFS QSPUFJO
" $)ຘຘຘ0 IZESPHFO CPOE JT JOEJDBUFE CZ B DIBSBDUFSJTUJD
DIFNJDBM TIJGU
5P GVSUIFS WFSJGZ UIF QSFTFODF PG UIF $)ຘຘຘ0 IZESPHFO CPOE
XF VTFE EFOTJUZ GVODUJPOBM UIFPSZ 	%'5
 	
 BU UIF #-:1
(	EQ
 MFWFM 	
 VTJOH BO JNQMJDJU XBUFS TPMWBUJPO NPEFM UP
NJOJNJ[F UIF HFPNFUSZ PG POF SFQSFTFOUBUJWF PG FBDI TUSVDUVSBM
FOTFNCMF BOE UIVT FYDMVEJOH UIF JOGMVFODF PG B GPSDF GJFME 5IF
SFTVMUJOH TUSVDUVSFT PG '$I# BOE -FY 	'JHT 4 " BOE #
 BSF WFSZ
TJNJMBS UP UIF JOJUJBM /.3 TUSVDUVSFT CVU TIPX TIPSUFS )ຘຘຘ0
EJTUBODFT PG   	5BCMF 
 OPX TJHOJGJDBOUMZ TIPSUFS UIBO UIF
TVN PG UIF WBO EFS 8BBMT SBEJJ PG   GVSUIFS TVQQPSUJOH UIF $
)ຘຘຘ0 IZESPHFO CPOE 'VSUIFSNPSF XF VTFE UIF XBWF GVODUJPOT
PCUBJOFE GSPN UIF %'5 DBMDVMBUJPOT UP MPDBMJ[F BOE DBMDVMBUF UIF
FMFDUSPO EFOTJUZ BU UIF CPOE DSJUJDBM QPJOUT ˮ	SD
 XJUIJO UIF $
)ຘຘຘ0 IZESPHFO CPOET XJUI #BEFSಬT BUPN JO NPMFDVMFT 	"*.

UIFPSZ 	
 	5BCMF 4
 5IF FYJTUFODF PG CPOE DSJUJDBM QPJOUT XJUI
B TVGGJDJFOUMZ IJHI FMFDUSPO EFOTJUZ ˮ	SD
 PG  BOE  BV JT
BOPUIFS DIBSBDUFSJTUJD PG IZESPHFO CPOET 	
 BOE UIVT DPOGJSNT
UIF FYJTUFODF PG UIF $)ຘຘຘ0 IZESPHFO CPOE JO '$I#
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&IG  #HARACTERISTIC CHEMICAL SHIFTS REPORT A #(ຘຘຘ/ HYDROGEN BOND !	 )NmUENCE OF THE STACKING 'LC.!C ON THE DOWNlELD SHIFT OF &UC ( #HEMICAL SHIFT
DIFFERENCES BETWEEN &#H" RED	 AND &UC˞'LC.!C THAT LACKS THE STACKING 'LC.!C BLUE	 ILLUSTRATED BY AN OVERLAY OF THEIR # (31# SPECTRA 3IGNALS OF &#H"
ARE LABELED AND CORRESPONDING SIGNALS IN THE DISACCHARIDE ARE CONNECTED BY LINES TO THE &#H" SIGNALS BLACK LABEL	 4HE STACKING 'LC.!C SIGNALS THAT ARE MISSING
IN THE DISACCHARIDE ARE LABELED GREY 3IGNALS OF THE METHYL GROUP AND THE SPACER AT THE REDUCING END ARE INDICATED BY ಫ-Eಬ AND ಫSPಬ "	 $EPENDENCE OF THE
CHEMICAL SHIFT ˡ IN A #(ຘຘຘ/ HYDROGEN BOND AND THE ELECTRON DENSITY AT THE BOND CRITICAL POINT ˮRC	 ON THE (/ DISTANCE AS CALCULATED WITH "ADERಬS ATOM IN
MOLECULES !)-	 THEORY USING THE MODEL SYSTEM I0RO/-E AND-E/-E	 INTRODUCED BEFORE 	 &OR COMPARISON THE ENERGETIC MINIMUM FOR THE SAMEMODEL
SYSTEM AS A FUNCTION OF THE (/ DISTANCE 	 IS SHOWN AT THE BOTTOM #	 3CHEMATIC REPRESENTATION OF ˞FUCOSYLATED CHITOBIOSE DISPLAYING A #(ຘຘຘ/ HYDROGEN
BOND 4HE CHARACTERISTIC CHEMICAL SHIFT OF ( OF &UC IS INDICATED IN BLUE $	 (ISTOGRAM OF ALL AVAILABLE CHEMICAL SHIFTS OF ( OF &UC WITHIN THE ',9#/3#)%.#%3DE
DATABASE 	 4HE (&UC	 CHEMICAL SHIFTS OF ˞FUCOSYLATED CHITOBIOSE AND OF ˞LFUCOSE ARE INDICATED BY A RED ARROW
5P GVSUIFS BOBMZ[F UIF MJOL CFUXFFO UIF DIBSBDUFSJTUJD EPXO
GJFME ) DIFNJDBM TIJGU PG UIF) PG 'VD BOE UIF $)ຘຘຘ0IZESPHFO
CPOE XF VTFE UIF (BVHF*OEFQFOEFOU "UPNJD 0SCJUBM 	(*"0

NFUIPE 	
 XJUIJO(BVTTJBO  	
 UP DBMDVMBUF UIF/.3TIJFME
JOH UFOTPS PG UIF %'5 PQUJNJ[FE TUSVDUVSFT PG '$I# BOE -FY
TUSVDUVSFT SFTQFDUJWFMZ 	5BCMF 4
 5IF BHSFFNFOU CFUXFFO UIF
DBMDVMBUFE BOE UIF FYQFSJNFOUBM DIFNJDBM TIJGUT JT HPPE FTQFDJBMMZ
DPOTJEFSJOH UIBU BQQSPYJNBUJPOT BSF VTFE UP NJNJD UIF TPMWFOU
*O QBSUJDVMBS UIF EPXOGJFME DIFNJDBM TIJGUT PG ) PG 'VD BSF
FYDFMMFOUMZ SFQSPEVDFE XJUI QSFEJDUJPOT PG  BOE  QQN
GPS '$I# BOE -FY SFTQFDUJWFMZ 5IF GBDUT UIBU UIF EJTUBODFT
PG   JO UIF VTFE %'5PQUJNJ[FE TUSVDUVSFT BSF UZQJDBM
GPS B $)ຘຘຘ0 IZESPHFO CPOE 	
 BOE UIBU UIF DIFNJDBM TIJGU
QSFEJDUJPOT BHSFF WFSZ XFMM XJUI UIF FYQFSJNFOUBM WBMVF QSPWJEFT
B EJSFDU TVQQPSU UIBU UIF EPXOGJFME DIFNJDBM TIJGU SFTVMUT GSPN
UIF IZESPHFO CPOE 'VSUIFSNPSF XF DBMDVMBUFE UIF EFQFOEFODF
PG UIF DIFNJDBM TIJGU DPOUSJCVUJPO PG UIF IZESPHFO CPOE 	Ⴄˡ
 PO
UIF )ຘຘຘ0 EJTUBODF VTJOH UIF NPEFM TZTUFN 	J1SP0.F BOE .F
0.F
 UIBU XF JOUSPEVDFE CFGPSF 	
 	'JH $
 5IF TIPSUFS
UIF IZESPHFO CPOE EJTUBODF UIF IJHIFS JT UIF EPXOGJFME DIFNJDBM
TIJGU DPOUSJCVUJPO 5IJT BMTP HPFT JO MJOF XJUI B IJHIFS FMFDUSPO
EFOTJUZ BU UIF CPOE DSJUJDBM QPJOU BU TIPSUFS EJTUBODFT 1SFWJPVTMZ
UIF FOFSHFUJD NJOJNVN XBT JEFOUJGJFE BU B EJTUBODF PG  
GPS UIBU NPEFM TZTUFN VTJOH IJHI MFWFM BC JOJUJP DBMDVMBUJPOT 	

'PS UIJT EJTUBODF SBOHF UIF DPOUSJCVUJPO PG UIF $)ຘຘຘ0 IZESPHFO
CPOE UP UIF DIFNJDBM TIJGU Ⴄˡ JT DBMDVMBUFE UP CF  QQN 5IJT
BHSFFT XFMM XJUI UIF PCTFSWFE EPXOGJFME TIJGU PG Ⴄˡ∼ QQN
PCTFSWFE GPS '$I# BOE -FY DPNQBSFE XJUI 'VD˞(MD/"D
*O DPODMVTJPO XF EFNPOTUSBUFE UIBU UIF DIBSBDUFSJTUJD ) 'VD
DIFNJDBM TIJGU DBO TFSWF BT BO JOEJDBUPS GPS UIF QSFTFODF PG UIF $
)ຘຘຘ0IZESPHFO CPOE CFUXFFO UIF TUBDLJOH TBDDIBSJEFT PG 'VD BOE
FJUIFS (MD/"D PS (BM JO UIF DBTF PG '$I# PS -FY SFTQFDUJWFMZ
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&IG  3TRUCTURAL MOTIFS WITHIN THE RESULTS OF THE ',9
#/3#)%.#%3DE DATABASE SEARCH 	 FOR CHARACTERISTIC
CHEMICAL SHIFTS OF ( OF &UC INDICATING A #(ຘຘຘ/ HYDRO
GEN BONDS /N THE LEFT TRISACCHARIDE GLYCAN CORES THAT
VERY LIKELY ADOPT A DElNED $ STRUCTURE 4HE NUMBER
OF STRUCTURES WITHIN EACH CATEGORY IS GIVEN AS WELL
4YPICAL EXAMPLES ARE SHOWN ON THE RIGHT 3TRUCTURES
INDICATED WITH AN ASTERICS WERE ABSENT IN THE DATABASE
SEARCH BUT WERE ADDED FROM TWO PUBLICATIONS  	
4HE ASSOCIATED CHEMICAL SHIFTS OF ( OF &UC THAT ARE
INDICATIVE OF A #(ຘຘຘ/ HYDROGEN BOND ARE PRESENTED
IN BLUE 'LYCANS WITH A THREEDIMENSIONAL STRUCTURE IN
THE 0$" DATABANK ARE INDICATED BY A LIGHT GREY BACK
GROUND 'LYCANS OF WHICH THE SOLUTION STRUCTURE WAS
DETERMINED BY .-2 SPECTROSCOPY WERE HIGHLIGHTED IN
LIGHT MAGENTA THIS WORK	
%BUBCBTF TFBSDI GPS DIBSBDUFSJTUJDBMMZ EPXOGJFME TIJGUFE SFT
POBODF PG ) PG GVDPTF
8F FYQMPSFE XIFUIFS TVDI $)ຘຘຘ0 IZESPHFO CPOET BSF
QSFTFOU JO PUIFS HMZDBO FQJUPQFT BOE XF VTFE UIF DIBSBDUFSJTUJD
) 'VD DIFNJDBM TIJGU 	'JH  " BOE $
 UP QFSGPSN BO FYUFOTJWF
TFBSDI GPS $)ຘຘຘ0 IZESPHFO CPOET JO HMZDBOT 8F TFBSDIFE UIF
/.3 EBUBCBTF PG (MZDPTDJFODFTEF 	
 XIJDI DPOUBJOT 
FOUSJFT GPS GVDPTF) DIFNJDBM TIJGUT PG XIJDI SPVHIMZ  DMVTUFS
BSPVOE  QQN 	'JH %
 UIF DIBSBDUFSJTUJD ) DIFNJDBM TIJGUT
PG -FY BOE '$I#  PMJHPTBDDIBSJEFT EJTQMBZFE B DIFNJDBM
TIJGU   QQN UIBU BSF TVNNBSJ[FE JO 'JHVSF  	GPS EFUBJMT TFF
5BCMF 4
 *O BEEJUJPO  WBMVFT GSPN QVCMJDBUJPOT XFSF JODMVEFE
	NBSLFE XJUI  JO 5BCMF 4
 *O HFOFSBM POMZ ˞ BOE ˞
GVDPTZMBUFE HMZDBOT XFSF GPVOE CVU OP SFQSFTFOUBUJWFT XJUI ˞
BOE ˞GVDPTZMBUJPO 'VDPTF JO ˞ QPTJUJPO JT BMXBZT BDDPN
QBOJFE XJUI B ˟MJOLFE TBDDIBSJEF UZQJDBMMZ (BM (MD/"D PS
(BM/"D XIFSFBT ˞MJOLFE GVDPTF JT BMXBZT BDDPNQBOJFE XJUI
B ˟MJOLFE TBDDIBSJEF UZQJDBMMZ (BM PS (MD/"D MFBEJOH UP UIF
GPMMPXJOH DPOTFOTVT TFRVFODFT 9˟<'VD˞>: BOE 9˟
<'VD˞>: JO XIJDI 9 TUBOET GPS UIF TUBDLJOH TBDDIBSJEF BOE :
JT B TBDDIBSJEF XJUI FRVBUPSJBM IZESPYZ HSPVQT BU QPTJUJPOT  BOE
 /JOF EJGGFSFOU CSBODIFE USJTBDDIBSJEF FMFNFOUT XFSF PCTFSWFE
BT TIPXO PO UIF MFGU PG 'JH  	UZQJDBM FYBNQMFT PO UIF SJHIU
 "MM
DMBTTFT EJTQMBZ B DIFNJDBM TIJGU GPS ) PG 'VD CFUXFFO  BOE
 QQN JOEJDBUJWF PG B $)ຘຘຘ0 IZESPHFO CPOE 5IJT TVHHFTUT
UIBU BMM PG UIPTF USJTBDDIBSJEF DPSF TUSVDUVSFT BEPQU B TUBCJMJ[FE
% TUSVDUVSF TJNJMBS UP '$I# BOE -FY &YDFQUJPOT BSF GPVS ˞
GVDPTZMBUFE HMZDBOT UIBU EJTQMBZ B DIFNJDBM TIJGU DMPTF UP UIF DVU
PGG TIJGU PG  QQN BOE TFFN UP CF QBSU PG BOPUIFS DMVTUFS 	'JH
%
 QSPCBCMZ SFGMFDUJOH B EJGGFSFOU LJOE PG TUBCJMJ[BUJPO
5IF GJSTU UXP DBUFHPSJFT DPOUBJO UIF XJEFMZ BCVOEBOU -FXJT
UZQF CMPPE HSPVQ BOUJHFOT -FB -FC -FY BOE -FZ BT XFMM BT
TVCTUJUVUFE WFSTJPOT UIFSFPG JODMVEJOH TJBMZM -FY 	T-FY
 BOE TFW
FSBM TVMGBUFE -FY -FZ BOE T-FY FQJUPQFT (MZDBOT DPOUBJOJOH
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&IG  #OMPARISON OF THE THREEDIMENSIONAL STRUCTURES OF METHYL ,EX METHYL ,EA &#H" ,$.& "V AND ,$&4 !	 2EPRESENTATIVE .-2 STRUCTURE OF METHYL
,EX 4HE #(ຘຘຘ/ HYDROGEN BOND IS INDICATED BY AN ORANGE DOTTED LINE AND THEIR #ದ/ DISTANCE IS GIVEN )N ADDITION THE CHEMICAL SHIFT OF ( OF &UC IS INDICATED
IN BLUE "&	 2EPRESENTATIVE .-2 STRUCTURES OF METHYL ,EA &#H" ,$.& "V AND ,$&4 RESPECTIVELY
'$I# BSF NFNCFST PG UIF UIJSE DBUFHPSZ UIBU JODMVEFT ˞
GVDPTZMBUFE /HMZDBO DPSFT UZQJDBMMZ GPVOE JO QMBOUT BOE JOWFSUF
CSBUFT 	
 *OUFSFTUJOHMZ TFWFSBM BEEJUJPOBM NPUJGT BSF QSFTFOU
˞'VDPTZMBUFE -BDEJ/"D 	-%/'
 QSFTFOU JO IFMNJOUIT 	

 BOE TFB TRVJSU 	
 TQFDJFTTQFDJGJD BNQIJCJBO FHH KFMMZ DPBUT
XJUI BO ˞GVDPTZMBUJPO 	
 BOE GVDPTZMBUFE DIPOESPJUJO TVMGBUF
	
 BMTP EJTQMBZ UIF EPXOGJFMETIJGUFE ) SFTPOBODF PG UIFJS 'VD
NPJFUZ .PSFPWFS -FXJTUZQFMJLF BOUJHFOT XIFSF UIF SFEVDJOH
FOE (MD/"D JT TVCTUJUVUFE CZ (MD GVMGJMM UIF TFBSDI DSJUFSJPO BT
XFMM *U JT OPUFXPSUIZ UIBU ˞MJOLFE 'VD BT GPVOE GPS FYBNQMF
JO EFUFSNJOBOUT GPS CMPPE HSPVQT " # BOE ) EP OPU EJTQMBZ
UIF DIBSBDUFSJTUJD EPXOGJFME DIFNJDBM TIJGU PG ) PG 'VD TVHHFTU
JOH UIBU UIPTF NPUJGT BSF OPU TUBCJMJ[FE CZ B DPNQBSBCMF JOUSB
NPMFDVMBS $)ຘຘຘ0 IZESPHFO CPOE
/.3 TUSVDUVSF EFUFSNJOBUJPO PG DBSCPIZESBUFT XJUI QSF
EJDUFE TUBCJMJ[BUJPO
*O B OFYU TUFQ XF XBOUFE UP WFSJGZ WBSJPVT TUSVDUVSFT PG 'JHVSF
 UIBU XFSF QSFEJDUFE UP CF TUBCJMJ[FE CZ B $)ຘຘຘ0 IZESPHFO
CPOE BOE XF VTFE PVS FGGJDJFOU BQQSPBDI CZ /.3 TQFDUSPTDPQZ
UP TUVEZ UIF % TPMVUJPO TUSVDUVSF PG UIF CMPPE HSPVQ FQJUPQF
-FB GVDPTZMBUFE -BDEJ/"D 	-%/'
 UIF BNQIJCJBO FHH HMZDBO
#W 	
 BOE MBDUPEJGVDPUFUSBPTF 	-%'5
 FBDI B SFQSFTFOUBUJWF
PG BOPUIFS USJTBDDIBSJEF DBUFHPSZ 	TFF UIF .FUIPET TFDUJPO BOE
5BCMF 4
 8F PCUBJOFE XFMMEFGJOFE TUSVDUVSFT UIBU BSF NBSLFEMZ
TJNJMBS UP '$I# BOE -FY BOE NPTU JNQPSUBOUMZ DPOUBJOFE B
DPNQBSBCMF $)ຘຘຘ0IZESPHFO CPOE CFUXFFO) PG 'VD BOE0 PG
FJUIFS (BM (BM/"D PS (MD/"D 	TFF 'JH 
 "MM TUSVDUVSFT TIPXFE
DPNQBSBCMF)ຘຘຘ0 EJTUBODFT JO UIF/.3FOTFNCMFT BOE TMJHIUMZ
TIPSUFS EJTUBODFT JO UIF %'5PQUJNJ[FE TUSVDUVSFT 	5BCMF 
 5IF
CPOE DSJUJDBM QPJOUT JOEJDBUFE UIF QSFTFODF PG B $)ຘຘຘ0 IZESPHFO
CPOE JO FBDI TUSVDUVSF 	5BCMF 4
 BOE UIF DBMDVMBUFE DIFNJDBM
TIJGUT PG) PG 'VD DPSSFTQPOEXFMM UP UIF FYQFSJNFOUBMMZ PCTFSWFE
POFT 	5BCMF 4
 JOEJDBUJOH UIF TJNJMBSJUZ PG UIPTF GPVS TUSVDUVSFT
SFQSFTFOUJOH GPVS BEEJUJPOBM DBUFHPSJFT JO 'JHVSF  XJUI -FY BOE
'$I#
5P GVSUIFS BOBMZ[F UIF TJNJMBSJUZ CFUXFFO UIF TJY EJGGFSFOU
TUSVDUVSFT XF VTFE EJIFESBMBOHMF QMPUT PG UIF HMZDPTJEJD MJOL
BHFT 	'JH 
 5IF EJIFESBM BOHMFT PG UIF HMZDPTJEJD MJOLBHFT BSF
CBTJDBMMZ JEFOUJDBM GPS -FY -FB '$I# -%/' #W BOE -%'5
JOEJDBUJOH UIBU UIFZ TIBSF UIF TBNF VOEFSMZJOH BSDIJUFDUVSF PG
XIJDI UIF $)ຘຘຘ0 IZESPHFO CPOE JT BO JOUFHSBM QBSU
%FUFDUJOH TUSVDUVSFE $)ຘຘຘ0 IZESPHFO CPOETUBCJMJ[FE DBS
CPIZESBUFT JO QSPUFJO DSZTUBM TUSVDUVSFT
5IF XFMMEFGJOFE /.3 TUSVDUVSFT PG -FY -FB '$I#
-%/' #W BOE -%'5 QSPNQUFE VT UP BOBMZ[F QSPUFJO DSZTUBM
TUSVDUVSFT DPOUBJOJOH PUIFS SFQSFTFOUBUJWFT PG UIF USJTBDDIBSJEFT
EJTQMBZFE JO 'JHVSF  FJUIFS BT MJHBOE PS XJUIJO B HMZDBO $SZTUBM
TUSVDUVSFT GPS GPVS PVU PG UIF OJOF USJTBDDIBSJEF DBUFHPSJFT BSF
BWBJMBCMF 	NBSLFE XJUI B HSFZ CBDLHSPVOE JO 'JH  5BCMFT 
BOE 4
 %VF UP JUT IJHI BCVOEBODF JO /HMZDBO DPSFT PG QMBOU
QSPUFJOT '$I# JT PWFSSFQSFTFOUFE 'PS DPNQBSJTPO XF JODMVEFE
BMTP B DSZTUBM TUSVDUVSF PG JTPMBUFE -FY GSPN UIF $BNCSJEHF
4USVDUVSBM %BUBCBTF 	$4%
 *O BMNPTU BMM PG UIF  FYUSBDUFE
DSZTUBM TUSVDUVSFT GSPN UIF 1%# UIF USJTBDDIBSJEF BEPQUT UIF
TBNF DPOGPSNBUJPO BT XF GPVOE GPS UIF TJY TPMVUJPO TUSVDUVSFT
PG -FY -FB '$I# -%/' #W BOE -%'5 0OMZ JO UIF DBTF PG
 DBSCPIZESBUF TUSVDUVSFT GSPN  1%# FOUSJFT UIF DBSCPIZESBUFT
BEPQUFE B EJGGFSFOU FYUFOEFE DPOGPSNBUJPO JOEJDBUFE CZ B MBSHF
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&IG  #OMPARISON OF THE GLYCOSIDIC LINKAGES OF METHYL ,EX METHYL
,EA &#H" ,$.& "V AND ,$&4 !	 #OMPARABLE PHIPSI PLOT OF THE &UC9
LINKAGES 7E CHOOSE THE .-2 ANGLE DElNITION PHI (#/#v8 PSI #
/#v8(v8	 RATHER THAN THE 8RAY DIHEDRAL ANGLE DElNITION PHI /#/
#v8 PSI #/#v8#v8	 BECAUSE THE LATTER WOULD LEAD TO DIFFERENT ANGLES
BETWEEN ˞ AND ˞FUCOSYLATED GLYCANS DIFFERING BY∼r !NGLES WERE
EXTRACTED BY #!20 	 "	 #OMPARABLE PHIPSI PLOT OF THE 89 LINKAGES IN
WHICH 8 STANDS FOR THE SACCHARIDE THAT STACKS WITH THE &UC AND 9 STANDS FOR
SACCHARIDE TO WHICH 9 AND &UC ARE CONNECTED
&IG  $ISTRIBUTION OF THE (/ DISTANCES BETWEEN &UC ( AND ITS CORRE
SPONDING HYDROGEN BONDED OXYGEN IN GLYCAN STRUCTURES FROM THE 0$" 4HE
SUM OF THE VAN DER 7AAL RADII IS INDICATED 4HE WHITE BARS REPRESENT THE
DISTANCES FROM THE STRUCTURE 3%* IN WHICH THE CARBOHYDRATE COORDINATES ARE
CHARACTERIZED BY UNUSUALLY HIGH "FACTORS
EJTUBODF CFUXFFO UIF GVDPTF BOE UIF TUBDLJOH TBDDIBSJEF 	5BCMF
4

*O UIF SFNBJOJOH  HMZDBO TUSVDUVSFT UIF EJTUBODF CFUXFFO
) PG 'VD BOE0 PG(BM(BM/"D(MD/"D DMVTUFST BSPVOE∼
&IG  3ECONDARY STRUCTURE IN GLYCANS !	 3UPERPOSITION OF A REPRESENTATIVE
.-2 STRUCTURE OF ,EX PURPLE	 ,EA CYAN	 &#H" GREEN	 ,$.& PINK	 "V
PALE GREEN	 AND ,$&4 BROWN	 4HE SHARED ARCHITECTURE IS COLORED IN YELLOW
AND THE #(ຘຘຘ/HYDROGEN BOND IS ILLUSTRATED BY A DOTTED ORANGE LINE 0ROTONS
ARE OMITTED FOR CLARITY EXCEPT &UC ( THAT IS COLORED IN GREY "	 #ONSENSUS
STRUCTURE OF BRANCHED TRISACCHARIDES STABILIZED BY A #(ຘຘຘ/ HYDROGEN BOND
/BSERVED MODIlCATIONS ARE GIVEN IN BLUE #	 3CHEMATIC PRESENTATION OF A
SHORT ˞HELIX 4HE AMINO ACID SITE CHAINS ARE INDICATED AS FUNCTIONAL GROUPS
2ಿ TO 2ಿ
	'JH  5BCMF  BOE 4
 &WFO JG TPNF PG UIFTF DMVTUFSFE EJTUBODFT
BSF TMJHIUMZ CJBTFE EVF UP SFQVMTJWF UFSNT CFUXFFO ಯOPOCPOEFEರ
BUPNT JO UIF BQQMJFE GPSDFGJFMET 	
 UIFZ BSF DMFBSMZ TIPSUFS UIBO
FYQFDUFE GSPN UIF TVN PG UIF WBOEFS8BBMT SBEJJ PG   	

5IFSF JT OP EJGGFSFODF JO UIF )0 EJTUBODF EFQFOEJOH PO UIF
LJOE PG USJTBDDIBSJEF 	5BCMF 
 *O UIF  1%# FOUSJFT XJUI UIF
FYUFOEFE DPOGPSNBUJPOT UIF EJTUBODF JT MBSHFS UIBO   BOE UIF
TUSVDUVSFT BSF TJHOJGJDBOUMZ EJGGFSFOU 0OF PG UIPTF FYDFQUJPOT JT B
HMZDBO JO DPNQMFY XJUI BO JOBDUJWBUFE HMZDPTJEF IZESPMBTF ()
	
 UIBU OPSNBMMZ DMFBWFT (BM˟(MD/"D MJOLBHFT ದ FYBDUMZ UIF
MJOLBHF UIBU JT EJTUPSUFE JO UIF TUSVDUVSF TP XF TQFDVMBUF UIBU UIJT
EJTUPSUJPO JT SFRVJSFE GPS UIF FO[ZNBUJD GVODUJPO
*O TVNNBSZ  PG DSZTUBM TUSVDUVSFT 	'JH  JOEJDBUFE CZ B
HSFZ CBDLHSPVOE
 DPOGJSN UIBU UIF HMZDPFQJUPQFT PG -FY -FZ -FB
-FC '$I# EJGVDPTZMBUFE /HMZDBO DPSFT -FBMJLF BOE B -FZ
MJLF NPUJGT 	(MD JOTUFBE PG (MD/"D
 TIBSF UIF TBNF BSDIJUFDUVSF
BOE DPOUBJO B $)ຘຘຘ0 IZESPHFO CPOE JO UIFJS USJTBDDIBSJEF NPUJG
XIFO CPVOE PS MJOLFE UP QSPUFJO
"MMPXFE TVCTUJUVUJPOT
5IF QSFTFOU XPSL TVHHFTUT UIF TBNF DPSF BSDIJUFDUVSF PG BMM
UIF HMZDBONPUJGT JO 'JHVSF  BOE5BCMF 4 DPOTJTUJOH PG BO˞-'VD
UIBU TUBDLT UP B (BM(MD/"D(BM/"D BOE B (MD/"D(MD(MD"
UIBU DPOOFDUT CPUI TUBDLJOH TBDDIBSJEFT XJUI FJUIFS ˞ BOE
˟ PS ˞ BOE ˟ MJOLBHFT 	CPUI JO FRVBUPSJBM QPTJUJPO
 "
TVQFSQPTJUJPO PG UIF TJY /.3 TUSVDUVSFT PG '$I# -FY -FB
-%/' #W BOE -%'5 JMMVTUSBUFT UIF TIBSFE BSDIJUFDUVSF 	'JH
"
 5IF WBSJPVT TVCTUJUVUJPOT BOE BEEJUJPOBM DBSCPIZESBUF MJOL
BHFT BSF TVNNBSJ[FE JO 'JHVSF # 8IFSFBT UIF -'VD NPJFUZ
JT NPTUMZ OPU NPEJGJFE 	FYDFQU BU 0 XJUI 3
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UIF(BM(MD/"D(BM/"DNPJFUJFT TUBDLFE VQPO'VD BSF GPVOE PO
BMM QPTJUJPOT $ 0 0 BOE 0 	GVODUJPOBM HSPVQT 3 3 3
3
 5IF (MD/"D(MD(MD" BU UIF CSBODI TJUF DBO CF DPOOFDUFE
JO UXP PSJFOUBUJPOT 	TXBQQJOH UIF FRVBUPSJBM 0 BOE0 MJOLBHFT

BOE DBO DPOUBJO WBSJPVT FRVBUPSJBM TVCTUJUVFOUT BU $ BOE $ 	3
BOE 3
 5IF ˞-'VD NPJFUZ JT UIF JOUFHSBM QBSU PG UIF DPOTFSWFE
TFDPOEBSZ TUSVDUVSF TJODF ˞DPOGJHVSBUJPO JT B QSFSFRVJTJUF GPS UIF
QSPQFS PSJFOUBUJPO PG UIF $)ຘຘຘ0 IZESPHFO CPOE -TBDDIBSJEFT
BSF SBSF BNPOH UIF DPNNPO HMZDBOT BOE POMZ ˞-SIBNOPTF
FYIJCJUJOH EFWJBUJOH DIJSBMJUZ GSPN ˞-'VD BU $ BOE $ NJHIU
GVMGJMM UIF SPMF PG UIF ˞-TBDDIBSJEF *OUFSFTUJOHMZ UIF SFDFOUMZ
BTTJHOFE DIFNJDBM TIJGUT PG UIF VOVTVBM 0BOUJHFO 	3IB ˞3IB
˞<(BM/"D˟>(MD/BD˞
O TIPXT BO 3IB ) SFTPOBODF BU
 QQN TVHHFTUJOH B TJNJMBS TUBCJMJ[BUJPO 	

$ISCUSSION
" TJNQMF IJHIMZ FGGJDJFOU NFUIPE UP PCUBJO UISFFEJNFOTJPOBM
TUSVDUVSFT PG TNBMM PMJHPTBDDIBSJEFT XJUI B NPMFDVMBS TJ[F 
 %B JT JOUSPEVDFE VTJOH /0&4: TQFDUSB NFBTVSFE BU MPX
UFNQFSBUVSF BOE VMUSBIJHI NBHOFUJD GJFMET 	ุ .)[
 5IF
TJNQMJDJUZ PG UIJT BQQSPBDI QSFEFTUJOFT JU GPS B CSPBEFS VTF BOE
UIF BQQMJDBUJPO UP PUIFS DMBTTFT PG NPMFDVMFT MJLF OBUVSBM QSPEVDUT
BOE TNBMM QFQUJEFT JODMVEJOH DZDMJD QFQUJEFT
5IF EFUFSNJOFE /.3 TUSVDUVSFT UPHFUIFS XJUI FYJTUJOH QSP
UFJODBSCPIZESBUF DSZTUBM TUSVDUVSFT PG ˞ BOE ˞GVDPTF
CSBODIFE PMJHPTBDDIBSJEFT 	'JH 
 TIPX UIBU BMM BEPQU B EFGJOFE
DPOGPSNBUJPO BOE TIBSF UIF TBNF TQBUJBM BSDIJUFDUVSF $PNNPO
UP UIPTF TUSVDUVSFT JT B DIBSBDUFSJTUJD DIFNJDBM TIJGU PG ) PG -
'VD UIBU JT JOEJDBUJWF PG B $)ຘຘຘ0 IZESPHFO CPOE CFUXFFO ) PG
'VD BOE UIF SJOH PYZHFO PG B OFJHICPSJOH (BM(MD/"D(BM/"D
NPJFUZ 4JY /.3 TPMVUJPO TUSVDUVSFT UXP DSZTUBM TUSVDUVSFT PG
BO JTPMBUFE DBSCPIZESBUF BOE BEEJUJPOBMMZ  PMJHPTBDDIBSJEF
TUSVDUVSFT GPVOE JO UIF 1%# EBUBCBTF TVQQPSU B DPNNPO BSDIJ
UFDUVSF PG 9˟<'VD˞>: PS 9˟<'VD˞>: HMZDPFQJ
UPQFT 	'JH 
 UIBU JT TUBCJMJ[FE CZ B $)ຘຘຘ0 IZESPHFO CPOE
5IF DPOTFOTVT TUSVDUVSF 	'JH #
 QSPWJEFT B DPODFQUVBM CBTJT
GPS VOEFSTUBOEJOH B MBSHF QBSU PG HMZDPFQJUPQFT CZ UIFJS TIBSFE
BSDIJUFDUVSF UIBU JT TJNJMBS UP TFDPOEBSZ TUSVDUVSF FMFNFOUT JO
QSPUFJOT 'PS FYBNQMF BO ˞IFMJY BT EFQJDUFE JO 'JH $ UIF WBSJFUZ
PG BNJOP BDJE TJEF DIBJOT 	3ಿ3ಿ
 QSPWJEF B TQFDJGJD TVSGBDF
GPS JOUFSBDUJPOT *O BOBMPHZ UIF SFDPHOJUJPO PG UIF HMZDPFQJUPQFT
	'JH #
 JT NFEJBUFE CZ UIFJS FYQPTFE GVODUJPOBM HSPVQT 	3
3
 8IFSFBT JO UIF EJTQMBZFE IFQUBQFQUJEF  CBDLCPOF BOHMFT
BSF NBJOMZ TUBCJMJ[FE CZ GPVS IZESPHFO CPOET 	∼ LDBMNPM
FBDI
 UIF GPVS HMZDPTJEJD BOHMFT PG UIF USJTBDDIBSJEFT 	'JH #

BSF TUBCJMJ[FE CZ POF $)ຘຘຘ0 IZESPHFO CPOE 	∼ LDBMNPM

UPHFUIFS XJUI PUIFS TUBDLJOH JOUFSBDUJPOT 	∼ LDBMNPM
 	

TUFSJD IJOESBODF BU UIF HMZDPTJEJD MJOLBHFT PS TPNFUJNFT CFUXFFO
CVMLZ TVCTUJUVUJPOT BOE GVSUIFS TUBCJMJ[BUJPO CZ UIF FYPBOPNFSJD
FGGFDU 8F OBNF UIBU TUSVDUVSBM FMFNFOU ಫ<>'CSBODIಬ TUBOEJOH
GPS B HMZDBO CSBODI QPJOU XJUI FJUIFS ˞ PS ˞'VD 4NBMM
NPEJGJDBUJPOT PG UIF TVCTUJUVUJPOT DIBOHF UIF HMZDPFQJUPQF UIBU
DBO MFBE UP NBSLFEMZ EJGGFSFOU SFDPHOJUJPO FWFOUT GPS FYBNQMF
B ಿTVMGP NPEJGJDBUJPO NBLFT T-FY JOWJTJCMF GPS -TFMFDUJO 	

CVU HFOFSBUFT B HMZDPFQJUPQF UIBU DBO CF SFDPHOJ[FE CZ 4JHMFD
 	
 ,FZ UP PVS DPODMVTJPOT XFSF DBSCPIZESBUF EBUBCBTFT UIBU
JODMVEFE TFBSDIBCMF DIFNJDBM TIJGU BOE TUSVDUVSBM EBUB 	 

$BSCPIZESBUFT XJUI B QSFEFGJOFE CJPMPHJDBMMZ BDUJWF TPMVUJPO
TUSVDUVSF BSF QFSGFDU MJHBOET TJODF UIFZ EP OPU SFRVJSF UP DIBOHF
UIFJS DPOGPSNBUJPO VQPO CJOEJOH BOE IBWF UIVT UIF BEWBOUBHF PG
B MPXFS FOUSPQJD QFOBMUZ BOE B GBTUFS POSBUF 	L0/
 VQPO CJOEJOH
UP UIFJS UBSHFU MFDUJO "O FYBNQMF JT '$I# XIJDI JT CPVOE CZ
UIF MFDUJO $$- XJUI B NPEFSBUFMZ IJHI BGGJOJUZ 	,%   ˩.

BOE BEPQUT UIF TBNF DPOGPSNBUJPO JO TPMVUJPO BOE JO UIF DPNQMFY
XJUI UIF MFDUJO 	
 5IF BEWBOUBHF PG B QSFEFGJOFE DPOGPSNBUJPO
JT CFTU JMMVTUSBUFE CZ T-FY BOBMPHVFT UIBU XFSF EFWFMPQFE BT &
TFMFDUJO BOUBHPOJTUT 	  
 *O UIF DBTF PG BO SFQMBDFNFOU
PG UIF (MD/"D NPJFUZ CZ FJUIFS DZDMPIFYBOFEJPM PS GMFYJCMF
FUIZMFOHMZDPM B NPSF UIBO GPME IJHIFS JOIJCJUPSZ DPODFOUSB
UJPO *$ JT PCTFSWFE GPS UIF GMFYJCMF BOBMPHVF DPNQBSFE UP UIF
DZDMPIFYBOF EFSJWBUJWF $ZDMPIFYBOFEJPMT NJNJD UIF (MD/"D
BOE EP OPU BMMPX GSFF SPUBUJPO XIJDI JT BMTP SFGMFDUFE CZ B )
DIFNJDBM TIJGU PG 'VD PG ದ QQN JOEJDBUJWF PG UIF QSFTFODF
PG B $)ຘຘຘ0 IZESPHFO CPOE XIFSFBT JU JT POMZ  QQN GPS UIF
GMFYJCMF WFSTJPO 5IJT TVQQPSUT PVS IZQPUIFTJT UIBU UIF QSFGPSNFE
TFDPOEBSZ TUSVDUVSF TUBCJMJ[FE CZ B $)ຘຘຘ0 IZESPHFO CPOE JT B
SFRVJSFNFOU GPS IJHI BGGJOJUZ SFDPHOJUJPO
"NPOH UIF HMZDBOT BEPQUJOH UIF QSFTFOUFE TFDPOEBSZ TUSVD
UVSF BSF IJHIMZ JNQPSUBOU HMZDPFQJUPQFT T-FY BOE TVMGP T-FY
OBUVSBM MJHBOET PG TFMFDUJOT UIBU BSF JOWPMWFE JO MFVDPDZUF SPMMJOH
BOE IPNJOH 	 
 T-FY JO UIF [POB QFMMVDJEB JT DSVDJBM GPS
IVNBO GFSUJMJ[BUJPO 	
 ಬTVMGP T-FY JT TQFDJGJDBMMZ SFDPHOJ[FE
CZ 4JHMFD 	
 BO JNNVOPTVQQSFTTJWF DPSFDFQUPS QSFTFOU PO
FPTJOPQIJMFT XIFSFBT TVMGP T-FY JT B MJHBOE GPS 4JHMFD 	

*O BEEJUJPO -%/' ದ B DFOUSBM QBSU PG BO BMMFSHFOJD TFB TRVJSU
QFOUBTBDDIBSJEF 	
 BOE QSFTFOU JO HMZDBOT PG QBSBTJUJD IFMNJOUIT
	
 BOE ˞GVDPTZMBUFE /HMZDBO DPSFT ದ NBKPS BMMFSHJD
EFUFSNJOBOUT PG QPMMFO BOE JOTFDU WFOPNT 	
 BSF GPVOE 4VS
QSJTJOHMZ BNPOH UIF TUBCJMJ[FE HMZDPFQJUPQFT JT BMTP GVDPTZMBUFE
DIPOESPJUJO TVMGBUF GPVOE JO DSBC 	
 BOE TFB DVDVNCFS 	
 UIBU
XBT QSPNPUFE BT TFMFDUJO BOUBHPOJTU 	

0VSXPSL HJWFT BMTP JOTJHIUT JOUP UIFNPMFDVMBS CBTJT GPS CFUUFS
VOEFSTUBOEJOH DFMM EJGGFSFOUJBUJPO TUFN DFMM BOE DBODFS SFTFBSDI
"NPOH UIF IFSFQSFTFOUFE TUSVDUVSFE HMZDPFQJUPQFT 	'JH 
 BSF
TFWFO DMVTUFST PG EJGGFSFOUJBUJPO 	$%
 OBNFMZ $% 	-FY BMTP
LOPXO BT TUBHF TQFDJGJD FNCSZPOJD BOUJHFO  PS 44&"
 $%V
	4-FY
 $%T 	T-FY
 $%TV 	4-FY
 $% 	JOUFSOBM -FY

$%T 	JOUFSOBM 4-FY
 BOE $% 	-FZ
 BDDPSEJOH UP UIF
(MZDP$% EBUBCBTF 	
 'PS FYBNQMF 44&" 	-FY $%
 XBT
GPVOE BT BO FOSJDINFOU NBSLFS GPS UVNPSJOJUJBUJOH DFMMT 	5*$T

JO IVNBO CSBJO UVNPST	
 BOE UIF OPWFM BOUJCPEZ DMPOF 
UIBU SFDPHOJ[FT B DFSUBJO JOUFSOBM -FY NPUJG DBO TFMFDU TVCQPQ
VMBUJPOT PG FNCSZPOJD NPVTF CSBJO DFMMT EJTQMBZJOH NVMUJQPUFODZ
BOE JODSFBTFE OFVSPTQIFSF GPSNJOH DBQBDJUZ 	
 #FJOH BXBSF
PG UIF QSFTFODF PG B ಫTFDPOEBSZ TUSVDUVSFಬ JO BMM UIFTF HMZDP
FQJUPQFT NJHIU HVJEF TUVEJFT UIBU GPDVT PO UIF NPMFDVMBS CBTJT
PG UIFJS GVODUJPOT JO QBSUJDVMBS UIFJS SPMFT JO EFWFMPQNFOU DFMM
EJGGFSFOUJBUJPO BOE DBODFS
*O TVNNBSZ UIF EJTDPWFSZ PG B TFDPOEBSZ TUSVDUVSF FMFNFOU
UIBU JODMVEFT B $)ຘຘຘ0 IZESPHFO CPOE BOE UIVT TUBCJMJ[FT DBSCP
IZESBUF DPOGPSNBUJPOT BEET B OFX EJNFOTJPO UP UIF HMZDPDPEF
BOE XF TQFDVMBUF UIBU NPSF TVDI TUBCJMJ[JOH JOUFSBDUJPOT BNPOH
HMZDPFQJUPQFT SFNBJO UP CF VODPWFSFE
.BUFSJBMT BOE .FUIJPET
&TUJNBUJPO PG UIF DPSSFMBUJPO UJNF ˱$ BOE UIF OVDMFBS 0WFS
IBVTFS FOIBODFNFOU5IF DPSSFMBUJPO UJNF XBT FTUJNBUFE BDDPSE
JOH UP UIF 4UPLFTಬ MBX BOE BO FTUJNBUJPO PG UIF IZESPEZOBNJD SB
EJVT GPSN UIF NPMFDVMBS XFJHIU BDDPSEJOH UP $BWBOBHI FU BM 	

BTTVNJOH BO BWFSBHF TQFDJGJD WPMVNF PG UIF DBSCPIZESBUF PG 
DNH BOE B IZESBUJPO MBZFS PG   7JTDPTJUZ WBMVFT SFQPSUFE GPS
%0 	
 XFSF VTFE 5IF OVDMFBS 0WFSIBVTFS FOIBODFNFOU XBT
DBMDVMBUFE GPS B USBOTJFOU /0& FYQFSJNFOU JO EFQFOEFODF PG UIF
NBHOFUJD GJFME BDDPSEJOH UP /FVIBVT BOE 8JMMJBNTPO 	

$BSCPIZESBUF TBNQMFT -FY NFUIZM HMZDPTJEF -FB NFUIZM
HMZDPTJEF 'VD˞(MD/"D NFUIZM HMZDPTJEF BOE -%'5 XFSF QVS
DIBTFE GSPN $BSCPTZOUI 	6,
 5IF TZOUIFTJT PG -%/' BOE PG
'$I# JT EFTDSJCFE JO UIF 4* .FUIPET #W XBT B HFOFSPVT HJGU
PG UIF MBCPSBUPSZ PG :BOO (VFSBSEFM 	-JMMF
 $BSCPIZESBUFT XFSF
EJTTPMWFE JO FJUIFS %0 PS  )0 %0 XJUI DPODFOUSB
UJPOT CFUXFFO  BOE  N.
/.3 4QFDUSPTDPQZ "MM TQFDUSB XFSF BDRVJSFE PO #SVLFS
"WBODF ***  .)[  .)[ BOE  .)[ TQFDUSPNFUFST
FRVJQQFE XJUI DSZPHFOFUJD USJQMFSFTPOBODF QSPCFT 4QFDUSB XFSF
QSPDFTTFE JO 5PQTQJO  	#SVLFS (FSNBOZ
 BOE BOBMZ[FE JO
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4QBSLZ 	5 % (PEEBSE BOE % ( ,OFMMFS 41"3,:  6OJ
WFSTJUZ PG $BMJGPSOJB 4BO 'SBODJTDP
 3FTPOBODF BTTJHONFOU XBT
BDIJFWFE XJUI % )$ )42$ % )$ ).#$ BOE % )
) 50$4: TQFDUSB XJUI NJYJOH UJNFT SBOHJOH GSPN  NT UP 
NT % )) /0&4: FYQFSJNFOUT XFSF SFDPSEFE XJUI NJYJOH
UJNFT PG  NT "MM TQFDUSB BSF SFGFSFODFE UP EJNFUIZM
TJMBQFOUBOFTVMGPOJD BDJE 	%44
 $ DIFNJDBM TIJGUT XFSF JOEJ
SFDUMZ SFGFSFODFE VTJOH B TDBMJOH GBDUPS ˌ PG  BD
DPSEJOH UP .BSLMFZ FU BM 	
 "TTJHOFE )$ )42$ TQFDUSB
PG BMMJOWFTUJHBUFE PMJHPTBDDIBSJEFT BSF TIPXO JO UIF 4VQQPSUJOH
*OGPSNBUJPO 	'JH 4

/.3 TUSVDUVSF DBMDVMBUJPOT 5P WFSJGZ PVS BQQSPBDI PG PC
UBJOJOH /0&T BU VMUSBIJHI GJFMET UPHFUIFS XJUI MPX UFNQFSBUVSFT
XF SFDPSEFE/0&4: TQFDUSB BU EJGGFSFOU UFNQFSBUVSFT &YDFMMFOU
/0& DSPTTQFBLT JO % /0&4: TQFDUSB XFSF PCUBJOFE BU MPX
UFNQFSBUVSF JMMVTUSBUFE GPS '$I# JO 'JH # XIFSFBT TFWFSBM
LFZ TJHOBMT BSF NJTTJOH JO B DPSSFTQPOEJOH TQFDUSVN BU  ,
	'JH 4"#
 5IBU EJGGFSFODF JT FWFO NPSF ESBTUJD GPS -FY 	'JH
4$%
 5IF DPOGPSNBUJPO JT OPU JOGMVFODFE CZ TVDI B UFNQFS
BUVSF DIBOHF BT KVEHFE GSPN BMNPTU OP DIFNJDBM TIJGU DIBOHFT
CFUXFFO OBUVSBM BCVOEBODF $)42$ TQFDUSB PG '$I# BOE
-FY SFDPSEFE BU UIF UXP EJGGFSFOU UFNQFSBUVSFT 	'JH 4&'
 *O
UIF DBTF PG '$I# GPSUZUXP /0&T IBWF CFFO VOBNCJHVPVTMZ
BTTJHOFE JODMVEJOH  JOUFSSFTJEVF /0&T 	'JH $ BOE 5BCMF
4
 'PS UIF SFNBJOJOH HMZDBOT XF DPVME FYUSBDU  EJTUBODF
SFTUSBJOUT JODMVEJOH  JOUFSSFTJEVF SFTUSBJOUT 	'JHT 4 4
BOE 5BCMFT 44
 5IF /0& DSPTTQFBLT XFSF RVBOUJGJFE BOE
DPOWFSUFE JOUP QSPUPOದQSPUPO EJTUBODFT UIBU XFSF VTFE JO TUSVD
UVSF DBMDVMBUJPOT BT VQQFSMJNJU SFTUSBJOUT 	5BCMFT 44
 .PSF
QSFDJTFMZ TJHOBM UP OPJTF 	4/
 SBUJPT PG UIF /0& DSPTT QFBLT
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Figure S1. Three-dimensional structure determination of methyl Lex. (A) 900 MHz 2D NOESY spectra of 
methyl Lex (3.7 mM) in either H2O (red, left) or in D2O (blue, right) measured at 277 K. Chemical shift 
assignments are indicated on the top for isolated resonances. (B) Schematic presentation of methyl Lex with the 
observed inter-residue NOEs indicated by red arrows. (C) The ensembles of 20 best structures based on NOESY 
data recorded at 277 K. (D) Most representative NMR structure (yellow) superimposed with a representative 
obtained from a Lex-protein conjugate recorded at 293 K (purple)(1). For simplicity only heavy atoms are 
shown. The C-H⋅⋅⋅O hydrogen bond is shown as a dashed green line. (E) Comparison with the crystal structure 
ABUCEF of methyl Lex that contained two molecules in the asymmetric unit (cyan) with the most representative 
NMR structure obtained from 277 K data (yellow). 
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Figure S2. Structures of 3FChB, Lex, Lea, LDNF, Bv9 and LDFT optimized with density functional theory 
(DFT) and bond critical points of the C-H⋅⋅⋅O hydrogen bonds. (A) Overlay of the DFT-optimized structure 
(yellow) with the representative NMR structure (sky blue) of 3FChB. The latter was used as start structure for 
the DFT optimization. (B) Comparison of the DFT-optimized structure (yellow) with the representative NMR 
structure (sky blue) of Lex. (C) Structure of 3FChB optimized with DFT with the bond critical point of the C-
H⋅⋅⋅O hydrogen bond indicated as magenta sphere. (D) DFT-optimized structure of Lex with the bond critical 
point. (E) DFT-optimized structure of Lea with the bond critical point. (F) DFT-optimized structure of LDNF 
with the bond critical point. (G) DFT-optimized structure of Bv9 with the bond critical point. (H) DFT-
optimized structure of LDFT with the bond critical point. 
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Figure S3. Structure determination of methyl Lea, LDNF, Bv9 and LDFT. (A) 2D NOESY spectra of methyl Lea 
(3.7 mM) in either H2O (red, left) or in D2O (blue, right) recorded at 900 MHz and 275 K. On the top, chemical 
shift assignments of isolated resonances are indicated. (B) Schematic presentation of methyl Lea displaying the 
observed inter-residue NOEs by red arrows. (C) 2D NOESY spectra of LDNF (2.2 mM) in either H2O (red, left) 
or in D2O (blue, right) recorded at 900 MHz and 275 K. (D) Schematic presentation of LDNF displaying the 
observed inter-residue NOEs by red arrows. (E) 2D NOESY spectra of Bv9 (1 mM) in either H2O (red, left) or in 
D2O (blue, right) recorded at 900 MHz and 273 K. (F) Schematic presentation of Bv9 displaying the observed 
inter-residue NOEs by red arrows. The hexene-tetrol at the reducing end is indicated by ‘sp’. (G) 2D NOESY 
spectrum of LDFT (3.2 mM) in D2O recorded at 900 MHz and 275 K. (H) Schematic presentation of LDFT(β) 
displaying the observed inter-residue NOEs by red arrows. Only NOEs of the major β anomer are shown. 
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Figure S4. Influence of temperature on 2D NOESY spectra and chemical shifts of 3FChB and Lex methyl 
glycoside. (A) Region of a 2D NOESY spectrum of 3FChB (2.8 mM) recorded at 298 K and 900 MHz. 
Intermolecular NOE cross-peaks are indicated by a red arrow. (B) Corresponding region of a 2D NOESY 
spectrum recorded at 277 K and 900 MHz. (C) Region of a NOESY spectrum of Lex methyl glycoside (3.7 mM) 
recorded at 293 K and 900 MHz. (D) Corresponding region of 2D NOESY spectrum recorded at 277 K and 900 
MHz. All spectra are referenced to DSS. (E) Overlay of two 1H-13C HSQC spectra of 3FChB (2.8 mM) recorded 
at 900 MHz and either 277 K (blue) or 298 K (red). The spectra are referenced to DSS. (F) 1H-13C HSQC spectra 
of Lex methyl glycoside (3.7 mM) recorded at 900 MHz and either 277 K (blue) or 298 K (red). All spectra are 
referenced to DSS. 
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Figure S5. 1H-13C HSQC spectra of all investigated oligosaccharides all referenced to DSS. (A) Three regions of 
the 1H-13C HSQC spectrum of α1,3-fucosylated chitobiose (2.8 mM) measured at 600 MHz and 277 K. The 
proximal N-acetylglucosamine that harbours the α1,3 branch is indicated as "GlcNAc1", the distal N-
acetylglucosamine that stacks to the fucose is labeled "GlcNAc2". The signals of the linker 6-hydroxy hexanoate 
(-O-(CH2)5COOH) remaining from the chemical synthesis are labeled with "sp". The two correlations indicated 
with "#" originate from an impurity. (B) 1H-13C HSQC spectrum of Lex methylglycoside (3.7 mM) measured at 
900 MHz and 277 K. (C) 1H-13C HSQC spectrum of Lea methylglycoside (3.7 mM) spectrum measured at 275 
K. The two regions on the top are recorded at 900 MHz. The anomeric region (bottom) of a spectrum recorded at 
500 MHz is shown at the bottom (better perfomance of 13C decoupling compared to 900 MHz spectrum). (D) 1H-
13C HSQC spectrum of LDNF with a β–(CH2)8COOH linker (2.2 mM) measured at 900 MHz and 275 K. 
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Figure S5 (continuation). (E) 1H-13C HSQC spectrum of Bv9 with a β–hexene-tetrol moiety at the reducing end 
(1 mM) measured at 500 MHz and 273 K. Please note that 273 K was required so that the water signal was not 
overlapping with Fuc3 H1 but upfield of it. The proximal N-acetylglucosamine that harbours the α1,3 branch is 
indicated as "GlcNAc1", the distal N-acetylglucosamine that stacks to the fucose is labeled "GlcNAc2". (F) 1H-
13C HSQC spectrum LDFT with free OH at the reducing end (3.2 mM) measured at 500 MHz and 275 K. The 
spectrum is referenced to DSS. Fuc3 corresponds to the α1,2-linked fucose, Fuc4 to the α1,3-linked fucose. 
Signals depending on the anomeric state of the glucose are labeled with (α) or (β). 
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Figure S5 (continuation).  
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Table S1 NMR structure determination statistics of 3FChB (fucosylated chitobiose, 
GlcNAcβ1,4[Fucα1,3]GlcNAcβ), methyl Lex, methyl Lea, LDNF (fucosylated LacdiNAc, 
GalNAcβ1,4[Fucα1,3]GlcNAcβ) the amphibian glycan Bv9 (GlcNAcβ1,3[Fucα1,4]GlcNAcβ) and 
LDFT (Lactodifucotetraose β anomer, Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ). 
 3FChB methyl Lex methyl Lea LDNF Bv9 LDFT(β) 
NMR distance and dihedral constraints       
Distance restraints        
   Total NOE 42 29 29 42 32 42 
   Intra-residue 31 20 20 21 15 19 
   Inter-residue 11 9 9 21 17 23 
Total dihedral angle restraints 2 0 0 0 0 0 
    HN-CO peptide bonds of acetamido 2 0 0 0 0 0 
       
Structure statistics       
Violations (mean and s.d.)       
   Number of distance violations > 0.1 Å 0.0±0.0 
 
0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
   Number of dihedral angle violations > 5º 0.0±0.0 
 
0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
   Max. dihedral angle violation (º) 0.0±0.0 
 
0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 
   Max. distance constraint violation (Å)  0.04±0.00 
 
0.07±0.00 0.00±0.00 0.09±0.00 0.01±0.01 0.09±0.01 
Deviations from idealized geometry       
   Bond lengths (Å)     0.01463± 
0.0001 
 
0.01537± 
0.0002 
0.0155± 
0.0001 
0.0143± 
0.0001 
0.0147± 
0.0001 
0.0166± 
0.0002 
   Bond angles (º) 1.84±0.02 
 
1.90±0.05 1.90±0.04 1.97±0.06 1.82±0.04 2.05±0.02 
Average pairwise r.m.s. deviation* (Å)           
     all heavy  0.05±0.02 0.15±0.15 0.14±0.13 0.26±0.16 0.14±0.13 0.07±0.03 
* Pairwise r.m.s. deviation was calculated among 20 refined structures. 
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Table S2: Experimental chemical shift assignments and calculated chemical shifts using the GIAO 
method.  
 
carbohy-
drates 
Fuc α1,
3GlcNA
c 
3FChB  Lex  Lea  LDNF  Bv9  LDFT 
(β) 
 
 exp. exp. GIAO 
calc. 
exp. GIAO 
calc. 
exp. GIAO 
calc. 
exp. GIAO 
calc. 
exp. GIAO 
calc. 
exp. GIAO 
calc. 
GlcNAc/Glc 
(reducing 
end)  
 
    
  
   
 
 
H1 4.55 4.46 4.30 4.45 4.33 4.43 4.30 4.47 4.29 4.44 4.18 4.62 4.64 
H2 3.83 3.89 3.92 3.91 3.95 3.90 3.98 3.89 3.94 3.85 3.99 3.47 3.38 
H3 3.64 3.81 3.55 3.83 3.57 4.04 3.60 3.80 3.49 3.97 3.62 3.70 3.74 
H4 3.49 3.88 3.91 3.93 3.43 3.73 3.41 3.88 3.47 3.73 3.33 3.87 3.65 
H5 3.47 3.49 3.12 3.58 3.42 3.55 3.46 3.49 3.36 3.50 3.32 3.46 3.43 
H61 3.72 3.92 3.93 3.86 4.06 3.98 4.29 3.91 3.94 3.96 4.18 3.98 3.87 
H62 3.91 3.74 3.84 4.00 3.70 3.87 3.78 3.73 3.70 3.87 3.64 3.79 3.64 
Q8 2.02 2.01 (1.83) 2.02 (1.84) 2.03 (1.84) 2.01 (1.83) 2.08 (1.88) — — 
GlcNAc/Gal
/GalNAc 
(stacking 
with Fuc) 
   
    
  
  
 
 
H1 — 4.52 4.80 4.44 4.21 4.48 4.44 4.45 4.14 4.62 4.64 4.49 4.28 
H2 — 3.75 3.87 3.49 3.66 3.48 3.53 3.99 4.11 3.63 3.92 3.63 3.85 
H3 — 3.52 3.44 3.65 3.62 3.62 3.55 3.70 3.66 3.59 3.51 3.84 3.77 
H4 — 3.23 3.37 3.88 3.82 3.86 3.75 3.89 3.99 3.19 3.22 3.84 3.50 
H5 — 3.42 3.52 3.59 3.59 3.57 3.57 3.56 3.64 3.39 3.42 3.58 3.35 
H61 — 3.96 3.92 3.72 3.57 3.72 4.02 3.71 3.78 3.97 3.86 3.75 3.84 
H62 — 3.60 3.68 3.70 4.05 3,72 3.57 3.76 4.13 3.57 3.61 3.70 3.95 
Q8 — 2.04 (1.80) — — — — 2.03 (1.84) 1.99 (1.91) — — 
Fuc 
(stacking) 
             
H1 4.98 5.12 5.02 5.10 5.02 5.02 4.67 5.11 4.97 5.02 4.70 5.45 5.30 
H2 3.70 3.68 3.55 3.67 3.54 3.79 3.60 3.67 3.51 3.80 3.49 3.79 3.65 
H3 3.83 3.95 3.62 3.90 3.60 3.88 3.67 3.94 3.60 3.92 3.44 3.97 3.78 
H4 3.80 3.80 3.85 3.78 3.86 3.78 3.86 3.82 3.83 3.80 3.58 3.81 3.88 
H5 4.33 4.78 4.88 4.86 4.92 4.90 4.92 4.89 4.85 4.85 5.10 4.89 4.89 
Q6 1.16 1.26 (1.27) 1.17 (1.13) 1.17 (1.14) 1.26 (1.37) 1.27 (1.26) 1.24 (1.31) 
a The carbohydrates of which the experimental shifts were obtained were either β-methyl glycosides (Lex, Lea), 
contained a free OH (LDFT) or a spacer (-[CH2]3-NH2 in case of Fuc α1,3GlcNAc and LDNF; -[CH2]5-
COONa in 3FChB and hexenetetrol in Bv9). Calculations were obtained for the β-methyl glycosides except for 
LDFT for which the free OH as β-anomer was used. 
b Experimental values were measured at 273-278 K (see experimental section, the slightly different values were 
necessary to avoid overlap with the water signal) and referenced to DSS (0.00 ppm corresponds to 0.00 ppm 
referenced to TMS). Fuc H5 is shown in bold. The methylene groups H61 and H62 were not stereospecifically 
assigned. 
c Obtained with the GIAO chemical shift calculation in Gaussian 09 for a water environment (CPCM), values 
were referenced to TMS (separate calculation). These values are comparable to the experimental values 
because both TMS and DSS have identical 1H chemical shifts (0.00 ppm). The predicted methyl group 
chemical shifts are the average of the three calculated chemical shifts, but since methyl groups rotate fast and 
sample a full cone, the average of three individual positions is not a good approximation. Therefore the values 
are in brackets. 
 
Table S3: The hydrogen bond lenght (H...O), electron density ρ(rc), the Laplacian of the electron 
density ∇2 ρ(rc) and the ellipticity ε at the bond critical points of the DFT-minimized structures.  
 
carbohydrate Distance (H...O) 
[Å] 
ρ(rc) at bond critical 
point [au] 
∇2 ρ(rc) at bond 
critical point [au] 
ε at bond critical 
point [au] 
3FChB 2.35 0.013 0.037 0.045 
Lex 2.32 0.014 0.039 0.041 
Lea 2.33 0.013 0.038 0.046 
LDNF 2.41 0.012 0.034 0.019 
Bv9 2.33 0.013 0.038 0.049 
LDFT 2.47 0.010 0.030 0.031 
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Table S4: Carbohydrate structures with a characteristic Fuc H5 chemical shift between 4.5 and 5.0 
ppm found by a GLYCOSCIENCES.DE database search, ordered in respect to the central glyco-
motifs, together with 21 additional values from the literature (marked by +).  
 
# a Carbohydrate structure b Motif c Chemical 
shift of 
Fuc H5 d 
LINUCS ID 
or 
Referencee 
 
Lex containing carbohydrates 
   
1 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3GlcNAcβ1,3]Galβ1,4Glc Lex 4.866 1670 
2 Galβ1,4[Fucα1,3]GlcNAcβ1,4[Galβ1,4GlcNAcβ1,2]Manα1,3[Galβ1,4Glc
NAcβ1,2 Manβ1,6]Manβ1,4GlcNAcβ1,4GlcNAcβ-Asn Le
x 4.835 274 
3 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3]GalNAc-ol Lex 4.835 4286 
4 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Fucα1,2Galβ1,4GlcNA
cβ1,3]GalNAc-ol Le
x 4.835 12503 
5 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Fucα1,2Galβ1,3GlcNA
cβ1,3]GalNAc-ol Le
x 4.834 12501 
6 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,3GalNAc-ol Lex 4.833 4285 
7 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4Glc Lex 4.832 212 
8 Galβ1,4[Fucα1,3]GlcNAcβ1,4[Galβ1,4GlcNAcβ1,2]Manα1,3[Galβ1,4Glc
NAcβ1,6[Galβ1,4GlcNAcβ1,2]Manβ1,6]Manβ1,4GlcNAcβ1,4GlcNAcβ-Asn Le
x 4.832 275 
9 Galβ1,4[Fucα1,3]GlcNAcβ1,2[Galβ1,4GlcNAcβ1,6]Manα1,6[Galβ1,4Glc
NAcβ1,4[Galβ1,4GlcNAcβ1,2]Manβ1,3]Manβ1,4GlcNAcβ1,4GlcNAcβ-Asn Le
x 4.832 276 
10 Galβ1,4[Fucα1,3]GlcNAcβ1,4[Galβ1,4GlcNAcβ1,2]Manα1,6[Galβ1,4Glc
NAcβ1,4[Galβ1,4GlcNAcβ1,2]Manβ1,3]Manβ1,4GlcNAcβ1,4GlcNAcβ-Asn Le
x 4.832 277 
11 Neu5Acα2,3Galβ1,3[Neu5Acα2,6]GalNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAc
β1,6]Galβ1,4Glc Le
x 4.832 1174 
12 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,6[Galβ1,3]GlcNAcβ1,3]Galβ1,4
Glc Le
x 4.832 2835 
13 Galβ1,4[Fucα1,3]GlcNAcβ1,3[Fucα1,2]Galβ1,4GlcNAcβ1,6[GlcNAcβ1,3]
GalNAc-ol Le
x 4.831 12496 
14 Galβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,6Manβ1,4GlcNAcβ1,4[Fucα1,6] 
GlcNAcβ-Asn Le
x 4.83 273 
15 Galβ1,4[Fucα1,3]GlcNAcβ1,6[GlcNAcβ1,3]GalNAc-ol Lex 4.83 4288 
16 Galβ1,4[Fucα1,3]GlcNAcβ1,4Manα1,3Manβ1,4GlcNAcβ1,4[Fucα1,6]Glc
NAcβ-Asn Le
x 4.83 12533 
17 Galβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,3[Manα1,6]Manβ1,4GlcNAcβ1,4[Fu
cα1,6]GlcNAcβ-Asn Le
x 4.83 12538 
18 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4GlcNAcβ1,2Manα1,6Manβ1,4GlcN
Acβ1,4[Fucα1,6]GlcNAcβ-Asn Le
x 4.83 12548 
19 Galβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,6[Neu5Acα2,6Galβ1,4GlcNAcβ1,2
Manβ1,3]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAcβ-Asn Le
x 4.829 278 
20 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,4GlcNAcβ1,3]GalNAc-ol Lex 4.829 4294 
21 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Lex 4.829 4298 
22 Neu5Acα2,6Galβ1,4GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Galβ1,4G
lc Le
x 4.829 8313 
23 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]Galβ1,4Glc Lex 4.827 2838 
24 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3GlcNAcβ1,6]Galβ1,4G
lc Le
x 4.825 2837 
25 Galβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,3Manβ1,4GlcNAcβ1,4[Fucα1,6]Glc
NAcβ-Asn Le
x 4.822 272 
26 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,4GlcNAcβ1,2]Manα1,3[Galβ1,4Glc
NAcβ1,2Manβ1,6]Manβ1,4GlcNAcβ1,4GlcNAcβ-Asn Le
x 4.82 279 
27 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,3GlcNAcβ1,3]Galβ1,4Glc Lex 4.819 1668 
28 Galβ1,4[Fucα1,3]GlcNAcβ1,3[KDNα2,6]GalNAc-ol Lex 4.818 3508 
29 Galβ1,4[Fucα1,3]GlcNAcβ1,3GalNAc-o Lex 4.813 4278 
30 Galβ1,4[Fucα1,3]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Galβ1,4Glc Lex 4.829 6680 
31 Galβ1,4[Fucα1,3]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Galβ1,4Glc Lex 4.821 6680 
32 Galβ1,4[Fucα1,3]GlcNAcβ1,2[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Manα1,6Ma
nβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAcβ-Asn Le
x 4.83 12544 
33 Galβ1,4[Fucα1,3]GlcNAcβ1,2[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Manα1,6Ma
nβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAcβ-Asn Le
x 4.83 12544 
34 Galβ1,4[Fucα1,3]GlcNAcβ1,2 Manα1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,2 
Manα1,6]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAcβ-Asn Le
x 4.829 12545 
35 Galβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,2 
Manα1,6]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAcβ-Asn Le
x 4.829 12546 
36 Galβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,2 
Manα1,6]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAcβ-Asn Le
x 4.829 12546 
37 Galβ1,4[Fucα1,3]GlcNAcβ1,2 Manα1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,2 Lex 4.822 12545 
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Manα1,6]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAcβ-Asn 
38 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Galβ
1,4GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Le
x 4.81 12417 
39 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Galβ
1,4Glc Le
x 4.823 8107 
40 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,3GalN
Ac-ol Le
x 4.851 12507 
41 Neu5Acα2,3Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]
Galβ1,4Glc Le
x 4.795 4124 
42 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Neu5Acα2,3Galβ1,3[F
ucα1,4]GalNAcβ1,3]Galβ1,4Glc Le
x 4.789 4222 
43 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3[Fucα1,4]GlcNAcβ1,3]Galβ1,4Glc Lex 4.873 1671 
44 Galβ1,3GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]G
alNAc-ol Int Le
x 4.806 12413 
45 Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]G
alNAc-ol Int Le
x 4.806 12414 
46 Galβ1,3GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3]GalNAc-ol Int Lex 4.806 12419 
47 Galβ1,3GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,3GlcNA
cβ1,3]Galβ1,4Glc Int Le
x 4.801 14252 
48 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4GlcNAcβ1,6]Galβ1,4[Fucα
1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Int Le
x 4.81 12418 
49 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3GlcN
Acβ1,3]Galβ1,4Glc Int Le
x 4.801 2727 
50 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNA
cβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Int Le
x 4.81 12416 
51 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3 
Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4Glc Int Le
x 4.811 14239 
52 GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,9-9-hydroxy-Nonanoate-OMe Int Lex 4.82 9296 
53 Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,9-9-hydroxy-Nonanoate-
OMe Int Le
x 4.82 9297 
54 Neu5Acα2,6Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,9-9-hydroxy-
Nonanoate-OMe Int Le
x 4.82 9299 
55 Neu5Acα2,3Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,9-9-hydroxy-
Nonanoate-OMe Int Le
x 4.81 8860 
56 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1
,4[Fucα1,3]GlcNAcβ1,3Galβ1,4Glc Int Le
x 4.812 12761 
57 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,
4[Fucα1,3]GlcNAcβ1,3Galβ1,4Glc Int Le
x 4.812 12761 
58 Fucα1,2Galβ1,3GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,
3[Fucα1,4]GlcNAcβ1,3]Galβ1,4Glc Int Le
x 4.814 12762 
59 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα
1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3]Galβ1,4Glc Int Le
x 4.8 12763 
60 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,3GalN
Ac-ol Int Le
x 4.865 12507 
61 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,9-
9-hydroxy-Nonanoate-OMe Int Le
x 4.82 8861 
62 Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3[F
ucα1,4]GalNAcβ1,3]Galβ1,4Glc Int Le
x 4.776 4221 
63 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,4GlcNAcβ1,3]GalNAc-
ol 
Sia Lex 4.83 12342 
64 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,3GlcNAcβ1,3]G
alNAc-ol Sia Le
x 4.821 12697 
65 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,3GalNAc-ol Sia Lex 4.82 12340 
66 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[GlcNAcβ1,3]GalNAc-ol Sia Lex 4.82 12341 
67 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,3]GalNAc-ol Sia Lex 4.82 12388 
68 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,3[Neu5Acα2,6]GalNAc-
ol Sia Le
x 4.819 17378 
69 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,3[Neu5Acα2,6]GalNAc-ol Sia Lex 4.804 12408 
70 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]Galβ1,4G
lc Sia Le
x 4.798 6665 
71 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,9-
9-hydroxy-Nonanoate-OMe Sia Le
x 4.82 8861 
72 3S-Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,3]GalNAc-ol 3S-Lex 4.806 17382 
73 3S-Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol 3S-Lex 4.805 17388 
74 3S-Galβ1,4[Fucα1,3]GlcNAcβ1,3[Neu5Acα2,6]GalNAc-ol 3S-Lex 4.802 12406 
75 Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3[6S]Galβ1,4[6S]GlcNAc-ol 6S-Lex 4.783 4412 
76 Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3Galβ1,4[6S]GlcNAc-ol 6S-Lex 4.782 4410 
77 Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3[6S]Galβ1,4[6S]GlcNAcβ1,3Gal-ol 6S-Lex 4.778 3526 
78 Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAc-ol 6S-Lex 4.782 4408 
79 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3Galβ1,4Gl
cβ 
Int 6S-
Lex 4.805 22552 
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80 Fucα1,2Galβ1,3GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3Galβ1,4Glc
β 
Int 6S-
Lex 4.823 22550 
81 Fucα1,2Galβ1,3GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3Galβ1,4Glc
α 
Int 6S-
Lex 4.823 22551 
82 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3Galβ1,4Gl
cβ 
Int 6S-
Lex 4.805 22553 
83 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3G
alβ1,4Glcα 
Int 6S-
Lex 4.819 22556 
84 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3G
alβ1,4Glcβ 
Int 6S-
Lex 4.819 22557 
85 Neu5Acα2,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalN
Ac-ol 
6S-Sia 
Lex 4.802 17385 
 
Ley containing carbohydrates 
   
86 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,6Galβ1,4GlcNAcβ1,3]G
alβ1,4Glc Le
y 4.88 8312 
87 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Fucα1,2]Galβ1,4GlcNAcβ1,6[GlcN
Acβ1,3]GalNAc-ol Le
y 4.88 12499 
88 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Fucα1,2]Galβ1,4GlcNAcβ1,6[Fucα
1,2GlcNAcβ1,3]GalNAc-ol  Le
y 4.88 12504 
89 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Neu5Acα2,3Galβ1,4GlcNAcβ1,6]
GalNAc-ol Le
y 4.877 12695 
90 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,3GlcNAcβ1,3] 
GalNAc-ol Le
y 4.874 8956 
91 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Neu5Acα2,6]GalNAc-ol Ley 4.874 12386 
92 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Galβ1,4GlcNAcβ1,6]Galβ1,3GalN
Ac-ol Le
y 4.874 12508 
93 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Fucα1,2Galβ1,4GlcNAcβ1,6]Galβ1
,3GalNAc-ol Le
y 4.874 12511 
94 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3 Galβ1,3GalNAc-ol Ley 4.873 6679 
95 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,6[GlcNAcβ1,3]GalNAc-ol Ley 4.872 8949 
96 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,3]GalNAc-ol Ley 4.871 1667 
97 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Ley 4.87 12286 
98 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Fucα1,2Galβ1,4GlcNAcβ1,6] 
GalNAc-ol Le
y 4.867 8953 
99 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3GalNAc-ol Ley 4.866 4284 
100 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3]GalNAc-ol Ley 4.85 4292 
101 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ
1,6]GalNAc-ol Le
y 4.873 12510 
102 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ1,3[Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ
1,6]GalNAc-ol Le
y 4.873 12510 
103 Fucα1,2Galβ1,4[6S][Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-
ol 6S-Le
y 4.854 17381 
 
Lea containing carbohydrates 
   
104 Galβ1,3[Fucα1,4]GlcNAc Lea 4.881 1708 
105 Galβ1,3[Fucα1,4]GlcNAcβ1,3[Neu5Acα2,6Galβ1,4GlcNAcβ1,6]Galβ1,4G
lc Le
a 4.876 2836 
106 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc Lea 4.871 1223 
107 Galβ1,3[Fucα1,4]GlcNAcβ Lea 4.78 668 
108 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3Galβ1,4Gl
cβ Le
a 4.883 22552 
109 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3Galβ1,4Gl
cβ Le
a 4.883 22553 
110 Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3[Fucα1,4]GlcNAcβ1,3]Galβ1,4Glc Lea 4.915 1671 
111 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Galβ
1,4GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Le
a 4.86 12417 
112 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3GlcN
Acβ1,3]Galβ1,4Glc Le
a 4.869 2727 
113 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcN
Acβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Le
a 4.86 12416 
114 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Neu5Acα2,3Galβ1,3[F
ucα1,4]GalNAcβ1,3]Galβ1,4Glc Le
a 4.839 4223 
115 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3[Fucα1,4]GlcNAcβ1,3]
Galβ1,4Glc Le
a 4.873 2826 
116 Neu5Acα2,3Galβ1,3[Neu5Acα2,6][Fucα1,4]GlcNAcβ1,3Galβ1,4Glc Int. Lea 4.878 2780 
117 Neu5Acα2,3Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc Sia Lea 4.864 1632 
118 Galβ1,3GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Neu5Acα2,3Galβ1,3[Fucα1,4]Gl
cNAcβ1,3]Galβ1,4Glc Sia Le
a 4.838 4220 
119 Neu5Acα2,3Galβ1,3[Fucα1,4]GlcNAcβ1,3[Neu5Acα2,6Galβ1,4GlcNAcβ1 Sia Lea 4.837 4125 
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,6]Galβ1,4Glc 
120 Neu5Acα2,3Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4GlcNAcβ1,6]Galβ1,4G
lc Sia Le
a 4.836 4123 
121 Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Neu5Acα2,3Galβ1,3[Fu
cα1,4]GlcNAcβ1,3]Galβ1,4Glc Sia Le
a 4.839 4222 
122 Neu5Acα2,3Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]
Galβ1,4Glc Sia Le
a 4.836 4124 
123 Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Neu5Acα2,3Galβ1,3[Fu
cα1,4]GlcNAcβ1,3]Galβ1,4Glc Sia Le
a 4.839 4223 
124 Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3[Fu
cα1,4]GlcNAcβ1,3]Galβ1,4Glc Sia Le
a 4.838 4221 
125 3S-Galβ1,3[Fucα1,4]GlcNAcα 3S-Lea 4.874 13788 
126 3S-Galβ1,3[Fucα1,4]GlcNAcβ 3S-Lea 4.861 13788 
 
Leb containing carbohydrates 
   
127 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,3GalNAc-ol Leb 4.88 5022 
128 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Neu5Acα2,6Galβ1,4GlcNAcβ1,6]G
alβ1,4Glc Le
b 4.866 2839 
129 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[GlcNAcβ1,3]G
alNAc-ol Le
b 4.866 12497 
130 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Galβ1,4GlcNA
cβ1,3]GalNAc-ol Le
b 4.866 12506 
131 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4GlcNAcβ1,6[Fucα1,2Galβ1,
3]GalNAc-ol Le
b 4.865 12502 
132 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,3[Galβ1,4GlcNAcβ1,6]GalN
Ac-ol Le
b 4.865 12514 
133 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc Leb 4.86 1225 
134 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4GlcNAcβ1,3Galβ1,4GlcNAc
β1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Le
b 4.86 12415 
135 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Fucα1,2]Galβ1,4GlcNAcβ1,6[GlcN
Acβ1,3]GalNAc-ol Le
b 4.855 12505 
136 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,6[Galβ1,4GlcNAcβ1,3]GalNAc-ol Leb 4.82 4291 
137 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1
,2Galβ1,3[Fucα1,4]GlcNAcβ1,3]Galβ1,4Glc Le
b 4.853 12763 
138 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα
1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3]Galβ1,4Glc Le
b 4.853 12763 
139 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Galβ
1,4Glc Le
b 4.861 8107 
140 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3G
alβ1,4Glcα Le
b 4.871 22556 
141 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[6S][Fucα1,3]GlcNAcβ1,3G
alβ1,4Glcβ Le
b 4.871 22557 
142 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3 
Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1,4Glc Le
b 4.86 14239 
143 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4[Fucα1,3]GlcNAcβ1,6]Galβ
1,4GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Le
b 4.86 12417 
144 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3[Galβ1,4GlcNAcβ1,6]Galβ1,4[Fucα
1,3]GlcNAcβ1,6[Neu5Acα2,3Galβ1,3]GalNAc-ol Le
b 4.86 12418 
145 Fucα1,2Galβ1,3GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Fucα1,2Galβ1,3
[Fucα1,4]GlcNAcβ1,3]Galβ1,4Glc Le
b 4.868 12762 
146 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4[Fucα1,3]GlcNAcβ1,3Galβ1
,4[Fucα1,3]GlcNAcβ1,3Galβ1,4Glc Le
b 4.853 12761 
147 GalNAcα1,3[Fucα1,2]Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc Int Leb 4.853 1271 
148 GalNAcα1,3[Fucα1,2]Galβ1,3[Fucα1,4]GlcNAcβ1,3Gal Int Leb 4.853 14257 
 
3-Fucosylated chitobiose containing carbohydrates 
   
149 Manα1,6[Xylβ1,2]Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn 3FChB 4.722 4566 
150 Manα1,6[Manα1,3][Xylβ1,2]Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAc 3FChB 4.721 1024 
151 Manα1,6[Manβ1,3]Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn 3FChB 4.72 12525 
152 Manα1,6[Manβ1,3]Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAc 3FChB 4.71 2900 
 
4-Fucosylated GlcNAcβ1,3GlcNAc cont. carbohydrates 
   
153 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,4GalAα1,3Fucα  4.71 26716 
+1 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6-Hexene-tetrol  4.816 Coppin 2003 
+2 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[Galβ1,3]GalNAc-ol  4.809 Coppin 2003 
+3 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[GlcNAcα1,4Galβ1,3]GalNAc-ol  4.805 Coppin 2003 
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+4 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[Fucα1,2Galβ1,3]GalNAc-ol  4.809 Coppin 2003 
+5 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[Kdnα2,3Galβ1,3]GalNAc-ol  4.807 Coppin 2003 
+6 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[Kdnα2,3[Galβ1,4]Galβ1,3]GalNAc-ol  4.809 Coppin 2003 
+7 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[Kdnα2,3[GlcNAcα1,4Galβ1,4]Galβ1,3]
GalNAc-ol 
 4.811 Coppin 2003 
+8 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[NeuAcα2,3[Galβ1,4]Galβ1,3]GalNAc-ol  4.809 
Coppin 
2003 
+9 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[NeuGcα2,3Galβ1,3]GalNAc-ol  4.809 Coppin 2003 
+10 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[NeuGcα2,3[Galβ1,4]Galβ1,3]GalNAc-ol  4.807 
Coppin 
2003 
+11 GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[NeuGcα2,3[GlcNAcα1,4Galβ1,4]Galβ1,3]GalNAc-ol  4.812 
Coppin 
2003 
+12 Galβ1,4GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[Kdnα2,3Galβ1,3]GalNAc-ol  4.79 Coppin 2003 
+13 GlcNAcα1,4Galβ1,4GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[GlcNAcα1,4Galβ1,3]GalNAc-ol  4.775 
Coppin 
2003 
+14 GlcNAcα1,4Galβ1,4GlcNAcβ1,3[Fucα1,4]GlcNAcβ1,6[Kdnα2,3Galβ1,3]GalNAc-ol  4.78 
Coppin 
2003 
 
3-Fucosylated LAcDiNAc (LDNF) cont. carbohydrates 
   
154 GalNAcβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,3[GalNAcβ1,4GlcNAcβ1,2Man
β1,6]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAc LDNF 4.862 13355 
155 GalNAcβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,6[GalNAcβ1,4GlcNAcβ1,2Man
β1,3]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAc LDNF 4.862 13356 
156 GalNAcβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,3[Neu5Acα2,3Galβ1,4GlcNAcβ
1,2Manβ1,6]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAc LDNF 4.861 13760 
157 GalNAcβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3]GalNAc-ol LDNF 4.85 13039 
158 GalNAcβ1,4[Fucα1,3]GlcNAcβ1,3GalNAc-ol LDNF 4.841 13884 
159 GalNAcβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,3[GalNAcβ1,4[Fucα1,3]GlcNAc
β1,2Manβ1,6]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAc LDNF 4.853 13757 
160 GalNAcβ1,4[Fucα1,3]GlcNAcβ1,2Manα1,3[GalNAcβ1,4[Fucα1,3]GlcNAc
β1,2Manβ1,6]Manβ1,4GlcNAcβ1,4[Fucα1,6]GlcNAc LDNF 4.853 13757 
161 GalNAcα1,2Fucα1,3[GalNAcβ1,4]GlcNAcβ1,3GalNAc-ol iLDNF 4.837 2816 
+15 Tyv α1,3GalNAcβ1,4[Fucα1,3]GlcNAcβOMe iLDNF 4.82 Zhang 1996 
+16 Tyv β1,3GalNAcβ1,4[Fucα1,3]GlcNAcβOMe iLDNF 4.84 Zhang 1996 
 
Lex-like containing carbohydrates 
   
162 Galβ1,4[Fucα1,3]Glcβ Le
x 
like 4.78 27042 
163 Neu5Acα2,3Galβ1,3[Neu5Acα2,6]GlcNAcβ1,3Galβ1,4[Fucα1,3]Glcα  int Le
x 
like 4.82 2781 
164 Neu5Acα2,3Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]Glcα  int Le
x 
like 4.819 2737 
165 Neu5Acα2,3Galβ1,3[Neu5Acα2,6]GlcNAcβ1,3Galβ1,4[Fucα1,3]Glcβ int Le
x 
like 4.81 2781 
166 Neu5Acα2,3Galβ1,4GlcNAcβ1,3Galβ1,4[Fucα1,3]Glcβ int Le
x 
like 4.806 2737 
167 Neu5Acα2,3Galβ1,4[Fucα1,3]Glcβ Sia Le
x 
like 4.81 1630 
168 Neu5Acα2,3Galβ1,4[Fucα1,3]Glcα Sia Le
x 
like 4.82 1630 
 
Ley-like containing carbohydrates 
   
169 Galα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcα int Le
y 
like 4.872 3993 
170 Galα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ int Le
y 
like 4.854 3993 
171 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcα int Le
y 
like 4.851 1273 
172 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ int Le
y 
like 4.835 1273 
+17 Fucα1,2Galβ1,4[Fucα1,3]Glcβ  Le
y 
like 4.88 
Ishizuka 
1999 
 
Lea-like containing carbohydrates 
   
+18 3S-Galβ1,3[Fucα1,4]Glcβ-sp 3S-Le
a 
like 4.840 Kurutz 1997 
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+19 6S-Galβ1,3[Fucα1,4]Glcβ-sp 6S-Le
a 
like 4.839 Kurutz 1997 
+20 3S,6S-Galβ1,3[Fucα1,4]Glcβ-sp 
3S,6S-
Lea 
like 
4.873 Kurutz 1997 
 
Leb-like containing carbohydrates 
   
173 Galα1,3[Fucα1,2]Galβ1,3[Fucα1,4]Glc int Le
b 
like 4.97 14260 
174 GalNAcα1,3[Fucα1,2]Galβ1,3[Fucα1,4]Glc int Le
b 
like 4.969 14259 
 
4-Fucosylated chitobiose-like containing carbohydrates 
   
175 Glcα1,2Glcβ1,3GlcNAcβ1,3[Fucα1,4]GlcαP 3FChB like 4.84 27088 
 
3-Fucosylated chondroitin sulfate 
   
+21 3S-GlcAβ1,3[4S]GalNAcβ1,4[Fucα1,3]GlcAβ1,3[4S]GalNAc  4.80 Kitagawa 1997 
 
Miscellaneous carbohydrates 
   
176 Galα1,3[Fucα1,2]Galβ1,3[Fucα1,4]Glc  4.665 14260 
177 GalNAcα1,3[Fucα1,2]Galβ1,3[Fucα1,4]Glc  4.662 14259 
178 Manα1,3[Fucα1,2]RhaαOMe  (4.96)f 27238 
179 Xylα1,6Glcβ1,4[Galβ1,2Xylα1,6]Glcβ1,4[Fucα1,2Galβ1,2Xylα1,6]Glcβ1,
4Glc-ol  4.523 3764 
180 Xylα1,6Glcβ1,4[Xylα1,6]Glcβ1,4[Fucα1,2Galβ1,3Xylα1,6]Glcβ1,4Glc-ol  4.519 3762 
 
a Consecutive numbering of the results from the database search. Few additional data found in the literature are 
indicated by a + sign. 
b The motif with the characteristic Fuc H5 chemical shift is indicated in bold. 
c The following abbreviations are used to indicate the Glyco motif: Lex – Lewisx; Int Lex – internal Lewisx; Sia 
Lex – sialyl Lewisx; 3S-Lex – 3-sulfo Lewisx; 6S-Lex – 6-sulfo Lewisx; Int 6S-Lex – internal 6-sulfo Lewisx; 6S-
Sia Lex – 6-sulfo sialyl Lewisx; Ley – Lewisy; 6S-Ley – 6-sulfo Lewisy; Lea – Lewisa; Int Lea – internal Lewisa; 
Sia Lea – sialyl Lewisa; 3S-Lea – 3-sulfo Lewisa; Leb – Lewisb; Int Leb – internal Lewisb; 3FChB – α1,3-
fucosylated chitobiose; LDNF – fucosylated LacDiNAc; iLDNF – internal fucosylated LacDiNAc;  
d Chemical shift values are given in ppm.  
e Additional data are used, indicated with an +: from five publications (2-6).  
f Probably an artifact of the database, Kochetkov et al. reports an H5 chemical shift of 4.09 ppm for the same 
compound (number 13) (7). 
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Table S5: Three-dimensional coordinates of representatives for most structural motifs found in the 
Protein Databank (PDB) and the Cambridge Structural database (CSD).  
 
PDB or 
CSD 
accession 
code  
Chain and 
residue 
numbers  
Carbohydrate structure  Distance 
H5–O5  
 
Distance 
C5–O5  
Resolution  Refinement 
program  
  
Lex containing carbohydrates 
    
ABUCEF 1 Galβ1,4[Fucα1,3]GlcNAcβ-OMe (pure carbohydrate) 2.3 3.3  direct 
ABUCEF 2 Galβ1,4[Fucα1,3]GlcNAcβ-OMe (pure carbohydrate) 2.3 3.3  direct 
1SL6 G 1-3 Galβ1,4[Fucα1,3]GlcNAcα  2.4 
a
 3.4 2.25 CNS 1.1 
1SL6 H 1-3 Galβ1,4[Fucα1,3]GlcNAcα  2.4 
a
 3.4 2.25 CNS 1.1 
1SL6 I 1-3 Galβ1,4[Fucα1,3]GlcNAcα  2.9 
a
 3.9 2.25 CNS 1.1 
1SL6 J 1-3 Galβ1,4[Fucα1,3]GlcNAcα  2.9 
a
 3.9 2.25 CNS 1.1 
1SL6 K 1-3 Galβ1,4[Fucα1,3]GlcNAcα  3.0 
a
 4.00 2.25 CNS 1.1 
1SL6 L 1-3 Galβ1,4[Fucα1,3]GlcNAcα  3.0 
a
 3.9 2.25 CNS 1.1 
1UZ8 A 1213-
1214 
Galβ1,4[Fucα1,3]GlcNAcβ-OMe 
2.4 
a
 3.5 1.8 REFMAC 5.2 
1UZ8 H 1213-
1214 
Galβ1,4[Fucα1,3]GlcNAcβ-OMe 
2.2 
a
 3.3 1.8 REFMAC 5.2 
1SL5 C 1-4 Galβ1,4[Fucα1,3]GlcNAcβ1,3Gal 2.8
 a
 3.7 1.7 CNS 1.1 
3ZW1 A 105-108 Galβ1,4[Fucα1,3]GlcNAcβ1,3Gal β 4.3 
a,b,c
 4.6 
b,c 1.6 REFMAC 5.5 
3ZW1 B 99-103 Galβ1,4[Fucα1,3]GlcNAcβ1,3Gal α/β 4.6 
a,b,c
 4.9 
b,c 1.6 REFMAC 5.5 
2OX9 E 1-3 Galβ1,4[Fucα1,3]GlcNAcβ  2.1 
a
 3.2 1.95 CNS 1.1 
2OX9 F 1-3 Galβ1,4[Fucα1,3]GlcNAcβ  2.3 
a
 3.3 1.95 CNS 1.1 
2OX9 G 1-3 Galβ1,4[Fucα1,3]GlcNAcβ  2.2 
a
 3.3 1.95 CNS 1.1 
2OX9 H 1-3 Galβ1,4[Fucα1,3]GlcNAcβ  2.3 
a
 3.4 1.95 CNS 1.1 
3AP9 A 155-160 Galβ1,4[Fucα1,3]GlcNAcβ1,3Gal β1,4Glc 2.8 
a
 3.8 1.33 REFMAC 5.5 
3KMB 1 222-224 3S-Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.2 
a
 3.2 2.0 X-PLOR 3.54 
3KMB 3 222-224 3S-Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.1 
a
 3.1 2.0 X-PLOR 3.54 
4KMB 1 222-224 4S-Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.4 
a
 3.4 2.0 X-PLOR 3.54 
4KMB 3 222-224 4S-Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.4 
a
 3.4 2.0 X-PLOR 3.54 
2RDG A 601-604 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcα  2.3 
a
 3.4 1.6 REFMAC 5.3 
3PVD A 1-4 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcα  2.2 
a
 3.3 1.9 PHENIX 
3PVD B 1-4 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcα  2.3 
a
 3.4 1.9 PHENIX 
4DXG A 301-304 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcα  2.4 
a
 3.4 2.5 REFMAC 5.5 
2R61 A 601-604 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ 2.3 a 3.4 2.75 REFMAC 5.3 
2Z8L A 601-604 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ 2.3 a 3.4 1.65 REFMAC 5.3 
1G1R A 901-904 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.6 
a
 3.6 3.4 CNS 
1G1R B 901-904 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.0 
a
 3.1 3.4 CNS 
1G1R D 901-904 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.4 
a
 3.5 3.4 CNS 
1G1T A 901-904 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.4 
a
 3.4 1.5 CNS 
1KMB 1 222-224 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.3 
a
 3.4 2.1 X-PLOR 3.54 
1KMB 2 222-224 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.3 a 3.3 2.1 X-PLOR 3.54 
1KMB 3 222-224 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.3 a 3.3 2.1 X-PLOR 3.54 
2KMB 1 222-224 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.3 
a
 3.4 2.0 X-PLOR 3.54 
2KMB 2 222-224 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.2 a 3.3 2.0 X-PLOR 3.54 
2KMB 3 222-224 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.3 a 3.3 2.0 X-PLOR 3.54 
1G1S C 629-634 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3]GalN
acα-Thr616 2.4
 a 3.4 1.9 CNS 
1G1S D 629-634 Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAcβ1,6[Galβ1,3]GalN
acα-Thr616 2.3
 a 3.4 1.9 CNS 
  
Ley containing carbohydrates 
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1GSL A 252-255 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ-OMe 2.5 a 3.5 2.00 X-PLOR 
1S3K H 223-226 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcα  2.4 
a
 3.5 1.9 CNS 1.0 
2J1T A 1150-
1153 
Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ  
2.5 
a
 3.5 1.6 REFMAC 5.1 
2WMG  A 1590-
1593 
Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ  
5.4
 a,b,d
 6.2
 b,d
 2.3 REFMAC 5.2 
2WMK A 2006-
2010 
GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]GlcNAcβ  
5.0
 a,b,d
 5.8
 b,d
 1.9 REFMAC 5.2 
2WMK B 2006-
2010 
GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]GlcNAcβ  
5.0
 a,b,d
 5.8
 b,d
 1.9 REFMAC 5.2 
3EYV H 223-226 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcα  2.3 
a
 3.4 2.5 CNS 1.0 
3LEG A 1186 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ  2.8 
a
 3.8 2.0 REFMAC 5.5 
3PA2 A 1-4 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ  2.7 
a
 3.7 1.48 PHENIX 
3PUN A 1-4 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcα  2.4 
a
 3.5 2.05 PHENIX 
3PUN B 1-4 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcα  2.2 
a
 3.3 2.05 PHENIX 
4AH5 A 930-933 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcα  4.3 
a,b,e
 4.3
 b,e
 1.99 REFMAC5 
4AH5 A 960-963 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcα  2.5 
a
 3.5 1.99 REFMAC5 
4AH5 B 930-933 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcα  4.3 
a,b,e
 4.3
 b,e
 1.99 REFMAC5 
4GWI A 205 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ  2.5 
a
 3.5 1.6 REFMAC5 
1CLY H 228-231 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ−sp 2.3 a 3.4 2.51 X-PLOR 
1CLZ H 232-235 Fucα1,2Galβ1,4[Fucα1,3]GlcNAcβ−sp 2.4 a 3.5 2.78 X-PLOR 
  
Lea containing carbohydrates 
    
1FWV A 2001-
2003 
3S-Galβ1,3[Fucα1,4]GlcNAcβ 
2.6 
a
 3.6 2.2 CNS 
1W8H A 331-333 Galβ1,3[Fucα1,4]GlcNAcα /β 2.4 a 3.5 1.75 REFMAC 5.1 
1W8H B 331-333 Galβ1,3[Fucα1,4]GlcNAcα /β  2.4 
a
 3.5 1.75 REFMAC 5.1 
1W8H C 331-333 Galβ1,3[Fucα1,4]GlcNAcα /β 2.3 a 3.4 1.75 REFMAC 5.1 
1W8H D 331-333 Galβ1,3[Fucα1,4]GlcNAcβ 2.3 a 3.4 1.75 REFMAC 5.1 
3ASR A 1002-
1004 
Galβ1,3[Fucα1,4]GlcNAcβ-O-p-nitrophenol 
2.3 
a
 3.3 1.6 
COOT, 
REFMAC5 
3ASR B 1002-
1004 
Galβ1,3[Fucα1,4]GlcNAcβ-O-p-nitrophenol 
2.4 
a
 3.4 1.6 
COOT, 
REFMAC5 
3UET A 502-504 Galβ1,3[Fucα1,4]GlcNAcβ  
4.4 
a,b,f
 4.4
 b,f
 2.1 
COOT, 
REFMAC5 
3UET B 502-504 Galβ1,3[Fucα1,4]GlcNAcβ  
4.2 
a,b,f
 4.2
 b,f
 2.1 
COOT, 
REFMAC5 
  
Leb containing carbohydrates 
    
1LED A 252-255 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ-OMe 
2.6 
a
 3.6 2.0 
X-PLOR, 
PROLSQ 
3ASS A 1001-
1005 
Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ-O-p-nitrophenol 
2.5 
a
 3.5 1.6 
COOT, 
REFMAC5 
3ASS B 1001-
1005 
Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ-O-p-nitrophenol 
2.5 
a
 3.5 1.6 
COOT, 
REFMAC5 
3AST A 1001-
1005 
Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ-O-p-nitrophenol 
2.5 
a
 3.5 1.4 
COOT, 
REFMAC5 
3AST B 1001-
1005 
Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ-O-p-nitrophenol 
2.5 
a
 3.5 1.4 
COOT, 
REFMAC5 
3LEK A1185 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcα  
2.7 
a
 3.7 2.2 
COOT, 
REFMAC5 
3SEJ B 1-6 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc (1.9) a,g 2.9 g 3.04 REFMAC 
3SEJ C 1-6 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc (2.5) a,g 3.4 g 3.04 REFMAC 
3SEJ C 532-537 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc (1.8) 
a,g
 2.9 
g
 3.04 REFMAC 
3SEJ D 1-6 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc (1.8) 
a,g
 2.8 
g
 3.04 REFMAC 
3SEJ E 1-6 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc (2.2) 
a,g
 3.2 
g
 3.04 REFMAC 
3SEJ F 1-6 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc (2.2) 
a,g
 3.1 
g
 3.04 REFMAC 
3SEJ G 1-6 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc (1.8) 
a,g
 2.7 
g
 3.04 REFMAC 
3SEJ J 1-6 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ1,3Galβ1,4Glc (2.0) 
a,g
 2.9 
g
 3.04 REFMAC 
4GWJ A 205-208 Fucα1,2Galβ1,3[Fucα1,4]GlcNAcβ  2.5 
a
 3.6 1.6 REFMAC5 
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3-Fucosylated chitobiose containing 
carbohydrates 
    
1LK9 A 500-503 Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn146 
2.2 
a
 3.3 1.53 
REFMAC 
4.0.6 
1JU2 B 544-547 Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn392 2.3 a 3.4 1.45 CNS 1.1 
1JU2 A 539-543 Manα1,6Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn135 2.2 a 3.3 1.45 CNS 1.1 
1JU2 B 539-543 Manα1,6Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn135 2.3 a 3.4 1.45 CNS 1.1 
1JU2 A 544-548 Manβ1,3Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn392 2.4 
a
 3.4 1.45 CNS 1.1 
1E4M M 941-945 Xylβ1,2Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn265 2.5 
a
 3.5 1.2 REFMAC 
1E4M M 951-957 Manα1,3[Manα1,6][Xylβ1,2]Manβ1,4GlcNAcβ1,4[Fucα1
,3]GlcNAcβ-Asn292 2.5
 a 3.5 1.2 REFMAC 
1E6Q M 941-945 Xylβ1,2Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn265 2.5 
a
 3.5 1.35 REFMAC 
1E6Q M 951-957 Manα1,3[Manα1,6][Xylβ1,2]Manβ1,4GlcNAcβ1,4[Fucα1
,3]GlcNAcβ-Asn292 2.7
 a 3.7 1.35 REFMAC 
1E6S M 941-945 Xylβ1,2Manβ1,4GlcNAcβ1,4[Fucα1,3]GlcNAcβ-Asn265 2.5 
a
 3.5 1.35 REFMAC 
1E6S M 951-957 Manα1,3[Manα1,6][Xylβ1,2]Manβ1,4GlcNAcβ1,4[Fucα1
,3]GlcNAcβ-Asn292 2.6
 a 3.6 1.35 REFMAC 
1YM0 A 1-5 Manβ1,3Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAc
β-Asn161 2.4
 a
 3.5 2.06 CNS 
2B9L A 416-419 GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn32 2.6
 a
 3.6 2.0 CNS 1.1 
2F9N B 1000-
1003 
GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn113 
2.5
 a
 3.5 1.6 CNS 1.1 
2F9N D 1000-
1003 
GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn113 
2.4
 a
 3.5 1.6 CNS 1.1 
2QQM D 1-4 GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn261 2.6
 a
 3.6 2.0 REFMAC 5 
3L9R A 501-507 Manβ1,3Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAc
β-Asn57 2.3
 a
 3.4 2.3 REFMAC 5.5 
3L9R C 501-507 Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn57 2.5
 a
 3.6 2.3 REFMAC 5.5 
3L9R E 501-507 Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn57 2.3
 a
 3.4 2.3 REFMAC 5.5 
3L9R G 501-507 Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn57 2.4
 a
 3.5 2.3 REFMAC 5.5 
3QW9 A 187-191 Manα1,3[Manα1,6]Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1
,6]GlcNAcβ-Asn14(B) 2.3
 a
 3.3 1.84 REFMAC 5 
3QW9 A 200-204 Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn14 2.4
 a
 3.4 1.84 REFMAC 5 
3U0P A 301-304 GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn20 5.6
 a,b,h 5.9
 b,h
 2.8 PHENIX 
4ARN C 501-507 Manα1,3[Manα1,6]Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1
,6]GlcNAcβ-Asn140 2.4
 a
 3.5 2.41 BUSTER 
4GWM A 706-712 Manα1,3[Manα1,6]Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1
,6]GlcNAcβ-Asn370 2.2
 a
 3.3 1.85 BUSTER 
4GWM B 705-710  Manα1,3Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAc
β-Asn370 2.2
 a
 3.3 1.85 BUSTER 
4GWM B 711-714 GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn445 2.3
 a
 3.4 1.85 BUSTER 
4GWN A 705-711 Manα1,3[Manα1,6]Manβ1,4GlcNAcβ1,4[Fucα1,3][Fucα1
,6]GlcNAcβ-Asn370 2.6
 a
 3.6 3.0 BUSTER 
4GZT D 508-511 GlcNAcβ1,4[Fucα1,3][Fucα1,6]GlcNAcβ-Asn146 2.2
 a
 3.3 2.19 REFMAC 5.5 
  
Lex-like containing carbohydrates 
    
1W8F A 1118-
1121 
GalNAcα1,3Galβ1,4[Fucα1,3]Glcβ 
2.3 
a
 3.4 1.05 REFMAC 5.1 
1W8F B 1118-
1122 
Galβ1,4GalNAcα1,3Galβ1,4[Fucα1,3]Glcβ 
2.4 
a
 3.5 1.05 REFMAC 5.1 
1W8F C 1118-
1120 
Galβ1,4[Fucα1,3]Glcβ 
2.4 
a
 3.5 1.05 REFMAC 5.1 
1W8F D 1118-
1122 
Galβ1,4GalNAcα1,3Galβ1,4[Fucα1,3]Glcβ 
2.4 
a
 3.4 1.05 REFMAC 5.1 
  
Ley-like containing carbohydrates 
    
2O2L N 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ 2.3 a 3.4 2.53 REFMAC 
2O2L O 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ 2.4 a 3.5 2.53 REFMAC 
2O2L P 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ 2.6 a 3.6 2.53 REFMAC 
2O2L Q 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ 2.8 a 3.7 2.53 REFMAC 
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2O2L R 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.6 
a
 3.6 2.53 REFMAC 
2O2L S 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  4.3 
a,b,i
 5.1 
b,i
 2.53 REFMAC 
2O2L T 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.6 
a
 3.6 2.53 REFMAC 
2O2L U 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.5 
a
 3.5 2.53 REFMAC 
2O2L V 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.4 
a
 3.5 2.53 REFMAC 
2O2L W 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.6 
a
 3.7 2.53 REFMAC 
3EFX D 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.6 
a
 3.6 1.94 REFMAC 
3EFX E 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.2 
a
 3.3 1.94 REFMAC 
3EFX F 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.3 
a
 3.4 1.94 REFMAC 
3EFX G 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.5 
a
 3.6 1.94 REFMAC 
3EFX H 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.3 
a
 3.3 1.94 REFMAC 
3EFX I 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.5 
a
 3.5 1.94 REFMAC 
3EFX J 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.5 
a
 3.4 1.94 REFMAC 
3EFX K 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.4 
a
 3.4 1.94 REFMAC 
3EFX L 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.6 
a
 3.6 1.94 REFMAC 
3EFX M 201-205 GalNAcα1,3[Fucα1,2]Galβ1,4[Fucα1,3]Glcβ  2.7 
a
 3.7 1.94 REFMAC 
 
a protons were added to the structures by Maestro (Schrödinger) because the crystal structures lacked protons; 
disances are in brackets when the heavy atoms are characterized by high B-factors 
b flipped away, value not used for average distance and histogram 
c the electron density is of good quality and the resolution is good; in this case the interactions with the protein 
seem to be so favorable that Lex is distorted into an elongated conformation; in one of the structures the 
Fucα1,3GlcNAc linkage angles are significantly different and in the other structure the GlcNAc pucker is 
distorted 
d the two structures 2WMG and 2WMK of glycoside hydrolases (GH98, inactivated enzymes by a point mutant) 
show very unusual Galβ1,4GlcNAc phi angles, however in that case this might be linked with the function of 
the WT enzymes − cleaving the very same Galβ1,4GlcNAc linkage. 
e the electron density seems to be of good quality, the resolution is with 2 Å moderate; in this case the 
interactions with the protein seem to be so favorable that Ley is distorted into an elongated conformation 
f the inactive double mutant D172A/E217A of the 1,3 -1,4-α-L-fucosynthase crystallized with 
Galβ1,3[Fuc1,4]GlcNAcβ1,3Galβ1,4Glc (LNFP II) showed only electron density of three moieties of which 
Fuc and Gal could be clearly assigned but GlcNAc was ‘partially ambiguous’ as stated in the corresponding 
publication (8); the fucosynthase is based on a natural fucosidase and in this context it might be plausible that 
the Fuc1,4GlcNAc linkage gets distorted by the enzyme to facilitate cleavage 
g high B-factors (74-122) compared to an average B-factor of 38 for the protein; values not used for the average 
distance 
h high B-factors (96-163) compared to an average B-factor of 68 for the protein; sugar puckers are very distorted 
including two boat conformations; axial O2,O3 and O4 in Fuc302; axial O3,O4 and acetamide at C2 in 
GlcNAc303; phi-psi angles in disallowed regions; value not used for average distance and histogram 
i sugar chain S in the binding site of protein chain I does show only very weak intensity at the fucose position; 
according to the associated publication (9) this site is characterized by weak electron density for Fucα1,3 and 
Glcβ; the occupancy in the pdb file is only 50%; all other nine binding sites that are equivalent in the two 
pentamers of the asymetric unit show the expected stacked structure; value not used for average distance and 
histogram 
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Table S6. Intra- and inter-residual NOEs of 3FChB at 277 K and 900 MHz and their corresponding 
distances. 
 
proton pair average S/N of NOEs cross peaks 
corresponding 1H-1H 
distanceb [Å] 
intra   
GlcNAc2 H1-H2 489a 2.79 
GlcNAc2 H1-H3 553 2.73 
GlcNAc2 H1-H5 1151.5 2.41 
GlcNAc2 H2-H4 398.5 2.88 
GlcNAc2 H2-Q8 100a 4.36e 
GlcNAc2 H3-H5 499a 2.78 
GlcNAc2 H4-H62 409 2.87 
GlcNAc2 H4-H61 255 3.11 
GlcNAc2 H5-H62 462 2.81 
GlcNAc2 H5-H61 684.5 2.63 
(GlcNAc2 H61-H62, D2O)c 7424.5 (1.77) 
(GlcNAc2 H61-H62, H2O)d 3303.5 (1.77) 
GlcNAc2 HN2-H1 150.5 2.96 
GlcNAc2 HN2-H2 219 2.78 
GlcNAc2 HN2-H3 373 2.55 
GlcNAc2 HN2-Q8 490 2.92e 
GlcNAc1 H1-H3 421.5 2.86 
GlcNAc1 H1-H5 1256 2.38 
GlcNAc1 H3-H5 496.5 2.78 
GlcNAc1 H5-H61 750a 2.59 
GlcNAc1 H5-H62 762a 2.59 
GlcNAc1 HN2-H1 157 2.94 
GlcNAc1 HN2-H2 108a 3.13 
GlcNAc1 HN2-H3 257.5 2.71 
GlcNAc1 HN2-Q8 559.5 2.86e 
Fuc3 H1-H2 636 2.67 
Fuc3 H1-H5 24a 4.60 
Fuc3 H1-Q6 117a 4.25e 
Fuc3 H3-H4 374a 2.91 
Fuc3 H3-H5 655.5 2.65 
(Fuc3 H3-H5, H2O) 244a (2.73) 
Fuc3 H4-H5 1354 2.35 
Fuc3 H4-Q6 940a 3.00e 
Fuc3 H5-Q6 3583.5 2.40e 
inter   
GlcNAc2 H1 - GlcNAc1 H4 1029a 2.46 
GlcNAc2 H1 - GlcNAc1 H62 444a 2.83 
GlcNAc2 HN2 - GlcNAc1 H62 140 3.00 
GlcNAc2 H2 - Fuc3 H5 475a 2.80 
GlcNAc2 H2 - Fuc3 Q6 545a 3.29e 
GlcNAc2 H62 - Fuc3 H4 204.5 3.22 
GlcNAc2 H4 - Fuc3 H5 102.5 3.61 
GlcNAc1 H3 - Fuc3 H1 406a 2.87 
GlcNAc1 H2 - Fuc3 H1 104a 3.61e 
GlcNAc1 HN2 - Fuc3 H1 347a 2.58 
GlcNAc1 Q8 - Fuc3 H1 237a 3.77e 
a Only one cross-peak was used because of artifacts or severe spectral overlap.  
b The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H3-H5 cross-
peak of Fuc3 as a reference with a distance of 2.65 Å assuming a 1/r6 dependence of the NOE intensities. For 
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the structure calculations the herein reported distances were increased by 0.2 Å tolerance and used as upper 
limit restraints. 
c Reference restraint for the NOESY measured in D2O.  
d Reference restraint for the NOESY measured in H2O.  
e Signal to noise ratios from cross-peaks involving methyl or methylene protons were divided by 3 and 2 for the 
calculation, respectively.  
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Table S7: Intra- and inter-residual NOEs of Lex β-methyl glycoside at 277 K and 900 MHz and their 
corresponding distances. 
 
proton pair average S/N of NOEs cross peaks 
corresponding 1H-
1H distanceb [Å] 
intra   
Gal2 H1-H2 345a 2.76 
Gal2 H1-H3 433a 2.65 
Gal2 H1-H5 824 2.38 
Gal2 H3-H4 616a 2.50 
Gal2 H4-H5 992 2.31 
Gal2 H4-Q6 375a 3.05e 
GlcNAc1 H1-H3 240a 2.93 
GlcNAc1 H1-H5 837 2.38 
GlcNAc1 H1-Q1 345 3.31 
GlcNAc1 H5-H62 312a 2.80 
GlcNAc1 H5-H61 456a 2.63f 
GlcNAc1 HN2-H1 87 2.84 
GlcNAc1 HN2-H2 42a 3.20 
GlcNAc1 HN2-H3 114a 2.71 
GlcNAc1 HN2-Q8 203a 2.96e 
Fuc3 H1-H2 403 2.69 
Fuc3 H3-H5 c 437.5 2.65 
(Fuc3 H3-H5, H2O)d 131a (2.65) 
Fuc3 H4-H5 823 2.39 
Fuc3 H4-Q6 472a 3.14e 
Fuc3 H5-Q6 1580a 2.57e,f 
inter   
Gal2 H1 - GlcNAc1 H4 744a 2.43 
Gal2 H1 - GlcNAc1 H61 416a 2.67 
Gal2 H1 - GlcNAc1 H62 312a 2.80 
Gal2 H2 - Fuc3 H5 323a 2.79 
Gal2 H2 - Fuc3 Q6 288a 3.41e 
Gal2 Q6 - Fuc3 H3 381a 3.04e 
GlcNAc1 H3 - Fuc3 H1 258a 2.89 
GlcNAc1 HN2 - Fuc3 H1 143a 2.61 
GlcNAc1 Q8 - Fuc3 H1 90a 4.14e 
a Only one cross-peak was used because of artifacts or severe spectral overlap.  
b The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H3-H5 cross-
peak of Fuc3 as a reference with a distance of 2.65 Å assuming a 1/r6 dependence of the NOE intensities. For 
the structure calculations the herein reported distances were increased by 0.2 Å tolerance and used as upper 
limit restraints. 
c Reference restraint for the NOESY measured in D2O.  
d Reference restraint for the NOESY measured in H2O.  
e Signal to noise ratios from cross-peaks involving methyl or methylene protons were divided by 3 and 2 for the 
calculation, respectively.  
f Because of overlap and close artifacts, the distance is not reliable and we used 6 Å as a conservative restraint.  
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Table S8: Intra- and inter-residual NOEs of Lea β-methyl glycoside at 275 K and 900 MHz and their 
corresponding distances.  
 
proton pair average S/N of NOEs cross peaks 
corresponding 1H-1H 
distanceb [Å] 
intra   
Gal2 H1-H3 194.5 2.78 
Gal2 H1-H5 394.5 2.47 
Gal2 H3-H4 286a 2.60 
Gal2 H4-H5 369a 2.49 
Gal2 H4-Q6 556a 2.62e 
Gal2 H5-Q6 1011a 2.37e 
GlcNAc1 H1-H2 67.5 3.31 
GlcNAc1 H1-H3 131 2.96 
GlcNAc1 H1-H5 360.5 2.50 
GlcNAc1 H2-H3 394 2.47f 
GlcNAc1 H3-H5 190 2.79 
GlcNAc1 H5-H62 275a 2.62f 
GlcNAc1 H5-H61 260a 2.64 
GlcNAc1 HN2-H1 283a 3.04 
GlcNAc1 HN2-H3 533.5 2.74 
GlcNAc1 HN2-Q8 962a 2.98e 
Fuc3 H1-H2 367.5 2.50 
Fuc3 H3-H5 c 257 2.65 
(Fuc3 H3-H5, H2O)d 645a (2.65) 
Fuc3 H4-H5 419.5 2.44 
Fuc3 H4-Q6 229a 2.70 
inter   
Gal2 H1 - GlcNAc1 H3 248.5 2.66 
Gal2 H1 - GlcNAc1 HN2 440a 3.50 
Gal2 H2 - Fuc3 H5 212.5 2.74 
Gal2 H2 - Fuc3 Q6 225a 3.25e 
Gal2 Q6 - Fuc3 H3 427 2.73e 
Gal2 Q6 - Fuc3 H5 70 3.69e 
GlcNAc1 H4 - Fuc3 H1 335.5 2.53 
GlcNAc1 H62 - Fuc3 H1 286a 2.60 
GlcNAc1 H61 - Fuc3 H1 134a 2.95 
a Only one cross-peak was used because of artifacts or severe spectral overlap.  
b The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H3-H5 cross-
peak of Fuc3 as a reference with a distance of 2.65 Å assuming a 1/r6 dependence of the NOE intensities. For 
the structure calculations the herein reported distances were increased by 0.2 Å tolerance and used as upper 
limit restraints. 
c Reference restraint for the NOESY measured in D2O.  
d Reference restraint for the NOESY measured in H2O.  
e Signal to noise ratios from cross-peaks involving methyl or methylene protons were divided by 3 and 2 for the 
calculation, respectively.  
f Because of overlap and close artifacts, the distance is not reliable and we used 6 Å as a conservative restraint.  
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Table S9. Intra- and inter-residual NOEs of LDNF at 275 K and 900 MHz and their corresponding 
distances. 
proton pair average S/N of NOEs cross peaks 
corresponding 1H-1H 
distanceb [Å] 
intra   
GalNAc H1-H3 880 2.68 
GalNAc H1-H5 1977 2.34 
GalNAc HN2-H1 270 2.78 
GalNAc HN2-H3 447 2.56 
GalNAc HN2-H5 35 3.91 
GalNAc HN2-Q8 530a 2.49 
GlcNAc H1-H3 416.5 3.04 
GlcNAc H1-H5 1490.5 2.46 
GlcNAc H3-H5 533 2.92 
GlcNAc H5-H61 770a 2.74 
GlcNAc H5-H62 652a 2.84 
GlcNAc HN2-H1 192.5 2.94 
GlcNAc HN2-H3 284.5 2.76 
GlcNAc HN2-H5 28 4.06 
GlcNAc HN2-Q8 618a 2.91e 
Fuc H1-H2 965.5 2.64 
Fuc H1-H5 150 3.60 
Fuc H3-H4 1855 2.37 
Fuc H3-H5c 948 2.65 
(Fuc H3-H5, H2O)d 361a (2.65) 
Fuc H4-H5 1877 2.36 
Fuc H4-Q6 1098a 3.11e 
inter   
GalNAc H1 - GlcNAc H4 1579 2.43 
GalNAc H1 - GlcNAc H62 1326a 2.51 
GalNAc H1 - GlcNAc H61 792a 2.73 
GalNAc Q8 - GlcNAc H5 69a 4.93e 
GalNAc Q8 - GlcNAc H62 115a 4.52e 
GalNAc Q8 - GlcNAc H61 113a 4.54e 
GalNAc HN2 - GlcNAc H5 26.5 4.10 
GalNAc HN2 - GlcNAc H62 213.5 2.89 
GalNAc HN2 - GlcNAc H61 178.5 2.98 
GalNAc H2 - Fuc H5 796.5 2.73 
GalNAc H61 - Fuc H5 78.5 4.01 
GalNAc H62 - Fuc H3 771 2.74 
GalNAc H62 - Fuc H5 134.5 3.67 
GalNAc H2 - Fuc Q6 734 3.32e 
GalNAc HN2 - Fuc Q6 18a 5.25e 
GlcNAc H3 - Fuc H1 721 2.77 
GlcNAc H3 - Fuc Q6 119a 4.50e 
GlcNAc HN2 - Fuc H1 543a 2.48 
GlcNAc HN2 - Fuc H2 22 4.22 
GlcNAc Q8 - Fuc H1 358.5 3.74e 
GlcNAc Q8 - Fuc H2 63a 5.00e 
a Only one cross-peak was used because of artifacts or severe spectral overlap.  
b The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H3-H5 cross-
peak of Fuc as a reference with a distance of 2.65 Å assuming a 1/r6 dependence of the NOE intensities. For the 
structure calculations the herein reported distances were increased by 0.2 Å tolerance and used as upper limit 
restraints. 
c Reference restraint for the NOESY measured in D2O.  
d Reference restraint for the NOESY measured in H2O.  
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e Signal to noise ratios from cross-peaks involving methyl or methylene protons were divided by 3 and 2 for the 
calculation, respectively.  
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Table S10. Intra- and inter-residual NOEs of Bv9 at 273 K and 900 MHz and their corresponding 
distances. 
 
proton pair average S/N of NOEs cross peaks 
corresponding 1H-1H 
distanceb [Å] 
intra   
GlcNAc2 H1-H3 174.5 2.83 
GlcNAc2 H1-H5 393.5 2.47 
GlcNAc2 HN2-H1 123a 2.93 
GlcNAc2 HN2-H2 34a 3.63 
GlcNAc2 HN2-H3 264a 2.58 
GlcNAc2 HN2-H5 15a 4.16 
GlcNAc1 H1-H3 166.5 2.86 
GlcNAc1 H3-H5 250a 2.67 
GlcNAc1 H5-H62 256a 2.66 
GlcNAc1 HN2-H1 189a 2.72 
GlcNAc1 HN2-H3 159a 2.80 
Fuc3 H1-H2 525.5 2.36 
Fuc3 H3-H4 661.5 2.27 
Fuc3 H3-H5c 260.5 2.65 
(Fuc3 H3-H5, H2O)d 223a (2.65) 
Fuc3 H4-Q6 401 2.96e 
inter   
GlcNAc2 H1 - GlcNAc1 H3 254 2.66 
GlcNAc2 H1 - GlcNAc1 HN2 276a 2.56 
GlcNAc2 H1 - GlcNAc1 Q8 57a 4.10e 
GlcNAc2 HN2 - GlcNAc1 
HN2 15.5 4.13 
GlcNAc2 HN2 - GlcNAc1 Q8 77a 3.80e 
GlcNAc2 H2 - Fuc3 H5 190.5 2.79 
GlcNAc2 H4 - Fuc3 H5 40 3.62 
GlcNAc2 H62 - Fuc3 H3 161a 2.87 
GlcNAc2 H62 - Fuc3 H5 34.5 3.71 
GlcNAc2 H2 - Fuc3 Q6 255 3.19e 
GlcNAc2 H4 - Fuc3 Q6 69a 3.97e 
GlcNAc2 HN2 - Fuc3 Q6 17a 4.89e 
GlcNAc1 H4 - Fuc3 H1 425 2.44 
GlcNAc1 H61 - Fuc3 H1 377a 2.49 
GlcNAc1 H62 - Fuc3 H1 699a 2.25 
GlcNAc1 H4 - Fuc3 H5 61.5 3.37 
GlcNAc1 H4 - Fuc3 Q6 47a 4.23e 
a Only one cross-peak was used because of artifacts or severe spectral overlap.  
b The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H3-H5 cross-
peak of Fuc3 as a reference with a distance of 2.65 Å assuming a 1/r6 dependence of the NOE intensities. For 
the structure calculations the herein reported distances were increased by 0.2 Å tolerance and used as upper 
limit restraints. 
c Reference restraint for the NOESY measured in D2O.  
d Reference restraint for the NOESY measured in H2O.  
e Signal to noise ratios from cross-peaks involving methyl or methylene protons were divided by 3 and 2 for the 
calculation, respectively.  
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Table S11. Intra- and inter-residual NOEs of LDFT at 275 K and 900 MHz and their corresponding 
distances. 
 
proton paira average S/N of NOEs cross peaks 
corresponding 1H-1H 
distanceb [Å] 
intra   
Fuc3 H1-H2 (β) 1857c 2.12 
Fuc3 H1-H5 (β) 112c 3.39 
(Fuc3 H3-H5 (β))d 488c (2.65) 
Fuc3 H4-H5 (β) 731c 2.48 
Fuc3 H4-Q6  670c 3.74f 
Gal2 H1-H3 1403c 2.75 
(Gal2 H1-H5)e 1759 (2.65) 
Gal2 H3-H5 2823.5 2.45 
Glc1 H1-H3 (β) 332 2.83 
Glc1 H1-H5 (β) 1137c 2.30 
Glc1 H2-H4 (β) 808c 2.44 
Glc1 H3-H5 (β) 777c 2.45 
Glc1 H5-H61 (β) 446.5 2.69 
Fuc4 H1-H2 (β) 595c 2.56 
Fuc4 H1-H3 (β) 95c 3.48 
Fuc4 H1-H5 (β) 80 3.58 
Fuc4 H1-Q6 (β) 72c 4.38 f 
Fuc4 H3-H5 (β) 703 2.49 
Fuc4 H3-Q6 (β) 87c 4.24 f 
Fuc4 H4-H5 (β) 1033c 2.34 
Fuc4 H4-Q6 814c 3.62f 
inter   
Fuc3 H1 - Gal2 H2  1218c 2.82 
Fuc3 H1 - Gal2 H3  236 3.70 
Fuc3 H5 - Gal2 H1 (β) 105c 3.42 
Fuc3 H5 - Gal2 H2 (β) 66c 3.70 
Fuc3 H5 - Glc1 H3 (β) 49c 3.89 
Fuc3 H5 - Glc1 H5 (β) 483 2.65 
Fuc3 H5 - Glc1 H61 (β) 177.5 3.14 
Fuc3 Q6 - Glc1 H1 (β) 45c 4.73f 
Fuc3 Q6 - Glc1 H3 (β) 187c 3.73f 
Fuc3 Q6 - Glc1 H5 (β) 81c 4.29f 
Fuc3 Q6 - Glc1 H61 (β) 161c 3.83f 
Fuc3 H1 - Fuc4 Q6  223c 4.49f 
Gal2 H1 - Glc1 H4 (β) 550c 2.60 
Gal2 H1 - Glc1 H61 465c 3.31 
Gal2 H1 - Glc1 H62 (β) 691c 2.50 
Gal2 H2 - Fuc4 H5 (β) 604 2.56 
Gal2 H2 - Fuc4 Q6 786c 3.64f 
Gal2 H61 - Fuc4 H3 597c 3.17 
Gal2 H62 - Fuc4 H3 194c 3.83 
Gal2 H61 - Fuc4 H5 65c 4.59 
Glc1 H2 - Fuc H1 (β) 72.5 3.64 
Glc1 H3 - Fuc H1 (β) 640.5 2.53 
Glc1 H3 - Fuc H5 (β) 106c 3.42 
a The nomenclature of the residues is as follows, Glc1: reducing end Glc; Gal2: stacking Gal; Fuc3: α1,2-linked 
Fuc; Fuc4: α1,3-linked Fuc. If the cross-peaks can be distinguished between the anomers at the reducing end, 
only the β-anomer is used and indicated by "β". 
b The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H3-H5 cross-
peak of Fuc and Gal as a reference with a distance of 2.65 Å assuming a 1/r6 dependence of the NOE 
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intensities. For the structure calculations the herein reported distances were increased by 0.2 Å tolerance and 
used as upper limit restraints. 
c Only one cross-peak was used because of artifacts or severe spectral overlap.  
d Reference restraint for signals corresponding to the β-anomer at the reducing end (separated signals for α and 
β; NOESY measured in D2O).  
e Reference restraint for signals indistinguishable for both anomers (no separate signals for α and β; NOESY 
measured in D2O).  
f Signal to noise ratios from cross-peaks involving methyl or methylene protons were divided by 3 and 2 for the 
calculation, respectively.  
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SI Methods 
Synthesis and characterisation of GlcNAcβ1,4[Fucα1,3]GlcNAcβ1-O-(CH2)5-COOH.  
OHOO
O
O
NHAc
O OH
OH
OH
OHOHO
HO
NHAc
O
OH
OBnOO
O
O
NHAc
O OBn
OBn
OBn
O
HO
NHAc
O
OH
O
OPh
Pd/C, H2
EtOH, H2O
quant.
1  
 
1 (10) (28 mg, 24 µmol) was dissolved in a mixture of ethanol (2 mL) and water (1 mL). Pd/C 10% 
(12 mg) was added and the solution was stirred. Vacuum and H2 were alternated and the mixture was 
allowed to stir under H2 overnight. The mixture was filtered off through Celite and concentrated. The 
residue was dissolved in water and filtered through a 0.45 µm syringe filter and concentrated. The 
residue was purified on a G15 column to give, after lyophilisation, 14 mg of the desired product (99%) 
as a white solid. [α]25D -80 (c 1.0, H2O). MS FAB+-HRMS m/z [M+C2H5]+ calcd for C30H53O17N2 
713.3344, found 713.3357. A 1H-13C HSQC spectrum with chemical shift assignment is shown in 
Figure S5A. Chemical shifts are deposited in the BMRB under the accession number 21032. 
 
 
Synthesis and characterisation of GalNAcβ1,4[Fucα1,3]GlcNAcβ1-O-(CH2)8-COOH.  
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O
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O
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HO
HO
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DMTST, DCM
1.) Bu3SnH, Pd(PPh3)4, Ac2O
2.) NaOMe, MeOH
3.) NaOH
4.) Pd(OH)2/C, H2,
     AcOH/DCM/MeOH/H2O
58% 44%
 
 
Compound 4 (11) (590 mg, 0.66 mmol) and thioglycoside 3 (791 mg, 1.64 mmol) were dissolved in 
dry DCM (25 mL) and stirred together with powdered 4Å activated molecular sieves (4 g) for 4 h at rt. 
DMTST (509 mg, 1.97 mmol) was dissolved in DCM (15 mL) and stirred together with powdered 4 Å 
activated molecular sieves (2 g) for 4 h at room temperature as well. Both suspensions were combined 
and stirred for 16 h at room temperature. The mixture was filtered over a short pad of celite, diluted 
with DCM (50 mL), and washed with a saturated solution of NaHCO3 (40 mL) and water (40 mL). 
The aqueous phases were extracted with DCM (3× 30 mL). The combined organic layers were dried 
(Na2SO4) and the solvent was removed in vacuo. The crude product was purified by flash 
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chromatography (petroleum ether/EtOAc, 40% to 70%) to yield 5 as a colorless oil (268 mg, 211 
mmol, 32%). Reactant 4 was recovered in 45% yield (263 mg, 293 µmol). [α]D22 -44.2 (c 2.5, CHCl3); 
1H NMR (500.1 MHz, CDCl3): δ 7.42 – 7.22 (m, 20H, Ar-H), 5.94 – 5.83 (m, 1H, CH2=CH-CH2), 
5.31 – 5.18 (m, 3H, 2x CH2=CH-CH2, GalNAc-H4), 5.16 – 5.09 (br s, 1H, Fuc-H1), 4.95 (d, J = 11.8 
Hz, 1H, Ph-CH2), 4.87 – 4.67 (m, 6H, 4x Ph-CH2, GalNAc-H3, GlcNAc-H1), 4.68 (d, J = 11.8 Hz, 
1H, Ph-CH2), 4.64 – 4.53 (m, 2H, Ph-CH2, CH2=CH-CH2), 4.49 (dd, J = 13.3, 5.4 Hz, 1H, CH2=CH-
CH2), 4.46 – 4.35 (m, 2H, Ph-CH2, GalNAc-H1), 4.26 – 4.16 (m, 1H, Fuc-H5), 4.17 – 4.07 (m, 3H, 
GalNAc-H6, Fuc-H2, GlcNAc-H3), 4.00 (dd, J = 10.8, 5.9 Hz, 1H, GalNAc-H6’), 3.92 (t, J = 6.2 Hz, 
1H, GlcNAc-H4), 3.88 – 3.83 (m, 1H, Fuc-H3), 3.78 – 3.67 (m, 5H, CH2 linker, GlcNAc-H6, GlcNAc-
H6’, GalNAc-H2, GlcNAc-H2), 3.65 (s, 3H, COO-Me), 3.65 – 3.53 (m, 3H, Fuc-H4, GalNAc-H5, 
GlcNAc-H5), 3.40 – 3.32 (m, 1H, CH2 linker), 2.28 (t, J = 7.5 Hz, 2H, CH2 linker), 2.02 – 1.92 (m, 
9H, 3x Ac), 1.83 – 1.75 (s, 3H, NH-CO-CH3), 1.63 – 1.54 (m, 2H, CH2 linker), 1.52 – 1.43 (m, 2H, 
CH2 linker), 1.32 – 1.18 (m, 8H, CH2 linker), 1.15 (d, J = 6.5 Hz, 3H, Fuc-H6); 13C NMR (125.8 MHz, 
CDCl3): δ 174.4, 170.5, 170.3, 170.3, 170.1 (4x Me-COO, COO-Me), 156.2 (NH-CO), 139.0, 138.7, 
137.9, 128.8 – 127.3 (24x Ar-C), 132.7 (CH2=CH-CH2), 117.9 (CH2=CH-CH2), 100.2 (GalNAc-C1), 
100.0 (GlcNAc-C1), 97.3 (Fuc-C1), 79.8 (Fuc-C3), 77.2 (Fuc-C4), 76.6 (Fuc-C2), 74.5 (Ph-CH2), 74.4 
(GlcNAc-C5), 74.3 (GlcNAc-C3), 73.9 (GlcNAc-C4), 73.6 (Ph-CH2), 73.4 (Ph-CH2), 72.7 (Ph-CH2), 
70.4 (GalNAc-C3), 70.4 (GalNAc-C5), 70.1 (GalNAc-C2), 69.6 (CH2 linker), 69.3 (GlcNAc-C6), 66.7 
(Fuc-C5), 66.3 (GalNAc-C4), 66.0 (CH2=CH-CH2), 60.7 (GalNAc-C6), 52.5 (GlcNAc-C2), 51.6 
(COO-Me), 34.2, 29.5, 29.3, 29.3, 29.2, 25.9, 25.0 (7x CH2 linker), 23.2 (NH-CO-CH3), 20.7 (3x CH3-
COO), 16.9 (Fuc-C6); ESI-MS: m/z: Calcd for C68H88N2NaO21 [M+Na]+: 1291.58, found: 1291.65. 
Compound 5 (87.0 mg, 68.5 µmol) was dissolved in DCM (2 mL) and Pd(PPh3)4 (1.6 mg, 1.37 µmol) 
and Bu3SnH (21.9 mg, 75.4 µmol) were added.  The solution was stirred for 5 min and Ac2O (7.8 µl, 
82.2 µmol) was added. The reaction mixture was stirred for 1 h at ambient temperature. The solvent 
was removed under reduced pressure and purified by flash chromatography (EtOAc/MeOH, 100% to 
80%) to yield the intermediate (50.0 mg, 40.7 µmol, 60%) as a white solid. The intermediate (39.4 mg, 
32.1 µmol) was suspended in MeOH (0.5 mL), treated with NaOMe/MeOH (320 µL, 0.02 M) and 
stirred for 16 h at room temperature. An aqueous solution of NaOH (64 µL, 10 M) was added and the 
reaction mixture stirred for 16 h at room temperature. The reaction was quenched with two drops of 
glacial acetic acid and concentrated in vacuo. The resulting alcohol was dissolved in 
DCM/MeOH/AcOH/H2O (1:1:2:2, 4 mL) and Pd(OH)2/C (10.0 mg) was added. The suspension was 
stirred under an atmosphere of hydrogen for 18 h. The reaction mixture was filtered and purified by 
size exclusion chromatography to yield 6 as a white foam (17.5 mg, 23.6 µmol, 74%). [α]D22 -49.0 (c 
5.6, H2O); HRMS: m/z: Calcd for C31H54N2NaO17 [M+Na]+: 749.3320, found: 749.3323; A 1H-13C 
HSQC spectrum with chemical shift assignment is given in Fig. S5D. Chemical shifts are deposited in 
the BMRB under the accession number 21053. 
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3.2 Acid pharmacophore orientation in sialyl Lewisx mimics and 
synthesis of antagonists pre-organized in their bioactive 
conformation 
 
3.2.1 “Bridging the gap” – Adjusting the acid pharmacophore in sLex 
mimics by ring closing metathesis (Manuscript) 
 
Contributions 
      • Manuscript preparation 
     • Synthesis of compounds 4a-c, 7-15, 19-27, 30-33 and S7-S13  
      • NMR spectra assignment and structure calculation of 3 
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Abstract 
Selectins play a crucial role in the body’s defense mechanism against inflammation. They 
initiate, induced by an inflammatory stimulus, tethering and rolling of leukocytes on the 
endothelial surface of blood vessels. This is an essential step to extravasate from the blood 
to the inflamed tissue. However, an excessive infiltration of leukocytes is observed in 
several acute and chronic diseases, and therefore, selectins represent an interesting 
therapeutic target. Sialyl Lewisx (sLex) is the natural ligand of selectins, however, the 
binding affinity is rather low and the high polarity and complexity of the molecule are 
challenges in the development of sLex mimics. In numerous studies the binding affinity and 
physicochemical parameters could be improved. Hydrophilic parts, which are not involved 
in binding, were replaced by hydrophobic moieties. Furthermore, the rigid core structure 
Lewisx could be mimicked by non-carbohydrate moieties and hence, 5 of the 6 
pharmacophores are pre-organized in the bioactive conformation in solution. Introducing an 
additional benzoate in 2’-position gave a further improvement in binding affinity (2→3). 
We could solve the conformation of 3 in solution by NMR spectroscopy and disclose an 
intramolecular σ-π interaction, that helps to pre-organized the acid pharmacophore in the 
bioactive conformation. A similar effect was obtained by introducing aromatic substituents, 
which can form interresidual π-π interactions. Taking advantage of this observation we 
synthesized a series of selectin antagonists that ‘bridge the gap’ by replacing the 
intramolecular hydrophobic interaction via a covalent bond using ring closing metathesis, 
and pre-organize all pharmacophores in the bioactive conformation.   
 
Introduction 
Selectins are an extensively studied class of carbohydrate binding proteins. They mediate 
the first contact and rolling of leukocytes on endothelia cells, followed by tighter integrin 
binding and leukocyte extravasation from blood circulation into the diseased or infected 
tissue.1 This mechanism is crucial in both, the adaptive and innate immune response.2,3 
Many acute and chronic diseases like asthma,4 psoriasis,5 reperfusion injury6 and 
rheumatoid arthritis7 are characterized by an excessive extravasations of leukocytes to the 
inflamed tissue. Furthermore, several types of tumors harness and exploit the selectin 
dependent mechanisms, as it is used by migrating leukocytes, to metastasize.8,9 Thus, 
selectins are a promising target to treat these diseases. 
 
Chapter 3.2.1 - Manuscript 2 
 114 
 
Figure 1. a) Schematic presentation of interactions between sLex (1) (pharmacophores highlighted in blue) 
and E-selectin. In sLex mimic 210, hydrophilic parts of 1 not involved in binding are replaced by hydrophobic 
moieties, leading to an 80 fold increase in binding affinity.11 An additional benzoyl group (2→3) improved the 
affinity to 5.2 µM. b) Overlay of crystal structures12 of compounds 2 (green) and 3 (blue) in complex with E-
selectin (the benzoate group of 3 is highlighted by a red circle).  
 
All native ligands of the selectins contain the common tetrasaccharide epitop sialyl Lewisx 
[Neu5Acα(2-3)Gal[Fucα(1-3)]β(1-4)GlcNAc, sLex (1)]. Because the binding affinities of 
sLex (1) is rather weak, it is often improved by a multivalent presentation.13,14 For the 
development of efficient drug-like selectin antagonists mimicking the sLex epitope, it is 
necessary to overcome the problems of low affinity, the high polarity of the sLex lead 
structure and to reduce the structural complexity.15  
Structural information on sLex (1) in solution and also bound to E-selectin are of major 
importance for the design of drug-like mimetics. The conformation of 1 bound to E-selectin 
was elucidated by NMR16-18 and crystallography,19,20 and disclosed the bioactive 
conformation and the pharmacophoric groups (Figure 1a). The solution conformation was 
investigated by several groups,17,18,21 and can be roughly divided in two structural elements, 
a rigid Galβ(1-4)[Fucα(1-3)]GlcNAc (Lex-core) and a Neu5NAc moiety linked by a rather 
flexible glycosidic bond to the D-galactose unit.21 The trisaccharide core is stabilized by an 
exo-anomeric effect,22,23 hydrophobic interactions,24 steric effects10,25,26 and a 
nonconventional hydrogen bond,27 and is almost identical to the bound conformation. The 
Neu5NAc is rather flexible and adopts mainly two conformations in solution, one of them 
similar to the bound conformation.21 
For the development of sLex mimics, the GlcNAc residue which task is the adjustment of 
the D-Gal and L-Fuc moiety, and the D-Neu5NAc which has just weak contacts to the 
protein were replaced by hydrophobic mimics (compound 2, Figure 1a).10,28 The stacked L-
fucose and D-galactose moieties are crucial, as they bear 5 of the 6 pharmacophores. The 
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unique orientation leads to a tight stacking and pre-organization of the pharmacophores in 
the bioactive conformation. Overall the affinity could be improved from sLex up to 80 fold 
(1→2), measured in a cell free competitive binding assay.10 A benzoate in 2’-position of the 
D-galactose improves the affinity by an additional factor of 2.5 (2→3).10 Thoma et al. 
presumed that the 2’ benzoylation has a stabilizing effect on the trisaccharide mimic core, 
and further improves its pre-organization.29  
 
Figure 2. Compound 2 with a flexible acid pharmacophore and strategies to pre-organization the acid 
functionality in the bioactive conformation.  
 
In recently solved crystal structures, 2 and 3 (cocrystallized with E-selectin) showed an 
almost identical binding mode (Figure 1b).12 The benzoate in antagonist 3 is pointing to the 
solvent, clearly disproving speculations on an increase in binding affinity due to benzoate-
protein interactions. However, the cyclohexane moiety of the cyclohexyl lactic acid in 3 is 
in spatial proximity to the benzoate enabling an intramolecular σ-π interactions.12 An 
interaction of the two residues in solution could contribute to a preferable orientation of the 
acid pharmacophore in the bioactive conformation. The pre-organized ligand 3 should show 
an entropic gain over its flexible counterpart 2 due to the reduced conformational entropy 
that is associated with restricting rotors.30,31  
To confirm this hypothesis, the aim of this communication was to elucidation the 
conformation of 3 in solution. Furthermore, compounds that are proposed to pre-organize 
the acid pharmacophore in solution by intramolecular aromatic π-π interactions, or by 
intramolecular cyclisation were developed (Figure 2). 
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Results 
Compound 3 is pre-organized in the bioactive conformation in solution. 
To prove our hypothesis, that in compound 3 the acid pharmacophore is pre-organized in 
the bioactive conformation by an interaction between the benzoate and the cyclohexyl lactic 
acid, we solved the conformation in solution. Recently, we demonstrated that NOESY NMR 
spectroscopy is an effective tool to analyze the conformation of oligosaccharides at ~275 K 
at 900 MHz high field in solution.32 We adopted the method to evaluate the solution 
conformation of 3. 
 
 
Figure 3. a) Schematic overview of interresidual NOEs between cyclohexan moieties and H2-benzoate (red 
arrows) protons; b) Ensemble of 20 lowest energy conformations of 3 at 277 K in solution, calculated and 
refined using experimental NOE restraints; c) Crystal structure of 3.12  
 
The chemical shift assignment of the resonances of compound 3 was achieved by homo- 
and heteronuclear 2D spectra recorded in D2O (SFigure 1, SFigure2). Using a 2D NOESY 
spectrum, we could extract 56 unambiguous NOE cross-peaks (36 intraresidual and 20 
interresidual) between various non-exchangeable protons (STable 1 and statistics in STable 
2). Specifically 10 interresidual NOEs between the benzoate and the two cyclohexane 
residues could be extracted (Figure 3a and STable1). With 57 NOE derived distance 
restraints we were able to calculate a well-defined structural ensemble of compound 3 using 
Cyana33 and subsequent refinement with AMBER 934 using the GAFF force field (Figure 
3b). A comparison of this ensemble of solution conformations and the crystal structure of 3 
displays an obvious similarity (Figure 3b and 3c). Furthermore, the dihedral angles of 
conformations of 3 observed in solution, crystal and by molecular dynamic calculations 
showed values in a narrow range in the core conformation/acid orientation plot (SFigure 3; 
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statistics in STable 2).35 Another confirmation for the interactions between the cyclohexyl 
lactic acid and the benzoate are the pronounced upfield shifts of cyclohexane protons with 
spatial proximity to the aromatic ring in 3 compared to 2 (SFigure 4).  
The results propose that the stabilization of the cyclohexyl lactic acid by the benzoate in 3 is 
established already in the solution, that guarantees a pre-organization of the acid 
pharmacophore before the binding event.  
 
Benzoylation in 2’-position of the D-galactose residue effects affinity in lactic acid 
derivatives. 
To confirm the assumption that intermolecular hydrophobic interactions have an effect on 
affinity, we synthesized a series of sLex mimics bearing 2 aromatic moieties in spatial 
proximity. They are uniformly benzoylated in 2’ position of the D-galactose residue and in 
contrast to 3, the (S)-cyclohexyl lactic acid residue is replaced by a (S)-phenyl lactic acide 
moiety (→5a), a phenyl group modified with electron donating(→5b), or electron 
withdrawing (→5c) substituents. We expected a strong π-π interaction between the aromatic 
residues, which would stabilize the acid orientation in a similar way to 3 and could lead to 
improved binding affinities. All three antagonists (5a, 5b and 5c) showed indeed favorable 
binding affinities, just slightly worse than the (S)-cyclohexyl lactic acid 3. Substitutions on 
the phenyl rings had only a small effect on the potency of the ligands. 
To quantify the effects of 2’-benzoylation, 2’-hydroxy derivatives 6a-c were synthesized. 
Debenzoylation (5a-c→6a-c) reduced affinities by a factor of 5 to 6, whereas 
debenzoylation of 3 just led to a 3.2 time reduction. Possible reasons are the reduced 
desolvation penalties, and different interactions between the phenyl/cyclohexane groups and 
protein side chains for 2 vs. 6a-c.  
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Figure 2. Binding affinities determined in a microscale thermophoresis assay for benzoates 3, 5a-c and 
compounds 2 and 6a-c that lack the benzoate substitution in 2’-position of the D-galactose moiety. The rKDs 
values are reported relative to lead compound 3. 
 
Acid pre-organization by intramolecular cyclisation.    
In a second attempt we replaced the benzoate and cyclohexane residues by an 
intramolecular alkyl bridge, to explore whether we can detect a similar effect to the 
intramolecular hydrophobic interaction. By modifying the chain length, we could optimize 
the balance between rigidity and retaining a certain degree of flexibility for the optimal 
adjustment of the acid pharmacophore upon binding in bigger cycles. The acid 
pharmacophore pre-organization in different ring sizes was evaluated by molecular dynamic 
calculations and displayed in acid orientation / core conformation plots (SFigure 5). We 
decided to synthesize cyclic compounds 4a-c as they show the best pharmacophore 
orientation.  
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Table 1. Affinities of selectin antagonists 1, 2, 3, 4a-c, 7. KD values in µM were determined by a microscale 
thermophoresis assay.[16] rKDs are in comparison to 3. 
 
 
The compounds were synthesized and to evaluate their binding properties the KDs were 
measured in a microscale thermophoresis assay. 
The best binding affinity was observed in the 9-membered ring 4a with a KD of 11.4 µM. 
The binding affinity was improved by a factor of 2 to the smaller 8-membered cycle 4c and 
by a factor of 11 to the 10-membered cycle 4b. The strong differences in binding affinity of 
the medium-size rings are probably due to changes in transannular interactions, 
conformational strains and a varying degree of pre-organization due to restricted 
rotations.36,37 4a showed an improved affinity to the flexible compound 2 by a factor of 1.3, 
but a drop in affinity by a factor of 2.5 compared to compound 3, which is stabilized by 
intramolecular hydrophobic interactions. 
As control, we synthesized compound 7 with a flexible alkyl chain. The binding affinity for 
7 is 4.7 mM, what is in agreement with the negative result in the acid orientation / core 
conformation plot obtained by MD simulations (SFigure 6). It predicted a 120° deviation of 
the acid orientation compared to the crystal structure, probably due to an intramolecular 
interaction of the acid and the hydroxy group in 2’-position of the D-galactose residue.  
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Synthesis of aromatic ligands 5a-c and 6a-c.  
We recently reported the synthesis of the Fucα(1-3)GlcNAc mimic 15.10 In this 
communication we describe a faster and more efficient approach to synthesize 15 from 
commercially available racemic seudenol (3-methyl-2-cyclohexenol, 8).38  
Using optimized conditions for the butanoylation of racemic seudenol with immobilized 
Candida antarctica lipase C (Novozym 435),39 we could isolate (R)-seudenolester 9.40 
Subsequent saponification with NaOH afforded (R)-seudenol 10 in 84% yield and 97.5% 
enantiomeric excess (ee). Since the protection group of the hydroxy group in 10 has to be 
stable under strongly basic and acidic conditions, should not hamper fucosylation by steric 
bulk, and finally allow cleavage under mild conditions orthogonal to benzyl protecting 
groups, a tert-butyldimethylsilyl (TBS) ether 11 was synthesized. Hydroboration followed 
by oxidation yielded all-trans 12 in 81% over two steps. Fucosylation of 12 under in situ 
anomerisation conditions9 gave 14, which was smoothly deprotected with 
tetrabutylammonium fluoride, affording pseudodisaccharide 1510 in excellent yield over two 
steps. Starting from racemic seudenol, this short sequence allowed the gram scale synthesis 
of 15 in 27% overall yield, requiring only four chromatographic purifications. 
In the following step disaccharide mimic 15 was glycosylated with the corresponding 
galactose donors 16a-c functionalized with different lactic acid derivatives (see scheme S3) 
using dimethyl(methylthio)sulfonium triflate (DMTST) as promoter, which gave products 
17a-c in good yields. In order to remove the benzyl protecting groups as well as the 
benzyliden acetal function, compounds 17a-c were hydrogenated under heterogeneous 
conditions using Pd(OH)2/C as catalyst resulting in final ligands 5a-c with a benzoyl moiety 
in position 2 of the galactose unit. To obtain the fully deprotected antagonists 6a-c, 
compounds 17a-c were additionally treated with LiOH after the hydrogenation step. 
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Scheme 1. Synthesis of sLex mimics, a) Novozyme 435, vinylbutyrate, heptane; b) aqueous NaOH, MeOH, 
84%; c) TBSCl, imidazol, DMAP, CH2Cl2; d) (i) BH3⋅THF, THF; (ii) H2O2, aqueous NaOH, 81% from 16; e) 
CuBr2, DTBMP, TBAB, CH2Cl2, DMF, mol. sieves (4Å), 87%; f) TBAF, THF, quant.; g) DMTST, DCM, 
mol. sieves (4Å) (a: 79%, b: 80%, c: 83%); h) H2, Pd(OH)2/C, MeOH (a: 42%, b: 37%, c: 63%) i) (i) H2, 
Pd(OH)2/C, MeOH;  (ii) LiOH, MeOH/H2O (a: 12%, b: 41%, c: 59%). 
 
Synthesis of cyclic ligands 4a-c. 
The key step of the synthesis was ring closure metathesis (RCM) reaction of a (R)-1-
methoxy-1-oxo-pent-4-en-2-yl group in 3’ position of the D-galactose and a terminal alkene 
with variable chain length in its 2’-position (Scheme 2).    
Galactosylation of 15 with galactosyl donor 1841 promoted by DMTST afforded 19 β-
selectively.10 The acetyl protection groups were hydrolysed under Zemplén conditions and 
gave 20, the precursor for macrocycles 4a,b and also for the non-cyclic control compound 
7.  
By tin mediated alkylation of 3’-position of the D-galactose residue, alkene 22 was 
obtained. Debenzylation by hydrogenolysis, subsequent saponification with lithium 
hydroxide followed by ion exchange chromatography gave 7.  
For the synthesis of macrocycles 4a,b, we selective introduced an acetonide protection 
group to 20 to get alcohol 23. Alkylation of 23 with allylbromid, or 3-butenyl triflate lead to 
24a and 24b, respectively. 
The acetal protection group was removed with AcOH to give diols 25a,b. Triflate 21 
(Scheme S3) was introduced in 3’-position by selective tin-mediated alkylation of the D-
galactose moiety and subsequently underwent RCM with Grubbs 2nd generation catalyst. 
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Debenzylation and saponification of the methylester with LiOH followed by ion exchange 
chromatography gave the 9- and 10-member macrocycles 4a and 4b.  
 
 
Scheme 2. a) DMTST, DCM, 4Å mol.sieves, 79%; b) NaOMe, MeOH, 81%; c) (i) Bu2SnO, MeOH; (ii) CsF, 
21, DCM 57%; d) Pd(OH)2/C, dioxane/H2O (4:1), H2, 52%; (ii) LiOH, H2O, 52%; e) Me2C(OMe)2, CuSO4, 
PPTS, acetone, 83%; f) NaH, Br(CH)nCH=CH2, DMF [a: 85%; b: 34% (42% of reactant recovered)]; g) 
AcOH (80%), 40°C (a: 78%; b: 91%); h) (i) Bu2SnO, MeOH; (ii) CsF, triflate 21, DCM (a: 57% b: 93%); i) 
Grubbs 2nd gen. cat., DCM (a: 86%; j) (i) Pd(OH)2/C, dioxane/H2O (4:1), H2; (ii) LiOH, H2O (a: 57%; b: 
25% over three steps). 
 
Synthesis of the smaller 8-membered macrocycle was not successful using a similar 
approach, as the vinyl group introduced in 2’-position of 23 turned to out to be unstable 
under acetonide deprotection conditions. We therefore modified the synthetic route and 
introduced the vinyl functionality in the last step before the RCM (Scheme 3).  
Thus, galactosylation of alcohol 15 with thioglalactoside 29 and DMTST promotion 
followed by hydrolysis of the benzoyl groups yielded 30. Alkylation via the tin acetal 
method in 3’ position and subsequent transvinylation catalysed by an iridium complex 
catalyst following the procedure of Chayajarus gave 32 in good yields.42,43 The 8-membered 
ring of 33 was established by RCM of dialkene 32. Deprotection and sodium exchange 
column chromatography gave 4c in 35 % overall yield from 30. 
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Scheme 3. a) DMTST, DCM, 4Å mol.sieves, 55%; b) NaOMe, MeOH, 94%; c) (i) Bu2SnO, MeOH; (ii) CsF, 
triflate 21, DCM, 85% over 2 steps; d) Na2CO3, vinyl acetate, Ir Cat., toluene, 70%; e) Grubbs 2nd Gen. Cat., 
DCM 86%; f) Pd(OH)2/C, dioxane/H2O (4:1), H2; (ii) LiOH, H2O, 68%. 
 
Conclusions 
We were able to determine the solution structure of the potent E-selectin antagonist 3, 
which mimics the conformation of the rigid Lex core of the natural E-selectin ligand sLex 
(1). In addition, the acid pharmacophore is pre-organized by hydrophobic interaction of a 
benzoate residue in 2’-position and a (S)-cyclohexyl lactic acid moiety in 3’-position of the 
D-galactose moiety. We assumed that the pre-organization of the acid functionality is a 
major factor for the improved binding affinity over the more flexible antagonist 2. 
Therefore, we designed and synthesized a series of cyclic E-selectin antagonists in which an 
intramolecular aliphatic bridge adjusts the acid functionality in the bioactive conformation 
already before binding. 
The ring size of the compounds had a strong influence on the binding properties. The best 
binding affinity was observed in medium-size cycle 4a, where a 9-membered ring adjusts 
the acid pharmacophore. It shows a 1.5 fold increase in binding affinity over the flexible 
mimic 2 but it is not as potential than compound 3, in which the acid is pre-organized by 
intramolecular hydrophobic interactions. The increase in affinity could be due to 
interactions of the cyclohexyl lactic acid in 3 with residues Glu98 and Lys99 of the protein 
and a stabilizing water cluster around the molecule.44  
In the future the binding mode and thermodynamic profile for E-selectin/ligand binding will 
be determined for the cyclic selectin ligands 4a-c. 
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Experimental methods 
Synthetic procedures and characterization of compounds are described in the 
supporting information. 
 
Molecular modeling. The 3D structure of the carbohydrate mimic molecules was built in 
the Maestro45 molecular modeling environment and a conformational analysis was 
performed using Macromodel46 by performing 5000 steps of the mixed torsional/low-mode 
sampling in combination with the OPLS-2005 force-field in implicit solvent conditions 
(water). 
Global minimum identified in the conformational search was then placed in a periodic 
boundary system (cube, side length 40.0 Å) filled with explicit water molecules (TIP3P 
parametrization). The system was minimized and a simulated annealing simulation (gradual 
heating of the system to the temperature of 400 K in 330 ps followed by slow gradual 
cooling to 300 K in 500 ps) was performed in Desmond47,48 in order to bring the system into 
equilibrium. The production phase molecular dynamics simulation of the total duration of 
48 ns was performed. Two critical structural descriptors – the core conformation and the 
acid orientation – were monitored every 4.8 ps (10 000 data points were saved). 
The pre-organization of the mimic molecule was evaluated by plotting the frequency of the 
two critical parameters in a two-dimensional color-coded plot using an in-house computer 
program. 
 
NMR spectroscopy for three-dimensional structure determination. Unless indicated 
otherwise spectra were measured at a 750 MHz Bruker Avance III spectrometer equipped 
with a TXI triple-resonance probe at 275 K. For complete chemical shift assignment of 
compounds 2 and 3 they were dissolved in D2O at concentrations of 6.6 mM 3 and 7.6 mM 
2, respectively. Assignment was achieved using the following 2D spectra:  13C-1H HSQC, 
13C-1H HMBC, 13C-1H HMQC-COSY49 and TOCSY 1H-1H TOCSY (mixing times 13 ms 
and 120 ms). The 13C-1H HMQC-COSY spectrum was especially useful for assigning the 
cyclohexane resonances, see Supplementary Fig. 2. Complete chemical shift assignments 
for compounds 3 and 4 can be found in Supplementary Figs. 1 and 6. A 2D NOESY 
spectrum of compound 3 was recorded at 900 MHz with a mixing time of 150 ms, 96 
transients and 2,048×530 points. Spectra were processed using Topspin 2.1 and analyzed by 
Sparky50. All spectra were referenced to DSS according to Markley et al..51  
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Structure Calculation and Refinement. Initial structures were calculated using CYANA 
3.0.52 Signal to noise (S/N) ratios of all NOE signals were extracted using the program 
Sparky50 and converted to distances using the r−6 dependence and the Cyc H3a−H3b cross-
peaks (1.77 Å) as reference. S/N ratios of signals involving CH2 and CH3 groups with 
coinciding 1H resonances were divided by a factor of 2 or 3, respectively. Upper limit 
restraints with an additional tolerance of 0.5 Å were applied. Out of 200 structures, the 30 
structures with the lowest target function were further refined in AMBER 934 applying the 
general AMBER force field (GAFF).53 A generalized Born model was used to mimic 
solvent.54 Initial charge parameters were generated by Antechamber for the GAFF force 
field. 
 
Microscale Thermophoresis. The measurements were performed using a Monolith NT.115 
(NanoTemper Technologies GmbH, Munich, Germany). The experiments were carried out 
at 25°C with 50% LED power, 50% laser power, laser on time of 30 sec, and laser off time 
of 5 sec with standard treated capillaries. The ligands were diluted 1:1 with a starting 
concentration of 1 – 4 mM with assay buffer (20 mM HEPES, 150 mM NaCl, 1 mM CaCl2, 
pH 7.4). In addition 0.05% Tween 20 and 10% DMSO were added. The protein E-
SelectinLEC2 was purified and labeled according to Zihlmann et al..55 The protein 
concentration was determined by HPLC-UV against a BSA standard.56,57 Throughout all 
experiments the E-SelectinLEC2 concentration was 0.2 µM. Every measurement was carried 
out three times. Datapoints were normalized using the bound and unbound borders achieved 
by NanoTemper Analysis 1.2.205 software (NanoTemper Technologies GmbH, Munich, 
Germany) and analyzed with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA).  
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Supplementary Methods 
 
Experimental 
General methods. Commercial materials (Sigma-Aldrich) were used without further 
purification, solvents were reagent grade (Acros). CH2Cl2 and MeOH were dried by passing 
through an Al2O3 (Fluka, type 5016 A basic) column. DMF extra dry (Acros) was used as 
is. All reactions were performed in oven dried glassware under an atmosphere of argon.  
1H and 13C NMR spectra were recorded on a Bruker Avance DMX-500 at room 
temperature. Chemical shifts are reported in ppm and referenced to TMS using residual 
solvent peaks.[1 For complex molecules the following prefixes were used: Fuc (fucose), Gal 
(galactose) and GlcNAc (N-acetyl glucosamine). The coupling constants (J) are reported in 
Hertz (Hz). Analytical TLC was performed on Merck silica gel 60 F254 glass plates and 
visualized by UV light and charring with a molybdate solution (a 0.02 M solution of 
ammonium cerium sulfate dihydrate and ammonium molybdate tetrahydrate in aq. 10% 
H2SO4) by heating for 5 min at 140°C. Column chromatography was performed on a 
CombiFlash Companion (Teledyne-ISCO, Inc.) using RediSep normal phase disposable 
flash columns (silica gel). Reversed phase chromatography was carried out with 
LiChroprepRP-18 (Merck, 40-63 µm). Optical rotations were determined on a Perkin-
Elmer Polarimeter 341. Low resolution mass spectra were measured on a Waters micromass 
ZQ. High resolution mass spectra (HRMS) were obtained on a micrOTOF spectrometer 
(Bruker Daltonics, Germany) equipped with a TOF hexapole detector. MALDI-TOF and 
ESI-MS glycoprotein analyses were recorded by the Functional Genomic Center Zurich 
(FGCZ). VIVASPIN 500 ultrafiltration tubes with 10000 MWCO, 10 kDa molecular 
weight cutoff PES membrane, and ZelluTrans/Roth dialysis membranes MWCO 8000-
10000 were used for glycoprotein concentration and dialysis 
 
 (R)-3-Methylcyclohex-2-en-1-yl butyrate (9) 
 
 
Immobilized Novozyme 435 (222 mg, 444 U, EC 232-619-9) was added to a solution of 8 
(10.0 g, 89 mmol) and vinyl butyrate (22.6 mL, 20.3 g, 178 mmol) in heptane (90 mL). The 
O
O
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mixture was stirred at 23°C and 200 rpm. After 2 h 25 min the mixture was filtered and 
volatiles were evaporated at 60°C and 10 mbar to give 12 g of a clear oil. Column 
chromatography on silica (CH2Cl2) yielded pure 9 (7.50 g, 41 mmol, 46%). 
[α]D
22 +168.7 (c 9.28, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 5.44 (m, 1H, H-2), 5.23 
(m, 1H, H-1), 2.24 (t, J = 7.4 Hz, 2H, COCH2CH2CH3), 2.02-1.84 (m, 2H, H-4, H-4’), 1.81-
1.56 (m, 9H, H-5, H-5’, H-6, H-6’, -CH3, COCH2CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, 
COCH2CH2CH3); 13C NMR (125.8 MHz, CDCl3): δ 173.5 (COCH2CH2CH3), 141.0 (C-3), 
120.2 (C-2), 68.6 (C-1), 36.7 (COCH2CH2CH3), 30.0 (C-4), 28.1 (C-6), 23.8 (-CH3), 19.1, 
18.7 (2C, C-5, COCH2CH2CH3), 13.7 (COCH2CH2CH3); MS (ESI) m/z: Calcd for 
C11H18NaO2+ [M+Na]+: 205.12; found: 204.83; elemental analysis calcd (%) for C11H18O2 
(182.26): C 72.49, H 9.95; found: C 72.87, H 9.65. 
 
(R)-seudenol (10) 
 
A solution of NaOH in H2O (10.3 mL, 4N) was slowly added to a solution of seudenol 
butyrate 9 (3.50 g, 19 mmol) in MeOH (30 mL) at 0°C and stirred at 0°C for 5 h. The 
mixture was diluted with H2O (25 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were washed with brine (25 mL) and dried over Na2SO4. Filtration 
and evaporation of volatiles (200 mbar, 40°C) gave spectroscopically pure (R)-seudenol 
(10) (1.81 g, 16.0 mmol, 84%) as a clear oil, which was directly used in the next step. 
[α]D +91.7 (c 0.74, CHCl3); HPLC: 97.5% ee, 98% purity; NMR data were in accordance 
with literature.7 
 
(1R,2R,3S)-1-[(tert-butyldimethylsilyl)oxy]-3-methylcyclohexan-2-ol (12) 
 
Imidazol (4.40 g, 65 mmol) was added to a solution of (R)-seudenol 10 (3.50 g, 31 mmol), 
DMAP (cat.), and TBSCl (7.31 g, 48 mmol) in anhydrous CH2Cl2 (65 mL) at r.t. under 
argon. After stirring for 15 h, the reaction mixture was quenched with satd. aq. NaHCO3 (50 
mL) and extracted with CH2Cl2 (20 mL). The organic layer was washed with aq. HCl (20 
OH
OTBDMS
OH
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mL, 0.01 N), satd. aq. NaHCO3 (20 mL), and brine (20 mL) and dried over Na2SO4. 
Filtration and evaporation of volatiles (200 mbar, 40°C) gave the TBS ether 11 as clear oil.  
A solution of BH3⋅THF (60 mL, 1M in THF) was slowly added to a solution of the crude 
TBS ether (11) in anhydrous THF (60 mL) under argon at 0°C. After stirring for 2 h at rt, 
the reaction mixture was cooled to 0°C again and aq. NaOH (180 mL, 3N) followed by aq. 
H2O2 (180 mL, 30%) were slowly added via dropping funnel (CAUTION: strong gas 
development). The mixture was stirred at 0°C for 1 h, subsequently acidified to pH 3 by 
slow addition of 10% aq. HCl via dropping funnel (CAUTION: strong gas development) 
and extracted with DCM (2 x 300 mL). The extracts were dried over Na2SO4, filtered, 
concentrated (100 mbar, 40°C) and purified by column chromatography (petroleum 
ether/Et2O 98.5/1.5) to yield pure 12 (6.20 g, 25 mmol, 81%) as clear oil. 
[α]D
22 - 13.7 (c 3.14, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 3.34 (m, 1H, H-1), 2.92 
(dd, J = 8.5 , 10.0 Hz, 1H, H-2), 2.47 (s, 1H, OH), 1.81 (m, 1H, H-6), 1.63-1.56 (m, 2H, H-
4, H-5), 1.41 (m, 1H, H-3), 1.34-1.99 (m, 2H, H-5’, H-6’), 1.04-0.92 (m, 4H, H-4’, Me), 
0.91-0.83 (m, 9H, SiC(CH3)3), 0.07 (s, 3H, SiCH3), 0.05 (s, 3H, SiCH3); 13C NMR (125.8 
MHz, CDCl3): δ = 81.0 (C-2), 77.0 (C-1), 37.0 (C-3), 33.4, 33.9 (2C, C-4, C-6), 25.9 (3C, 
SiC(CH3)3), 23.6 (C-5), 18.5 (-CH3), 18.1 (SiC(CH3)3), -3.9, -4.6 (SiCH3); HR-MS (ESI) 
m/z: calcd for C13H28NaO2Si+ [M+Na]+: 267.1751; found: 267.1752. 
 
[(1R,2R,3S)-1-(tert-Butyldimethylsilyl)oxy)-3-methyl-cyclohex-2-yl] 2,3,4-tri-O-benzyl-
6-deoxy-α-L- galactopyranoside (14) 
 
 
Ethylthio fucoside 1312 (3.90 g, 8.15 mmol) and TBAB (4.00 g, 12.4 mmol) were dried at 
high vacuum overnight. Powdered activated molecular sieves 4 Å (5.0 g), compound 12 
(1.00 g, 4.09 mmol), 2,6-di-tert-butyl-4-methylpyridine (2.50 g, 12.2 mmol), anhydrous 
DCM (35 ml) and DMF (5 ml) were added and the mixture was stirred for 4 h at rt under 
argon. CuBr2 (2.70 g, 12.1 mmol), dried under high vacuum overnight at 70°C, was added 
and the resulting dark mixture was stirred at rt under argon. After completion of the reaction 
(17 h), the solution was filtered through a pad of celite and the filtrate was washed with a 
solution of satd. aq. NH4Cl and aqueous NH3 (9/1 (v/v), 2 x 200 mL) and brine (100 mL). 
O
O
BnO OBn
OBn
TBDMSO
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The aqueous layers were extracted with DCM (2 x 200 mL) and the combined organic 
layers were dried (Na2SO4) and concentrated. Column chromatography on silica (petroleum 
ether/EtOAc 98/2 to 97/3) gave the pseudodisaccharide 14 as clear oil (2.34 g, 3.54 mmol, 
87%). 
[α]D - 53.7 (c 2.1, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ  = 7.47-7.27 (m, 15H, 3 C6H5), 
5.16 (d, 3J = 3.4 Hz, 1H, Fuc H-1), 5.03 (A of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.89, 4.85, 
4.78, 4.76 (4d, 2J = 11.8Hz, 4H, CH2Ph), 4.70 (B of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.26 (q, 
3J = 6.4 Hz, 1H, Fuc H-5), 4.10 (dd, 3J = 3.4, 10.2 Hz, 1H, Fuc H-2), 4.05 (dd, 3J = 2.6, 
10.2 Hz, 1H, Fuc H-3), 3.75 (m, 1H, H-1), 3.70 (m, 1H, Fuc H-4), 3.36 (t, 3J = 6.4 Hz, H-
2), 1.88-1.77 (m, 2H, H-3, H-6a), 1.76-1.68 (m, 2H, H-4a, H-5a), 1.43 (m, 1H, H-6b), 1.34-
1.11 (m, 8H, Fuc-H6, -CH3, H-4b, H-5b), 0.93 (s, 9H, SiC(CH3)3), 0.09 (s, 3H, SiCH3), 0.06 
(s, 3H, SiCH3); 13C NMR (125.8 MHz, CDCl3): δ 139.1, 138.9, 138.8, 128.4, 128.3, 128.2, 
127.6, 127.5 (18C, 3 C6H5), 96.8 (Fuc C-1), 81.5 (C-2), 79.3 (Fuc C-3), 78.2 (Fuc C-4), 
76.7 (Fuc C-2), 74.9 (CH2Ph), 73.6 (CH2Ph), 73.3 (C-1), 73.0 (CH2Ph), 66.4 (Fuc C-5), 
35.6 (C-3), 33.2 (C-6), 31.1 (C-5), 26.1 (3C, SiC(CH3)3), 19.8 (C-4), 18.9 (Fuc C-6), 18.2 
(SiC(CH3)3), 17.0 (CH3), -3.9, -5.0 (2C, SiCH3); HR-MS (ESI) m/z: Calcd for 
C40H56NaO6Si+ [M+Na]+: 683.3738; found: 683.3740. 
 
[(1R,2R,3S)-­1-­Hydroxy-­3-­methyl-­cyclohex-­2-­yl]	  2,3,4-­tri-­O-­benzyl-­6-­deoxy-­α-­L-­	  
galactopyranoside	  (15) 
 
 
Compound 14 (2.10 g, 3.18 mmol) was dissolved in a solution of TBAF in THF (20 mL, 
1M) and stirred for 24 h at rt. The solution was diluted with DCM (50 mL) and washed with 
H2O (100 mL). The aq. layer was extracted with DCM (2 x 50 mL) and the combined 
organic layers were dried (Na2SO4) and concentrated. Column chromatography on silica 
(petroleum ether/EtOAc 80/20) gave 15 as white solid (1.74 g, 3.18 mmol, quant.); [α]D - 
42.0 (c 0.45, CHCl3); NMR data were in accordance with literature.6 
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Scheme S1. Synthesis of triflate derivatives S3a-c a) BnOH, TsOH, benzene (a: 88%); or 
(i) NaNO2, H2SO4, H2O (ii) BnOH, TsOH, benzene (b: 57%, c: 50%); b) Tf2O, lutidine, 
DCM (a: 98%, b: 97%, c: 95%). 
 
(R)-Benzyl 2-hydroxy-3-phenylpropanoate (S2a) 
 
To a solution of 2-hydroxy-3-phenyl-2-(R)-propanoic acid S1a (1.94 g, 11.6 mmol) in 
benzene (25 mL) benzyl alcohol (1.62 mL, 15.6 mmol) and p-toluenesulfonic acid (200 mg, 
1.2 mmol) were added. The solution was refluxed at 80°C until completion of the reaction 
(3 h, TLC: DCM/MeOH, 19:1 and petroleum ether/EtOAc, 4:1). The reaction mixture was 
allowed to cool down to rt, diluted with EtOAc (50 mL) and washed with satd. aq. NaHCO3 
(20 mL), water (20 mL) and brine (10 mL). The organic layer was dried over Na2SO4, 
filtered and solvent was removed in vacuo. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-25%) to afford S2a as colorless wax 
(2.62 g, 10.2 mmol, 88%). Rf = (petroleum ether/EtOAc, 4:1) 0.50; [α]D22 +53.5 (c 0.69, 
CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.54 - 7.06 (m, 10H, Ar-H), 5.18 (s, 2H, Ar-
CH2), 4.50 (br s, 1H, H-2,), 3.22 - 3.06 (m, 1H, H-3), 3.09 - 2.90 (m, 1H, H-3’); 13C NMR 
(125.8 MHz, CDCl3): δ = 174.0 (C-1), 136.1, 135.0, 129.5, 128.7, 128.7, 128.6, 128.4 (8C, 
Ar-C); 71.3 (C-2); 67.5 (Ar-CH2); 40.5 (C-3); ESI-MS: m/z: Calcd for C16H16NaO3 
[M+Na]+: 279.3, found: 278.9. 
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(R)-Benzyl 2-hydroxy-3-(4-methylphenyl)-propanoate (S2b) 
 
A solution of sodium nitrite (11.7 g, 0.17 mol) in water (40 mL) was added dropwise to a 
stirred and ice-cooled solution of p-methyl-D-phenylalanine S1b (5.10 g, 28.4 mmol) in 1 M 
H2SO4 (50 mL) over 1 h, and the resulting mixture was stirred for 24 h at rt. The reaction 
mixture was extracted with Et2O (3 x 150 mL), the combined organic phases were washed 
with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude 
product (4.85 g) was dissolved in benzene (30 mL) and the resulting solution was treated 
with benzyl alcohol (3.63 mL, 35.0 mmol, 1.3 eq) and p-toluenesulfonic acid (463 mg, 2.70 
mmol, 0.1 eq). The solution was refluxed until completion of the reaction (5 h, TLC: 
DCM/MeOH, 19:1 and petroleum ether/EtOAc, 4:1). The reaction mixture was allowed to 
cool down to rt, diluted with EtOAc (150 mL) and washed with satd. aq. NaHCO3 (30 mL), 
water (30 mL) and brine (20 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc, gradient 0-25%) to afford S2b as colorless wax (4.2 g, 15.16 mmol, 53% over 
two steps). Rf = (petroleum ether/EtOAc, 4:1) 0.52; [α]D22 -46.5 (c 0.63, CHCl3); 1H NMR 
(500.1 MHz, CDCl3): δ = 7.40 - 7.30 (m, 5H, Ar-H), 7.05 (dd, J = 8.1 Hz, 4H, Ar-H); 5.15 - 
5.02 (m, 2H, Ar-CH2), 4.47 (dd, J = 4.7, 6.4 Hz, 1H, H-2), 3.09 (dd, J = 4.7, 13.9 Hz, 1H, 
H-3), 2.95 (dd, J = 6.4, 13.9 Hz, 1H, H-3’), 2.31 (s, 3H, Ar-Me); 13C NMR (125.8 MHz, 
CDCl3): δ = 174.2 (C-1), 136.6, 135.2, 133.0, 129.5, 129.3, 128.8, 128.7 (8C, Ar-C), 71.5 
(C-2), 67.5 (Ar-CH2), 40.2 (C-3), 21.2 (Ar-Me); ESI-MS: m/z: Calcd for C17H18NaO3 
[M+Na]+: 293.3, found: 292.9. 
 
(R)-Benzyl 2-hydroxy-3-(3,4-difluorophenyl)-propanoate (S2c) 
 
A solution of sodium nitrite (2.05 g, 39.8 mmol) in water (10 mL) was added dropwise to a 
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stirred and ice-cooled solution of 3,4-difluoro-D-phenylalanine S1c (1.00 g, 4.97 mmol) in 1 
M H2SO4 (10 mL) over 30 min, and the resulting mixture was stirred for 2 d at rt. The 
reaction mixture was extracted with Et2O (3 x 50 mL), the combined organic phases were 
washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The 
crude product (790 mg) was dissolved in benzene (10 mL) and the resulting solution was 
treated with benzyl alcohol (0.55 mL, 5.08 mmol) and p-toluenesulfonic acid (62 mg, 0.39 
mmol). The solution was refluxed at 80°C until completion of the reaction (4 h, TLC: 
DCM/MeOH, 19:1 and petroleum ether/EtOAc, 4:1). The reaction mixture was allowed to 
cool down to rt, diluted with EtOAc (50 mL) and washed with satd. aq. NaHCO3 solution 
(20 mL), water (20 mL) and brine (10 mL). The organic layer was dried over Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by flash chromatography 
(Tol/EtOAc, gradient 0-10%) to afford S2c as colorless wax (720 mg, 2.46 mmol, 50% over 
two steps). Rf = (petroleum ether/EtOAc, 4:1) 0.38; [α]D22 +61.9 (c 0.76, CHCl3); 1H NMR 
(500.1 MHz, CDCl3): δ = 7.43 - 7.21 (m, 6H, Ar-H), 7.03 - 6.91 (m, 2H, Ar-H), 6.87 - 6.77 
(m, 1H, Ar-H), 5.26 - 5.11 (m, 2H, Ar-CH2), 4.45 (q, J = 5.3 Hz, 1H, H-2,), 3.07 (dd, J = 
4.0, 14.1 Hz, 1H, H-3), 2.91 (dd, J = 6.2, 14.1 Hz, 1H, H-3’); 13C NMR (125.8 MHz, 
CDCl3): δ = 173.7 (C-1), 151.3 – 148.2 (m, 2C, ArF-C), 134.8 (Ar-C) 133.1 (m, Ar-C), 
128.9, 128.8 (2C, Ar-C), 125.5 (m, Ar-C), 118.4 (d, J = 17.1 Hz, Ar-C), 116.9 (d, J = 17.1 
Hz, Ar-C), 70.8 (C-2); 67.7 (Ar-CH2); 39.3 (C-3). ESI-MS: m/z: Calcd for C16H14F2NaO3 
[M+Na]+: 315.3, found: 314.6. 
 
(R)-Benzyl 3-phenyl-2-(trifluoromethyl)sulfonyloxy-propanoate (S3a) 
 
To a stirred solution of S2a (2.44 g, 8.35 mmol) and lutidine (1.16 mL, 10.8 mmol) in dry 
DCM (30 mL) Tf2O (1.68 mL, 10.0 mmol) was added dropwise at -60°C under argon. The 
reaction was stirred at -60°C for 20 min, then at -5°C for 40 min. TLC (petroleum 
ether/EtOAc, 9:1) indicated completion of the reaction and the mixture was quenched by 
addition of water (10 mL) at 0°C. The organic phase was separated and the water phase was 
extracted with DCM (50 mL). The combined organic phases were washed with water (20 
mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
OTf
COOBn
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by flash chromatography using a short silica pad (DCM/petroleum ether, 1:1) to afford 
(S3a) as pale orange oil. (3.17 g, 8.17 mmol, 98%). Rf = (petroleum ether/EtOAc, 9:1) 0.50; 
[α]D
22 +29.5 (c 1.33, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ  = 7.41 - 7.12 (m, 10H, Ar-
H), 5.30 - 5.20 (m, 1H, H-2), 5.24 (s, 2H, Ar-CH2), 3.34 (dd, J = 3.6, 14.6 Hz, 1H, H-3), 
3.21 (dd, J = 8.5, 14.6 Hz, 1H, H-3’); 13C NMR (126 MHz, CDCl3): δ = 166.5 (C-1), 134.2, 
133.2, 129.5, 128.9, 128.8, 128.7, 128.9, 127.8 (8C, Ar-C), 83.8 (C-2), 68.4 (Ar-CH2), 38.2 
(C-3). 
 
(R)-Benzyl 3-(4-methylphenyl)-2-(trifluoromethyl)sulfonyloxy-propanoate (S3b) 
 
To a stirred solution of S2b (4.10 g, 15.2 mmol) and lutidine (2.29 mL, 19.7 mmol) in dry 
DCM (30 mL) a solution of Tf2O in dry DCM (1 M, 18.2 mL, 18.2 mmol) was added at -
80°C under argon. The reaction was allowed to warm up to -20°C (2 h) and stirred at that 
temperature for an additional 1 h. TLC (petroleum ether/EtOAc, 9:1) indicated completion 
of the reaction and the mixture was quenched by addition of water (10 mL) at 0°C. The 
organic phase was separated and the water phase was extracted with DCM (2 x 50 mL). The 
combined organic phases were washed with water (20 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography using a 
short silica pad (DCM/petroleum ether, 1:1) to afford S3b as pale grey oil (5.90 g, 14.7 
mmol, 97%). Rf = (petroleum ether/EtOAc, 9:1) 0.45; [α]D22 -26.1 (c 1.22, CHCl3); 1H 
NMR (500 MHz, CDCl3): δ = 7.39 - 7.27 (m, 5H, Ar-H), 7.09 (d, J = 7.9 Hz, 2H, Ar-H), 
7.04 (d, J = 7.9 Hz, 2H, Ar-H), 5.26 (dd, J = 4.5, 8.1 Hz, 1H, H-2), 5.23 (s, 2H, Ar-CH2), 
3.29 (dd, J = 4.5, 14.6 Hz, 1H, H-3), 3.18 (dd, J = 8.1, 14.6 Hz, 1H, H-3’), 2.32 (s, 3H, Ar-
Me); 13C NMR (126 MHz, CDCl3): δ = 166.6 (C-1), 137.7, 134.4, 130.1, 129.6, 129.5, 
129.0, 128.8, 128.8 (8C, Ar-C), 84.0 (C-2), 68.5 (Ar-CH2), 38.0 (C-3), 21.2 (Ar-Me). 
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(R)-Benzyl 3-(3,4-difluorophenyl)-2-(trifluoromethyl)sulfonyloxy-propanoate (S3c) 
 
To a stirred solution of S2c (670 mg, 2.29 mmol) and lutidine (0.35 mL, 2.97 mmol) in dry 
DCM (10 mL) a solution of Tf2O in dry DCM (1 M, 2.75 mL, 2.75 mmol) was added at -
80°C under argon. The reaction was allowed to warm up to -20°C (1 h) and stirred at this 
temperature for an additional 1 h. TLC (petroleum ether/EtOAc, 9:1) indicated completion 
of the reaction and the mixture was quenched by addition of water (10 mL) at 0°C. The 
organic phase was separated and the water phase was extracted with DCM (2 x 30 mL). The 
combined organic phases were washed with water (10 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography using a 
short silica pad (DCM/petroleum ether, 1:1) to afford S3c as colorless oil (900 mg, 2.12 
mmol, 93%). Rf = (petroleum ether/EtOAc, 9:1) 0.40; [α]D22 +31.1 (c 0.62, CHCl3); 1H 
NMR (500 MHz, CDCl3): δ = 7.41 - 7.22 (m, 5H, Ar-H), 7.09 - 7.00 (m, 1H, Ar-H), 7.00 - 
6.92 (m, 1H, Ar-H), 6.89 - 6.83 (m, 1H, Ar-H), 5.32 - 5.14 (m, 3H, H-2, Ar-CH2), 3.28 (dd, 
J = 3.6, 14.8 Hz, 1H, H-3), 3.18 (dd, J = 7.9, 14.8 Hz, 1H, H-3’); 13C NMR (126 MHz, 
CDCl3): δ = 166.0 (C-1); 151.5 - 148.8 (m, 2C, ArF-C), 134.1 (Ar-C) 130.0 (m, Ar-C), 
129.1, 128.8 (2C, Ar-C), 125.7 (m, Ar-C), 118.6 (d, J = 17.6 Hz, Ar-C), 117.6 (d, J = 17.4 
Hz, Ar-C), 82.9 (C-2), 68.6 (Ar-CH2), 37.3 (C-3). 
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Scheme S2. Synthesis of galatose derivatives 22a-c: a) (i) Bu2SnO, MeOH; (ii) CsF, DME, 
S3a-c ((lactone) S5a: 16%, S5b: 25%, S5c: 25%; (open) S6a: 25%, S6b: 0%, S6c: 5%); b) 
BnOH, DMAP (cat.) (S6a: 73%, S6b: 80%, S6c: 65%); c) BzCl, py, DMAP (cat.) (16a: 
87%, 16b: 72%, 16c: 64%). 
 
Ethyl 4,6-O-benzylidene-2,3-O-((R)-3-(4-methylphenyl)-1-oxopropan-1,2-diyl)-1-thio-
β-D-galactopyranoside (S5b) 
 
Thiogalactoside S4 (50 mg, 0.16 mmol) and Bu2SnO (60 mg, 0.24 mmol) were dissolved in 
dry MeOH (3 mL) and refluxed at 65°C under argon for 4 h. The solvent was removed 
under reduced pressure and the crude product was dried in high vacuum for 16 h. The 
residue was dissolved in dry DME (3 mL) under argon and a solution of triflate S3b (193 
mg, 0.48 mmol) in dry DME (2 mL) was added followed by the addition of CsF (73 mg, 
0.48 mmol, dried in high vacuum at 100°C for 16 h). The turbid solution was stirred for 3 h 
after which TLC (petroleum ether/EtOAc, 9:1, DCM/MeOH, 19:1) indicated still presence 
of starting material S4 but no triflate S3b so another portion of S3b (128 mg, 0.32 mmol) 
was added and the mixture was stirred for additional 3 h. A solution of KF (10%) in aq. 
KH2PO4 (1 N, 10 mL) was added, and after stirring for 1 h, the reaction was extracted with 
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DCM (3 x 20 mL). The combined organic phases were washed with brine (10 mL) dried 
over Na2SO4 and the solvents were removed in vacuo. The crude product was purified by 
flash chromatography (petroleum ether/EtOAc, gradient 0-40%) to afford S5b as colorless 
wax (22.6 mg, 0.04 mmol, 25%). Rf = (petroleum ether/EtOAc, 7:3) 0.28; [α]D22 -44.4 (c 
1.25, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.48 - 7.42 (m, 2H, Ar-H), 7.38 - 7.31 (m, 
3H, Ar-H), 7.19 (d, J = 7.6 Hz, 2H, Ar-H), 7.11 (d, J = 7.6 Hz, 2H, Ar-H), 5.52 (s, 1H, Ph-
CH), 4.85 (t, J = 5.2 Hz, 1H, Lac-H2), 4.62 (t, J = 9.6 Hz, 1H, Gal-H2), 4.35 – 4.28 (m, 2H, 
Gal-H1, Gal-H6), 4.23 (s, 1H, Gal-H4), 4.02 (d, J = 12.4 Hz, 1H, Gal-H6’), 3.35 (s, 1H, 
Gal-H5), 3.30 - 3.23 (m, 2H, Gal-H3, Lac-H3), 3.16 (dd, J = 4.5, 14.5 Hz, Lac-H3’), 2.86 – 
2.70 (m, 2H, SCH2CH3), 2.33 (s, 3H, Ar-Me), 1.32 (t, J = 7.5 Hz, 3H, SCH2CH3); 13C NMR 
(126 MHz, CDCl3): δ = 168.5 (Lac-C1), 137.3, 136.7, 133.3, 129.6, 129.3, 129.2, 128.3, 
126.4 (8C, Ar-C), 101.3 (Ph-CH), 81.9 (Gal-C1), 75.4 (Lac-C2), 73.6 (Gal-C4), 73.4 (Gal-
C2, Gal-C3), 69.9 (Gal-C5), 69.2 (Gal-C6), 37.7 (Lac-C3), 23.5 (SCH2CH3), 21.1 (Ar-Me), 
15.0 (SCH2CH3); ESI-MS: m/z: Calcd for C25H28NaO6S [M+Na]+: 479.5, found: 479.1. 
 
Ethyl 4,6-O-benzylidene-2,3-O-((R)-3-(3,4-difluorophenyl)-1-oxopropan-1,2-diyl)-1-
thio-β-D-galactopyranoside (5c) 
 
Thiogalactoside derivative 4 (208 mg, 0.66 mmol) and Bu2SnO (247 mg, 1.00 mmolwere 
dissolved in dry MeOH (10 mL) and refluxed at 65°C under argon for 4 h. The solvent was 
removed under reduced pressure and the crude product was dried in high vacuum for 16 h. 
This residue was dissolved in dry DME (4 mL) under argon and a solution of triflate 3c 
(533 mg, 1.33 mmol) in dry DME (6 mL) was added followed by the addition of CsF (302 
mg, 2.00 mmol, dried in high vacuum at 100°C for 16 h). The turbid solution was stirred for 
3 h after which TLC (petroleum ether/EtOAc, 9:1, DCM/MeOH, 19:1) indicated still 
presence of starting material 4 but no triflate 3c so another portion of 3c (266 mg, 0.66 
mmol) was added and the mixture was stirred for additional 16 h. A solution of KF (10%) in 
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aq. KH2PO4 (1 N, 10 mL) was added, and after stirring for 1 h, the reaction was extracted 
with DCM (3 x 50 mL). The combined organic phases were washed with brine (10 mL), 
dried over Na2SO4 and the solvents were removed in vacuo. The crude product was purified 
by flash chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford S5c+S6c as 
colorless wax (94 mg, 0.196 mmol, 30%) containing 17 mol% of S5c. Rf = (petroleum 
ether/EtOAc, 3:2) 0.30; 1H NMR (500.1 MHz, CDCl3): δ = 7.49 - 7.42 (m, 2H, Ar-H), 7.41 
- 7.32 (m, 3H, Ar-H), 7.20 - 6.98 (m, 3H, Ar-H), 5.55 (s, 1H, Ph-CH), 4.80 (br s, 1H, Lac-
H2), 4.70 (t, J = 9.6 Hz, 1H, Gal-H2), 4.44 (d, J = 9.5 Hz, 1H, Gal-H1), 4.35 (d, J = 12.6 
Hz, 1H, Gal-H6), 4.30 (s, 1H, Gal-H4), 4.05 (d, J = 12.5 Hz, 1H, Gal-H6’), 3.50 - 3.40 (m, 
2H, Gal-H5, Gal-H3), 3.25 - 3.12 (m, 2H, Lac-H3), 2.88 - 2.71 (m, 2H, SCH2CH3), 1.33 (t, 
J = 7.4 Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): δ = 168.2 (Lac-C1), 153.0 - 
148.8 (m, 2C, ArF-C), 137.3 (Ar-C) 133.3 (m, Ar-C), 129.3 (Ar-C), 128.6 (m, Ar-C), 128.3, 
126.4 (Ar-C), 125.8 (m, Ar-C), 118.7 (d, J = 17.2 Hz, Ar-C), 117.1 (d, J = 16.8 Hz, Ar-C), 
101.3 (Ph-CH), 81.9 (Gal-C1), 74.5 (Lac-C2), 74.1 (Gal-C3), 73.7 (Gal-C4), 73.2 (Gal-C2), 
69.9 (Gal-C5), 69.2 (Gal-C6), 36.7 (Lac-C3), 23.7 (SCH2CH3), 15.0 (SCH2CH3); ESI-MS: 
m/z: Calcd for C24H24F2NaO6S [M+Na]+: 501.5, found: 501.1. 
 
Ethyl 4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-phenylpropan-2-yl]-1-thio-β-
D-galactopyranoside (S6a) 
 
Thiogalactoside S4 (482 mg, 1.544 mmol, 1 eq) and Bu2SnO (575 mg, 2.31 mmolwere 
dissolved in dry MeOH (15 mL) and refluxed at 65°C under argon for 4 h. The solvent was 
removed under reduced pressure and the crude product was dried in high vacuum for 16 h. 
The residue was dissolved in dry DME (10 mL) under argon and a solution of triflate 3a (2 
g, 5.14 mmol) in dry DME (10 mL) was added followed by the addition of CsF (700 mg, 
4.62 mmol, dried in high vacuum at 100°C for 16 h). The turbid solution was stirred for 5 h 
after which TLC (petroleum ether/EtOAc, 9:1, DCM/MeOH, 19:1) indicated still presence 
of starting material S4 but no triflate S3a so another portion of S3a (1 g, 2.57 mmol) was 
added and the mixture was stirred for additional 16 h. A solution of KF (10%) in aq. 
KH2PO4 (1 N, 10 mL) was added, and after stirring for 1 h, the reaction was extracted with 
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DCM (3 x 70 mL). The combined organic phases were washed with brine (20 mL) dried 
over Na2SO4 and the solvents were removed in vacuo. The crude product was purified by 
flash chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford a 1:1.6 mixture of 
S5a (lactone) and S6a (open) (330 mg, 41%), which was used in the following reaction 
without further purification. ESI-MS: m/z: Calcd for S5a (lactone) C24H26NaO6S [M+Na]+: 
465.5, found: 465.2; Calcd for S6a (open) C31H34NaO7S [M+Na]+: 573.7, found: 573.1. To 
a solution of the mixture (330 mg) obtained in the previous reaction in toluene (2 mL) 
benzyl alcohol (1mL) and DMAP (cat.) were added. The reaction was heated up to 60°C for 
4 h, then the solvents were removed in vacuo and the residue was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford pure S6a as white foam 
(260 mg, 0.47 mmol, 30% starting from S4). Rf = (petroleum ether/EtOAc, 7:3) 0.33; [α]D22 
-44.9 (c 0.31, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.52 - 7.47 (m, 2H, Ar-H), 7.41 - 
7.31 (m, 5H, Ar-H), 7.28 - 7.20 (m, 8H, Ar-H), 5.34 (s, 1H, Ph-CH), 5.10 (d, J = 12.1 Hz, 
1H, Ar-CH2), 5.04 (d, J = 12.1 Hz, 1H, Ar-CH2), 4.62 (dd, J = 4.8, 8.4 Hz, 1H, Lac-H2), 
4.26 - 4.16 (m, 3H, Gal-H1, Gal-H4, Gal-H6), 3.88 - 3.82 (m, 2H, Gal-H2, Gal-H6’), 3.37 
(dd, J = 3.4, 9.2 Hz, 1H, Gal-H3), 3.29 (br s, 1H, Gal-H5), 3.14 - 3.03 (m, 2H, Lac-H3), 
2.80 - 2.62 (m, 2H, SCH2CH3), 2.09 (d, J = 1.9 Hz, 1H, OH), 1.28 (t, J = 7.5 Hz, 3H, 
SCH2CH3); 13C NMR (125.8 MHz, CDCl3): δ = 172.3 (Lac-C1), 138.0, 137.0, 135.4, 129.6, 
128.9, 128.6, 128.5, 128.5, 128.5, 128.3, 128.1, 126.9, 126.4 (12C, Ar-C), 100.9 (Ph-CH), 
85.2 (Gal-C1), 81.8 (Gal-C3), 80.4 (Lac-C2), 75.2 (Gal-C4), 70.2 (Gal-C5), 69.2 (Gal-C6), 
68.7 (Gal-C2), 66.8 (Ph-CH2), 39.2 (Lac-C3), 23.0 (SCH2CH3), 21.1 (Ar-Me), 15.2 
(SCH2CH3); ESI-MS: m/z: Calcd for C31H34NaO7S [M+Na]+: 573.7, found: 573.1. 
 
Ethyl 4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(4-methylphenyl)-propan-2-
yl]-1-thio-β-D-galactopyranoside (S6b) 
 
To a solution of S5b (38 mg, 0.083 mmol) in benzyl alcohol (0.5 mL) DMAP (cat.) was 
added. The reaction was heated to 60°C for 4 h, then the reaction mixture was purified by 
flash chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford S6b as colorless 
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wax (30 mg, 0.053 mmol, 65%). Rf = (petroleum ether/EtOAc, 7:3) 0.30; [α]D22 -79.3 (c 
0.25, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.53 - 7.45 (m, 2H, Ar-H), 7.41 - 7.30 (m, 
6H, Ar-H), 7.12 (d, J = 7.4 Hz, 2H, Ar-H), 7.04 (d, J = 7.4 Hz, 2H, Ar-H), 5.34 (s, 1H, Ph-
CH), 5.09 (d, J = 12.1 Hz, 1H, Ar-CH2), 5.03 (d, J = 12.1 Hz, 1H, Ar-CH2), 4.66 - 4.54 (m, 
1H, Lac-H2), 4.26 - 4.20 (m, 2H, Gal-H1, Gal-H6), 4.18 (s, 1H, Gal-H4), 3.91 - 3.82 (m, 
2H, Gal-H2, Gal-H6’), 3.32 (d, J = 9.2 Hz, 1H, Gal-H3), 3.29 (s 1H, Gal-H5), 3.10 - 2.98 
(m, 2H, Lac-H3), 2.81 - 2.71 (m, 2H, SCH2CH3), 2.30 (s, 3H, Ar-Me), 1.28 (t, J = 7.5 Hz, 
3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): δ = 172.4 (Lac-C1), 138.3, 136.3, 135.4, 
133.8, 129.5, 129.1, 128.9, 128.6, 128.5, 128.5, 128.1, 126.4 (12C, Ar-C), 100.3 (Ph-CH), 
85.1 (Gal-C1), 81.9 (Gal-C3), 80.6 (Lac-C2), 75.1 (Gal-C4), 70.2 (Gal-C5), 69.2 (Gal-C6), 
68.6 (Gal-C2), 66.8 (Ph-CH2), 38.8 (Lac-C3), 23.0 (SCH2CH3), 21.1 (Ar-Me), 15.2 
(SCH2CH3); ESI-MS: m/z: Calcd for C32H36NaO7S [M+Na]+: 587.7, found: 587.2. 
 
Ethyl 4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(3,4-difluorophenyl)-propan-
2-yl]-1-thio-β-D-galactopyranoside (S6c) 
 
To a solution of S5c (90.0 mg, 0.188 mmol) in benzyl alcohol (1 mL) DMAP (cat.) was 
added. The reaction was heated to 60°C for 3 h, then the reaction mixture was purified by 
flash chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford S6c as colorless 
wax (88 mg, 0.15 mmol, 80%). Rf = (petroleum ether/EtOAc, 3:2) 0.32; [α]D22 -35.8 (c 
0.35, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.52 - 7.47 (m, 2H, Ar-H), 7.40 - 7.32 (m, 
6H, Ar-H), 7.31 - 7.24 (m, 2H, Ar-H), 7.12 - 7.05 (m, 1H, Ar-H), 6.92 - 6.82 (m, 2H, Ar-H), 
5.42 (s, 1H, Ph-CH), 5.11 (d, J = 12.0 Hz, 1H, Ar-CH2), 5.05 (d, J = 12.0 Hz, 1H, Ar-CH2), 
4.75 (t, J = 5.7 Hz, 1H, Lac-H2), 4.29 - 4.18 (m, 3H, Gal-H1, Gal-H4, Gal-H6a), 3.93 - 3.87 
(m, 2H, Gal-H2, Gal-H6b), 3.47 (d, J = 9.3 Hz, 1H, Gal-H3), 3.34 (s 1H, Gal-H5), 3.10 - 
2.95 (m, 2H, Lac-H3), 2.82 - 2.64 (m, 2H, SCH2CH3), 2.31 (br s, 1H, OH), 1.30 (t, J = 7.4 
Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): δ = 172.0 (Lac-C1), 153.5 - 148.1 (m, 
2C, ArF-C), 130.0, 135.3, 128.9, 128.7, 128.6, 128.1 (6C, Ar-C), 126.3 (Ar-C), 125.5 (m, 
Ar-C), 118.8 (d, J = 17.7 Hz, Ar-C), 116.6 (d, J = 17.0 Hz, Ar-C), 100.9 (Ph-CH), 85.7 
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(Gal-C1), 80.5 (Gal-C3), 79.3 (Lac-C2), 75.6 (Gal-C4), 70.4 (Gal-C5), 69.2 (Gal-C6), 69.1 
(Gal-C2), 66.8 (Ph-CH2), 38.2 (Lac-C3), 23.0 (SCH2CH3), 15.4 (SCH2CH3); ESI-MS: m/z: 
Calcd for C31H32F2NaO7S [M+Na]+: 573.7, found: 573.1. 
 
Ethyl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-phenylpropan-2-
yl]-1-thio-β-D-galactopyranoside (16a) 
 
To a solution of S6a (250 mg, 0.45 mmol) in pyridine (2 mL) DMAP (6 mg, 0.05 mmol) 
and benzoyl chloride (0.16 mL, 1.36 mmol) were added at 0°C. The reaction was stirred at 
rt for 3h after which TLC (petroleum ether/EtOAc, 3:2) indicated completion of the 
reaction. The solvent was removed in vacuo, the crude residue was taken up in DCM (100 
mL), washed with 0.5 M aq. HCl (20 mL), satd aq. NaHCO3 (20 mL) and brine (20 mL), 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford 16a as white solid (260 
mg, 0.40 mmol, 87%). Rf = (petroleum ether/EtOAc, 7:3) 0.45; [α]D22 -22.5 (c 2.0, CHCl3); 
1H NMR (500.1 MHz, CDCl3): δ = 7.95 (d, J = 7.3 Hz, 2H, Ar-H), 7.62 - 7.51 (m, 3H, Ar-
H), 7.46 - 7.28 (m, 10H, Ar-H), 7.02 (t, J = 7.3 Hz, 1H, Ar-H), 6.98 - 6.90 (m, 2H, Ar-H), 
7.02 (d, J = 7.2 Hz, 2H, Ar-H), 5.67 (t, J = 9.7 Hz, 1H, Gal-H2), 5.39 (s, 1H, Ph-CH), 5.05 - 
4.95 (m, 2H, Ar-CH2), 4.44 (d, J = 9.7 Hz, 1H, Gal-H1), 4.34 (t, J = 6.2 Hz, 1H, Lac-H2), 
4.30 - 4.24 (m, 2H, Gal-H6, Gal-H4), 3.88 (d, J = 12.2 Hz, Gal-H6’), 3.68 (d, J = 7.6 Hz, 
1H, Gal-H3), 3.34 (s, 1H, Gal-H5), 2.92 - 2.82 (m, 3H, Lac-H3, SCH2CH3), 2.77 - 2.66 (m, 
1H, SCH2CH3), 1.22 (t, J = 7.5 Hz, 3H, SCH2CH3); 13C NMR (126 MHz, CDCl3): δ = 172.0 
(Lac-C1), 164.8 (Bz-CO), 137.9, 136.0, 135.3, 133.1, 129.9, 129.8 129.4, 128.9, 128.7, 
128.6, 128.4, 128.2, 128.1, 126.5, 126.4 (16C, Ar-C), 100.9 (Ph-CH), 82.9 (Gal-C1), 81.3 
(Lac-C2), 79.9 (Gal-C3), 75.3 (Gal-C4), 70.3 (Gal-C5), 69.6 (Gal-C2), 69.2 (Gal-C6), 66.7 
(Ph-CH2), 39.2 (Lac-C3), 22.7 (SCH2CH3), 14.8 (SCH2CH3); ESI-MS: m/z: Calcd for 
C38H38O8S [M+Na]+: 577.8, found: 577.2. 
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Ethyl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(4-
methylphenyl)-propan-2-yl]-1-thio-β-D-galactopyranoside (16b) 
 
To a solution of S6b (195 mg, 0.34 mmol) in pyridine (2 mL) DMAP (4 mg, 0.03 mmol) 
and benzoyl chloride (0.12 mL, 1.04 mmol) were added at 0°C. The reaction was stirred at 
rt for 16 h after which TLC (petroleum ether/EtOAc, 3:2) indicated completion of the 
reaction. The solvent was removed in vacuo, the crude residue was taken up in DCM (100 
mL), washed with 0.5 M aq. HCl (20 mL), satd aq. NaHCO3 (20 mL) and brine (20 mL), 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford 16b as white solid (166 
mg, 0.25 mmol, 72%). Rf = (petroleum ether/EtOAc, 7:3) 0.48; [α]D22 -26.3 (c 0.45, 
CHCl3); 1H NMR (500.1 MHz, CDCl3): δ  = 7.94 (d, J = 7.7 Hz, 2H, Ar-H), 7.64 - 7.50 (m, 
3H, Ar-H), 7.49 - 7.29 (m, 8H, Ar-H), 7.25 - 7.17 (m, 2H, Ar-H), 6.81 - 6.68 (m, 4H, Ar-H), 
5.67 (t, J = 9.7 Hz, 1H, Gal-H2), 5.39 (s, 1H, Ph-CH), 5.01 (s, 2H, Ar-CH2), 4.43 (d, J = 9.6 
Hz, 1H, Gal-H1), 4.35 - 4.23 (m, 3H, Gal-H6, Lac-H2, Gal-H4), 3.88 (d, J = 12.2 Hz, Gal-
H6’), 3.67 (d, J = 9.6 Hz, 1H, Gal-H3), 3.35 (s 1H, Gal-H5), 2.93 - 2.66 (m, 4H, Lac-H3, 
SCH2CH3), 2.18 (s, 3H, Ar-Me), 1.23 (t, J = 7.7 Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, 
CDCl3): δ = 172.1 (Lac-C1), 164.8 (Bz-CO), 137.9, 135.8, 135.3, 133.0, 132.9, 129.9, 129.8 
129.3, 128.9, 128.8, 128.6, 128.6, 128.5, 128.3, 128.2, 126.5 (16C, Ar-C), 101.0 (Ph-CH), 
82.9 (Gal-C1), 81.7 (Lac-C2), 79.9 (Gal-C3), 75.3 (Gal-C4), 70.3 (Gal-C5), 69.5 (Gal-C2), 
69.2 (Gal-C6), 66.7 (Ph-CH2), 38.8 (Lac-C3), 22.7 (SCH2CH3), 21.0 (Ar-Me), 14.7 
(SCH2CH3); ESI-MS: m/z: Calcd for C39H40NaO8S [M+Na]+: 691.8, found: 691.2. 
 
Ethyl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(3,4-
difluorophenyl)-propan-2-yl]-1-thio-β-D-galactopyranoside (16c) 
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To a solution of S6c (73 mg, 0.2 mmol) in pyridine (2 mL) DMAP (1.5 mg, 0.01 mmol) and 
benzoyl chloride (0.045 mL, 0.37 mmol) were added at 0°C. The reaction was stirred at rt 
for 16 h after which TLC (petroleum ether/EtOAc, 3:2) indicated completion of the 
reaction. The solvent was removed in vacuo, the crude residue was taken up in DCM (100 
mL), washed with 0.5 M aq. HCl (20 mL), sat. NaHCO3 (20 mL) and brine (20 mL), dried 
over Na2SO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, gradient 0-50%) to afford 16c as white solid (55 
mg, 0.08 mmol, 64%). Rf = (petroleum ether/EtOAc, 7:3) 0.40; [α]D22 -35.3 (c 0.28, 
CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.92 (d, J = 7.7 Hz, 2H, Ar-H), 7.65 - 7.51 (m, 
3H, Ar-H), 7.50 - 7.32 (m, 8H, Ar-H), 7.32 - 7.22 (m, 2H, Ar-H), 6.77 - 6.53 (m, 3H, Ar-H), 
5.65 (t, J = 9.6 Hz, 1H, Gal-H2), 5.42 (s, 1H, Ph-CH), 5.13 (d, J = 11.9 Hz, 1H, Ar-CH2), 
5.02 (d, J = 11.9 Hz, 1H, Ar-CH2), 4.43 (d, J = 9.7 Hz, 1H, Gal-H1), 4.38 - 4.23 (m, 3H, 
Lac-H2, Gal-H6a, Gal-H4), 3.89 (d, J = 12.3 Hz, Gal-H6b), 3.69 (d, J = 9.5 Hz, 1H, Gal-
H3), 3.36 (s, 1H, Gal-H5), 2.93 - 2.66 (m, 4H, Lac-H3, SCH2CH3), 1.22 (t, J = 7.5 Hz, 3H, 
SCH2CH3); 13C NMR (125.8 MHz, CDCl3): δ = 171.6 (Lac-C1), 164.7 (Bz-CO), 160.8 - 
140.9 (m, 2C, Ar-C), 137.9, 135.1, 133.7, 133.3 (4C, Ar-C), 133.0 (m, Ar-C), 130.2, 129.7, 
129.0, 128.8, 128.8, 128.8, 128.5, 128.5, 128.2, 126.4 (10C, Ar-C), 125.7 - 125.4 (m, Ar-C), 
118.4 (d, J = 17.2 Hz, Ar-C), 116.6 (d, J = 17.0 Hz, Ar-C), 101.0 (Ph-CH), 82.9 (Gal-C1), 
80.8 (Lac-C2), 79.8 (Gal-C3), 75.5 (Gal-C4), 70.3 (Gal-C5), 69.6 (Gal-C2), 69.1 (Gal-C6), 
67.0 (Ph-CH2), 38.2 (Lac-C3), 22.7 (SCH2CH3), 14.7 (SCH2CH3); ESI-MS: m/z: Calcd for 
C38H36F2NaO8S [M+Na]+: 713.7, found: 713.1. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- cyclo-
hex-1-yl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-
phenylpropan-2-yl]-β-D-galactopyranoside (17a) 
 
A solution of donor 16a (101 mg, 0.159 mmol) and acceptor 152 (101 mg, 0.185 mmol) in 
dry DCM (5 mL) was added via syringe to activated 4Å molecular sieves (0.5 g) under 
argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST, 119 mg, 0.462 
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mmol) and activated 4Å molecular sieves (0.5 g) in DCM (5 mL) was prepared in a second 
flask under argon. Both suspensions were stirred at rt for 4 h, then the DMTST suspension 
was added via syringe to the other suspension. The reaction was stopped after 18 h, filtered 
through celite and the celite was washed with DCM (20 mL). The filtrate was successively 
washed with satd. aq. NaHCO3 (25 mL) and water (25 mL), dried over Na2SO4, filtered and 
concentrated. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc, gradient 0-50%) to afford 17a as white solid (138 mg, 0.12 mmol, 79%). Rf = 
(petroleum ether/EtOAc, 3:2) 0.35; [α]D22 -78.6 (c 0.39, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.99 (d, J = 7.7 Hz, 2H, Ar-H), 7.63 (d, J = 7.5 Hz, 2H, Ar-H), 7.59 (t, J = 7.2 
Hz, 1H, Ar-H), 7.45 (t, J = 7.4 Hz, 2H, Ar-H), 7.35 - 7.14 (m, 23H, Ar-H), 7.07 - 6.93 (m, 
5H, Ar-H), 5.57 (t, J = 8.8 Hz, 1H, Gal-H2), 5.42 (s, 1H, Ph-CH), 5.02 - 4.85 (m, 5H, 2 Ph-
CH2, Fuc-H1), 4.80 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.69 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.63 
(d, J = 11.5 Hz, 1H, Ph-CH2), 4.58 d, J = 11.3 Hz, 1H, Ph-CH2), 4.51 (d, J = 7.9 Hz, 1H, 
Gal-H1), 4.36 - 4.16 (m, 4H, Lac-H2, Gal-H6, Gal-H4, Fuc-H2), 4.00 - 3.87 (m, 3H, Gal-
H6’, Fuc-H3, Fuc-H5), 3.71 - 3.57 (m, 2H, Gal-H3, Fuc-H4), 3.51 (t, J = 9.5 Hz, 1H, 
MeCy-H2), 3.33 - 3.22 (m, 2H, Gal-H5, Fuc-H4), 3.13 (t, J = 9.5 Hz, 1H, MeCy-H1), 2.98 - 
2.85 (m, 2H, Lac-H3), 1.85 - 1.77 (m, 1H, MeCy-H3), 1.58 - 1.41 (m, 3H, MeCy-H6, 
MeCy-H4), 1.25 (d, J = 6.3 Hz, 3H, Fuc-H6), 1.01 (d, J = 6.0 Hz, 3H, MeCy-Me), 1.16 - 
0.81 (m, 3H, MeCy-H4’, MeCy-H5); 13C NMR (125.8 MHz, CDCl3): δ = 171.8 (Lac-C1), 
164.5 (Bz-CO), 139.8, 139.6, 138.8, 138,2, 136.0, 135.2, 133.0, 130.1, 129.7, 129.5, 128.7, 
128.6, 128.6, 128.5, 128.5, 128.4, 128.1, 128.0, 128.0, 127.8, 127.5, 127.4, 127.3, 127.0, 
126.8, 126.5, 126.0  (28C, Ar-C), 99.7 (Gal-C1), 99.5 (Ph-CH), 98.3 (Fuc-C1), 81.3 (MeCy-
C1), 81.1 (Lac-C2), 80.7 (MeCy-C2), 79.7 (Fuc-C3), 79.1 (Fuc-C4), 89.9 (Gal-C3), 75.7 
(Fuc-C5), 74.9 (2C, Gal-C4, Fuc-C4), 74.5 (Ph-CH2), 71.6 (Gal-C2), 71.2 (Ph-CH2), 69.2 
(Gal-C6), 66.7 (Ph-CH2), 66.4 (Ph-CH2), 66.3 (Gal-C5), 39.5 (MeCy-C6), 39.2 (Lac-C3), 
33.5 (MeCy-C4), 31.1 (MeCy-C3), 23.3 (MeCy-C5), 18.7 (MeCy-Me), 16.2 (Fuc-C6); ESI-
MS: m/z: Calcd for C70H74NaO14[M+Na]+: 1162.3, found: 1161.4. 
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(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- cyclo-
hex-1-yl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(4-methyl-
phenyl)-propan-2-yl]-β-D-galactopyranoside (17b) 
 
A solution of donor 16b (30 mg, 0.044 mmol, 1 eq) and acceptor 152 (30 mg, 0.058 mmol) 
in dry DCM (1.5 mL) was added via syringe to activated 4Å molecular sieves (0.2 g) under 
argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST, 35 mg, 0.134 
mmol) and activated 4Å molecular sieves (0.2 g) in DCM (1.5 mL) was prepared in a 
second flask under argon. Both suspensions were stirred at rt for 4 h, then the DMTST 
suspension was added via syringe to the other suspension. The reaction was stopped after 18 
h, filtered through celite and the celite was washed with DCM (10 mL). The filtrate was 
successively washed with satd. aq. NaHCO3 (15 mL) and water (15 mL), dried over 
Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography 
(petroleum ether/EtOAc, gradient 0-50%) to afford 17b as white solid (41 mg, 0.035 mmol, 
80%). Rf = (petroleum ether/EtOAc, 3:2) 0.33; [α]D22 -79.3 (c 0.25, CHCl3); 1H NMR 
(500.1 MHz, CDCl3): δ = 7.98 (d, J = 7.7 Hz, 2H, Ar-H), 7.64 (d, J = 7.4 Hz, 2H, Ar-H), 
7.59 (t, J = 7.2 Hz, 1H, Ar-H), 7.39 - 7.12 (m, 27H, Ar-H), 6.87 (d, J = 7.5 Hz, 2H, Ar-H), 
6.26 (d, J = 7.5 Hz, 2H, Ar-H), 5.56 (t, J = 9.6 Hz, 1H, Gal-H2), 5.43 (s, 1H, Ph-CH), 5.04 - 
4.90 (m, 5H, 2 Ph-CH2, Fuc-H1), 4.80 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.68 (d, J = 11.7 Hz, 
1H, Ph-CH2), 4.63 (d, J = 11.3 Hz, 1H, Ph-CH2), 4.58 (d, J = 11.3 Hz, 1H, Ph-CH2), 4.51 
(d, J = 9.7 Hz, 1H, Gal-H1), 4.30 - 4.15 (m, 4H, Lac-H2, Gal-H6, Gal-H4, Fuc-H2), 4.00 - 
3.86 (m, 3H, Gal-H6’, Fuc-H3, Fuc-H5), 3.71 - 3.57 (m, 2H, Gal-H3, Fuc-H4), 3.55 (t, J = 
9.5 Hz, 1H, MeCy-H2), 3.30 - 3.21 (m, 2H, Gal-H5, Fuc-H4), 3.13 (t, J = 9.5 Hz, 1H, 
MeCy-H1), 2.93 - 2.85 (m, 2H, Lac-H3), 2.18 (s, 3H, Ar-Me), 1.86 - 1.74 (m, 1H, MeCy-
H3), 1.55 - 1.40 (m, 3H, MeCy-H6, MeCy-H4), 1.25 (d, J = 6.0 Hz, 3H, Fuc-H6), 1.01 (d, J 
= 6.1 Hz, 3H, MeCy-Me), 1.16 - 0.81 (m, 3H, MeCy-H4’, MeCy-H5); 13C NMR (125.8 
MHz, CDCl3): δ = 172.0 (Lac-C1), 164.5 (Bz-CO), 139.8, 139.6, 138.8, 138,2, 135.9, 
135.3, 132.9, 132.9, 130.1, 129.7, 129,4, 128.8, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 
128.1, 128.0, 128.0, 127.8, 127.6, 127.5, 127.3, 127.0, 126.8, 126.0  (28C, Ar-C), 99.7 (Gal-
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C1), 99.5 (Ph-CH), 98.3 (Fuc-C1), 81.4 (Lac-C2, MeCy-C1), 80.7 (MeCy-C2), 79.7 (Fuc-
C3), 79.1 (Fuc-C4), 79.0 (Gal-C3), 75.7 (Fuc-C5), 74.9 (2C, Gal-C4, Fuc-C4), 74.5 (Ph-
CH2), 71.6 (Gal-C2), 71.2 (Ph-CH2), 69.2 (Gal-C6), 66.7 (Ph-CH2), 66.4 (Ph-CH2), 66.3 
(Gal-C5), 39.5 (MeCy-C6), 38.8 (Lac-C3), 33.5 (MeCy-C4), 31.1 (MeCy-C3), 23.3 (MeCy-
C5), 18.7 (MeCy-Me), 16.2 (Fuc-C6); ESI-MS: m/z: Calcd for C71H76NaO14 [M+Na]+: 
1176.3, found: 1175.6. 
 
 (1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- 
cyclohex-1-yl 2-O-benzoyl-4,6-O-benzylidene-3-O-[(R)-1-(benzyloxy)-1-oxo-3-(3,4-
difluorophenyl)-propan-2-yl]-β-D-galactopyranoside (17c) 
 
A solution of donor 16c (53 mg, 0.076 mmol) and acceptor 152 (50 mg, 0.092 mmol) in dry 
DCM (1.5 mL) was added via syringe to activated 4Å molecular sieves (0.25 g) under 
argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST, 60 mg, 0.230 
mmol) and activated 4Å molecular sieves (0.25 g) in DCM (1.5 mL) was prepared in a 
second flask under argon. Both suspensions were stirred at rt for 4 h, then the DMTST 
suspension was added via syringe to the other suspension. The reaction was stopped after 18 
h, filtered through celite and the celite was washed with DCM (10 mL). The filtrate was 
successively washed with satd. aq. NaHCO3 (20 mL) and water (20 mL), dried over 
Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography 
(petroleum ether/EtOAc, gradient 0-50%) to afford 17c as colorless wax (41 mg, 0.035 
mmol, 80%). Rf = (petroleum ether/EtOAc, 3:2) 0.28; [α]D22 -84.6 (c 0.60, CHCl3); 1H 
NMR (500.1 MHz, CDCl3): δ = 7.96 (d, J = 7.5 Hz, 2H, Ar-H), 7.66 - 7.55 (m, 3H, Ar-H), 
7.45 (t, J = 7.6 Hz, 2H, Ar-H), 7.40 - 7.14 (m, 23H, Ar-H), 6.89 - 6.81 (m, 1H, Ar-H), 6.74 - 
6.60 (m, 2H, Ar-H), 5.56 (t, J = 9.0 Hz, 1H, Gal-H2), 5.47 (s, 1H, Ph-CH), 5.09  (d, J = 12.0 
Hz, 1H, Ph-CH2), 4.98 (d, J = 12.0 Hz, 1H, Ph-CH2), 4.95 - 4.90 (m, 2H, Fuc-H1, Fuc-H2), 
4.80 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.69 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.63 (d, J = 11.5 Hz, 
1H, Ph-CH2), 4.58 (d, J = 11.3 Hz, 1H, Ph-CH2), 4.51 (d, J = 7.9 Hz, 1H, Gal-H1), 4.34 - 
4.24 (m, 3H, Lac-H2, Gal-H6, Gal-H4), 4.20 (d, J = 11.3 Hz, 1H, Ph-CH2), 4.00 - 3.88 (m, 
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3H, Gal-H6’, Fuc-H2, Fuc-H3), 3.68 (d, J = 8.2 Hz, 1H, Gal-H3), 3.63 (d, J = 11.3 Hz, 1H, 
Ph-CH2), 3.57 - 3.46 (m, 1H, MeCy-H2), 3.33 - 3.23 (m, 2H, Gal-H5, Fuc-H4), 3.13 (t, J = 
9.5 Hz, 1H, MeCy-H1), 2.94 - 2.80 (m, 2H, Lac-H3), 1.85 - 1.77 (m, 1H, MeCy-H3), 1.56 - 
1.40 (m, 3H, MeCy-H6, MeCy-H4), 1.25 (d, J = 6.3 Hz, 3H, Fuc-H6), 1.01 (d, J = 6.4 Hz, 
3H, MeCy-Me), 1.16 - 0.81 (m, 3H, MeCy-H4’, MeCy-H5); 13C NMR (126 MHz, CDCl3): 
δ = 171.5 (Lac-C1), 164.4 (Bz-CO), 150.9 - 145.1 (m, 2C, ArF-C), 139.8, 139.6, 138.8, 
138.1, 135.0, 133.1, 132.9, 130.1, 129.8, 129.6, 129.0, 128.8, 128.7, 128.6, 128.5, 128.2, 
128.1, 128.1, 128.0, 127.8, 127.6, 127.4, 127.3, 127.0, 126.8, 125.9, 125.5  (26C, Ar-C), 
118.5 (d, J = 17.3 Hz, Ar-C), 116.9 (d, J = 17.3 Hz, Ar-C), 99.6, 99.6 (2C, Gal-C1, Ph-CH), 
98.3 (Fuc-C1), 81.3 (MeCy-C1), 80.7 (Lac-C2), 80.5 (MeCy-C2), 79.7 (Fuc-C3), 79.1 (Fuc-
C4), 79.9 (Gal-C3), 75.7 (Fuc-C2), 75.1 (Gal-C4), 74.9 (Ph-CH2), 74.5 (Ph-CH2), 71.8 
(Gal-C2), 71.2 (Ph-CH2), 69.2 (Gal-C6), 66.7 (Ph-CH2), 66.4, 66.3 (2C, Gal-C5, Fuc-C5), 
39.5 (MeCy-C6), 38.2 (Lac-C3), 33.5 (MeCy-C4), 31.1 (MeCy-C3), 23.3 (MeCy-C5), 18.7 
(MeCy-Me), 16.2 (Fuc-C6); ESI-MS: m/z: Calcd for C70H72F2NaO14 [M+Na]+: 1198.3, 
found: 1198.9. 
 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 2-O-benzoyl-3-O-
[sodium (S)-1-carboxy-2-phenylethyl]-ß-D-galactopyranoside (5a) 
 
A suspension of 17a (76 mg, 0.068 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH (5 
mL) was hydrogenated (2 bar H2) at rt. After 1 h TLC (silica: petroleum ether/EtOAc, 3:2; 
C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture was 
filtered through celite and concentrated in vacuo. The crude product was purified by 
reversed phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by 
a Dowex 50 (Na+ form) ion exchange column, a Sephadex G15 column, and lyophilization 
from water to yield the product 5a as white foam (20.3 mg, 0.028 mmol, 42%). Rf = (C-18, 
H2O/MeOH, 1:1) 0.48; [α]D22 -97.6 (c 0.35, MeOH); 1H NMR (500 MHz, CDCl3): δ = 7.92 
(d, J = 8.1 Hz, 2H, Ar-H), 7.76 (t, J = 7.5 Hz, 1H, Ar-H), 7.57 (t, J = 7.9 Hz, 2H, Ar-H), 
7.04 - 7.96 (m, 2H, Ar-H), 6.87 - 6.75 (m, 2H, Ar-H), 5.19 (m, 1H, Gal-H2), 5.04 (d, J = 4.0 
Hz, 1H, Fuc-H1), 4.90 (q, J = 6.6 Hz, 1H, Fuc-H5), 4.70 (d, J = 8.1 Hz, 1H, Gal-H1), 4.12 
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(dd, J = 3.2, 9.7 Hz, 1H, Lac-H2), 4.04 (d, J = 2.5 Hz, 1H, Gal-H4), 3.91 - 3.75 (m, 5H, 
Gal-H6, Fuc-H2, Fuc-H3, Fuc-H4), 3.69 - 3.62 (m, 2H, Gal-H3, Gal-H5), 3.57 (m, 1H, 
MeCy-H1), 3.06 (t, J = 9.4 Hz, 1H, MeCy-H2), 3.00 (dd, J = 3.1, 14.3 Hz, 1H, Lac-H3), 
2.74 (dd, J = 9.7, 14.3 Hz, 1H, Lac-H3’), 1.95 (s, 1H, Ar-Me), 1.97 - 1.88 (m, 1H, MeCy-
H6), 1.55 - 1.39 (m, 3H, MeCy-H3, MeCy-H4a, MeCy-H5), 1.30 (d, J = 8.1 Hz, 3H, Fuc-
H6), 1.14 (m, 1H, MeCy-H5’), 1.01 (d, J = 6.4 Hz, 3H, MeCy-Me), 1.82 - 0.76 (m, 2H, 
MeCy-H4’, MeCy-H6’); 13C NMR (126 MHz, D2O): δ = 181.1 (Lac-C1), 167.8 (Bz-CO), 
137.9, 134.0, 129.9, 129.0, 128.7, 128.6, 128.1, 126.2 (8C, Ar-C), 98.7, 98.7 (2C, Gal-C1, 
Fuc-C1), 83.5 (MeCy-C2), 82.4 (Lac-C2), 80.9 (MeCy-C2), 79.8 (Gal-C3), 74.2 (MeCy-
C1), 72.1, 72.0 (2C, Gal-C5, Gal-C2), 69.3 (Fuc-C4), 68.2 (Fuc-C2), 66.5 (Fuc-C5), 66.4 
(Gal-C4), 61.7 (Gal-C6), 39.6 (Lac-C3), 38.5 (MeCy-C3), 32.9 (MeCy-C4), 30.8 (MeCy-
C6), 22.3 (MeCy-C5), 18.0 (MeCy-C6), 15.4 (Fuc-C6); HR-MS: m/z:  Calcd for 
C35H45Na2O14 [M+Na]+: 735.2605, found: 735.2607. 
 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 2-O-benzoyl-3-O-
[sodium (S)-1-carboxy-2-(4-methylphenyl)-ethyl]-ß-D-galactopyranoside (5b) 
 
A suspension of 17b (40 mg, 0.035 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH (5 
mL) was hydrogenated (2 bar H2) at rt. After 3 h TLC (silica: petroleum ether/EtOAc, 3:2; 
C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture was 
filtered through celite and concentrated in vacuo. The crude product was purified by 
reversed phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by 
a Dowex 50 (Na+ form) ion exchange column, a Sephadex G15 column, and lyophilization 
from water to yield the product 5b as colorless foam (9.4 mg, 0.013 mmol, 37%). Rf = (C-
18, H2O/MeOH, 1:1) 0.42; [α]D22 -64.5 (c 0.23, MeOH); 1H NMR (500.1 MHz, CDCl3): δ = 
7.92 (d, J = 7.9 Hz, 2H, Ar-H), 7.77 (t, J = 7.2 Hz, 1H, Ar-H), 7.59 (t, J = 7.7 Hz, 2H, Ar-
H), 6.92 (d, J = 7.5 Hz, 2H, Ar-H), 6.59 (d, J = 7.5 Hz, 2H, Ar-H), 5.19 (t, J = 8.7 Hz, 1H, 
Gal-H2), 5.03 (d, J = 2.8 Hz, 1H, Fuc-H1), 4.90 (dd, J = 6.5, 13.0 Hz, 1H, Fuc-H5), 4.71 (d, 
J = 8.1 Hz, 1H, Gal-H1), 4.08 (d, J = 10.4 Hz, 1H, Lac-H2), 4.03 (s, 1H, Gal-H4), 3.91 – 
3.73 (m, 5H, Gal-H6, Fuc-H2, Fuc-H3, Fuc-H4), 3.69 - 3.60 (m, 2H, Gal-H3, Gal-H5), 3.57 
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(t, J = 13.2 Hz, 1H, MeCy-H1), 3.08 (t, J = 9.3 Hz, 1H, MeCy-H2), 2.96 (d, J = 13.7 Hz, 
1H, Lac-H3a), 2.69 (m, 1H, Lac-H3b), 1.95 (s, 1H, Ar-Me), 1.93 (m, 1H, MeCy-H6), 1.58 - 
1.40 (m, 3H, MeCy-H3, MeCy-H4, MeCy-H5), 1.30 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.14 (m, 
1H, MeCy-H5’), 1.01 (d, J = 6.4 Hz, 3H, MeCy-Me), 1.93 - 0.76 (m, 2H, MeCy-H4’,  
MeCy-H6’); 13C NMR (125.8 MHz, D2O): δ = 181.2 (Lac-C1), 167.8 (Bz-CO), 136.0, 
134.9, 134.0, 129.7, 129.1, 128.8, 128.8, 128.6 (8C, Ar-C), 98.7, 98.7 (2C, Gal-C1, Fuc-
C1), 83.6 (MeCy-C2), 82.6 (Lac-C2), 80.5 (MeCy-C2), 80.9 (Gal-C3), 79.7 (MeCy-C1), 
74.2 (Gal-C5), 72.1 (2C, Gal-C2, Fuc-C3), 69.3 (Fuc-C4), 68.2 (Fuc-C2), 66.5 (Fuc-C5), 
66.4 (Gal-C4), 61.7 (Gal-C6), 39.2 (Lac-C3), 38.5 (MeCy-C3), 32.9 (MeCy-C4), 30.8 
(MeCy-C6), 22.3 (MeCy-C5), 20.0 (MeCy-Me), 18.0 (MeCy-C6), 15.0 (Fuc-C6); HR-MS: 
m/z: Calcd for C36H47Na2O14 [M+Na]+: 749.2761, found: 749.2760. 
 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 2-O-benzoyl-3-O-
[sodium (S)-1-carboxy-2-(3,4-difluorophenyl)-ethyl]-ß-D-galactopyranoside (5c) 
 
A suspension of 17c (48 mg, 0.040 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH (5 
mL) was hydrogenated (2 bar H2) at rt. After 1 h TLC (silica: petroleum ether/EtOAc, 3:2; 
C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture was 
filtered through celite and concentrated in vacuo. The crude product was purified by 
reversed phase column chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by 
a Dowex 50 (Na+ form) ion exchange column, a Sephadex G15 column, and lyophilization 
from water to yield the product 5c as colorless foam (18.8 mg, 0.025 mmol, 63%). Rf = (C-
18, H2O/MeOH, 1:1) 0.45; [α]D22 -80.7 (c 0.24, MeOH); 1H NMR (500.1 MHz, CDCl3): δ = 
7.86 (d, J = 7.7 Hz, 2H, Ar-H), 7.72 (t, J = 7.2 Hz, 1H, Ar-H), 7.54 (t, J = 7.7 Hz, 2H, Ar-
H), 6.95 (m, 1H, Ar-H), 6.77 (m, 1H, Ar-H), 6.58 (m, 1H, Ar-H), 5.16 (t, J = 8.8 Hz, 1H, 
Gal-H2), 5.03 (br s, 1H, Fuc-H1), 4.89 (dd, J = 6.6, 13.0 Hz, 1H, Fuc-H5), 4.70 (d, J = 8.1 
Hz, 1H, Gal-H1), 4.16 (d, J = 10.8 Hz, 1H, Lac-H2), 4.08 (br s, 1H, Gal-H4), 3.90 - 3.65 
(m, 7H, Gal-H6, Gal-H5, Fuc-H2, Fuc-H3, Fuc-H4, Gal-H3), 3.56 (t, J = 11.6 Hz, 1H, 
MeCy-H1), 3.05 (t, J = 9.3 Hz, 1H, MeCy-H2), 2.97 (d, J = 14.1 Hz, 1H, Lac-H3), 2.72 (m, 
1H, Lac-H3b), 1.90 (m, 1H, MeCy-H6), 1.57 - 1.34 (m, 3H, MeCy-H3, MeCy-H4, MeCy-
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H5), 1.30 (d, J = 6.2 Hz, 3H, Fuc-H6), 1.14 (m, 1H, MeCy-H5’), 1.01 (d, J = 6.2 Hz, 3H, 
MeCy-Me), 1.96 - 0.70 (m, 2H, MeCy-H4’,  MeCy-H6’); 13C NMR (125.8 MHz, D2O): δ = 
180.7 (Lac-C1), 167.4 (Bz-CO), 150.2 - 146.4 (m, 2C, ArF-C), 135.1, 134.0, 129.5, 128.6, 
128.5, 124.8 (8C, Ar-C), 117.1 (d, J = 17.2 Hz, Ar-C), 116.6 (d, J = 17.3 Hz, Ar-C), 98.8, 
98.7 (2C, Gal-C1, Fuc-C1), 83.6 (MeCy-C2), 82.2 (Lac-C2), 80.9 (MeCy-C2), 80.9 (Gal-
C3), 79.8 (MeCy-C1), 74.3 (Gal-C5), 72.1, 72.0 (2C, Gal-C2, Fuc-C3), 69.3 (Fuc-C4), 68.2 
(Fuc-C2), 66.6, 66.5 (Fuc-C5, Gal-C4), 61.7 (Gal-C6), 38.7 (Lac-C3), 38.5 (MeCy-C3), 
32.9 (MeCy-C4), 30.7 (MeCy-C6), 22.3 (MeCy-C5), 18.0 (MeCy-Me), 15.4 (Fuc-C6); HR-
MS: m/z:  Calcd for C35H43F2NaO14 [M+Na]+: 771.2416, found: 771.2415. 
 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 3-O-[sodium (S)-1-
carboxy-2-phenylethyl]-ß-D-galactopyranoside (6a) 
  
A suspension of 17a (15 mg, 0.013 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH (5 
mL) was hydrogenated (1 bar H2) at rt. After 2 h TLC (silica: petroleum ether/EtOAc, 3:2; 
C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture was 
filtered through celite and concentrated in vacuo. The residue was dissolved in MeOH/H2O 
(4:1, 1 mL) and treated with LiOH (16 mg, 0.65 mmol) for 7 days. The mixture was 
neutralized with Dowex 50X8 (H+ form), filtered through a Dowex 50 (Na+ form) ion 
exchange column and concentrated. The residue was purified by reversed phase column 
chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by a Sephadex G15 
column, and lyophilization from water to yield the product 6a as white foam (1.5 mg, 0.0024 
mmol, 18%).  Rf = (C-18, H2O/MeOH, 1:1) 0.25; 1H NMR (500.1 MHz, CDCl3): δ = 7.43 – 
7.36 (m, 4H, Ar-H), 7.35 – 7.30 (m, 1H, Ar-H), 5.10 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.86 – 
4.80 (m, 1H, Fuc-H5), 4.40 (d, J = 8.0 Hz, 1H, Gal-H1), 4.18 (dd, J = 4.7, 8.7 Hz, 1H, Lac-
H2), 3.92 (d, J = 2.8 Hz, 1H, Gal-H4), 3.89 (dd, J = 3.2, 10.6 Hz, 1H, Fuc-H3), 3.87 - 3.78 
(m, 2H, Fuc-H2. Fuc-H4), 3.76 - 3.65 (m, 3H, MeCy-H1, Gal-H6), 3.58 – 3.51 (m, 2H, Gal-
H2, Gal-H5), 3.30 (dd, J = 3.2, 9.5 Hz, 1H, Gal-H3), 3.22 (t, J = 9.6 Hz, 1H, MeCy-H2), 
3.15 (dd, J = 4.6, 14.0 Hz, 1H, Lac-H3), 2.98 (dd, J = 8.8, 14.0 Hz, 1H, Lac-H3’), 2.12 - 
2.05 (m, 1H, MeCy-H6), 1.70 - 1.53 (m, 3H, MeCy-H3, MeCy-H5), 1.37 - 1.21 (m, 2H, 
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MeCy-H6’, MeCy-H4), 1.18 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.01 (d, J = 6.3 Hz, 3H, MeCy-
Me), 1.14 – 1.04 (m, 1H, MCy-H4’); 13C NMR (125.8 MHz, D2O): δ = 181.0 (Lac-C1), 
138.2, 129.4, 128.6, 126.7 (4C, Ar-C), 99.4 (Gal-C1), 98.9 (Fuc-C1), 84.1 (MeCy-C2), 82.7 
(Gal-C3), 82.0 (Lac-C2),  78.6 (MeCy-C1), 74.2 (Gal-C2), 72.0 (Fuc-C2), 69.8 (Gal-C5), 
69.3 (Fuc-C3), 68.2 (Fuc-C4), 66.5 (Fuc-C5), 66.2 (Gal-C4), 61.6 (Gal-C6), 39.3 (Lac-C3), 
38.7 (MeCy-C3), 33.1 (MeCy-C4), 30.2 (MeCy-C6), 22.6 (MeCy-C5), 18.1 (MeCy-Me), 
15.5 (Fuc-C6); HR-MS: m/z: Calcd for C28H42NaO13+ [M+H]+: 609.2518, found: 609.2521. 
  
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 3-O-[sodium (S)-1-
carboxy-2-(4-methylphenyl)-ethyl]-ß-D-galactopyranoside (6b) 
 
A suspension of 17b (40 mg, 0.035 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH (5 
mL) was hydrogenated (2 bar H2) at rt. After 2 h TLC (silica: petroleum ether/EtOAc, 3:2; 
C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture was 
filtered through celite and concentrated in vacuo. The residue was dissolved in MeOH/H2O 
(4:1, 1 mL) and treated with LiOH (41 mg, 1.73 mmol) for 32 h. The mixture was 
neutralized with Dowex 50X8 (H+ form), filtered through a Dowex 50 (Na+ form) ion 
exchange column and concentrated. The residue was purified by reversed phase column 
chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by a Dowex 50 (Na+ form) 
ion exchange column, a Sephadex G15 column, and lyophilization from water to yield the 
product 6b as colorless foam (8.9 mg, 0.014 mmol, 41%). Rf = (C-18, H2O/MeOH, 1:1) 
0.31; [α]D22 -76.6 (c 0.26, MeOH); 1H NMR (500.1 MHz, CDCl3): δ = 7.28 (d, J = 8.0 Hz, 
2H, Ar-H), 7.23 (d, J = 8.0 Hz 1H, Ar-H), 5.10 (d, J = 4.02 Hz, 1H, Fuc-H1), 4.83 (m, 1H, 
Fuc-H5), 4.42 (d, J = 8.0 Hz, 1H, Gal-H1), 4.15 (dd, J = 4.6, 8.9 Hz, 1H, Lac-H2), 4.08 (br 
s, 1H, Gal-H4), 3.94 - 3.86 (m, 2H, Fuc-H3, Gal-H4), 3.83 - 3.78 (m, 2H, Fuc-H2, Fuc-H4), 
3.75 - 3.63 (m, 3H, MeCy-H1, Gal-H6), 3.58 - 3.49 (m, 2H, Gal-H2, Gal-H5), 3.28 (dd, J = 
3.2, 9.5 Hz, 1H, Gal-H3), 3.22 (t, J = 9.6 Hz, 1H, MeCy-H2), 3.12 (dd, J = 4.5, 14.0 Hz, 
1H, Lac-H3a), 2.93 (dd, J = 8.9, 14.0 Hz, 1H, Lac-H3b), 2.09 (m, 1H, MeCy-H6), 1.74 - 
1.52 (m, 3H, MeCy-H3, MeCy-H4, MeCy-H5), 1.31 - 1.20 (m, 2H, MeCy-H5’), 1.18 (d, J 
= 6.6 Hz, 3H, Fuc-H6), 1.01 (d, J = 6.2 Hz, 3H, MeCy-Me), 1.09 (m, 1H, MeCy-H4’); 13C 
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NMR (125.8 MHz, D2O): δ = 180.6 (Lac-C1), 136.7, 135.1, 129.4, 129.1 (4C, Ar-C),  99.4, 
98.9 (2C, Gal-C1, Fuc-C1), 84.1 (MeCy-C2), 82.7 (Gal-C3), 82.1 (Lac-C2),  78.6 (MeCy-
C1), 74.2 (Gal-C2), 72.0 (Fuc-C2), 69.8 (Gal-C5), 69.3 (Fuc-C3), 68.3 (Fuc-C4), 66.5 (Fuc-
C5), 66.2 (Gal-C4), 61.6 (Gal-C6), 38.9 (Lac-C3), 38.8 (MeCy-C3), 33.2 (MeCy-C4), 30.2 
(MeCy-C6), 22.6 (MeCy-C5), 18.1 (MeCy-Me), 15.5 (Fuc-C6); HR-MS: m/z: Calcd for 
C35H43F2Na2O14 [M+Na]+: 645.2499, found: 645.2496. 
 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 3-O-[sodium (S)-1-
carboxy-2-(3,4-difluorophenyl)-ethyl]-ß-D-galactopyranoside (6c) 
  
A suspension of 17c (12 mg, 0.010 mmol) and Pd(OH)2/C (50 mg, 10% Pd) in MeOH (5 
mL) was hydrogenated (2 bar H2) at rt. After 3 h TLC (silica: petroleum ether/EtOAc, 3:2; 
C-18: H2O/MeOH, 1:1) indicated completion of the reaction. The reaction mixture was 
filtered through celite and concentrated in vacuo. The residue was dissolved in MeOH/H2O 
(4:1, 1 mL) and treated with LiOH (12 mg, 0.51 mmol) for 7 days. The mixture was 
neutralized with Dowex 50X8 (H+ form), filtered through a Dowex 50 (Na+ form) ion 
exchange column and concentrated. The residue was purified by reversed phase column 
chromatography (C-18, H2O/MeOH, gradient 0-100%) followed by a Sephadex G15 
column, and lyophilization from water to yield the product 6c as white foam (3.5 mg, 0.0054 
mmol, 59%).  Rf = (C-18, H2O/MeOH, 1:1) 0.25; 1H NMR (500.1 MHz, CDCl3): δ = 7.33 – 
7.25 (m, 1H, Ar-H), 7.24 – 7.15 (m, 1H, Ar-H), 7.15 – 7.03 (m, 1H, Ar-H), 5.11 (d, J = 4.0 
Hz, 1H, Fuc-H1), 4.90 – 4.80 (m, 1H, Fuc-H5), 4.43 (d, J = 8.0 Hz, 1H, Gal-H1), 4.15 (dd, J 
= 4.8, 8.2 Hz, 1H, Lac-H2), 3.93 (d, J = 2.9 Hz, 1H, Gal-H4), 3.90 (dd, J = 3.2, 10.6 Hz, 1H, 
Fuc-H3), 3.87 - 3.78 (m, 2H, Fuc-H2. Fuc-H4), 3.76 - 3.66 (m, 3H, MeCy-H1, Gal-H6), 
3.59 – 3.53 (m, 2H, Gal-H2, Gal-H5), 3.33 (dd, J = 3.1, 9.5 Hz, 1H, Gal-H3), 3.22 (t, J = 9.6 
Hz, 1H, MeCy-H2), 3.09 (dd, J = 4.6, 14.1 Hz, 1H, Lac-H3), 2.97 (dd, J = 8.2, 14.1 Hz, 1H, 
Lac-H3’), 2.15 - 2.08 (m, 1H, MeCy-H6), 1.72 - 1.54 (m, 3H, MeCy-H3, MeCy-H5), 1.33 - 
1.22 (m, 2H, MeCy-H6’, MeCy-H4), 1.19 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.10 (d, J = 6.3 Hz, 
3H, MeCy-Me), 1.14 – 1.04 (m, 1H, MCy-H4’); 13C NMR (125.8 MHz, D2O): δ = 180.2 
(Lac-C1), 135.1 (m, Ar-C), 125.7 (m, Ar-C), 118.3 (d, J = 17.0 Hz, Ar-C), 116.8 (d, J = 16.7 
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Hz, Ar-C), 99.7 (Gal-C1), 98.9 (Fuc-C1), 84.2 (MeCy-C2), 82.4 (Gal-C3), 81.6 (Lac-C2),  
78.7 (MeCy-C1), 74.1 (Gal-C2), 72.0 (Fuc-C2), 69.8 (Gal-C5), 69.3 (Fuc-C3), 68.2 (Fuc-
C4), 66.5 (Fuc-C5), 66.2 (Gal-C4), 61.7 (Gal-C6), 38.7 (Lac-C3), 38.4 (MeCy-C3), 33.2 
(MeCy-C4), 30.3 (MeCy-C6), 22.6 (MeCy-C5), 18.1 (MeCy-Me), 15.5 (Fuc-C6); HR-MS: 
m/z: Calcd for  C28H39F2Na2O13+ [M+H]+: 667.2149, found: 667.2150. 
 
 
 
Scheme S3: Synthesis of triflate 21: a) (i) PCC, DCM; (ii) PPh3BrMe, LiHMDS, THF (33% over two steps); 
b) TsOH·H2O, MeOH (97%);  c.) CSA, para-anisaldehyde dimethyl acetal (55%); d) DIBAL-H, toluene; e) (i) 
DMSO, (COCl)2, Et3N, DCM; (ii) tBuOH, NaH2PO4, 2-methyl-2-butene, NaClO2; (iii) TMSCHN2, 
MeOH/toluene (81% over 3 steps); f) DDQ, DCM, H2O (87%); g) Tf2O, DTBMP, DCM (87%). 
 
4-Allyl-2,2-dimethyl-1,3-dioxolane (S8) 
 
 
(4S)-(+)-4-(2-Hydroxyethyl)-2,2-dimethyl-1,3-dioxolane S7 (1.00 g, 6.87 mmol) was 
dissolved in DCM (60 mL) and pyridinumchlorochromate (7.40 g, 34.4 mmol) was added at 
0°C. The reaction mixture was poured into Et2O (100 mL) and the resulting mixture was 
filtered through a pad of celite. The solvent was removed in vacuo and the crude aldehyde 
used without further purification in the next step. 
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Methyltriphenylphosphonium bromide (3.70 g, 10.3 mmol) was suspended in THF (30 mL) 
and LiHMDS (1.0 M solution in THF, 8.93 ml, 8.93 mmol) was added dropwise at -78°C. 
The mixture was stirred for 30 min at this temperature and additional 45 min at 0°C. The 
crude aldehyde of the previous step was added and the mixture was stirred at room 
temperature for 16 h. Water (30 mL) was added and the solution was washed with DCM (3 
x 200 mL). The combined organic layers were dried (Na2SO4), filtrated and the solvent was 
removed in vacuo. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc 20:1) to yield S8 as a colorless syrup (321 mg, 2.26 mmol, 33%).       
Rf (petroleum ether/EtOAc 10:1) 0.67; [α]D22 1.3 (c 4.90, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 5.82 - 5.73 (m, 1H, R-H4), 5.13 - 5.05 (m, 2H, R-H5), 4.17 - 4.11 (m, 1H, R-
H2), 4.01 (dd, J = 6.0, 8.0, 1H, R-H1), 3.56 (dd, J = 7.2, 7.9, 1H, R-H1’), 2.42 - 2.36 (m, 
1H, R-H3), 2.30 - 2.23 (m, 1H, R-H3’), 1.40 (s, 1H, Me), 1.34 (s, 1H, Me). 13C NMR (125.8 
MHz, CDCl3): δ  = 133.8 (R-C4), 117.81 (R-C5), 109.2 (C(CH3)2), 75.4 (R-C2), 69.1 (R-
C1), 38.2 (R-C3), 27.1 (Me), 25.8 (Me). 
 
(S)-Pent-4-ene-1,2-diol (S9) 
 
Acetal S8 (673 mg, 4.73 mmol) was dissolved in MeOH (25 mL) and p-toluenesulfonic acid 
monohydrate (450 mg, 2.37 mmol) was added. The solution was stirred for 2.5 h at rt. The 
solvent was removed in vacuo and the crude product was purified by flash chromatography 
(DCM/MeOH 10:1) to yield S9 as colorless oil (465 mg, 4.55 mmol, 96%).  
Rf (petroleum ether/EtOAc 5:3) 0.14; [α]D22 11.4 (c 2.30, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 5.82 (ddt, J = 17.2, 10.2, 7.2 Hz, 1H, R-H5), 5.19 – 5.10 (m, 2H, R-H4), 3.81 – 
3.73 (m, 1H, R-H2), 3.67 (dd, J = 11.2, 3.1 Hz, 1H, R-H1’), 3.48 (dd, J = 11.2, 7.2 Hz, 1H, 
R-H1), 2.30 – 2.18 (m, 2H, R-H3); 13C NMR (125.8 MHz, CDCl3): δ =134.2 (R-C5), 118.4 
(R-C4), 71.3 (R-C2), 66.4 (R-C1), 38.0 (R-C3). 
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 (4S)-4-Allyl-2-(4-methoxyphenyl)-1,3-dioxolane (S10) 
 
Diol S9 (465 mg, 4.55 mmol) was dissolved in DCM (25 mL) and camphorsulfonic acid and 
p-methoxybenzaldehyde dimethyl acetal (1.66 g, 9.11 mmol) were added. The solution was 
stirred at 50°C for 15 h. The reaction was quenched with Et3N and the solvent was removed 
in vacuo. The residue was purified by flash chromatography (petroleum ether/EtOAc 19:1) 
to give S10 as mixture of diastereomers (1.0 g, 4.55 mmol, quant.) which was used without 
further purification in the next step. 
Rf (petroleum ether/EtOAc 5:1) 0.75. 
 
(S)-2-((4-Methoxybenzyl)oxy)pent-4-en-1-ol (S11) 
 
Acetal S10 (1.00 g, 4.55 mmol) was dissolved in 50 ml toluene and DIBAL-H (1M in 
toluene, 9.1 mL) was added at 0°C. The reaction mixture was allowed to reach room 
temperature over 4 h and was filtered through a short pad of silica. The filtrat was 
evaporated and the crude product was purified by flash chromatography (petroleum 
ether/EtOAc 10:1 to 4:1) to yield S11 as a colorless liquid (0.72 g, 3.23 mmol, 71%). 
Rf (petroleum ether/EtOAc 5:1) 0.12; [α]D22 24.1 (c 1.40, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.30 - 7.26 (m, 2H, Ar), 6.90 - 6.88 (m, 2H, Ar), 5.85 - 5.77 (m, 1H, R-H4), 
5.15 – 5.05 (m, 2H, R-H5), 4.60 (d, J = 11.7 Hz, 2H, Ph-CH2), 4.47 (d, J = 11.2 Hz, 1H, Ph-
CH2), 3.80 (s, 3H, Me), 3.68 - 3.65 (m, Hz, 1H, R-H1), 3.58 - 3.51 (m, 2H, R-H1’, R-H2), 
2.42 - 2.37 (m, 1H, R-H3), 2.34 – 2.25 (m, 1H, R-H3’); 13C NMR (125.8 MHz, CDCl3): δ = 
134.3 (R-C4), 128.9 (Ar), 117.7 (R-C5), 114.1 (Ar), 78.9 (R-C2), 71.4 (Ph-CH2), 65.2 (R-
C1), 55.5 (Me), 35.5 (R-C3).  
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(S)-1-Methoxy-1-oxopent-4-en-2-yl 4-methoxybenzoate (S12) 
 
Oxalylchloride (556 µl, 6.56 mmol) was dissolved in DCM (25 mL) and dimethylsulfoxid 
(622 µL, 8.75 mmol) was added at -78°C and the mixture was stirred for 15 min at this 
temperature. A solution of alcohol S11 (487 mg, 2.19 mmol) DCM (5 mL) was added 
tropwise. The suspension was stirred for 35 min at -78°C, Et3N (1.83 ml, 13.1 mmol) was 
added and the resulting solution was stirred for 1 h at rt. The reaction was quenched with 
water (80 mL) and the mixture was extracted with DCM (3 x 50 mL). The combined 
organic layers were dried, evaporated and used without further purification for the next step.  
The crude aldehyde was dissolved in tBuOH (17 mL) and NaH2PO4 (420 mg, 3.5 mmol, in 
2.8 mL H2O), 2-methylbut-2-ene (40 mL, 2M in THF) and NaClO2 (633 mg, 7.00 mmol) 
were added successively. The resulting solution was stirred for 2.5 h and the volatiles 
evaporated under reduced pressure. The residue was solved in DCM (60 ml) and the 
solution was dried (Na2SO4), concentrated under reduced pressure and used without further 
purification in the next step.  
The crude acid was dissolved MeOH/toluene (1:2, 30 mL) and TMSCHN2 (1.42 ml, 2 M in 
hexane) was added tropwise. The persisten of the yellow color indicated the end of the 
reaction. The solution was stirred for 1 h at rt, quenched with a few drops of Ac2O and 
evaporated in vacuo. The crude ester was purified by flash chromatography (petroleum 
ether/EtOAc 6:1) to yield S12 (444 mg, 1.77 mmol, 81 %) as a colorless liquid. 
Rf (petroleum ether/EtOAc 5:1) 0.60; [α]D22 -78.8 (c 0.90, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.27 (d, J = 8.7 Hz, 2H, Ar), 6.87 (d, J = 8.6 Hz, 2H, Ar), 5.80 (ddt, J = 17.2, 
10.2, 7.0 Hz, 1H, R-H4), 5.15 – 5.04 (m, 2H, R-H5), 4.63 (d, J = 11.4 Hz, 1H, PhCH2), 4.38 
(d, J = 11.4 Hz, 1H, PhCH2), 4.02 – 3.96 (m, 1H, R-H2), 3.80 (s, 3H, Me), 3.74 (s, 3H, 
COOMe), 2.53 - 2.48 (m, 2H, H-3); 13C NMR (125.8 MHz, CDCl3): δ = 133.2 (R-C4), 
129.9 (Ar), 129.8 (Ar), 129.6 (Ar), 118.1 (R-C5), 113.9 (Ar), 77.6 (R-C2), 72.12 (PhCH2), 
55.4 (Me), 52.0 (COOMe), 37.5 (R-C3). 
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(S)-Methyl 2-hydroxypent-4-enoate (S13) 
 
Ester S12 (100 mg, 400 µmol) was dissolved in DCM (9 mL) and H2O (0.4 mL) and DDQ 
(95.3 mg, 420 µM) were added. The reaction mixture was stirred for 16 h at rt. The volatiles 
were removed under reduced pressure and the crude product was purified by flash 
chromatography (petroleum ether/EtOAc 5:1) to yield S13 (45.5 mg, 350 µmol, 87%) as a 
colorless liquid.   
Rf (petroleum ether/EtOAc 5:1) 0.27; [α]D22 10.5 (c 4.40, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 5.80 (ddt, J = 17.2, 10.2, 7.1 Hz, 1H, R-H4), 5.20 – 5.11 (m, 2H, R-H5), 4.28 
(dd, J = 6.3, 4.6 Hz, 1H, R-H2), 3.79 (s, 3H, COOMe), 2.62 – 2.54 (m, 1H, R-H3), 2.48 – 
2.41 (m, 1H, R-H3’); 13C NMR (125.8 MHz, CDCl3): δ = 154.4 (COOMe), 132.7 (R-C4), 
119.1 (R-C5), 70.2 (R-C2), 52.8 (Me), 38.9 (R-C3). 
 
(S)-Methyl 2-(((trifluoromethyl)sulfonyl)oxy)pent-4-enoate (21) 
 
Alcohol S13 (35.2 mg, 270 µM) was dissolved in DCM (1.5 ml) and DTBMP (222 mg, 108 
mM) and triflic anhydride (123 µL, 730 µmol) were added dropwise at -20°C - -30°C. The 
resulting solution was stirred for 45 min at this temperature and further 45 min at 0°C. The 
reaction was diluted with DCM (50 mL) and washed with ice cold KH2PO4 (40 ml, 1M in 
H2O). The aqueous layer was washed with DCM (2 x 50 mL). The organic phase was dried 
(Na2SO4) and the solvent removed in vacuo. The residue was purified by flash 
chromatography (petroleum ether/EtOAc 6:1) to yield triflate 21 (61.6 mg, 235 µM) as a 
colorless liquid.   
Rf (petroleum ether/EtOAc 5:1) 0.61; [α]D22 -14.1 (c 2.00, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 5.80 – 5.69 (m, 1H, R-H4), 5.28 - 5.22 (m, 2H, R-H5), 5.16 (dd, J = 7.5, 4.5 
Hz, 1H, R-H2), 3.85 (s, 3H, Me), 2.83 – 2.68 (m, 2H, R-H3); 13C NMR (125.8 MHz, 
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CDCl3): δ = 167.1 (COO), 129.5 (R-C4), 121.3 (R-C5), 123.85 – 112.31 (q, J = 319.9 Hz, 
CF3), 82.6 (R-C2), 53.4 (Me), 36.4 (R-C3). 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 2,3,4-tri-O-benzoyl-6-O-benzyl-β-D-galactopyranoside (19) 
  
Compound 152  (871 mg, 1.59 mmol) and thioglycoside 18  (1.10 g, 1.75 mmol) were 
dissolved in dry DCM (30 mL) and stirred together with powdered 4 Å activated molecular 
sieves (3 g) for 4 h at rt. DMTST (1.23 g, 4.77 mmol) was dissolved in DCM (10 mL) and 
stirred together with powdered 4 Å activated molecular sieves (1 g) for 3.5 h at rt as well. 
Both suspensions were combined and stirred for 3 days at rt. The mixture was filtered over a 
short pad of celite, washed with a sat. solution of NaHCO3 (40 mL) and water (40 mL). The 
combined aqueous phases were extracted with DCM (3 x 30 mL). The combined organic 
layers were dried (Na2SO4) and the solvent was removed in vacuo. The crude product was 
purified by flash chromatography (petroleum ether/EtOAc 4:1) to afford 19 (1.40 g; 1.26 
mmol; 79 %) as a white solid. Analytical data were in accordance with literature.2 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-β-D-galactopyranoside (20) 
  
Benzoate 19 was suspended in a freshly prepared solution of NaOMe (12.6 mL, 0.02 M). 
The solution formed after a few minutes was stirred for 16 h at rt. The reaction mixture was 
neutralized with Dowex ion exchange resin (50x8), filtered and concentrated in vacuo. The 
crude product was purified by flash chromatography (CH2Cl2/MeOH 35/1) to yield 20 as a 
white solid (815 mg, 1.02 mmol, 81 %). Analytical data were in accordance with literature.2 
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(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-3,4-O-isopropylidene-β-D-galactopyranoside (23) 
  
Alcohol 20 (810 mg, 1.01 mmol) was dissolved in acetone (50 mL) and 2,2-
dimethoxypropane (497 µL, 4.06 mmol), CuSO4 (2.43 g, 15.2 mmol) and PPTS (25.5 mg, 
0.10 mmol) were added. The mixture was stirred for 16 h and additional 2,2-
dimethoxypropane (248 µL, 505 µmol) and PPTS (50.9 mg, 0.20 mmol) were added. The 
suspension was stirred for 24 h and filtered over a short pad of Al2O3. The solvent was 
removed in vacuo and the crude product was purified by flash chromatography (petroleum 
ether/EtOAc 3:2) to yield 23 as a white solid (708 mg, 844 µmol, 83 %).   
Rf (petroleum ether/EtOAc 1:1) 0.50; [α]D22 -47.4 (c 0.70, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.35 – 7.21 (m, 20H, Ar-H), 5.08 (d, J = 3.6 Hz, 1H, Fuc-H1), 4.95 (d, J = 11.6 
Hz, 1H, Ph.CH2), 4.81 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.74 (d, J = 11.7 Hz, 2H, 2x Ph-CH2), 
4.67 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.63 – 4.55 (m, 3H, 2x Ph-CH2, Fuc-H5), 4.51 (d, J = 
11.9 Hz, 1H, Ph-CH2), 4.24 (d, J = 8.3 Hz, 1H, Gal-H1), 4.18 (dd, J = 5.5, 2.1 Hz, 1H, Gal-
H4), 4.09 – 4.00 (m, 3H, Fuc-H2, Gal-H3, Fuc-H3), 3.89 (td, J = 6.2, 2.0 Hz, 1H, Gal-H5), 
3.78 (dd, J = 9.7, 6.2 Hz, 1H, Gal-H6), 3.76 – 3.68 (m, 2H, Gal-H6', MeCy-H1), 3.65 – 3.63 
(m, 1H, Fuc-H4), 3.46 (t, J = 7.8 Hz, 1H, Gal-H2), 3.24 (t, J = 9.4 Hz, 1H, MeCy-H2), 2.14 
– 2.07 (m, 1H, MeCy-H6), 1.67 – 1.58 (m, 3H, MeCy-H3, MeCy-H5, MeCy-H4), 1.44 (s, 
3H, Me), 1.36 (s, 3H, Me), 1.34 – 1.14 (m, 2H, MeCy-H6’, Cy-H5’), 1.11 – 1.07 (m, 6H, 
Fuc-H6, MeCy-Me), 1.06 – 0.95 (m, 1H, MeCy-H4'); 13C NMR (125.8 MHz, CDCl3) δ 
139.2, 139.0, 138.6, 138.3, 128.4 - 127.5 (24C, Ar-C), 110.1 (C(CH3)2), 99.5 (Gal-C1), 98.2 
(Fuc-C1), 83.6 (MeCy-C2), 80.1 (Fuc-C3), 79.0 (Gal-C3), 78.8 (MeCy-C1), 78.2 (Fuc-C4), 
76.5 (Fuc-C2), 74.9 (Ph-CH2), 74.3 (Ph-CH2), 73.7 (Ph-CH2), 73.7 (Ph-CH2), 73.5 (Gal-4), 
72.9 (Gal-C2), 72.4 (Gal-C5), 69.5 (Gal-C6), 66.5 (Fuc-C5), 39.0 (MeCy-C3), 33.7 (MeCy-
C4), 31.1 (MeCy-C6), 28.4 (Me), 26.4 (Me), 23.2 (MeCy-C5), 19.1 (MeCy-Me), 17.1 (Fuc-
C6) ); ESI-MS: m/z: Calcd for C50H62NaO11 [M+Na]+: 861.42, found: 861.35. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 2-O-allyl-6-O-benzyl-3,4-O-isopropylidene-β-D-galactopyranoside (24a) 
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Alcohol 23 (204 mg, 243 µmol) was solved in 8 mL DMF and sodium hydride (60 % oil 
dispersion, 19.5 mg, 486 µmol) was added at 0°C. The mixture was stirred at this 
temperature for 1 h. The reaction was allowed to reach rt and allylbromide (63.0 µL, 723 
µmol) was added. The suspension was stirred for 16 h and diluted with MeOH (30 mL) and 
Et2O (30 ml). The solution was extracted with H2O (40 mL) and the aqueous phase was 
washed with Et2O (2 x 40 mL). The combined organic layers were dried (Na2SO4), 
concentrated and the crude product was purified by flash chromatography (petroleum 
ether/EtOAc 3:1) to give 24a as a white foam (182 mg, 207 µmol, 85 %). 
Rf (petroleum ether/EtOAc 2:1) 0.67; [α]D22 -30.2 (c 1.20, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.34 - 7.19 (m, 20H, Ar-H), 5.94 - 5.84 (m, 1H, CH2=CH-CH2), 5.32 - 5.25 (m, 
1H, CH2=CH), 5.15 - 5.10 (m, 1H, CH2=CH), 5.10 - 5.07 (m, 1H, Fuc-H1), 4.95 (d, J = 
11.6 Hz, 1H, Ph-CH2), 4.81 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.79 - 4.75 (m, 1H, Ph-CH2), 
4.75 - 4.71 (m, 2H, 2x Ph-CH2), 4.66 (d, J = 11.4 Hz, 1H, Ph-CH2), 4.62 (d, J = 11.6 Hz, 
1H, Ph-CH2), 4.58 (d, J = 12.0 Hz, 1H, Ph-CH2), 4.48 (d, J = 12.0 Hz, 1H, Ph-CH2), 4.33 - 
4.27 (m, 1H, CH2=CH-CH2), 4.26 (d, J = 8.3 Hz, 1H, Gal-H1), 4.22 - 4.15 (m, 2H, 
CH2=CH-CH2, Gal-H4), 4.07 - 4.03 (m, 3H, Fuc-H2, Fuc-H3, Gal-H3), 3.85 - 3.79 (m, 1H, 
Gal-H5), 3.79 - 3.70 (m, 2H, Gal-H6, Gal-H6'), 3.68 - 3.65 (m, 1H, Fuc-H4), 3.64 - 3.58 (m, 
1H, MeCy-H1), 3.27 (t, J = 9.1 Hz, 1H, MeCy-H2), 3.22 - 3.16 (m, 1H, Gal-H2), 2.08 - 
2.01 (m, 1H, MeCy-H6), 1.66 - 1.58 (m, 3H, MeCy-H3, MeCy-H4, MeCy-H5), 1.41 (s, 3H, 
Me), 1.35 (s, 3H, Me), 1.33 - 1.14 (m, 2H, MeCy-H5', MeCy-H6'), 1.13 - 1.08 (m, 6H, 
MeCy-Me, Fuc-H6), 1.08 - 0.99 (m, 1H, MeCy-H4'); 13C NMR (125.8 MHz, CDCl3): δ = 
13C NMR (125.8 MHz, CDCl3) δ 139.2, 139.13, 138.78, 138.30, 128.72 – 127.3 (24x Ar-C), 
135.2 (CH2=CH-CH2), 116.7 (CH2=CH-CH2), 109.7 (C(CH3)2), 101.3 (Gal-C1), 98.2 (Fuc-
C1), 82.5 (MeCy-C2), 80.3 (Fuc-C3), 80.2 (Gal-C2), 80.0 (MeCy-C1), 79.4 (Gal-C3), 78.2 
(Fuc-C4), 76.6 (Fuc-C2), 74.8 (Ph-CH2), 74.3 (Ph-CH2), 73.7 (Ph-CH2), 73.7 (Gal-C4), 73.0 
(Ph-CH2), 72.8 (Ph-CH2), 71.8 (Gal-H5), 69.3 (Gal-C6), 66.1 (Fuc-C5), 39.1 (MeCy-C3), 
24a
O
O
BnO OBn
OBn
O
O
O
O
O
BnO
Chapter 3.2.1.1 - Manuscript 2 
 164 
33.6 (MeCy-C4), 23.0 (MeCy-C5), 19.1 (Fuc-C6), 17.3 (MeCy-Me); ESI-MS: m/z: Calcd 
for C53H66NaO11 [M+Na]+: 901.45, found: 901.47. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-2-O-(but-3-en-1-yl)-3,4-O-isopropylidene-β-D-galactopyranoside 
(24b) 
 
Alcohol 23 (716 mg, 854 µmol) was dissolved in DMF (8 mL) and sodium hydride (60 % 
oil dispersion, 68.3 mg, 1.71 mmol) was added at 0°C. The mixture was stirred at this 
temperature for 1 h. The reaction was allowed to reach rt and triflate 21 (375 mg, 1.84 
mmol) was added. The suspension was stirred for 16 h and diluted with MeOH (100 mL) 
and Et2O (100 mL). The solution was extracted with H2O (80 mL) and the aqueous phase 
was washed with Et2O (2x 80 mL). The combined organic layers were dried (Na2SO4), 
concentrated and the crude product was purified by flash chromatography (petroleum 
ether/EtOAc 3:1) to give 24b as a white foam (258 mg, 289 µmol, 34 % (58%)). Reactant 
23 was recovered in 42% yield (301 mg, 359 µmol).    
Rf (petroleum ether/EtOAc 1:1) 0.36; [α]D22 -44.4 (c 0.50, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.34 – 7.17 (m, 20H, Ar-H), 5.86 – 5.74 (m, 1H, CH2=CH-CH2), 5.10 – 5.03 
(m, 2H, Fuc-H1, CH2=CH-CH2), 5.02 – 4.97 (m, 1H, CH2=CH-CH2), 4.94 (d, J = 11.7 Hz, 
1H, Ph-CH2), 4.82 – 4.75 (m, 2H, Ph-CH2, Fuc-H5), 4.72 (d, J = 10.0 Hz, 2H, 2x Ph-CH2), 
4.66 (d, J = 11.4 Hz, 1H, Ph-CH2), 4.61 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.57 (d, J = 12.0 Hz, 
1H, Ph-CH2), 4.47 (d, J = 12.0 Hz, 1H, Ph-CH2), 4.22 (d, J = 8.2 Hz, 1H, Gal-H1), 4.17 – 
4.13 (m, 1H, Gal-H4), 4.07 – 4.04 (m, 2H, Fuc-H2, Fuc-H3), 4.03 – 3.99 (m, 1H, Gal-H3), 
3.83 – 3.63 (m, 6H, 2x CH2-CH2-O, Gal-H5, Gal-H6, Gal-H6', Fuc-H4), 3.63 – 3.56 (m, 1H, 
MeCy-H1), 3.25 (t, J = 9.1 Hz, 1H, MeCy-H2), 3.13 – 3.08 (m, 1H, Gal-H2), 2.33 – 2.26 
(m, 2H, CH2=CH-CH2), 2.05 – 1.99 (m, 1H, MeCy-H6), 1.65 – 1.54 (m, 3H, MeCy-H3, 
MeCy-H5, MeCy-H4), 1.41 (s, 3H, Me), 1.34 (s, 3H, Me), 1.31 – 1.12 (m, 2H, MeCy-H6', 
MeCy-H5'), 1.12 – 0.99 (m, 7H, Fuc-H6, MeCy-Me, MeCy-H4); 13C NMR (125.8 MHz, 
CDCl3): δ = 139.2, 139.1, 138.8, 138.3, 128.6 – 127.3 (24C, Ar-C), 135.4 (CH2=CH-CH2), 
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116.4 (CH2=CH-CH2), 109.7 (Gal-C1), 101.1 (Fuc-C1), 98.1 (C(CH3)2), 82.3 (MeCy-C2), 
81.1 (Gal-C2), 80.3 (Fuc-C3), 79.8 (MeCy-C1), 79.4 (Gal-C3), 78.2 (Fuc-C4), 76.6 (Fuc-
C2), 74.8 (Ph-CH2), 74.3 (Ph-CH2), 73.7 (Ph-CH2), 73.7 (Gal-C4), 72.8 (Ph-CH2), 71.9 
(CH2-CH2-O), 71.8 (Gal-C5), 69.4 (Gal-C6), 66.1 (Fuc-C5), 39.1 (MeCy-C3), 34.8 
(CH2=CH-CH2), 33.6 (MeCy-C4), 31.0 (MeCy-C6), 28.3 (Me), 26.4 (Me), 21.0 (MeCy-C5), 
19.1 (Fuc-C6), 17.3 (MeCy-Me); ESI-MS: m/z: Calcd for C54H68NaO11 [M+Na]+: 915.47, 
found: 915.62. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 2-O-allyl-6-O-benzyl-β-D-galactopyranoside (25a) 
 
Acetic acid (1 mL, 80 %) was added to acetonide 24a (55.0 mg, 62.6 µmol) and the reaction 
mixture was stirred for 3 d at rt. The acetic acid was removed in vacuo and coevaporated 
with toluene. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc 0 to 2:3) to yield 25a in (41.0 mg, 48.9 µmol, 78%) as a white solide. 
Rf (petroleum ether/EtOAc 2:1) 0.13; [α]D22 -45.6 (c 3.64, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.36 – 7.21 (m, 20H, Ar-H), 5.96 – 5.86 (m, 1H, CH2=CH), 5.30 – 5.24 (m, 1H, 
CH2=CH), 5.19 – 5.14 (m, 1H, CH2=CH), 5.08 (d, J = 3.1 Hz, 1H, Fuc-H1), 4.93 (d, J = 
11.5 Hz, 1H, PhCH2), 4.87 – 4.79 (m, 2H, Fuc-H5, Ph-CH2), 4.76 – 4.71 (m, 2H, 2x Ph-
CH2), 4.66 (d, J = 11.4 Hz, 1H, Ph-CH2), 4.58 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.50 (s, 2H, 2x 
Ph-CH2), 4.49 – 4.44 (m, 1H, CH2=CH-CH2), 4.35 (d, J = 7.7 Hz, 1H, Gal-H1), 4.15 – 4.09 
(m, 2H, Ph-CH2, CH2=CHCH2), 4.08 – 4.02 (m, 3H, Fuc-H3, Gal-H4, Fuc-H2), 3.77 (dd, J 
= 9.4, 6.9 Hz, 1H, Gal-H6), 3.73 – 3.71 (m, 1H, Fuc-H4), 3.70 – 3.59 (m, 2H, Gal-H6', 
MeCy-C1), 3.57 – 3.51 (m, 2H, Gal-H3, Gal-H5), 3.34 (dd, J = 9.2, 7.9 Hz, 1H, Gal-H2), 
3.25 (t, J = 9.2 Hz, 1H, MeCy-H2), 2.11 – 2.05 (m, 1H, MeCy-H6), 1.70 – 1.59 (m, 3H, 
MeCy-H3, MeCy-H4, MeCy-H5), 1.37 – 1.17 (m, 2H, MeCy-H6', MeCy-H5'), 1.14 (d, J = 
6.5 Hz, 3H, Fuc-H6), 1.10 (d, J = 6.5 Hz, 3H, MeCy-Me), 1.09 - 1.00 (m, 1H, MeCy-H4'); 
13C NMR (125.8 MHz, CDCl3): δ = 139.3, 139.2, 138.7, 137.9, 128.8 – 127.3 (Ar-C), 135.0 
(CH2=CH), 117.3 (CH2=CH), 101.4 (Gal-C1), 98.4 (Fuc-C1), 82.7 (MeCy-C2), 80.3 (Fuc-
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C3), 79.7 (MeCy-C1), 79.1 (Gal-C1), 78.5 (Fuc-C4), 76.6 (Fuc-C2), 75.1 (Ph-CH2), 74.4 
(Ph-CH2), 73.8 (Ph-CH2), 73.7 (Gal-C3), 73.5 (Gal-C5), 72.6 (Ph-CH2), 69.1 (Gal-C6), 68.5 
(Gal-C4), 66.3 (Fuc-C5), 39.2 (MeCy-C3), 33.6 (MeCy-C4), 31.1 (MeCy-C6), 23.1 (MeCy-
C5), 19.0 (MeCy-Me), 17.2 (Fuc-C6); ESI-MS: m/z: Calcd for C50H62NaO11 [M+Na]+: 
861.42, found: 861.35. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-2-O-(but-3-en-1-yl)-β-D-galactopyranoside (25b) 
 
Acetic acid (2 ml, 80 %) was added to acetonide 24b (23.5 mg, 26.3 µmol) and the reaction 
mixture was stirred for 3 d at rt. The acetic acid was removed in vacuo and coevaporated 
with toluene. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc 0 to 60%) to yield 25b in 91 % (20.5 mg, 24.0 µmol). 
Rf (petroleum ether/EtOAc 2:1) 0.15; [α]D22 -77.9 (c 0.40, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.37 – 7.19 (m, 20H, Ar-H), 5.87 – 5.77 (m, 1H, CH2=CH), 5.16 – 5.10 (m, 1H, 
CH2=CH), 5.10 – 5.06 (m, 2H, CH2=CH, Fuc-H1), 4.94 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.88 
– 4.79 (m, 2H, Fuc-H5, Ph-CH2), 4.77 – 4.71 (m, 2H, 2x Ph-CH2), 4.67 (d, J = 11.4 Hz, 1H, 
Ph-CH2), 4.59 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.50 (s, 2H, 2x Ph-CH2), 4.32 (d, J = 7.7 Hz, 
1H, Gal-H1), 4.09 – 3.98 (m, 4H, Fuc-H2, Fuc-H4, Gal-H4, CH2=CH-CH2), 3.77 (dd, J = 
9.4, 7.0 Hz, 1H, Gal-H6), 3.75 – 3.72 (m, 1H, Fuc-H4), 3.71 – 3.59 (m, 3H, Gal-H6', MeCy-
H2, CH2=CH-CH2), 3.56 – 3.49 (m, 2H, Gal-H5, Gal-H3), 3.31 – 3.22 (m, 2H, Gal-H2, 
MeCy-H2), 2.37 – 2.26 (m, 2H, O-CH2-CH2), 2.12 – 2.04 (m, 1H, MeCy-H6), 1.69 – 1.55 
(m, 3H, MeCy-H5, MeCy-H3, MeCy-H4), 1.35 – 1.18 (m, 2H, MeCy-H6', MeCy-H5'), 1.15 
(d, J = 6.5 Hz, 3H, Fuc-H6), 1.11 (d, J = 6.5 Hz, 3H, MeCy-Me), 1.09 – 1.00 (m, 1H, 
MeCy-H4');13C NMR (125.8 MHz, CDCl3): δ = 139.3, 139.2, 138.7, 138.0, 128.8 – 127.3 
(Ar-C), 136.0 (CH2=CH), 117.1 (CH2=CH), 101.3 (Gal-C1), 98.3 (Fuc-C1), 82.6 (MeCy-
C2), 80.2 (Fuc-C3), 79.5 (MeCy-C1), 79.5 (Gal-C2), 78.5 (Fuc-C4), 76.5 (Fuc-C2), 75.1 
(Ph-CH2), 74.4 (Ph-CH2), 73.7 (Ph-CH2), 73.6 (Gal-C3), 72.7 (Gal-C5), 72.6 (Ph-CH2), 71.8 
(CH2=CH-CH2), 69.0 (Gal-C6), 68.2 (Gal-C4), 66.23 (Fuc-C5), 39.2 (Cy-C3), 34.8 (O-CH2-
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CH2), 33.6 (MeCy-C4), 31.1 (MeCy-C6), 23.1 (MeCy-C5), 19.0 (MeCy-Me), 17.2 (Fuc-
C6); ESI-MS: m/z: Calcd for C51H64NaO11 [M+Na]+: 875.43, found: 875.47. 
  
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 2-O-allyl-6-O-benzyl-3-O-((R)-1-methoxy-1-oxo-pent-4-en-2-yl)-β-D-
galactopyranoside (26a) 
 
Alcohol 25a (38.5 mg, 45.9 mmol) and Bu2SnO (34.3 mg, 138 µmol) were dried for 16 h at 
rt, suspended in MeOH (3 mL) and refluxed for 2 h. The resulting solution was concentrated 
and coevaporated with toluene and the tin acetal was dried for 16 h under reduces pressure. 
The acetal was dissolved in freshly dried (Al2O3 column) DME (3 mL) and added to CsF 
(dried for 2 h at high vacuo at 100°C, 12.5 mg, 82.6 µmol). Triflate 21 (18.0 mg, 68.8 µmol) 
was added and the suspension was stirred for 16 h at rt. A 10 % solution of KF (in aq. 1M 
KH2PO4, 3 mL) was added. After stirring for 1 h at rt DCM (4 mL) was added and the aq. 
phase was extracted with DCM (2 x 10 ml). The combined organic layers were dried 
(Na2SO4) and concentrated under reduced pressure. Column chromatography on silica 
(petroleum ether/EtOAc 2:1) afforded 26a (25.0 mg, 26.3 µmol, 57%) as a white solid. Rf 
(petroleum ether/EtOAc 2:1) 0.49; [α]D22 -39.2 (c 2.90, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.39 – 7.15 (m, 20H, Ar-H), 5.93 – 5.75 (m, 2H, R-H4, O-CH2CH=CH2), 5.25 – 
5.13 (m, 3H, O-CH2-CH=CH2, 2x R-H5), 5.12 – 5.04 (m, 2H, O-CH2-CH=CH2), 4.94 (d, J 
= 11.5 Hz, 1H, Ph-CH2), 4.88 – 4.80 (m, 2H, Fuc-H5, Ph-CH2), 4.76 – 4.66 (m, 3H, 3x Ph-
CH2), 4.60 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.49 (s, 2H, 2x Ph-CH2), 4.40 – 4.34 (m, 1H, O-
CH2-CH=CH2), 4.29 (d, J = 6.9 Hz, 1H, Gal-H1), 4.21 (dd, J = 8.0, 4.7 Hz, 1H, R-H2), 4.10 
– 4.03 (m, 3H, O-CH2CH=CH2, Fuc-H2, Fuc-H3), 4.00 – 3.96 (m, 1H, Gal-H4), 3.79 – 3.75 
(m, 2H, Fuc-H4, Gal-H6), 3.71 (s, 3H, Me), 3.66 – 3.57 (m, 2H, Gal-H6', MeCy-H1), 3.47 – 
3.43 (m, 1H, Gal-H5), 3.43 – 3.35 (m, 2H, Gal-H2, Gal-H3), 3.24 (t, J = 9.2 Hz, 1H, MeCy-
H2), 2.56 – 2.43 (m, 2H, R-H3), 2.08 – 1.98 (m, 1H, MeCy-H6), 1.64 – 1.53 (m, 3H, MeCy-
H3, MeCy-H4, MeCy-H5), 1.37 – 1.23 (m, 2H, MeCy-H6', MeCy-H5'), 1.15 (d, J = 6.5 Hz, 
3H, Fuc-H6), 1.12 – 0.98 (m, 4H, MeCy-Me, Cy-H4'); 13C NMR (125.8 MHz, CDCl3): δ = 
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172.0 (COO), 139.4, 139.3, 138.8, 138.1, 128.8 – 127.2 (24C, Ar-C), 135.5 (CH2-CH2-
CH=CH2), 133.3 (R-C4), 119.1 (R-C5), 116.2 (CH2-CH2-CH=CH2), 101.3 (Gal-C1), 98.3 
(Fuc-C1), 82.3 (Cy-C2), 81.5 (Gal-C3), 80.3 (Fuc-C3), 79.4 (Cy-C1), 78.6 (Fuc-C4), 77.9 
(Gal-C2), 76.5 (Fuc-C2), 75.1 (Ph-CH2), 74.4 (Ph-CH2), 73.8 (Ph-CH2), 72.6 (Ph-CH2), 72.2 
(CH2-CH2-CH=CH2), 72.1 (Gal-C5), 68.7 (Gal-C6), 66.4 (Gal-C4), 66.2 (Fuc-C5), 52.1 
(Me), 39.2 (MeCy-C3), 37.9 (R-C3), 34.8 (CH2-CH2-CH=CH2), 33.7 (MeCy-C4), 31.1 
(MeCy-C6), 23.1 (MeCy-C5), 19.0 (MeCy-Me), 17.2 (Fuc-C6); ESI-MS: m/z: Calcd for 
C56H70NaO13 [M+Na]+: 973.47, found: 973.48. 
 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 2-O-(but-3-en-1-yl)-6-O-benzyl-3-O-((R)-1-methoxy-1-oxo-pent-4-en-2-yl)-β-D-
galactopyranoside (26b) 
 
Alcohol 25b (24.5 mg, 28.7 mmol) and Bu2SnO (21.4 mg, 86.2 µmol) were dried for 16 h at 
rt, suspended in MeOH (1.5 mL) and refluxed for 2 h. The resulting solution was 
concentrated and coevaporated with toluene and the tin acetal was dried for 16 h under 
reduces pressure. The acetal was dissolved in freshly dried (Al2O3 column) DME (1.5 mL) 
and added to CsF (dried for 2 h at high vacuo at 100°C, 7.85 mg, 51.7 µmol). Triflate 21 
(11.3 mg, 43.1 µmol) was added and the suspension was stirred for 16 h at rt. A 20% 
solution of KF (in aq. 1M KH2PO4, 2 mL) was added. After stirring for 1 h at rt DCM 
(4mL) was added and the aqueous phase was extracted with DCM (2 x 10 ml). The 
combined organic layers were dried (Na2SO4) and concentrated under reduced pressure. 
Column chromatography on silica (petroleum ether/EtOAc 2:1) afforded 26b (25.9 mg, 26.9 
µmol, 93%) as a white solid.  
Rf (petroleum ether/EtOAc 2:1) 0.65; [α]D22 -51.9 (c 0.60, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.37 – 7.20 (m, 20H, Ar-H), 5.86 – 5.75 (m, 2H, R-H4, CH2-CH2-CH=CH2), 
5.21 – 5.14 (m, 2H, R-H5, R-H5'), 5.08 – 4.98 (m, 3H, 2x CH2-CH2-CH=CH2, Fuc-H1), 
4.94 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.88 – 4.80 (m, 2H, Fuc-H5, Ph-CH2), 4.75 – 4.67 (m, 
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3H, 3x Ph-CH2), 4.60 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.49 (s, 2H, 2x Ph-CH2), 4.28 (d, J = 
7.2 Hz, 1H, Gal-H1), 4.24 (dd, J = 7.9, 4.8 Hz, 1H, R-H2), 4.08 – 4.02 (m, 2H, Fuc-H2, 
Fuc-H3), 4.00 – 3.96 (m, 1H, Gal-H4), 3.90 – 3.84 (m, 1H, CH2-CH2-CH=CH2), 3.80 – 3.74 
(m, 2H, Gal-H6, Fuc-H4), 3.73 (s, 3H, Me), 3.67 – 3.55 (m, 3H, Gal-H6', MeCy-H1, CH2-
CH2CH=CH2), 3.46 – 3.41 (m, 1H, Gal-H5), 3.38 – 3.31 (m, 2H, Gal-H2, Gal-H3), 3.24 (t, J 
= 9.2 Hz, 1H, MeCy-H2), 2.58 – 2.43 (m, 2H, R-H3), 2.30 – 2.23 (m, 2H, 2x CH2-CH2-
CH=CH2), 2.07 - 2-01 (d, 1H, MeCy-H6), 1.70 - 1-53 (m, 3H, MeCy-H3, MeCy-H5, MeCy-
H4), 1.32 – 1.18 (m, 2H, MeCy-H6', MeCy-H5'), 1.15 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.12 – 
0.97 (m, 4H, MeCy-Me, MeCy-H4'); 13C NMR (125.8 MHz, CDCl3): δ = 172.0 (COO), 
139.4, 139.3, 138.8, 138.1, 128.8 – 127.2 (24C, Ar-C), 135.5 (CH2-CH2-CH=CH2), 133.3 
(R-C4), 119.1 (R-C5), 116.2 (CH2-CH2-CH=CH2), 101.3 (Gal-C1), 98.3 (Fuc-C1), 82.3 
(Cy-C2), 81.5 (Gal-C3), 80.3 (Fuc-C3), 79.4 (Cy-C1), 78.6 (Fuc-C4), 77.9 (Gal-C2), 76.5 
(Fuc-C2), 75.1 (Ph-CH2), 74.4 (Ph-CH2), 73.8 (Ph-CH2), 72.6 (Ph-CH2), 72.2 (CH2-CH2-
CH=CH2), 72.1 (Gal-C5), 68.7 (Gal-C6), 66.4 (Gal-C4), 66.2 (Fuc-C5), 52.1 (Me), 39.2 
(MeCy-C3), 37.9 (R-C3), 34.8 (CH2-CH2-CH=CH2), 33.7 (MeCy-C4), 31.1 (MeCy-C6), 
23.1 (MeCy-C5), 19.0 (MeCy-Me), 17.2 (Fuc-C6); ESI-MS: m/z: Calcd for C57H72NaO13 
[M+Na]+: 987.49, found 987.65. 
 
Compound 27a 
 
ompound 26a (10.0 mg, 10.5 µmol) was dissolved in DCM (2 mL) and Grubbs 2nd 
generation catalyst (0.89 mg, 1.05 µmol) was added and the solution stirred for 2 h at rt. The 
solvent was removed in vacuo and the crude product purified by flash chromatography 
(petroleum ether/EtOAc 3:1) to yield 27a (8.30 mg, 8.99 µmol, 86%) as a white solid. 
Rf (petroleum ether/EtOAc 3:1) 0.27; [α]D22 -25.1 (c 0.57, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.36 – 7.17 (m, 20H, Ar-H), 5.60 – 5.52 (m, 2H, R-H4, R-H5), 5.07 (d, J = 2.6 
Hz, 1H, Fuc-H1), 4.93 – 4.86 (m, 2H, Ph-CH2, Fuc-H5), 4.82 (d, J = 11.7 Hz, 1H, Ph-CH2), 
4.75 – 4.68 (m, 2H, 2x Ph-CH2), 4.65 (d, J = 11.4 Hz, 1H, Ph-CH2), 4.59 – 4.46 (m, 4H, 3x 
Ph-CH2, R-H5), 4.41 (dd, J = 12.6, 2.5 Hz, 1H, R-H2), 4.26 (d, J = 7.7 Hz, 1H, Gal-H1), 
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4.20 – 4.11 (m, 2H, Gal-H4, R-H5'), 4.08 – 4.02 (m, 2H, Fuc-H2, Fuc-H3), 3.80 – 3.70 (m, 
6H, Gal-H3, Me, Fuc-H4, Gal-H6), 3.68 – 3.60 (m, 2H, MeCy-H1, Gal-H6'), 3.55 – 3.46 (m, 
2H, R-H3, Gal-H5), 3.24 (t, J = 9.2 Hz, 1H, MeCy-H2), 3.18 (t, J = 8.2 Hz, 1H, Gal-H2), 
2.35 – 2.29 (m, 1H, R-H3'), 2.11 – 2.03 (m, 1H, MeCy-H6), 1.68 – 1.59 (m, 3H, MeCy-H3, 
MeCy-H4, MeCy-H5), 1.33 – 1.15 (m, 2H, MeCy-H5’, MeCy-H6’), 1.13 (d, J = 6.5 Hz, 3H, 
Fuc-H6), 1.10 (d, J = 6.5 Hz, 3H, MeCy-Me), 1.08 – 0.97 (m, 1H, MeCy-H4’); 13C NMR 
(125.8 MHz, CDCl3): δ = 172.5 (COO), 139.4, 139.3, 138.8, 138.2, 130.8, 128.8 – 127.3, 
126.9 (26C, 24x Ar-C, CH=CH), 101.5 (Gal-C1), 98.3 (Fuc-C1), 82.5 (MeCy-C2), 80.5 
(Gal-C2), 80.3 (Fuc-C3), 80.0 (MeCy-C1), 78.7 (Fuc-C4), 76.6 (R-C2), 76.5 (Fuc-C2), 76.2 
(Gal-C3), 75.1 (Ph-CH2), 74.4 (Ph-CH2), 73.7 (Ph-CH2), 72.6 (Gal-C5), 72.6 (Ph-CH2), 71.9 
(R-C5), 69.5 (Gal-C6), 69.2 (Gal-C4), 66.3 (Fuc-C5), 52.1 (Me), 39.1 (MeCy-C3), 33.7 
(MeCy-C4), 31.6 (R-C3), 31.0 (MeCy-C6), 23.0 (MeCy-C5), 19.0 (MeCy-Me), 17.1 (Fuc-
C6); ESI-MS: m/z: Calcd for C54H66NaO13 [M+Na]+: 945.44, found: 945.47. 
 
Compound 4a 
 
Compound 27a (12.2 mg, 13.2 µmol) was dissolved in dioxane/water (4:1, 1 mL) and 
Pd(OH)2/C (1.5 mg, 10% Pd(OH)2) was added. The suspension was stirred for 16 h under 
an atmosphere of hydrogen. Solvent was removed in vacuo.  
The resulting ester was dissolved in H2O (1 mL) and LiOH (0.63 mg, 26.4 µmol) was 
added. The turbid reaction mixture was stirred for 24 h at rt and the solvent was removed 
under reduced pressure. The residue was purified via RP chromatography (MeOH/H2O), 
eluated through a sodium exchange column (Dowex 50/8 sodium form) and finally purified 
via size exclusion chromatography. Lyophilization from water/dioxane gave 4a (4.30 mg, 
7.51 µmol, 57 %) as a white fluffy foam. 
Rf (DCM/MeOH/H2O 10:5:0.4) 0.30; [α]D22  -68.1 (c 1.10, H2O); 1H NMR (500.1 MHz, 
D2O) δ = 5.13 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.94 - 4.89 (m, 1H, Fuc-H5), 4.49 (d, J = 7.8 Hz, 
1H, Gal-H1), 4.32 - 4.26 (m, 1H, R-H2), 4.18 - 4.15 (m, 1H, Gal-H5), 3.97 - 3.90 (m, 2H, 
Fuc-H3, R-H5), 3.84 - 3.78 (m, 3H, Fuc-H4, Fuc-H2, R-H5'), 3.77 - 3.65 (m, 4H, Gal-H6', 
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Gal-H6, Gal-H3, Cy-H1), 3.53 (t, J = 5.9 Hz, 1H, Gal-H4), 3.35 (dd, J = 9.2, 8.2 Hz, 1H, 
Gal-H2), 3.24 (t, J = 9.4 Hz, 1H, Cy-H2), 2.20 - 2.09 (m, 3H, R-H4, R-H2, MeCy-H6), 1.86 
- 1.73 (m, 3H, R-H2', R-H3, R-H3'), 1.73 - 1.58 (m, 3H, MeCy-H5, MeCy-H4, MeCy-H3), 
1.46 - 1.39 (m, 1H, R-H4), 1.37 - 1.24 (m, 2H, MeCy-H6', MeCy-H5'), 1.22 (d, J = 6.6 Hz, 
3H, Fuc-H6), 1.11 (d, J = 6.4 Hz, 4H, MeCy-Me, MeCy-H4’); 13C NMR (125.8 MHz, D2O): 
δ = 180.3 (COO), 100.1 (Gal-C1), 98.7 (Fuc-C1), 83.8 (MeCy-C2), 81.0 (R-C1), 79.0 
(MeCy-C1), 77.6 (Gal-C2), 75.3 (Gal-C3), 74.6 (Gal-C4), 74.0 (R-C5), 72.0 (Fuc-C4), 69.3 
(Fuc-C3), 69.0 (Gal-C5), 68.2 (Fuc-C2), 66.5 (Fuc-C5), 61.7 (Gal-C6), 38.5 (MeCy-C3), 
33.1 (MeCy-C4), 30.4 (MeCy-C6), 29.0 (R-C2), 26.1 (R-C3), 25.3 (R-C4), 22.4 (MeCy-
C5), 18.2 (MeCy-Me), 15.7 (Fuc-C6); ESI-MS: m/z: Calcd for C25H42NaO13 [M+H]+: 
573.2523, found: 573.2525. 
 
Compound 4b 
 
Compound 26a (25.5 mg, 26.4 µmol) was dissolved in DCM (mL) and Grubbs 2nd 
generation catalyst (4.49 mg, 5.28 µmol) was added. The solution was stirred for 2 h at rt. 
The solvent was removed in vacuo and the crude product purified by short column of silica 
(petroleum ether/EtOAc 3:1) to give 27a  (20.4 mg) as a white solid. 
3.7 mg of the olefin 27a (3.95 µmol) was dissolved in dioxane/water (4:1) and Pd(OH)2/C 
(1 mg, 10% Pd(OH)2) was added. The suspension was stirred for 16 h under an atmosphere 
of hydrogen. The solvent was removed under reduced pressure. The residue was dissolved 
H2O (1 mL) and LiOH (0.19 mg, 7.90 µmol) was added.  The resulting turbid reaction 
mixture was stirred for 24 h at rt. The solvent was removed under reduced pressure and the 
crude product was purified by RP chromatography (MeOH/H2O), eluated through a sodium 
exchange column (Dowex 50/8 sodium form) and finally purified by size exclusion 
chromatography. Lyophilization from water/dioxane afforded 4b (800 µg, 1.42 µmol, 25 %) 
as a white fluffy foam. 
Rf (DCM/MeOH/H2O 10:5:0.4) 0.28; 1H NMR (500.1 MHz, CDCl3): δ = 5.14 (d, J = 4.0 
Hz, 1H, Fuc-H1), 4.99 – 4.93 (m, 1H, Fuc-H5), 4.52 (d, J = 7.3 Hz, 1H, Gal-H1), 4.40 – 
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4.35 (m, 1H, R-H2), 4.24 – 4.19 (m, 1H, R-H7), 4.11 – 4.08 (m, 1H,Gal-H5), 3.92 (dd, J = 
10.5, 3.3 Hz, 1H, Fuc-H3), 3.82 (d, J = 22.7 Hz, 4H, Fuc-H2, Gal-H6, R-H7', Fuc-H4), 3.70 
(m, 4H, Gal-H2, Gal-H6', MeCy-H1, Gal-H3), 3.54 (t, J = 6.0 Hz, 1H, Gal-H4), 3.25 (t, J = 
9.5 Hz, 1H, MeCy-H2), 2.20 - 2.13 (m, 1H, MeCy-H6), 1.87 – 1.49 (m, 10H, MeCy-H3, 
MeCy-H5, MeCy-H4, R-H3, MeCy-H3', MeCy-H4, MeCy-H4', MeCy-H5, MeCy-H5', 
MeCy-H6), 1.44 - 1.28 (m, 3H, MeCy-H6', R-H6', MeCy-H5'), 1.27 (d, J = 6.6 Hz, 3H, 
Fuc-H6), 1.11 (d, J = 6.4 Hz, 3H, MeCy-Me); 13C NMR (125.8 MHz, D2O): δ = 180.3 
(COO), 100.1 (Gal-C1), 98.7 (Fuc-C1), 83.8 (MeCy-C2), 81.0 (R-C1), 79.0 (MeCy-C1), 
77.6 (Gal-C2), 75.3 (Gal-C3), 74.6 (Gal-C4), 74.0 (R-C5), 72.0 (Fuc-C4), 69.3 (Fuc-C3), 
69.0 (Gal-C5), 68.2 (Fuc-C2), 66.5 (Fuc-C5), 61.7 (Gal-C6), 38.5 (MeCy-C3), 33.1 (MeCy-
C4), 30.4 (MeCy-C6), 29.0 (R-C2), 26.1 (R-C3), 25.3 (R-C4), 22.4 (MeCy-C5), 18.2 
(MeCy-Me), 15.7 (Fuc-C6); ESI-MS: m/z: Calcd for C26H44NaO13 [M+H]+: 587.2680, 
found: 587.2681. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-3-O-((R)-1-methoxy-1-oxo-pent-4-en-2-yl)-β-D-galactopyranoside 
(22) 
 
Alcohol 20 (30.8 mg, 38.6 µmol) and Bu2SnO (28.8 mg, 116 µmol) were dried for 8 h at rt, 
suspended in MeOH (2 mL) and refluxed for 2 h. The resulting solution was concentrated 
and coevaporated with toluene. The resulting tin acetal was dried for 16 h under reduces 
pressure. The residue was dissolved in DME (1.5 mL) and added to CsF (dried for 2 h at 
high vacuo at 100°C, 10.5 mg, 69.4 µmol). Triflate 21 (15.2 mg, 57.8 µmol) was added and 
the suspension was stirred for 16 h at rt. A 20% solution of KF (in 1M KH2PO4 solution, 3 
mL) was added. After stirring for 1 h at rt DCM (10 mL) was added. The aqueous phase 
was extracted with DCM (2 x 10 mL). The combined organic layers were dried (Na2SO4), 
concentrated under reduced pressure and purified by column chromatography on silica 
(petroleum ether/EtOAc 2:1) to yield 22 (20.1 mg, 22.1 µmol, 57%) as a white solid. 
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Rf (petroleum ether/EtOAc 1:1) 0.3; [α]D22 -21.5 (c 0.64, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.36 – 7.21 (m, 20H, Ar-H), 5.91 – 5.80 (m, 1H, R-H4), 5.26 – 5.17 (m, 2H, R-
H5, R-H5’), 5.07 (d, J = 3.5 Hz, 1H, Fuc-H1), 4.94 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.81 (d, J 
= 11.7 Hz, 1H, Ph-CH2), 4.77 – 4.70 (m, Ph-CH2, 3H), 4.68 (d, J = 11.4 Hz, 1H, Ph-CH2), 
4.60 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.52 (s, 2H, 2x Ph-CH2), 4.30 (d, J = 7.7 Hz, 1H, Gal-
H1), 4.13 (dd, J = 9.1, 3.7 Hz, 1H, R-H2), 4.06 (dd, J = 10.3, 3.5 Hz, 1H, Fuc-H2), 4.02 (dd, 
J = 10.3, 2.5 Hz, 1H, Fuc-H3), 3.97 (d, J = 2.8 Hz, 1H, Gal-H4), 3.77 (dd, J = 9.3, 7.4 Hz, 
1H, Gal-H6), 3.75 (s, 3H, Me), 3.73 – 3.63 (m, 4H, MeCy-H1, Fuc-H4, Gal-H2, Gal-H6'), 
3.52 – 3.47 (m, 1H, Gal-H5), 3.30 – 3.24 (m, 2H, Gal-H3, MeCy-H2), 2.63 – 2.56 (m, 1H, 
R-H3), 2.52 – 2.44 (m, 1H, R-H3'), 2.11 – 2.05 (m, 1H, MeCy-H6), 1.68 – 1.55 (m, 3H, 
MeCy-H5, MeCy-H3, MeCy-H4), 1.38 – 1.24 (m, 1H, MeCy-H6'), 1.24 – 1.16 (m, 1H, 
MeCy-H5'), 1.14 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.09 (d, J = 6.4 Hz, 3H, MeCy-Me), 1.07 – 
0.97 (m, 1H, MeCy-H4’); 13C NMR (125.8 MHz, CDCl3): δ = 173.2 (COO), 139.3, 139.2, 
138.7, 138.1, 128.7 – 127.3 (24x Ar-C),133.5 (R-C4), 119.3 (R-C5), 100.5 (Gal-C1), 98.3 
(Fuc-C1), 83.0 (MeCy-C2), 82.9 (Gal-C3), 80.2 (Fuc-C3), 79.0 (MeCy-C1), 78.6 (Fuc-C4), 
76.5 (Fuc-C2), 75.0 (Ph-CH2), 74.6 (Ph-CH2), 73.8 (Ph-CH2), 72.7 (Gal-C5), 72.6 (Ph-CH2), 
69.9 (Gal-C2), 68.7 (Gal-C6), 66.4 (Fuc-C5), 65.7 (Gal-C4), 52.6 (Me), 39.1 (MeCy-C3), 
37.6 (R-C3), 33.7 (MeCy-C4), 30.9 (MeCy-C6), 23.1 (MeCy-C5), 19.1 (MeCy-Me), 17.0 
(Fuc-C6); ESI-MS: m/z: Calcd for C53H66NaO13 [M+Na]+: 933.44, found: 933.53. 
 
(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl 3-O-[sodium (R)-1-
carboxybutane]-ß-D-galactopyranoside (7) 
 
 
Compound 22 (14.0 mg, 15.4 µmol) was dissolved in dioxane/water (4:1) and Pd(OH)2/C 
(2.0 mg, 10% Pd(OH)2) was added. The suspension was stirred for 16 h under an 
atmosphere of hydrogen. The solvent was removed in vacuo. The residue was dissolved in 
H2O (1 ml) and LiOH (0.74 mg, 30.8 µmol) was added. The turbid mixture was stirred for 
16 h at ambient temperature. The solvent was removed under reduced pressure and the 
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residue was purified via RP chromatography (MeOH/H2O), eluated through a sodium 
exchange column (Dowex 50/8 sodium form) and finally purified by size exclusion 
chromatography. Lyophilization from water/dioxane gave 7 (4.30 mg, 7.98 µmol, 52 %) as a 
white fluffy foam. 
Rf (DCM/MeOH/H2O 10:5:0.4) 0.22; [α]D22 -7.6 (c 0.48, H2O); 1H NMR (500.1 MHz, 
D2O): δ = 5.13 (d, J = 4.1 Hz, 1H, Fuc-H1), 4.90 – 4.85 (m, 1H, Fuc-H5), 4.49 (d, J = 7.8 
Hz, 1H, Gal-H1), 4.16 (dd, J = 7.6, 5.0 Hz, 1H, R-H2), 4.08 (d, J = 3.1 Hz, 1H, Gal-H4), 
3.92 (dd, J = 10.5, 3.3 Hz, 1H, Fuc-H3), 3.84 – 3.79 (m, 2H, Fuc-H2, Fuc-H4), 3.79 – 3.70 
(m, 3H, MeCy-H1, Gal-H6, Gal-H6'), 3.65 (dd, J = 9.7, 7.9 Hz, 1H, Gal-H2), 3.57 (dd, J = 
7.8, 4.1 Hz, 1H, Gal-H5), 3.48 (dd, J = 9.8, 3.2 Hz, 1H, Gal-H3), 3.25 (t, J = 9.6 Hz, 1H, 
MeCy-H2), 2.19 – 2.12 (m, 1H, MeCy-H6), 1.78 – 1.70 (m, 2H, R-H2, R-H2', MeCy-H5), 
1.70 – 1.57 (m, 3H, MeCy-H4, R-H3', MeCy-H3), 1.51 – 1.41 (m, 2H, R-H4, R-H4'), 1.35 – 
1.24 (m, 2H, MeCy-H6', MeCy-H5'), 1.21 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.11 (d, J = 6.4 Hz, 
4H, MeCy-Me), 0.94 (t, J = 7.4 Hz, 3H, R-H5); 13C NMR (125.8 MHz, D2O): δ = 179.1 
(COO), 99.9 (Gal-C1), 98.8 (Fuc-C1), 84.0 (MeCy-C2), 81.2 (Gal-C3), 78.9 (R-C2), 78.7 
(Cy-C1), 74.8 (Gal-C5), 72.1 (Fuc-C4), 69.6 (Gal-C2), 69.3 (Fuc-C3), 68.2 (Fuc-C2), 66.5 
(Fuc-C5), 66.0 (Gal-C4), 61.6 (Gal-C6), 38.7 (MeCy-C3), 34.7 (R-C3), 33.2 (MeCy-C4), 
30.3 (MeCy-C6), 22.6 (MeCy-C5), 18.2 (MeCy-Me), 18.2 (R-C4), 15.5 (Fuc-C6), 12.9 (R-
C5); ESI-MS: m/z: Calcd for C24H42NaO13 [M+H]+: 561.2523, found: 561.2523. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 2,3-di-O-acetyl-4,6-O-benzylidene-β-D-galactopyranoside (S14)  
 
 
Compound 15 (300 mg, 549 µmol) and thioglycoside 29 (283 mg, 713 mmol) were 
dissolved in dry DCM (10 mL) and stirred together with 1 g powdered 4 Å activated 
molecular sieves for 4 h at rt. DMTST (425 mg, 1.65 mmol) was dissolved in DCM (5 mL) 
and stirred together with 0.5 g powdered 4 Å activated molecular sieves for 3.5 h at rt as 
well. Both suspensions were combined and stirred for 3 days at ambient temperature. The 
mixture was filtered through a short pad of celite, washed with an aq. sat. solution of 
O
O
BnO OBn
OBn
O
O
OAc
AcO
O
O
Ph S14
Chapter 3.2.1.1 - Manuscript 2 
 
 175 
NaHCO3 (40 mL) and water (40 mL). The combined organic phases were extracted with 
DCM (3 x 30 mL). The combined organic layers were dried (Na2SO4) and the solvent was 
removed in vacuo. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc 3:2) to yield S14 (266 mg, 302 µmol, 55%) as a white solid. Analytical data 
were in accordance with literature.2 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 4,6-O-benzylidene-β-D-galactopyranoside (30) 
 
Acetate S14 (156 mg, 178 µmol) was suspended in MeOH (5 mL) and sodium was added.  
The solution, formed after a few minutes was stirred for 16 h rt. The reaction mixture was 
neutralized by adding a few drops of glacial acetic acid and concentrated under reduced 
pressure. The crude product was purified by flash chromatography to yield 30 as a white 
solid (132 mg, 166 µmol, 94 %). Analytical data were in accordance with literature.2 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- cyclo-
hex-1-yl 4,6-O-Benzylidene-3-O-((R)-1-methoxy-1-oxo-pent-4-en-2-yl)-β-D-
galactopyranoside (31) 
 
Alcohol 30 (60.0 mg, 75.3 µmol) and Bu2SnO (56.2 mg, 226 µmol) were dried for 2.5 h at 
high vacuo, suspended in MeOH (4 mL) and refluxed for 2 h. The resulting solution was 
concentrated and coevaporated with toluene and the stannyl acetal was dried for 16 h at high 
vacuo. The residue was solved in DME (2 mL) and added together with triflate 21 (29.6 mg, 
113 µmol) to CsF (dried for 2 h at high vacuo at 100°C, 20.6 mg, 136 µmol). The 
suspension was stirred for 16 h at rt.  A 10% solution of KF (in 1M KH2PO4 solution, 3 mL) 
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was added and the suspension was stirred for additional 1 h at rt. DCM (10 mL) was added 
and the aqueous phase was separated. The aqueous phase was extracted with DCM (2 x 12 
mL). The combined organic layers were dried (Na2SO4), concentrated under reduced 
pressure and purified by flash chromatography (petroleum ether/EtOAc 2:1) to afforded 31 
(58.4 mg, 64.2 µmol, 85 %) as a white solid. 
Rf (petroleum ether/EtOAc 1:1) 0.35; [α]D22 -18.5 (c 0.10, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ =  7.61 – 7.14 (m, 20H, Ar-H), 6.00 – 5.85 (m, 1H, R-H4), 5.58 (s, 1H, Ph-CH), 
5.17 – 5.11 (m, 1H, R-H5), 5.04 – 4.99 (m, 1H, R-H5'), 4.97 (d, J = 3.4 Hz, 1H, Fuc-H1), 
4.94 – 4.88 (m, 1H, Fuc-H5), 4.81 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.70 (d, J = 11.7 Hz, 1H, 
Ph-CH2), 4.60 (s, 2H, 2x Ph-CH2), 4.37 – 4.31 (m, 2H, Gal-H6, Gal-H1), 4.25 (d, J = 11.3 
Hz, 1H, Ph-CH2), 4.20 – 4.17 (m, 1H, Gal-H4), 4.14 (t, 1H, R-H2), 4.10 – 4.04 (m, 1H, Gal-
H6'), 3.98 – 3.88 (m, 3H, Fuc-H3, Fuc-H2, Gal-H2), 3.76 (s, 3H, Me), 3.65 – 3.58 (m, 2H, 
MeCy-H1, Ph-CH2), 3.41 (dd, J = 9.6, 3.3 Hz, 1H, Gal-H3), 3.34 – 3.30 (m, 1H, Gal-H5), 
3.28 – 3.20 (m, 2H, MeCy-H2, Fuc-H4), 2.59 – 2.53 (m, 2H, R-H3, R-H3'), 2.12 – 2.04 (m, 
1H, MeCy-H6), 1.70 – 1.48 (m, 3H, MeCy-H5, MeCy-H3, MeCy-H4), 1.45 – 1.34 (m, 1H, 
MeCy-H6'), 1.29 – 1.15 (m, 1H, MeCy-H5'), 1.12 – 0.99 (m, 7H, Fuc-H6, MeCy-Me, Me-
Cy-H4'); 13C NMR (125.8 MHz, CDCl3): δ = 173.2 (COO), 139.86, 139.68, 138.83, 138.25, 
128.9 - 126.0 (24x Ar-C), 133.3 (R-C4), 118.3 (R-C5), 101.5 (Gal-C1), 99.8 (Ph-CH), 98.6 
(Fuc-C1), 82.3 (MeCy-C2), 81.2 (Gal-C3), 80.3 (MeCy-C1), 79.9 (Fuc-C3), 78.9 (Fuc-C4), 
77.2 (R-C2), 75.7 (Fuc-C2), 74.9 (Ph-CH2), 74.6 (Ph-CH2), 72.5 (Gal-C4), 71.4 (Ph-CH2), 
69.8 (Gal-C6), 68.9 (Gal-C2), 66.4 (Gal-C5), 66.2 (Fuc-C5), 52.5 (Me), 39.7 (MeCy-C3), 
37.6 (R-C3), 33.9 (MeCy-C4), 31.5 (MeCy-C6), 23.5 (MeCy-C5), 19.0 (Fuc-H6), 16.7 
(MeCy-Me); ESI-MS: m/z: Calcd for C53H64NaO13 [M+Na]+: 931.42, found: 931.50. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl- cyclo-
hex-1-yl 4,6-O-Benzylidene-3-O-((R)-1-methoxy-1-oxo-pent-4-en-2-yl)-2-O-vinyl-β-D-
galactopyranoside (32) 
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Alcohol 31 (14.1 mg, 15.5 µmol) and sodium carbonate (822 mg, 7.76 µmol) were 
dissolved in toluene (1 mL) and vinyl acetate (1 mL) and chloro(1,5- 
cyclooctadiene)iridium (I) dimer  was added. The mixture was refluxed at 80 °C for 48 h. 
The reaction mixture was diluted with DCM (20 mL) and washed with sat. aq. sodium 
bicarbonate solution (30 mL). The aqueous phase was washed with DCM (2 x 10 ml). The 
combined organic layers were dried (Na2SO4) and concentrated in vacuo. The crude product 
was purified by flash chromatography (0 to 50% petroleum ether/EtOAc + 0.5% TEA) to 
yield 32 in 70 % (10.1 mg, 10.8 µmol). 
Rf (petroleum ether/EtOAc 2:1) 0.38; [α]D22 -4.4 (c 0.195, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.61 – 7.56 (m, 2H, Ar-H), 7.37 – 7.13 (m, 18H, Ar-H), 6.38 (dd, J = 13.7, 6.3 
Hz, 1H, CH2=CHO), 5.93 – 5.82 (m, 1H, R-H4), 5.59 (s, 1H, Ph-CH), 5.17 – 5.09 (m, 1H, 
R-H5), 5.06 – 5.01 (m, 1H, R-H5'), 4.99 – 4.91 (m, 2H, Fuc-H1, Fuc-H5), 4.81 (d, J = 11.7 
Hz, 1H, Ph-CH2), 4.70 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.64 – 4.57 (m, 2H, 2x Ph-CH2), 4.37 
(d, J = 7.7 Hz, 1H, Gal-H1), 4.36 – 4.29 (m, 2H, CH2=CHO, Gal-H6), 4.26 – 4.21 (m, 2H, 
Gal-H4, Ph-CH2), 4.17 (dd, J = 7.3, 5.6 Hz, 1H, R-H2), 4.11 – 4.04 (m, 1H, Gal-H6'), 3.99 – 
3.86 (m, 4H, CH2=CHO, Fuc-H3, Fuc-H2, Gal-H2), 3.70 (s, 3H, Me), 3.66 (dd, J = 9.6, 3.5 
Hz, 1H, Gal-H3), 3.61 – 3.54 (m, 2H, Ph-CH2, MeCy-H1), 3.34 – 3.31 (m, 1H, Gal-H5), 
3.26 – 3.20 (m, 2H, Fuc-H4, MeCy-H2), 2.58 – 2.49 (m, 2H, R-H3, R-H3'), 2.04 – 1.96 (m, 
1H, MeCy-H6), 1.68 – 1.57 (m, 3H, MeCy-H3, MeCy-H5, MeCy-H4), 1.40 – 1.11 (m, 2H, 
MeCy-H6', MeCy-H5'), 1.12 – 0.95 (m, 7H, MeCy-H4', Fuc-H6, MeCy-Me); 13C NMR 
(125.8 MHz, CDCl3): δ = 153.8 (COO), 133.6 (R-C4), 129.0 - 125.9 (24x Ar-C), 118.1 (R-
C5), 100.9 (Gal-C1), 99.9 (Ph-CH), 98.5 (Fuc-C1), 88.7 (CH2=CHO), 82.0 (MeCy-C2), 81.5 
(MeCy-C1), 79.8 (Fuc-C3), 78.9 (Gal-C3), 78.9 (Fuc-C4), 78.8 (Gal-C2), 77.9 (R-C2), 77.4 
(Fuc-C2), 75.8 (Ph-CH2), 75.0 (Ph-CH2), 74.6 (Gal-C4), 73.7 (Ph-CH2), 71.5 (Ph-CH2), 69.6 
(Gal-C6), 66.2 (Gal-C5), 66.1 (Fuc-C5), 52.1 (Me), 39.7 (MeCy-C3), 37.8 (R-C3), 37.8 
(MeCy-C4), 31.2 (MeCy-C6), 23.5 (MeCy-C5), 19.9 (Fuc-C6), 16.8 (MeCy-Me); ESI-MS: 
m/z: Calcd for C55H66NaO13 [M+Na]+: 957.44, found: 957.41. 
 
Compound 4c 
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Compound 32 (4.2 mg, 4.49 µmol) was dissolved in DCM (1 mL) and Grubbs 2nd 
generation catalyst (0.76 mg, 0.90 µmol) was added.  The solution was stirred for 6 h at rt. 
Additional Grubbs 2nd generation catalyst (0.76 mg, 0.90 µmol) was added and the solution 
stirred for another 10 h at ambient temperature. The solvent was removed under reduced 
pressure and the crude product purified by a short column of silica (petroleum ether/EtOAc 
3:1). The olefin was dissolved in dioxane/water (4:1; 1 mL) and Pd(OH)2/C (0.5 mg, 10% 
Pd(OH)2) was added. The suspension was stirred for 16 h under an atmosphere of hydrogen, 
filtered and concentrated.   
The residue was solved in an aqueous LiOH solution (2 mL, 2.4 mM, 4.85 µmol) was added 
and the turbid mixture was stirred for 24 h at rt. The residue was purified via RP 
chromatography (MeOH/H2O), eluated through a sodium exchange column (Dowex 50/8 
sodium form) and finally purified via size exclusion chromatography. Lyophilization from 
water/dioxane gave 4c (1.46 mg, 2.62 µM, 58 %) as a white fluffy foam. 
Rf (DCM/MeOH/H2O 10:5:0.4) 0.30; [α]D22 -74.7 (c 0.28, H2O); 1H NMR (500.1 MHz, 
D2O): δ = 5.13 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.89 - 4.75 (m, Fuc-H5), 4.62 (d, J = 7.9 Hz, 
1H, Gal-H1), 4.27 (dd, J = 12.4, 2.3 Hz, 1H, R-H1), 4.23 - 4.19 (m, J = 3.1 Hz, 1H, Gal-
H4), 4.19 - 4.13 (m, 1H, R-H4), 4.02 (dd, J = 9.7, 3.2 Hz, 1H, Gal-H3), 3.93 (dd, J = 10.6, 
3.3 Hz, 1H, Fuc-H3), 3.90 – 3.71 (m, 6H, R-H4', Fuc-H4, Fuc-H2, MeCy-H1, Gal-H6, Gal-
H6'), 3.62 (t, J = 5.9 Hz, 1H, Gal-H5), 3.40 (dd, J = 9.5, 8.0 Hz, 1H, Gal-H2), 3.27 (t, J = 
9.6 Hz, 1H, MeCy-H2), 2.20 – 2.06 (m, 2H, MeCy-H6, R-H2), 2.03 – 1.87 (m, 2H, R-H3, 
R-H2'), 1.73 – 1.55 (m, 4H, R-H3, MeCy-H4, MeCy-H5, MeCy-H3), 1.34 – 1.24 (m, 2H, 
MeCy-H5', MeCy-H6'), 1.21 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.11 (d, J = 6.3 Hz, 3H), 1.16 - 
1.06 (m, MeCy-H4'); 13C NMR (125.8 MHz, D2O): δ = 99.6 (Fuc-C1), 98.5 (Gal-C1), 84.6 
(MeCy-C2), 80.8 (R-C1), 79.9 (Gal-C2), 79.2 (Gal-C3), 79.2 (Gal-C4), 76.4 (Gal-C3), 75.9 
(Gal-C5), 72.9 (Fuc-C4), 70.6 (R-C4), 70.2 (Fuc-C3), 69.1 (Fuc-C2), 67.3 (Fuc-C5), 62.5 
(Gal-C6), 39.8 (MeCy-C3), 34.0 (Cy-C4), 30.9 (MeCy-C6), 28.0 (R-C3), 25.2 (R-C2), 23.5 
(MeCy-C5), 19.2 (MeCy-Me), 16.5 (Fuc-C6); ESI-MS: m/z: Calcd for C24H40NaO13 
[M+H]+: 559.2367, found: 559.2365. 
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Supplementary Figures 
 
 
SFigure 1. 13C-1H HSQC of 3 recorded at 750 MHz and 275 K with assignments. The aliphatic region is 
shown on top, the carbohydrate region at the bottom. 
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SFigure 2. Chemical shift assignment of cyclohexane resonances using a 13C-1H HMQC-COSY. The small 
unassigned signals originating from two-bond scalar couplings 2JCH are ideally suited to assign the 
cyclohexane resonances by following the dotted lines. Resonances from axial protons were distinguished from 
equatorial ones by their strength of 3JHH scalar coupling constants and NOE signal intensities (data not shown). 
As is typical the axial resonances are more upfield than the equatorial ones. 
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SFigure 3. a) Acid orientation / core conformation blot of 3: crystal structure of sLex (black cross),3 molecular 
dynamics simulations (blue) and the ensemble of 20 solution conformations determined by NMR at 277 K at 
900 MHz high field (red crosses). b) Schematic overview of core conformation (= relativ orientation of D-
galactose and L-fucose) and acid orientation (= tilting angle of the carboxylic acid relative to the core). 
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SFigure 4. Confirmation of the three-dimensional solution structure by chemical shift deviations caused by 
the benzoyl group. a) Overlay of HSQC spectra of compound 3 (red) and compound 2 (blue). The region with 
signals of the methyl-cyclohexane diol mimic and the (S)-cyclohexan lactic acid are shown. Corresponding 
signals are connected by dotted lines. The benzoyl group causes a large variety of upfield chemical shift 
changes, which are typically caused by ring current effects on protons perpendicular to the aromatic ring 
plane. b) Histogramm of the chemical shift deviations of cyclohexane protons caused by the benzoyl group. c) 
Representative of the obtained structural ensemble by solution NMR spectroscopy. Relevant protons in the 
proximity of the aromatic ring are labeled. The closest protons perpendicular to the aromatic plane are 
expected to experience the largest ring current effect and indeed they show the largest chemical shift 
perturbation. 
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SFigure 5. 13C-1H HSQC of 2 recorded at 750 MHz and 275 K with assignments. The aliphatic region is 
shown on top, the carbohydrate region at the bottom. 
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SFigure 6. The predicted pre-organization of pharmacophores of 1, 2, 3, 4a-c, 7 and S14-S16 is determined in 
acid orientation/core conformation plots (from light blue (not likely) to dark blue (most likely)). The acid 
orientation of sLex (1) in the crystal structure is highlighted by a red cross.3  
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Supplementary Tables 
STable 1. Intra and interresidual NOEs of 3 at 275K with the corresponding calculated 1H-1H distances. 
 
 a 
Only one cross-peak was used because of artifacts or overlap. 
b  The 1H-1H distances were calculated from experimentally obtained NOE intensities using the H3a-H3b 
cross-peak of Cyc as a reference with a distance of 1.77 Å assuming a r-6 dependence of the NOE 
intensities. 
 d Reference restraints for the 13C-filtered-filtered NOESY. 
 e,f Signal to noise ratios from cross-peaks involving methyl- or methylene protons with coinciding f 
  requencies were divided by 3 or 2, respectively 
 
proton pair 
S/N of 
NOEs 
cross peaks 
Corresponding 
1H-1H distanceb 
 
proton pair 
S/N of NOEs 
cross peaks 
Corresponding 
1H-1H distanceb 
Intra    Intra   
Lac H2-H3ax 476 2.6  Cyc H3eq-H5ax 167 3.1 
Lac H2-H3eq 943 2.3  Cyc H3ax-H4eq 848 2.4 
Lac H2-H4eq 187 3.0  Cyc H5ax-H7 303f 2.8 
Lac H3ax-H4eq 441 2.6  Fuc H1-H2 798 2.4 
Lac H4-H6ax 268a 2.9  Fuc H1-H3 113a 3.3 
Lac H4-H8ax 231a 2.9  Fuc H3-H5 962 2.3 
Lac H3ax-H5ax 312 2.8  Fuc H4-H5 1494 2.1 
Lac H3eq-H5ax 407 2.7  Inter   
Lac H5ax-H6ax 341 2.7  Lac H9eq-Gal H3 223 2.9 
Lac H7ax-H8eq 413a 2.7  Lac H4-Bz H2 88a,e 3.4 
Lac H2-H9eq 1012 2.3  Lac H6ax-Bz H2 56a,e 3.7 
Lac H2-H9ax 261 2.9  Lac H8eq-Bz H2 84a,e 3.5 
Lac H3ax-H9ax 102 3.4  Lac H8ax-Bz H2 114a,e 3.3 
Lac H7ax-H9ax 335 2.7  Lac H9eq-Bz H2 80a,e 3.5 
Gal H1-H5 1271 2.2  Gal H1-Cyc H2 1221 2.2 
Gal H1-H2 277 2.8  Gal H1-Cyc H3a 969 2.3 
Gal H1-H3 541 2.5  Gal H1-Cyc H3b 167 3.1 
Gal H2-H3 198a 3.0  Gal H2-Fuc H5 387 2.7 
Gal H4-H5 1568a 2.1  Gal H2-Fuc H6 241f 2.9 
Cyc H1-H2 290 2.8  Gal H6-Fuc H6 62 e,f 3.6 
Cyc H1-H3eq 146 3.2  Gal H1-Bz H2 57a,e 3.7 
Cyc H1-H3ax 712 2.4  Bz H2-Cyc H3eq 157e 3.1 
Cyc H1-H5ax 612 2.5  Bz H2-Cyc H3ax 123a,e 3.2 
Cyc H1-H7 424f 2.6  Fuc H1-Cyc H1 1576 2.1 
Cyc H2-H3 929 2.3  Fuc H1-Cyc H6 173 3.1 
Cyc H2-H4ax 625a 2.5  Fuc H1-Cyc H7 777f 2.4 
Cyc H3eq-H3ax 4648d 1.77  Fuc H5-Cyc H1 173a 3.1 
Cyc H3eq-H4eq 894 2.3  Fuc H5-Cyc H2 140 3.2 
Cyc H3eq-H4ax 742 2.4     
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STable 2. NMR structure determination statistics of 3 in solution. 
 
*       for an ensemble of 20 refined structures 
**     phi is defined as O5-C1-Ox-C'x and psi as C1-Ox-C'x-C'x-1 
†       extracted by XtalView 
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 Structure of 3 
NMR distance and dihedral restraints  
Total NOE restraints 56 
Intra-residue 36 
Inter-residue 20 
Sequential (|i – j| = 1) 10 
Nonsequential (|i – j| > 1 ) 10 
  
Structure statistics *  
Violations (mean and s.d.)  
Number of distance constraint violations > 0.1 Å 0±0 
Max. distance constraint violation [Å] 0.10±0.01 
Deviations from idealized geometry  
Bond lengths [Å] 0.0125±0.0002 
Bond angles [º] 1.54±0.03 
Heavy atom RMSD to mean [Å] 0.79±0.30 
  
Glycosidic linkage phi / psi angles **  
Fuca(1,1)CycMe -68.9±0.8/-100.5±0.4 
(crystal: -78.0/-101.4) 
Galb(1,2)CycMe -75.1±4.8/151.3±2.3 
(crystal: -99.8/142.4) 
Acid Orientation 82.0±6.4 
(crystal: 120.5) 
Core -37.8±3.6 
(crystal: -41.6) 
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3.2.1.2 Additional experiments: Ring closing metathesis trials for amide 
            and ester series 
   
Contributions 
      • Manuscript preparation 
     • Compound synthesis  
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Abstract 
Analogue to the ether macrocycles (chapter 3.2.1), we planned to synthesize and evaluate a 
series of lactons and lactams. The rigidity of those compounds should be even higher than 
that of the corresponding ether series. Furthermore, molecular dynamic (MD) calculations 
predicted the orientation of the acid pharmacophore in the bioactive conformation. To take 
advantage of our experience obtained from the cyclic ether derivatives, we decided to follow 
a ring closing metathesis synthesis route. But in contrast to the ether series the ring closing 
metathesis (RCM) strategy was not successful and led to oligomerization. MD simulations 
led to the conclusion, that an unfavorable orientation of the intramolecular olefins in the 
reactants was responsible for failure of the RCM, and instead intermolecular cross 
metathesis (CM) and acyclic diene metathesis polymerization reactions (ADMET) were 
preferred. 
 
 
Figure 1. Acid orientation (y-axis) and core conformation (x-axis) plots for sLex (1) (a), compound 3 (c) and 
lactam 34 (b) and lactone 35 (d). 
 
Introduction 
In chapter 3.2.1 we synthesized a series of ether macrocycles, where the acid pharmacophore 
is incorporated in a ring system and thus, locked in the bioactive conformation. Due to the 
formation of the 8- to 10-membered rings to the D-galactose moiety with its defined chair 
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conformation, the conformational flexibility is restricted. A further stabilizing effect 
originated from an amide bond or ketone functionality in the ring system could further 
improve pre-organization and thus, guarantee a maximal entropic gain upon binding. But 
this almost total loss of flexibility could also turn out as disadvantage, when the acid cannot 
adjust properly to the selectin upon binding. The additional hydrogen bond acceptors and 
donors contributed by the amide (or ketone) functionality could also turn out to be a 
disadvantage regarding the pharmacokinetic properties, e.g. oral availability. However, MD 
analysis clearly indicated that acid orientation and also core conformation were excellent 
displayed (Figure 1). 
 
Results and Discussion 
Thioglycoside 361 was deacetylated using Zemplén conditions. For benzylation in the 6-
position, a benzylidene acetal was introduced, followed by selective ring opening with 
MeNH2•BH3 and subsequent acetylation. This gave glycosyldonor 37 in 60 % over 4 steps. 
Glycosylation of pseudodisaccharide 152 by DMTST mediated activation of glycosyldonor 
37, followed by deacetylation gave diol 38, which serves as precursor for RCM substrate 39. 
Bu3SnH mediated alloc deprotection of 38 and subsequent reaction of the amino group with 
acryloyl chloride gave acrylamide 40. A selective tin-mediated alkylation of the hydroxy 
group in the 3-position of the D-galactose moiety with triflate 21 (chapter 3.2.1) afforded 
olefin 41, which was used as substrate for RCM trials. As control the alloc protected diol 38 
was alkylated with triflate 21. In the resulting compound 39 the terminal olefin of the alloc 
protection group served as substrate for the RCM. The prolonged size, accompanied with 
increased flexibility of the olefin moiety and the absence of an electron withdrawing group 
in immediate proximity to the alkene, should allow a successful RCM.  
The substrate for the lactone series was synthesized from starting material 30 (see chapter 
3.2.1). In analogy to the amide series, the 3’-position of the D-galactose residue of 30 was 
alkylated with triflate 21. Alcohol 31 was converted to acrylate 42 by esterification with 
acryloyl chloride.  
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Scheme 1. a.) (i) NaOMe, MeOH; (ii) PhCH(OMe)2, MeCN; (iii) MeNH2•BH3, AlCl3, H2O, THF; (iv) Ac2O, 
pyridine, 47 % over 4 steps; b.) DMTST, DCM, 4Å mol.sieves, ; c.) NaOMe, MeOH, 25% over 2 steps; d.) (i) 
Bu2SnO, MeOH; (ii) CsF, 21, DCM 88%; e.) (i) Bu4SnH, DCM, ; (i) Acroyloylchloride, 69%; f.) (i) Bu2SnO, 
MeOH; (ii) CsF, triflate 21, DCM, 65%; h.) (i) Bu2SnO, MeOH; (ii) CsF, triflate 21, DCM, 85%; i.) Acryloyl 
chloride, Et3N, 44%. 
 
For RCM reaction with amide 41 different catalysts, reaction times and temperatures were 
explored (Table 1). The olefin metathesis with Grubbs 1st generation catalyst 433 was not 
successful in DCM, although 0.5 equivalents of catalyst at 40°C were used. The Grubbs’ 2nd 
generation catalyst 444, with higher affinity did also not lead to product formation with 
different amounts of catalyst at 22°C. However, at 40°C, substrate 41 reacted to a series of 
side products, which were verified as oligomers of 41 by mass spectrometry. A similar result 
was observed with the Grubbs-Hoveyda catalyst 455. Oligorimization was also observed 
with acrylate 42 and 2nd generation catalyst 43 at 40°C.  
Surprisingly, the alloc protected trisaccharide 39, which was assumed to be optimally suited 
for RCM, decomposed. According to MS analysis, no product formation occurred.  
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Table 1. (a) Reaction conditions for RCM trials in DCM; (b) Ruthenium(II) based Grubbs’ 1st generation   
catalyst 433, Grubbs’ 2nd generation catalyst 444 and 2nd generation Grubbs-Hoveyda catalyst 445.  
 
Discussion 
It is known that acyclic diene metathesis polymerization (ADMET) is a competitive reaction 
to the RCM.6 To explain the failure of RCM in our ester and amide trials we 
 
Scheme 2. Proposed mechanism for the olefin metathesis of compound 11 with Grubbs 2nd Gen. catalyst 444. 
a b 
Reactant Catalyst Time Temperature Product 
/ ratio  [h] [°C] 
41 43 / 0.5 eq 24 40 no reaction 
41 44 / 0.1 eq 24 22 no reaction 
41 44 / 0.25 eq 24 22 no reaction 
41 44 / 0.1 eq 3 40 polymerisation 
41 45 / 0.1 eq 3 40 polymerisation 
42 44 / 0.1 eq 3 40 polymerisation 
39 44/ 0.1 eq 3 40 decomposition 
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propose a mechanism for the olefin metathesis for amide 41 with Grubbs 2nd generation 
catalyst 4 (Scheme 2). The substrate 41 is characterized by an electron rich type 1 olefin and 
a electron poor type 2 olefin, classified by the empirical model for olefin reactivity in cross 
metathesis published by Chatterjee et al..7 Type 1 olefins are categorized as those able to 
undergo a rapid homodimerization and which homodimers can participate in cross 
metathesis (CM) as well as their terminal olefin counterpart, whereas type 2 olefins 
homodimerize slowly, and unlike Type I olefins, their homodimers can only be sparingly 
consumed in subsequent metathesis reactions.7 The initial step is characterized by trialkyl 
phosphin dissociation of catalysator 44, followed by coordination of the electron rich type 1 
olefin of the substrate and formation of a metallacyclobutane intermediate 46. 
Cycloreversion yields the key intermediate, the alkylidene 47. Compound 47 can either act 
as substrate for RCM or an ADMET reaction. We propose that the reason for failure of 
RCM is the reduced flexibility of the amide bond. In contrast, the flexible ether group 
readily underwent RCM (chapter 3.2.1). Thus, we propose that the probability for the two 
double bonds to be in RCM-distance is low, leading predominantly to the intermolecular 
CM in this compound class. The dimerisation of two electron rich type 1 alkene (47→51) is 
more likely but reversible.  
 
  
Figure 2. MD simulation of distance distribution between highlighted sp2-hybridized atoms involved in olefin 
metathesis reaction in allylether 55 (red), acrylate 42 (blue) and acrylamide 41 (green) in octane at 303 K.  
Dimer 53 is rarely formed by CM between a type 1 and type 2 olefin, and would rather act 
as substrate for continuous CM than do the reverse reaction to 47, as the terminal type 1 
olefin is more reactive than the electron poor type 2 olefin undergoing dimerization (Scheme 
2), the first step in the acyclic diene metathesis polymerization. We proposed a similar 
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mechanism for the ester 42, caused by rigification of the metathesis substrate due to the 
carbonyl group. 
To support our hypothesis, that the probability of vicinal proximity between the 
intramolecular olefins is unfavorable for RCM, we performed a series of MD studies. We 
analyzed the distance of the carbon atoms involved in the metathesis reaction at 303 K in 
octanol (the dielectricity constant for octanol and DCM is similar) for ether 55, ester 42 and 
amide 41 (Figure 4). As resumed, the distance distribution of the ether 55 is significantly 
shifted to shorter distances. On the other hand, distances closer than 5.5 Å are hardly 
observed for compound 42 and 41, probably due to the rigidifying carbonyl and amide bond. 
Therefore, the energy barrier to arrange the two olefins in an optimal distance for RCM, 
would be higher for 41 and 42 compared to more flexible substrates like 55, and thus 
benefits CM and ADMET.   
 
Methods 
Molecular modeling. The 3D structure of the carbohydrate mimic molecules was built in 
the Maestro8 molecular modeling environment and a conformational analysis was performed 
using Macromodel9 by performing 5000 steps of the mixed torsional/low-mode sampling in 
combination with the OPLS-2005 force-field in implicit solvent conditions (water). 
Global minimum identified in the conformational search was then placed in a periodic 
boundary system (cube, side length 40.0 Å) filled with explicit water molecules (TIP3P 
parametrization). The system was minimized and a simulated annealing simulation (gradual 
heating of the system to the temperature of 400 K in 330 ps followed by slow gradual 
cooling to 300 K in 500 ps) was performed in Desmond10,11 in order to bring the system into 
equilibrium. The production phase molecular dynamics simulation of the total duration of 48 
ns was performed. Two critical structural descriptors – the core conformation and the acid 
orientation – were monitored every 4.8 ps (10 000 data points were saved). 
The pre-organization of the mimic molecule was evaluated by plotting the frequency of the 
two critical parameters in a two-dimensional color-coded plot using an in-house computer 
program. 
 
General methods. Commercial materials (Sigma-Aldrich) were used without further 
purification, solvents were reagent grade (Acros). CH2Cl2 and MeOH were dried by passing 
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through an Al2O3 (Fluka, type 5016 A basic) column. DMF extra dry (Acros) was used as is. 
All reactions were performed in oven dried glassware under an atmosphere of argon.  
1H and 13C NMR spectra were recorded on a Bruker Avance DMX-500 at room temperature. 
Chemical shifts are reported in ppm and referenced to TMS using residual solvent peaks.12 
For complex molecules the following prefixes were used: Fuc (fucose), Gal (galactose) and 
GlcNAc (N-acetylglucosamine). The coupling constants (J) are reported in Hertz (Hz). 
Analytical TLC was performed on Merck silica gel 60 F254 glass plates and visualized by 
UV light and charring with a molybdate solution (a 0.02 M solution of ammonium cerium 
sulfate dihydrate and ammonium molybdate tetrahydrate in aq. 10% H2SO4) by heating for 5 
min at 140°C. Column chromatography was performed on a CombiFlash Companion 
(Teledyne-ISCO, Inc.) using RediSep® normal phase disposable flash columns (silica gel). 
Reversed phase chromatography was carried out with LiChroprep®RP-18 (Merck, 40-63 
µm). Optical rotations were determined on a Perkin-Elmer Polarimeter 341. Low resolution 
mass spectra were measured on a Waters micromass ZQ. High resolution mass spectra 
(HRMS) were obtained on a micrOTOF spectrometer (Bruker Daltonics, Germany) 
equipped with a TOF hexapole detector. MALDI-TOF and ESI-MS glycoprotein analyses 
were recorded by the Functional Genomic Center Zurich (FGCZ). VIVASPIN® 500 
ultrafiltration tubes with 10000 MWCO, 10 kDa molecular weight cutoff PES membrane, 
and ZelluTrans/Roth dialysis membranes MWCO 8000-10000 were used for glycoprotein 
concentration and dialysis. 
 
Phenyl 3,4-O-acetyl-6-O-benzyl-2-deoxy-2-[((2-propen-1-yl-oxy)carbonyl)amino]-1-
thio-β-D-galactopyranoside (37) 
 
 
Compound 36 (7.00 g, 14.5 µmol) was suspended in MeOH (120 mL). Sodium (50.0 mg, 
2.17 µmol) was added and the resulting solution was stirred for 18 h at rt. AcOH was added 
(250 µL) and the solvent was removed in vacuo. The residue was suspended MeCN (450 
mL) and camphorsulfonic acid (1.25 g, 5.38 mmol) and C5H6CH(OMe)2 (6.54 ml, 43.6 
µmol) were added. The resulting solution was stirred for 24 h at rt and quenched with 1.3 ml 
O
OBnAcO
AcO
NH
SPh
O
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Et3N. Volatiles were evaporated and the crude product was purified by flash chromatograph 
(petroleum ether/EE 2:1→1:3). 2.25 g (5.07 µmol) of the resulting benzylidene acetal were 
dissolved in THF (100 mL) and Me3N•BH3 (1.48 g, 20.3 mmol), AlCl3 (4.09 g, 30.4 mmol) 
and H2O (183 µl, 10.2 mmol) were added. The turbid reaction mixture was stirred for 16 h at 
ambient. An aq. solution of HCl (200 mL, 0.5 M) was added and extracted with EtOAc (2 x 
200 mL). The combined organic layers were washed with brine (150 mL), dried and 
evaporated in vacuo. The crude product was purified by flash chromatography (petroleum 
ether/EtOAc 1:2). The resulting alcohol was dissolved in pyridine (125 mL) and acetic 
anhydride (13.8 mmol, 1.31 ml) was added. The solution was stirred for 48 h at rt. The 
reaction mixture was quenched with MeOH and the solvents removed under reduced 
pressure. Column chromatography (petroleum ether/EtOAc 3:2) gave 37 (1.39 g, 3.1 mmol, 
47 % over 4 steps) as a white solid.    
Rf (petroleum ether/EtOAc 3:2) 0.35; [α]D22 -24.2 (c 2.3, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.55 – 7.50 (m, 2H, Ar-H), 7.37 – 7.26 (m, 8H, Ar-H), 5.95 – 5.86 (m, 1H, 
CH=CH2), 5.48 – 5.43 (m, 1H, Gal-H4), 5.33 – 5.27 (m, 1H, CH=CH2), 5.24 – 5.19 (m, 1H, 
CH=CH2), 5.15 – 5.08 (m, 1H, Gal-H3), 4.90 – 4.82 (m, 1H, Gal-H1), 4.53 (d, J = 11.8 Hz, 
1H, Ph-CH2), 4.42 (d, J = 11.8 Hz, 1H, Ph-CH2), 3.94 (m, 1H, Gal-H2), 3.88 (t, J = 6.3 Hz, 
1H, Gal-H5), 3.60 (dd, J = 9.7, 6.3 Hz, 1H, Gal-H6), 3.50 (dd, J = 9.7, 6.3 Hz, 1H, Gal-H6'), 
2.05 (s, 3H, Me), 1.99 (s, 3H, Me); 13C NMR (126 MHz, CDCl3): δ = 170.5, 170.3, 155.7, 
137.8, 132.7, 132.2, 132.2, 129.1 – 128.0 (8H), 117.8, 87.9, 76.2, 73.7, 71.6, 68.1, 67.6, 
66.0, 51.4, 20.8, 20.8; ESI-MS: m/z: Calcd for C53H62NaO13 [M+Na]+: 929.41, found: 
929.45. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-2-deoxy-2-[((2-propen-1-yl-oxy)carbonyl)amino]-β-D-
galactopyranoside (38) 
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Disaccharide mimic 15 (979 mg, 1.79 mmol), galactosyldonor 37 (1.13 g, 2.15 mmol) and 4 
Å molecular sieves (8 g) were suspended in DCM (50 mL) and stirred for 4 h at rt. DMTST 
(1.39 g, 5.38 mmol) and 4Å molecular sieves (4 g) was suspended in DCM (20 mL) and 
stirred for 4 h in a second reaction vessel for 4 h at rt and subsequently added via syringe to 
the reaction mixture. The suspension was stirred for 20 h at rt, filtered and extracted with a 
sat. aq. NaHCO3 solution (50 mL) and water (50 mL). The combined aq. phases were 
extracted with DCM (3 x 30 mL). The combined organic layers were dried, evaporated and 
purified by flash chromatography (petroleum ether/EtOAc 3:2). The resulting trisaccharide 
mimic was suspended in MeOH (20 mL) and sodium (1.2 mg, 53.1 µmol) was added. The 
resulting solution was stirred for 16 h, quenched with a few drops of AcOH and the solvent 
was removed under reduced pressure. The crude product was purified by flash 
chromatography to give 38 (505 mg, 572 µmol, 32 % over 2 steps) as a white solide. 
Rf (petroleum ether/EtOAc 1:4) 0.62; [α]D22 -34.4 (c 0.90, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.36 – 7.19 (m, 20H, Ar-H), 5.94 – 5.84 (m, 1H, CH2=CH-CH2-O), 5.33 – 5.27 
(m, 1H, CH2=CH-CH2-O), 5.24 – 5.19 (m, 1H, CH2=CH-CH2-O), 5.06 (d, J = 3.3 Hz, 1H, 
Fuc-H1), 4.92 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.82 (d, J = 11.6 Hz, 1H, Ph-CH2), 4.76 – 4.64 
(m, 4H, Fuc-H5, 3x Ph-CH2), 4.60 – 4.49 (m, 5H, 3x Ph-CH2, 2x CH2=CH-CH2-O), 4.45 (d, 
J = 6.8 Hz, 1H, Gal-H1), 4.08 – 3.98 (m, 2H, Fuc-H2, Fuc-H3), 3.98 – 3.94 (m, 1H, Gal-
H4), 3.87 – 3.74 (m, 2H, Gal-H3, Gal-H6), 3.74 – 3.66 (m, 3H, Gal-H6', Fuc-H4, MeCy-
H1), 3.62 – 3.56 (m, 1H, Gal-H5), 3.45 – 3.38 (m, 1H, Gal-H2), 3.22 (t, J = 9.1 Hz, 1H, 
MeCy-H1), 2.02 – 1.94 (m, 1H, MeCy-H6), 1.65 – 1.53 (m, 3H, MeCy-H3, MeCy-H4, 
MeCy-H5), 1.23 – 1.14 (m, 2H, MeCy-H6', MeCy-H5'), 1.12 (d, J = 6.5 Hz, 3H, Fuc-H6), 
1.09 (d, J = 6.5 Hz, 3H, MeCy-Me), 1.06 – 0.95 (m, 1H, MeCy-H4'); 13C NMR (125.8 MHz, 
CDCl3): δ = 171.3, 139.2, 139.1, 138.7, 137.9, 132.5, 128.6 - 127.4 (20C), 118.4, 98.4, 82.7, 
80.2, 78.5, 76.5, 75.1, 74.4, 73.7, 73.2, 72.6, 69.3, 68.1, 66.4, 66.4, 60.5, 55.8, 39.0, 33.4, 
30.7, 22.9, 21.1, 18.9, 16.9, 14.3; ESI-MS: m/z: Calcd for C51H63NNaO12 [M+Na]+: 904.42, 
found: 904.28. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-2-deoxy-2-[((2-propen-1-yl-oxy)carbonyl)amino]-3-O-((R)-1-
methoxy-1-oxo-pent-4-en-2-yl)-β-D-galactopyranoside (39) 
 
Chapter 3.2.1.2 - Manuscript 2 
 
 197 
 
Alcohol 38 (21.0 mg, 23.8 µmol) and Bu2SnO (17.8 mg, 71.4 µmol) were dried for 16 h at 
rt, suspended in MeOH (2 mL) and refluxed for 2 h. The resulting solution was concentrated 
and coevaporated with toluene. The tin acetal was dried for 16 h at high vacuo, solved in 
freshly dried (Al2O3 column) DME (1.5 mL) and added to CsF (dried for 2 h at high vacuo 
at 100°C, 6.5 mg, 42.9 µmol). Triflate 21 (18.7 mg, 71.4 µmol) was added and the 
suspension was stirred for 16 h at rt. A 20% solution of KF (in 1M KH2PO4 solution, 2 mL) 
was added. After stirring for 1 h at rt DCM (10 mL) was added and the aq. phase was 
extracted with DCM (2 x 10 ml). The combined organic layers were dried (Na2SO4) and 
evaporated under reduced pressure. Column chromatography on silica (petroleum 
ether/EtOAc 2:1) afforded 39 (20.1 mg, 20.8 µmol, 88 %) as a white solid.  
Rf (petroleum ether/EtOAc 3:2) 0.63; 1H NMR (500.1 MHz, CDCl3): δ = 7.39 – 7.20 (m, 
20H, Ar-H), 5.97 – 5.86 (m, 1H, R-H4), 5.86 – 5.78 (m, 1H, CH2=CH-CH2-O), 5.33 – 5.27 
(m, 1H, CH2=CH-CH2-O), 5.23 – 5.12 (m, 4H, CH2=CH-CH2-O, R-H5, R-H5', Gal-H1), 
5.05 (d, J = 3.5 Hz, 1H, Fuc-H1), 4.94 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.85 – 4.76 (m, 2H, 
Fuc-H5, Ph-CH2), 4.76 – 4.56 (m, 6H, 4x Ph-CH2, Gal-H2, CH2=CH-CH2-O), 4.52 – 4.47 
(m, 3H, 2x Ph-CH2, CH2=CH-CH2-O), 4.09 – 3.96 (m, 4H, R-H2, Gal-H3, Fuc-H2, Fuc-
H3), 3.79 – 3.73 (m, 1H, Gal-H6), 3.73 – 3.69 (m, 4H, Fuc-H4, Me), 3.65 – 3.60 (m, 1H, 
Gal-H6'), 3.60 – 3.54 (m, 1H, MeCy-H1), 3.54 – 3.48 (m, 1H, Gal-H5), 3.22 (t, J = 9.1 Hz, 
1H, MeCy-H2), 2.59 – 2.51 (m, 1H, R-H3), 2.50 – 2.42 (m, 1H, R-H3'), 1.94 – 1.87 (m, 1H, 
MeCy-H6), 1.68 – 1.60 (m, 3H, MeCy-H3, MeCy-H4, MeCy-H5), 1.33 – 1.16 (m, 2H, 
MeCy-H5', MeCy-H6'), 1.13 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.08 (d, J = 6.5 Hz, 3H, MeCy-
Me), 1.06 – 0.95 (m, 1H, MeCy-H4'); 13C NMR (125.8 MHz, CDCl3): δ = 172.2, 160.3, 
139.4, 139.2, 138.8, 138.1, 133.6, 133.1, 128.7 - 127.4 (20C), 119.5, 117.6, 98.3, 82.5, 80.4, 
79.6, 78.6, 76.5, 75.1, 74.4, 73.7, 72.6, 72.2, 68.6, 66.3, 65.5, 64.7, 52.3, 39.1, 37.5, 33.5, 
33.4, 32.1, 31.1, 31.1, 30.8, 24.9, 22.8, 19.0, 17.0; ESI-MS: m/z: Calcd for C57H71NNaO14 
[M+Na]+: 1016.48, found: 1016.62. 
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(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-2-deoxy-2-[(1-oxo-prop-2-en-1-yl)amino]-β-D-galactopyranoside 
(40) 
 
Compound 38 (63.8 mg, 72.3 µmol) was dissolved in DCM (10 mL) and PPh4 (1.7 mg, 1.44 
µmol) and Bu3SnH (23.2 mg, 79.6 µmol) in DCM (1 mL) was added. The solution was 
stirred for 30 min and the product purified by a short column of silica (DCM/MeOH 10:3). 
The resulting amine was dissolved in DCM (10 mL) and Et3N (37 µl, 265 µmol) and 
acryloylchloride (8.6 µl, 106 µmol) were added at 0°C. The reaction mixture was stirred for 
2.5 h at this temperature. The solvent was removed under reduced pressure and purified by 
flash chromatography (DCM/MeOH 10:1) to yield 40 (58.2 mg, 68.3 µmol, 57 %) as a white 
solid.   
Rf (EtOAc) 0.32; [α]D22 -30.9 (c 0.33, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 7.33-7.22 
(m, 20H, Ar-H), 6.28 (d, 1H, J = 16.9, 0.8 Hz, 1H, CH2=CHCO), 6.09 (dd, J = 10.3, 16.9 
Hz, 1H, CH2=CH-CO), 5.70 (dd, J = 10.4, 0.8 Hz, 1H, CH2=CH-CO), 5.03 (d, J = 3.3, 1H, 
Fuc-H1), 4.91 (d, J = 11.4 Hz, 1H, PhCH2), 4.81 (d, J = 11.6 Hz, 1H, Ph-CH2), 4.73-4.64 
(m, 4H, 3x Ph-CH2, Fuc-H5), 4.59-4.48 (m, 3H, 3x Ph-CH2), 4.47 (d, J = 8.3 Hz, 1H Gal-
H1), 4.05 (dd, J = 10.3 Hz, 3.4 Hz, 1H, Fuc-H2), 4.01 (dd, J = 10.3 Hz, 2.4 Hz, 1H, Fuc-
H3), 3.96 (d, J = 2.4 Hz, 1H, Gal-H4), 3.85-3.78 (m, 2H, Gal-H3, Gal-H6), 3.76-3.68 (m, 
3H, Fuc-H4, MeCy-H1, Gal-H6'), 3.63-3.53 (m, 2H, Gal-H2, Gal-H5), 3.2 (t, 1H, J = 9.3 
Hz, MeCy-H1), 2.05-1.98 (m, 1H, MeCy-H6), 1.67-1.55 (m, 3H, MeCy-H3, MeCy-H4, 
MeCy-H5), 1.30-1.16 (m, 2, MeCy-H6', MeCy-H5'), 1.10-1.06 (d, J = 6.4 Hz, 6H, Fuc-H6, 
MeCy-Me), 1.06 - 0.86 (m, 1H, MeCy-H4') ppm. 13C NMR (125.8 MHz, CDCl3): δ = 168.1, 
139.2, 139.2, 138.7, 138.2, 130.3, 128.8 – 127.4 (21C), 98.6, 97.7, 82.9, 80.3, 78.6, 78.4, 
76.4, 75.2, 74.6, 73.9, 73.7, 72.7, 69.4, 67.9, 66.6, 56.6, 39.1, 33.5, 31.0, 29.9, 23.1, 19.0, 
17.0, 14.4; ESI-MS: m/z: Calcd for C50H61NNaO11 [M+Na]+: 874.41, found: 874.46. 
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(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-2-deoxy-2-[(1-oxo-prop-2-en-1-yl)amino]-3-O-((R)-1-methoxy-1-
oxo-pent-4-en-2-yl)-β-D-galactopyranoside (41) 
 
Compound 40 (82.4 mg, 96.7 µmol) and Bu2SnO (72.2 mg, 290 µmol) were dried for 4 h at 
rt and suspended in MeOH (6 mL). The reaction mixture was refluxed for 2 h, concentrated 
under reduced pressure and coevaporated with toluene. The stannyl acetal was dried for 16 h 
under high vacuum, dissolved in freshly dried DME (1.5 mL) and added to CsF (dried for 2 
h at high vacuo at 100°C, 26.4 mg, 174 µmol). Triflate 21 (76.0 mg, 290 µmol) was added 
and the suspension was stirred for 18 h at rt. A 20% solution of KF (in 1M KH2PO4 solution, 
2 mL) was added and the resulting mixture stirring for 1 h at rt. DCM (10 mL) was added 
and the aqueous phase was extracted with DCM (2 x 15 mL). The combined organic layers 
were dried (Na2SO4) and evaporated under reduced pressure. The crude product was purified 
by flash chromatography (petroleum ether/EtOAc 2:1) and afforded 41 (49.0 mg, 50.8 µmol 
(15.7 mg of reactant were recovered), 65 %) as a white solid. 
Rf (petroleum ether/EtOAc 1:1) 0.61; [α]D22 -23.1 (c 0.45, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.38 – 7.20 (m, 20H), 6.25 – 6.20 (m, 1H, CH2=CHCO), 6.14 – 6.07 (m, 1H, 
CH2=CH-CO), 6.00 (d, J = 6.7 Hz, 1H, NH), 5.86 – 5.76 (m, 1H, R-H4), 5.64 – 5.60 (m, 1H, 
CH2=CH-CO), 5.23 – 5.13 (m, 2H, R-H5, R-H5'), 5.04 (d, J = 3.4 Hz, 1H, Fuc-H1), 4.98 – 
4.92 (m, 2H, Gal-H1, Ph-CH2), 4.86 – 4.77 (m, 3H, Fuc-H5, Ph-CH2), 4.75 – 4.62 (m, 5H, 
3x Ph-CH2), 4.60 (d, J = 11.5 Hz, 1H, Ph-CH2), 4.51 (s, 2H, 2x Ph-CH2), 4.24 (dd, J = 10.5, 
2.8 Hz, 1H, Gal-H3), 4.11 – 3.96 (m, 3H, Fuc-H2, Fuc-H3, Gal-H4), 3.87 – 3.70 (m, 3H, 
Gal-H6, Fuc-H4), 3.69 – 3.62 (m, 4H, Me, Gal-H6'), 3.62 – 3.51 (m, 2H, MeCy-H1, Gal-
H5), 3.44 – 3.34 (m, 1H, Gal-H2), 3.19 (t, J = 9.1 Hz, 1H, MeCy-H2), 2.57 – 2.49 (m, 1H, 
R-H3), 2.48 – 2.39 (m, 1H, R-H3'), 1.87 (m, 1H, MeCy-H6), 1.65 – 1.49 (m, 3H, Cy-H3, 
MeCy-H4, MeCy-H5), 1.36 – 1.10 (m, 5H, MeCy-H5', MeCy-H6', Fuc-H6), 1.07 (d, J = 6.5 
Hz, 3H, MeCy-Me), 1.03 – 0.92 (m, 1H, MeCy-H4'); 13C NMR (125.8 MHz, CDCl3): δ = 
172.4, 166.4, 139.3, 139.2, 138.8, 138.1, 133.5, 131.5, 128.7 - 127.4 (21x C), 126.3, 119.5, 
98.4, 97.7, 82.7, 80.3, 79.7, 78.6, 76.6, 76.5, 75.1, 74.4, 73.7, 72.6, 72.1, 68.6, 66.3, 64.8, 
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54.5, 52.4, 39.1, 37.6, 33.5, 30.8, 23.0, 19.0, 17.1; ESI-MS: m/z: Calcd for C56H69NNaO11 
[M+Na]+: 986.47, found: 986.42. 
 
(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-methyl-cyclo-
hex-1-yl 6-O-benzyl-2-O-[(1-oxo-prop-2-en-1-yl)amino]-3-O-((R)-1-methoxy-1-oxo-
pent-4-en-2-yl)-β-D-galactopyranoside (42) 
 
 
Alcohol 31 (23.9 mg, 26.3 µmol) was dissolved in DCM (2 mL) and Et3N (9.1 µL, 65.7 
µmol) and acryloylchloride (3.3 µL, 39.4 µL) were added at 0°C. The reaction mixture was 
allowed to reach rt over 16 h. The reaction mixture was quenched with a few drops of 
MeOH and the solvent was removed under reduced pressure. The crude product was purified 
by flash chromatography (petroleum ether/EtOAc 2:1) to give 42 (11.2 mg, 11.6 µmol, 44%) 
as a white solide.    
Rf (petroleum ether/EtOAc 1:1) 0.67; [α]D22 -39.7 (c 0.27, CHCl3); 1H NMR (500.1 MHz, 
CDCl3): δ = 7.62 – 7.14 (m, 20H, Ar-H), 6.50 – 6.42 (m, 1H, CH2=CH-CO), 6.22 – 6.12 (m, 
1H, CH2=CH-CO), 5.89 – 5.77 (m, 2H, CH2=CH-CO), 5.58 (s, 1H, Ph-CH), 5.44 – 5.36 (m, 
1H, Gal-H2), 5.11 - 5.02 (m, 1H, R-H5), 5.01 – 4.92 (m, 3H, R-H5', Fuc-H5, Fuc-H1), 4.80 
(d, J = 11.7 Hz, 1H, Ph-CH2), 4.69 (d, J = 11.7 Hz, 1H, Ph-CH2), 4.58 – 4.50 (m, 3H, Gal-
H6, Gal-H6', Gal-H1), 4.38 – 4.31 (m, 2H, Gal-H4, Ph-CH2), 4.29 – 4.23 (m, 1H, R-H2), 
4.20 (d, J = 11.3 Hz, 1H, Ph-CH2), 4.09 (d, J = 12.0 Hz, 1H, Ph-CH2), 3.99 – 3.88 (m, 2H, 
Fuc-H2, Fuc-H3), 3.87 – 3.81 (m, 1H, Gal-H3), 3.62 (d, J = 11.3 Hz, 1H, Ph-CH2), 3.59 - 
3.50 (m, 4H, MeCy-H1, Me), 3.39 – 3.35 (m, 1H, Gal-H5), 3.28 – 3.18 (m, 2H, Fuc-H4, 
MeCy-H2), 2.52 – 2.39 (m, 2H, R-H3), 1.95 – 1.88 (m, 1H, MeCy-H6), 1.65 – 1.50 (m, 3H, 
MeCy-H3, MeCy-H4, MeCy-H5), 1.35 – 1.12 (m, 5H, MeCy-H6', Fuc-H6, MeCy-H5'), 1.09 
– 0.95 (m, 4H, MeCy-Me, Cy-H4'); 13C NMR (125.8 MHz, CDCl3): δ = 172.4, 164.8, 139.9, 
139.7, 138.9, 137.9, 133.3, 131.0, 129.0 - 126.1 (21H), 118.0, 100.0, 99.9, 98.39, 81.50, 
81.07, 79.9, 79.1, 77.3, 75.7, 75.7, 75.0, 74.6, 73.3, 71.3, 69.6, 69.3, 66.4, 51.9, 39.7, 37.9, 
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33.8, 31.4, 29.9, 23.5, 18.9, 16.5; ESI-MS: m/z: Calcd for C56H66NaO14 [M+Na]+: 985.44, 
found: 985.55. 
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3.2.2 Bioisosteric modification of the acid pharmacophore in cyclic selectin 
         antagonists (Manuscript) 
   
Contributions 
      • Manuscript preparation 
     • Compound synthesis  
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Abstract 
In the mammalian immune system selectins are key players in inflammation. They initiate 
the first step in leukocyte extravasation from blood to infected and inflamed tissue. An 
excessive recruitment can be observed in several acute and chronic diseases. Blocking this 
selectin mediated rolling is a promising approach to treat diseases with inflammatory 
component.  
The selectin antagonists investigated in chapter 3.2.1 showed an excellent pre-organization 
and a limited number of free rotatable bonds, which is an important parameter in the design 
of oral available drugs. But the high polar surface area and the low lipophilicity reduce the 
chance for oral availability. The replacement of polar pharmacophores by more lipophilic 
bioisosteres is a promising approach to improve the druglike properties. In this 
communication we analyzed the possibility of a replacement of the acid pharmacophore by 
bioisosteres. When the carboxylate was replaced by a methylamide a loss of affinity in an E-
selectin binding assay was observed, which is probably due to repulsions between the 
hydrogen of the amide to the methylene groups of the macrocycle, or the N-methyl group to 
the amino acids of E-selectin. These spatial limitations in our cyclic antagonist will shift the 
focus to the hydroxy pharmacophores in further bioisosteric replacement studies.   
 
Introduction 
Selectins are mammalian lectins and involved in the initial step of the recruitment 
leukocytes to the inflamed tissue. Many inflammatory diseases like asthma,1 psoriasis,2 
reperfusion injury3 and rheumatoid arthritis4 are associated with an excessive infiltration of 
leukocytes to the inflamed tissue. Furthermore, several metastatic cancers harness the 
selectin mediated extravasation mechanism from the blood vessels.5,6 Thus, selectins are an 
attractive therapeutic target.  
To predict oral availability of test compounds, there are several physicochemical and 
structural rules and filters, e.g. the Lipinski rule of 5 (RO5)7,8 or the observation that 
compounds with less than 10 free rotatable bonds and a polar surface area (PSA) smaller 
than 140 Å2 are beneficial for oral availability.9 The cyclic selectin antagonists 4a-c 
described in chapter 3.2.1 are violating 2 of 4 rules of the RO5. The number of free rotatable 
bonds is smaller than 10, but the PSA exceed the limit of 140 Å2. This is due to the high 
number of oxygen atoms in the mimics. 
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By replacing the hydrophilic groups by bioisosteres, lipohilicity can be increased and the 
PSA be reduced.10 The aim of this short communication is to evaluate bioisosteres of the 
carboxylate. 
 
 
Figure 1. Bioisosteric replacements of the carboxylic acid of selectin antagonist 56.11  
In previous work, the effects of bioisosteric replacements of the acid pharmacophore in sLex 
mimics were evaluated. Compound 5612 served as model system and the binding affinities of 
the acid bioisosteres 57 - 64 were compared in a competitive binding assay13 (Figure 1). An 
additional methylene group (→64), the replacement of the acid functionality by sulfate 
(→63), or terazole (→62) moieties led to a loss in affinity exceeding a factor of 14. In 
contrast, a series of amides (→57-61) showed rIC50 values between 0.8 and 5.1.  
The methylamide fits best to our purpose to reduce the PSA on the one hand and to retain 
the binding affinity on the other hand. We therefore planed to adopt the methyl amide 
modification to our cyclic selectin antagonist.          
 
Results and discussion 
Synthesis of methyl amide 66 and biological evaluation. 
To investigate the effects of the bioisostere methylamide modification on the affinity and the 
clogP, we converted the 9-member cyclic intermediate 27a (chapter 3.2.1) to the methyl 
amide 66.  
The benzyl protecting groups and the double bond were hydrogenated with Pd(OH)2/C in 
dioxane/water. Aminolysis of the resulting methylester 65 afforded methylamide 66. 
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Scheme 1. a.) Pd(OH)2/C, dioxane/H2O (4:1), H2; b.) MeNH2 in THF and MeNH2 in EtOH (70 % over 2 
steps). 
Compared to 4a (Table 1; chapter 3.2.1), the experimental logD7.4 showed a minor gain of 
methylamide 66 and a more favorable value for methylester 65. The calculated PSA values 
are reduced by approximately 15 Å2 compared to acid 4a.  
But unfortunately amide 66 showed an unexpected drop in affinity by a factor of 10 
compared to the acid 4a. This is not in accordance with the only minor decrease in affinity 
observed for the selectin antagonists 56→58 (Figure 1).11 One possible explanation is a 
different binding mode for amides 58 and 66. While the cyclic antagonist 66 is rigid and the 
methylamide is locked in tone conformation, the amide functionality in the (S)-phenyl lactic 
acid antagonist 58 is rather flexible and can adjust upon binding. The affinity of the 
metylester 65 was even lower and could not be detected in our IC50 assay. 
Table 1. Calculated PSA,14 experimental logD7.4, and IC50 values of acid 4a, methyl ester 65 and methyl amide 
66.  
 
Bulky acid isosteres are unfavorable in macrocycles.  
To support this hypothesis, the low energy conformations of cyclic sLex mimic 66 was 
calculated and docked to E-selectin. The pharmacophores are oriented similar to the crystal 
structure of compound 3 (Figure 2; chapter 3.2.1).  
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In the preferred low-energy conformations (Figure 2c) the methyl group is oriented toward 
Tyr48 (red circle in Figure 2a) and causes steric repulsion. A conformer with favorably 
oriented amide group (Figure 2b) on the other hand is sterically unfavorable, because of 
repulsion to the methylen group of the macrocycle (3.6 kcal/mol above the global 
minimum). This would explain the significant drop in affinity from 4a to 66. The (S)-phenyl 
lactic acid analogue 58 on the other hand has more rotational freedom and could probably 
adjust the methylamide in the required orientation. This would explain the only minor drop 
in binding affinity from acid to amide in the (S)-phenyllactic acid series (56→58), in 
contrast to the major loss in the macrocyclic antagonists (4a→66). 
 
 
 
Figure 2. Crystal structure15 of 3 (chapter 3.2.1) bound to E-selectin (a) and high (b) and low (c) energy 
conformation of 66 docked to E-selectin.  
Experimental part 
Molecular modeling. The 3D structure of the reactant molecule (before ring closing) was 
built in the Maestro16 molecular modeling environment and a conformational analysis was 
performed using Macromodel17 by performing 5000 steps of the mixed torsional/low-mode 
sampling in combination with the OPLS-2005 force-field in implicit solvent conditions 
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(octanol). Unfortunately, in Macromodel there is no solvation model available for the 
dichloromethane, which was used in experimental setup for the ring-closing reactions. 
Therefore a solvent model for octanol (ε = 9.86) with the dielectric constant similar to that 
of the dichloromethane (ε = 8.93) was chosen from the list of available solvent models. 
Global minimum identified in the conformational search was then placed in a periodic 
boundary system (cube, side length 40.0 Å) filled with explicit octanol molecules. The 
system was minimized and a simulated annealing simulation (gradual heating of the system 
to the temperature of 400 K in 330 ps followed by slow gradual cooling to 300 K in 500 ps) 
was performed in Desmond18,19 in order to bring the system into equilibrium. The 
production phase molecular dynamics simulation of the total duration of 48 ns was 
performed. The distance between the key atoms involved in the ring closing reaction was 
monitored every 4.8 ps (10 000 data points were saved). 
The average distance of the key atoms was calculated and the frequency of conformations 
(with a short key atom distance) where ring closing reaction could eventually occur was 
evaluated. 
 
logD7.4 determination.20 The in silico prediction tool ALOGPS21,22 was used to estimate the 
logP values of the compounds. Depending on these values, the compounds were classified 
into three categories: hydrophilic compounds (logP below zero), moderately lipophilic 
compounds (logP between zero and one) and lipophilic compounds (logP above one). For 
each category, two different ratios (volume of 1-octanol to volume of buffer) were defined 
as experimental parameters (Table X): 
 
Table 2. 
Compound type logP Ratios (1-octanol: buffer) 
hydrophilic  < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
 
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and shaken 
vigorously for 5 min to saturate the phases. The mixture was left until separation of the two 
phases occurred, and the buffer was retrieved. Stock solutions of the test compounds were 
diluted with buffer to a concentration of 1 µM. For each compound, six determinations, i.e., 
three determinations per 1-octanol:buffer ratio, were performed in different wells of a 96-
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well plate. The respective volumes of buffer containing analyte (1 µM) were pipetted to the 
wells and covered by saturated 1-octanol according to the chosen volume ratio. The plate 
was sealed with aluminium foil, shaken (1350 rpm, 25 °C, 2 h) on a Heidoph Titramax 1000 
plate-shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and 
centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). 
The aqueous phase was transferred to a 96-well plate for analysis by liquid chromatography-
mass spectrometry (LC-MS).  
logD7.4 was calculated from the 1-octanol:buffer ratio (o:b), the initial concentration of the 
analyte in buffer (1 µM), and the concentration of the analyte in buffer (cB) with 
equilibration:  
 
 
 
The average of the three logD7.4 values per 1-octanol:buffer ratio was calculated. If the two 
mean values obtained for a compound did not differ by more than 0.1 unit, the results were 
accepted. 
 
General methods. Commercial materials (Sigma-Aldrich) were used without further 
purification, solvents were reagent grade (Acros). CH2Cl2 and MeOH were dried by passing 
through an Al2O3 (Fluka, type 5016 A basic) column. DMF extra dry (Acros) was used as is. 
All reactions were performed in oven dried glassware under an atmosphere of argon.  
1H and 13C NMR spectra were recorded on a Bruker Avance DMX-500 at room temperature. 
Chemical shifts are reported in ppm and referenced to TMS using residual solvent peaks.[S14] 
For complex molecules the following prefixes were used: Fuc (fucose), Gal (galactose) and 
GlcNAc (N-acetyl glucosamine). The coupling constants (J) are reported in Hertz (Hz). 
Analytical TLC was performed on Merck silica gel 60 F254 glass plates and visualized by 
UV light and by charring with a molybdate solution (a 0.02 M solution of ammonium 
cerium sulfate dihydrate and ammonium molybdate tetrahydrate in aq. 10% H2SO4) by 
heating for 5 min at 140°C. Column chromatography was performed on a CombiFlash 
Companion (Teledyne-ISCO, Inc.) using RediSep® normal phase disposable flash columns 
(silica gel). Reversed phase chromatography was carried out with LiChroprep®RP-18 
(Merck, 40-63 µm). Optical rotations were determined on a Perkin-Elmer Polarimeter 341. 
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Low resolution mass spectra were measured on a Waters micromass ZQ. High resolution 
mass spectra (HRMS) were obtained on a micrOTOF spectrometer (Bruker Daltonics, 
Germany) equipped with a TOF hexapole detector. Purity of final compound was 
determined on an Agilent 1100 HPLC; detector: ELS, Waters 2420; column: Waters Atlantis 
dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 90% acetonitrile + 10% water 
+ 0.1% TFA; linear gradient: 0 - 1 min 5% B; 1 - 16 min 5 to 70% B; flow: 0.5 mL/min 
MALDI-TOF and ESI-MS glycoprotein analyses were recorded by the Functional Genomic 
Center Zurich (FGCZ). VIVASPIN® 500 ultrafiltration tubes with 10000 MWCO, 10 kDa 
molecular weight cutoff PES membrane, and ZelluTrans/Roth dialysis membranes MWCO 
8000-10000 were used for glycoprotein concentration and dialysis. 
 
Compound 65 
 
Compound 27a (11.4 mg, 12.3 µmol) was dissolved in dioxane/water (4:1, 4 mL) and 
Pd(OH)2/C (6 mg, 10% Pd(OH)2) was added. The suspension was stirred for 16 h under an 
atmosphere of hydrogen. Solvent was removed in vacuo. The residue was purified via RP 
chromatography (MeOH/H2O), eluated through a sodium exchange column (Dowex 50/8 
sodium form) and finally purified via size exclusion chromatography. Lyophilization from 
water/dioxane gave 65 (4.9  mg, 868 µmol, 70%) as a white fluffy foam. 
Rf (DCM/MeOH 10:1) 0.12; [α]D22 -68.1 (c 1.10, H2O); 1H NMR (500.1 MHz, MeOD): δ = 
4.95 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.90 – 4.84 (m, 1H, Fuc-H5), 4.47 – 4.42 (m, 1H, R-H1), 
4.25 (d, J = 7.6 Hz, 1H, Gal-H1), 4.08 (d, J = 3.1 Hz, 1H, Gal-H5), 3.81 – 3.72 (m, 2H, Fuc-
H3, R-H5), 3.71 – 3.53 (m, 10H, Fuc-H2, Fuc-H4, R-H5', COOMe, Gal-H6, Gal-H6', Gal-
H3, MeCy-H2), 3.34 – 3.20 (m, 2H, Gal-H4, Gal-H2), 3.13 (t, J = 9.2 Hz, 1H, MeCy-H1), 
2.45 – 2.34 (m, 1H, R-H2), 2.25 – 2.13 (m, 1H, R-H4), 2.10 – 2.02 (m, 1H, MeCy-H6), 1.80 
– 1.70 (m, 3H, R-H2, R-H3, R-H3'), 1.65 – 1.52 (m, 4H, MeCy-H5, MeCy-H5', MeCy-H4, 
MeCy-H3), 1.31 – 1.17 (m, 4H, R-H2, R-H3, R-H4', MeCy-H6'), 1.13 (d, J = 5.2 Hz, 3H, 
Fuc-H6), 1.07 (d, J = 6.4 Hz, 3H, MeCy-Me), 1.10 – 0.99 (m, 1H, MeCy-H4); 13C NMR 
(125.8 MHz, MeOD) δ 174.8 (COO), 102.4 (Gal-C1), 100.2 (Fuc-C1), 84.1 (MeCy-C1), 
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80.2 (MeCy-C2), 79.9 (R-C1), 78.6 (Gal-C2), 77.7 (Gal-C3), 76.0 (Gal-C4), 74.8 (R-C5), 
73.8 (Fuc-C4), 71.4 (Fuc-C3), 70.4 (Fuc-C2), 70.4 (Gal-C5), 67.4 (Fuc-C5), 63.0 (Gal-C6), 
52.2 (COOMe), 40.2 (MeCy-C3), 34.8 (MeCy-C4), 32.1 (MeCy-C6), 30.2 (R-C2), 28.7 (R-
C3), 26.8 (R-C4), 24.0 (MeCy-C5), 19.5 (MeCy-Me), 16.9 (Fuc-C6); HR-MS: m/z: Calcd 
for C26H44NaO13 [M+Na]+: 587.2680, found: 587.2684. 
 
Compound 66 
 
 
 
Compound 65 (3.90 mg, 6.9 µmol) was dissolved in MeNH2 in THF (2M, 1 ml) and MeNH2 
in EtOH (8M, 1ml) and stirred at rt for 24 h. The solvent was removed under reduced 
pressure and the crude product purified by RP flash chromatography and size exclusion 
chromatography to give 66 as a white solid (3.9 mg, 6.9 µmol, quant.). 
[α]D22 -16.0 (c 0.28, H2O); 1H NMR (500.1 MHz, D2O): δ = 5.13 (d, J = 3.2 Hz, 1H, Fuc-
H1), 4.98 – 4.90 (m, 1H, Fuc-H5), 4.55 – 4.48 (m, 2H, R-H2, Gal-H1), 3.99 – 3.95 (m, 1H, 
Gal-H4), 3.94 – 3.87 (m, 2H, R-H6, Fuc-H3), 3.87 – 3.75 (m, 4H, R-H6', Fuc-H2, Fuc-H4, 
Gal-H3), 3.74 – 3.62 (m, 3H, Cy-H1, Gal-H6, Gal-H6'), 3.59 – 3.48 (m, 2H, Gal-H2, Gal-
H5), 3.24 (t, J = 9.4 Hz, 1H, MeCy-H2), 2.77 (s, 3H, NH-CH3), 2.18 – 2.10 (m, 1H, MeCy-
H6), 2.00 – 1.84 (m, 2H, R-H3, R-H3’), 1.83 – 1.54 (m, 8H, MeCy-H3, MeCy-H4, MeCy-
H5, R-H4, R-H4’, R-H5, R-H5’), 1.39 – 1.21 (m, 2H, MeCy-H6’, MeCy-H5’), 1.24 (d, J = 
6.4 Hz, 3H, Fuc-H6), 1.17 – 1.04 (m, 1H, Cy-H4’), 1.10 (d, J = 6.2 Hz, 3H, MeCy-Me); 13C 
NMR (125.8 MHz, D2O): δ = 176.3 (COO), 100.5 (Gal-C1), 98.6 (Fuc-C1), 83.8 (Cy-C2), 
79.2 (Cy-C1), 76.4 (Gal-C3), 75.5 (R-C2), 74.8 (Gal-C5), 73.8 (Gal-C2), 72.0 (Fuc-C4), 
71.9 (Fuc-C2), 69.3 (Fuc-C3), 69.0 (R-C6), 68.2 (Gal-C4), 66.5 (Fuc-C5), 61.4 (Gal-C6), 
38.5 (Cy-C3), 33.1 (Cy-C4), 30.5 (Cy-C6), 29.9 (R-C2), 25.5 (Me), 23.8 (R-C3), 22.4 (Cy-
C5), 21.1 (R-C4), 18.2 (Cy-Me), 15.7 (Fuc-C3); HR-MS: m/z: Calcd for C26H45NNaO12 
[M+Na]+: 586.28 , found: 586.31. 
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Selectins are involved in several inflammatory diseases and cancer, and therefore, represent 
an interesting therapeutic target.1 SLex is the natural ligand of selectins, however, due to its 
low binding affinity and the high polarity and complexity it is far from being druglike. In the 
past several sLex mimics were developed that showed improved binding affinities and more 
favorable physicochemical parameters.2 
For complex ligands a certain degree of pre-organization in solution is crucial to reach 
adequate binding affinities to their target. Elucidating the structure of the Lex trisaccharide 
core conformation in solution by NMR spectroscopy a nonconventional C–H⋅⋅⋅O hydrogen 
bond between H-C(5) of L-fucose and O(5) of D-galactose was identified as additional 
stabilizing element to the previous reported hydrophobic interaction between L-fucose and 
the b-face of D-galactose, the exo-anomeric effect and the steric repulsion between the L-
fucose to the N-acetyl group of the adjacent GlcNAc (Figure 1).3 This nonconventional 
hydrogen bond in branched trisaccharides was not reported in literature yet, although it 
contributes with 40 % to the overall stabilization energy. It was shown that besides the Lex 
trisaccharide the solution conformations of several other branched oligosaccharides are 
stabilized by these nonconventional C–H⋅⋅⋅O hydrogen bonds. 
 
 
Figure 1. Stabilizing factors of the sLex tetrasaccharide 1 (a), mimic 3 (b) and the cyclic selectin antagonist 4a 
(c) in solution. Pharmacophores are highlighted in blue (bold). 
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The recently published selectin antagonist 32, mimics the conformation of the Lex core and 
adopts all the stabilizing elements. Furthermore, the D-GlcNAc and D-Neu5NAc residues 
were replaced by hydrophobic moieties, which lead to favorable desolvation properties upon 
binding and an increase in affinity by a factor of almost 250 to the lead compound sLex.  
By solving the solution conformation of 3 an additional stabilizing factor was identified. An 
interaction between the benzoate and cyclohexyl lactic acid moiety contributes to a 
preferable orientation of the acid pharmacophore in the bioactive conformation (Figure 1b). 
Assuming, that the pre-organization of the acid functionality is a major factor for this strong 
binding affinity, we synthesized a series of cyclic compounds in which the acid 
pharmacophore is oriented in the bioactive conformation. Our most promising cyclic ligand 
4a has a similar affinity to compound 3, while the molecular weight and number of free 
rotatable bonds is reduced, both important parameters for the design of oral available drugs.  
In the future the binding mode and the thermodynamic profile for E-selectin binding will be 
determined for the cyclic selectin ligands 4a-c. To further improve the binding affinity 
hydrophobic substituents could be introduced in the ring structure. Furthermore, replacing 
hydroxy pharmacophores by bioisosteres could increase lipohilicity and reduce the polar 
surface area and thus, improve the druglike properties. 
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